FIELD OF INVENTION
The present invention relates to the field of medicine, in particular personalized medicine in cancer therapy.
BACKGROUND OF THE INVENTION
The therapeutic care of the patients having cancer is primarily based on surgery, radiotherapy and chemotherapy which have to be used according to standard protocols. The curative surgery consists in removal of all the tumoral mass. However, this is not always possible to guarantee the absence of any residual disease after the ablation of the observable part of the tumour, even by experienced surgeons. This is why the surgery is generally used in combination is with radiotherapy and/or chemotherapy. Chemotherapy and/or radiotherapy can be used as neoadjuvant therapy or auxiliary or adjuvant therapy, or alone when the surgery is impossible. Neoadjuvant therapy is usually used when the tumoral mass is too important and requires a reduction before surgery. Auxiliary or adjuvant chemotherapy is used to treat the residual tumoral diseases and to limit the local recurrences or the metastatic relapses. When a tumour is detected at an inoperable stage, then the therapeutic care is only based on chemotherapy and/or radiotherapy. Surgery is marginally used in this context and has palliative objectives.
In any case, the choice of chemotherapy always raises the following questions: Which drug or combination of drugs is adapted to this type of cancer? What is the most adapted therapeutic strategy for this patient? What are the chances for observing a therapeutic benefit with the selected drugs?
The current medical practice consists in treating the patients according to the existing therapeutic protocols. In the majority of the cases, the choice of the therapeutic protocol is based on the anatomo-pathological and clinical data. These protocols apply in first, second, even third therapeutic line. When there is therapeutic failure, or for the metastatic stages, certain patient are included in clinical trials generally using broad selection criteria defining primarily, the location of the primitive tumour, the extension of the disease, the situation of the vital functions of the patient and certain specific contraindications of the drug under trial. Whatever the therapeutic approach (standard or clinical trial), only part of the treated population profits from the treatment whereas the remainder of the patients do not respond and show a progressing disease even under treatment.
To improve this situation, since many years, physicians and researchers are trying to identify markers for predicting the efficacy of the treatments for a given patient and to be able to adapt the treatment of each patient. Thus the concept of personalized medicine consists in adapting the therapeutic decision according to the anatomo-pathological, clinical characteristics but especially of the biological characteristics of the tumour.
Several examples are known without representing a solution useful for any patient having a cancer.
A first approach was the so-called “test-companion” assay, used for the first time for the trastuzumab (Herceptin®), a monoclonal antibody targeting the Her2/Neu receptor. In breast cancers, this drug is administered only when an amplification/overexpression of this receptor is observed. However, this overexpression does not guarantee a therapeutic response. Some resistances to Herceptin® can be explained by an activation of the Akt pathway, for instance. The association of an mTOR inhibitor (targeting the Akt pathway) can restore the sensitivity to Herceptin. Nevertheless, for some patients, the therapeutic benefit was observed in the absence of an amplification of the receptor.
The measurement of the expression level of the Her2 receptor is the first example of test companion and the majority of pharmaceutical companies or researchers are trying to reproduce this model considered as the first example of personalized medicine. The following examples are relevant to illustrate the concept of selection of the patients who could profit from a given drug:
- Mutation or amplification of EGFR receptor and erlotinib/gefitinib;
- Mutations c-Kit/PDGFRa and imatinib;
- Translocation of Bcr-Abl and imatinib;
- Amplification of HER2 and HER2 inhibitors;
- Amplification of TOP2A and anthracyclines;
- Deletion of PTEN and mTOR inhibitors;
- Amplification of FGFR1 and FGFR1 inhibitors;
- ERCC1 negative-treatment and platinum salts;
- RAS mutations and treatment of colon cancer
- etc.
In the case of breast cancer, prognostic molecular signatures, such as the tests Mamaprint® (developed by the Agendia company) or OncotypeDX® (company Genomic Health) are available. These signatures are used to determine if an auxiliary chemotherapy is necessary or not. But, although these tests make it possible to conclude on the need from an auxiliary chemotherapy, they do not make it possible to select the optimal therapy.
In short, the concept of personalized medicine corresponds to a selection of patients on biological criteria to increase the chances of response to a given therapy. Currently, these tests companion are rather used for the treatments by targeted therapies and make it possible to select the patients likely to profit from a given therapy but not to select the best therapy for a given patient. This is a major conceptual difference which constitutes the main interest of the present invention compared to the other markers proposed to date.
The anomalies of strong amplitude of the gene copy number (amplifications or deletions) modify the levels of gene expression. This mechanism of genomic deregulation is involved in the ontogenesis of many cancers. Amplifications of the EGFR gene are found in approximately 30% of lung cancers. The inhibition of EGFR in case of amplification is associated with a significant benefit in this same pathology. Similarly, MYCN is amplified in approximately 25% of the neuroblastoma and several studies showed the prognostic value of this anomaly in this pathology. Other oncogenes/anti-oncogenes (tumour suppressor genes) are frequently amplified/deleted in other types of tumours such HER, PTEN, PUTS, and the like.
Breast cancer presents an important frequency of chromosomal aberrations. Gene HER2 (ErbB2) is amplified in 10 to 20% of the cases. This amplification is associated with a hyper-expression of the Her2 protein and is involved in the tumoral transformation. A therapeutic strategy based on the targeting of this anomaly showed a benefit in the patients having HER2-positive breast cancer. In addition, the gene coding for the topoisomerase II is amplified in approximately 7% of breast cancers. This amplification is correlated with a good sensitivity to the anthracyclines, a class of drugs targeting the topoisomerase II. Other anomalies have often been observed in breast cancer. A1B1 gene is amplified in 10% of the cases, and leads to ontogenesis via the activation of AKT by the IGFR. FGF1R gene is amplified in 10% of case. The targeting of this protein by a tyrosine kinase inhibitor leads in vitro to a reduction of the cell multiplication. Similarly, amplifications of the genes EGFR, IGF1R or the deletions of PTEN can be treated by molecules targeting EGFR, IGF1R or mTOR, respectively.
In the scientific literature, certain works, among which those of A. Potti et al., propose a prediction of the drug's efficacy, primarily cytotoxicity, based on the analysis of the expression of genes selected from experiments on well-established cell lines (panel NCI60). These data allow the identification of expression profiles associated with the response for each tested molecule and this prediction is transposed to the human tumours. However, if this approach allows a molecule by molecule prediction, it does not allow the comparison of the efficacy of each molecule for a given patient in order to select the best drug. In addition, the one skilled in the art knows the limitations of in vitro model to perform in vivo predictions. These approaches tend to enrich the patient cohort for a given chemotherapy rather than to select a targeted individual therapy for a given patient on the basis of the intrinsic tumoral characteristics.
However, the choice of the appropriate chemotherapy in cancer treatment is a crucial issue. Indeed, most of the chemotherapies have very significant adverse effects and an erroneous choice (i.e., treatment without any therapeutic benefit) could lead to a cancer progression.
Up today, there is no marker efficient to select the most optimal therapeutic strategy for a given individual having a cancer. Accordingly, there is a strong need to methods of personalized medicine in the field of cancer treatment allowing the selection for a given individual of the most appropriate chemotherapy strategy.
SUMMARY OF THE INVENTION
The present invention concerns a method for predicting the relative efficacy of a plurality of drugs for treating a cancer in a patient comprising:
- characterizing molecular anomalies of a tumour or metastase sample from the patient in comparison to a normal sample from the same patient, thereby determining the deregulated genes in the tumour;
- providing a database comprising the target genes for each drug of the plurality of drugs;
- determining a score for each drug of the plurality of drugs essentially based on the percentage of deregulated genes among the target genes for each drug in the tumour sample from the patient, thereby a higher score is predictive of a higher relative efficacy of the drug for treating the tumour in the patient. Preferably, the normal sample is the normal histologic counterpart to the primary tumor.
In particular, the step of characterizing molecular anomalies of a tumour sample comprises determining the genes differentially expressed in the tumour in comparison to the normal sample, and/or determining the gain or loss of gene copy number and/or detecting the presence of a mutation in a gene. Preferably, the step of characterizing molecular anomalies of a tumour sample comprises determining a fold change (F) for the differentially expressed genes and/or for the gain or loss of gene copy number and, optionally, further determining the intensity of the gene transcription (Int) for the differentially expressed genes.
Preferably, the target genes for each drug are classified in the database into the major target genes (CM), the minor target genes (Cm) and the resistance genes (CR).
In a first embodiment, the score (W) for a given drug is determined by the following algorithm:
W
=
Pz
(
∑
C
F
c
>
2
)
n
C
F
c
>
2
wherein
W is the score for the given drug;
P is the percentage of target genes for the given drug which are deregulated in the tumour of the patient;
z is an optional multiplication coefficient associated to the presence of a mutation in a target gene of the given drug;
Σ is sum;
Fc>2 is the fold change of each deregulated target gene for the given drug with a Fold Change higher than 2;
nCFc>2 refers to the number of target genes for the given drug with a Fold Change higher than 2.
Preferably, Fc>2 is the Fold Change of each over-expressed target gene for the given drug with a Fold Change higher than 2 and nCFc>2 is either the number of target genes for the given drug with a Fold Change higher than 2, or the number of over-expressed target genes for the given drug with a Fold Change higher than 2.
In a second embodiment, the score (W) for a given drug is determined by the following algorithm:
W
=
P
(
(
∑
CM
F
CM
)
n
1
CM
q
1
z
1
+
(
∑
Cm
F
Cm
)
n
2
Cm
q
2
z
2
-
(
∑
CR
F
CR
)
n
3
CR
q
3
z
3
)
wherein
W is the score for the given drug;
P is the percentage of target genes for the given drug which are deregulated in the tumour of the patient;
Σ is sum;
CM refers to major target genes for the given drug;
Cm refers to minor target genes for the given drug;
CR refers to resistance genes for the given drug;
n1CM, n2Cm and n3CR are respectively the number of deregulated target genes with a defined threshold for major target genes, minor target genes and resistance genes;
FCM, FCm and FCR are the Fold change of each gene higher than the defined threshold for major target genes, minor target genes and resistance genes, respectively;
q1, q2 and q3 are optional multiplication coefficients for major target genes, minor target genes and resistance genes, respectively;
z1, z2 and z3 are optional multiplication coefficients associated to the presence of a mutation in a major target gene, a minor target gene and a resistance gene, respectively.
In a third embodiment, the score (W) for a given drug is determined by the following algorithm:
W
=
P
CM
(
∑
CM
F
CM
)
n
1
CM
q
1
z
1
+
P
Cm
(
∑
Cm
F
Cm
)
n
2
Cm
q
2
z
2
-
P
CR
(
∑
CR
F
CR
)
n
3
CR
q
3
z
3
wherein the meaning of W, Σ, CM, Cm, CR, FCM, FCm, FCR, q1, q2, q3, z1, z2 and z3 are the same than the previous algorithm and PCM, PCm and PCR are the percentage of genes for the given drug which are deregulated in the tumour of the individual for major target genes, minor target genes and resistance genes, respectively.
In a fourth embodiment, the score (W) for a given drug is determined by one of the following algorithms:
W
=
P
(
(
∑
CM
F
CM
×
Int
CM
)
n
1
CM
q
1
z
1
+
(
∑
Cm
F
Cm
×
Int
Cm
)
n
2
Cm
q
2
z
2
-
(
∑
CR
F
CR
×
Int
CR
)
n
3
CR
q
3
z
3
)
or
W
=
P
CM
(
∑
CM
F
CM
×
Int
CM
)
n
1
CM
q
1
z
1
+
P
Cm
(
∑
Cm
F
Cm
×
Int
Cm
)
n
2
Cm
q
2
z
2
-
P
CR
(
∑
CR
F
CR
×
Int
CR
)
n
3
CR
q
3
z
3
wherein the meaning of W, Σ, CM, Cm, CR, FCM, FCm, FCR, q1, q2, q3, z1, z2 and z3, and if present PCM, PCm and PCR, are the same than the previous algorithm and IntCM, IntCm and IntCR are the intensity for major target genes, minor target genes and resistance genes, respectively.
In a fifth embodiment, the score (W) for a given drug is determined by one of the following algorithms:
W
=
P
(
(
∑
CM
F
CM
)
n
1
CM
q
1
z
1
-
(
∑
CR
F
CR
)
n
3
CR
q
3
z
3
)
or
W
=
P
CM
(
∑
CM
F
CM
)
n
1
CM
q
1
z
1
-
P
CR
(
∑
CR
F
CR
)
n
3
CR
q
3
z
3
or
W
=
P
(
(
∑
CM
F
CM
×
Int
CM
)
n
1
CM
q
1
z
1
-
(
∑
CR
F
CR
×
Int
CR
)
n
3
CR
q
3
z
3
)
or
W
=
P
CM
(
∑
CM
F
CM
×
Int
CM
)
n
1
CM
q
1
z
1
-
P
CR
(
∑
CR
F
CR
×
Int
CR
)
n
3
CR
q
3
z
3
wherein the meaning of W, Σ, CM, CR, FCM, FCR, q1, q3, z1 and z3, and if present PCM, PCR, IntCM, and IntCR are the same as the previous algorithms.
Preferably, in the second to fifth embodiment, FCM, FCm and FCR are the Fold Change of each over-expressed target gene for the given drug with the defined threshold and n1CM, n2Cm and n3CR are either the number of target genes for the given drug with the defined threshold, or the number of over-expressed target genes for the given drug with the defined threshold. More preferably, the defined threshold is a Fold change of at least 2 or higher than 2.
In addition, in the second to fifth embodiment, multiplication coefficients for the target genes can be comprised between 10 and 1,000 for major target genes (q1), 0.1 and 10 for minor target genes (q2) and 10 to 1,000 for resistance genes (q3).
Furthermore, in the second to fifth embodiment, multiplication coefficients associated to a mutation z1, z2 and z3 are 1 when no mutation exists and, depending on the functional impact of the mutation, can be comprised between 10 and 1,000.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1: Thoracic scanner in October 2005 of the patient of Example 1.
FIG. 2: Thoracic scanner in November 2008 of the patient of Example 1.
FIG. 3: Thoracic scanner in April 2009 of the patient of Example 1.
FIG. 4: Thoracic scanner in July 2009 of the patient of Example 1.
FIG. 5: Thoracic scanners in January and March 2010 of the patient of Example 3.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a new concept for selecting the most appropriate therapy at the individual level. The drug selection is based on the biologic characteristics of the tumor of the individual to be treated in comparison to a normal sample from the same individual. Based on a score essentially based on the percentage of deregulated target genes or microRNAs for each drug, the relative efficacy of the drugs can be predicted for the individual in order to treat the specific tumour.
General Concept
It is at the level of the optimal therapeutic strategy choice that applies the object of the present invention. For selecting the most appropriate therapeutic strategy, the method of the present invention is taking into account of, on one hand, the biological data of the tumor to be treated as a whole and, on the other hand, a plurality of drugs, preferably all existing drugs (either registered or in development). A score is determined for each drug based on the biological characteristics of the specific tumour to be treated for a given subject. This score makes it possible to order the various drugs in decreasing order for their potential efficacy. The physician can use these scores to select the optimal drug or combination of drugs for the given subject. This approach, allowing the association of each drug with a score depending on the biological characteristics of the tumour, constitutes the basis of this invention. Therefore, this invention is likely to meet the present needs for personalized medicine.
The method can be used both for registered drugs and for developed drugs (e.g., temporary authorization of use or clinical trials).
This concept thus consists in considering the choice of the therapy for the patient at the level of the individual depending on the intrinsic characteristics of his tumour and not on global results obtained from large groups of individuals.
The present invention is based on the combination of three fundamental points, detailed below, and which are combined together to optimize the choice of the strategy for each individual having a cancer:
- The first point corresponds to the analysis, as exhaustive as possible, of the biological or gene anomalies (amplification, deletions, mutations, gene expression, microRNAs expression and the like) which characterize a given tumour for an individual.
- The second point consists in the identification of genes known to be in relation with a drug.
- The third point corresponds to the establishment of the connection between each drug and the anomalies detected in the tumour to be treated in an individual. An algorithm has been indentified for calculating a score for each drug in consideration of the tumour characteristics and the genes known to be in relation with a drug.
The method of the invention will allow guiding the therapeutic choice because the available drugs will be ordered on their score basis, reflecting their potential therapeutic efficacy for the given tumour in an individual.
One advantage of the present method is that the relative efficacy of a plurality of drugs can be predicted for an individual without exposing the individual to drugs. By a plurality of drugs is intended at least or about 10, 20, 30, 40, 50 or 100 different drugs. Indeed, when a panel of drugs is available for treatment, one cannot be envisaged to try the treatment by each drug on the patient. The present method allows the consideration of all potential therapeutic strategy and the selection of the most appropriate for the patient.
Indeed, the scores for the plurality of drugs allow the determination of the relative efficacy of the plurality of drugs for treating the tumour of the considered individual. Indeed, a drug having a higher score than another drug is predicted to have a higher efficacy for treating the tumour. By treating is intended that the drug allows to stop or slow down the growth of the tumour, and/or to decrease the size of tumour even up to its disappearance. By treating is also intended to avoid the metastasis, the recurrence or the relapse.
Another advantage is that the method does not depend on a cancer type. The method of the invention can be used for any type of cancer including haematological tumour (e.g. leukemia, lymphoma) and bladder, breast, stomach, thyroid, prostate, testis, liver, pancreatic, bone, pancreatic, kidney, endometrial, melanoma, lung, gastric, colorectal, prostate, head or neck tumours, brain, neuroblastoma, and ovarian cancer.
In a preferred embodiment, the patient or individual is a human being.
Tumour Characterization
Tumour characterization corresponds to the analysis, as exhaustive as possible, of the biological or gene anomalies (amplification, deletions, mutations, gene expression and the like) which characterize a given tumour for an individual. In particular, the anomalies are determined in a tumour from the patient in comparison with a normal tissue of the same patient. Preferably, the tumour sample and the normal sample provides from the same type of tissue. For the tumour characterization, several technologies are available and can be combined.
The first technology is the gene analysis. This analysis can be carried out by CGH (Comparative Genomic Hybridization) which makes it possible to compare the tumoral DNA with the normal DNA of the same individual to detect chromosomal aberrations, i.e. the chromosomal losses or gains. This technology is well-known by the man skilled in the art. As an illustration of this knowledge, the following reviews or reference books can be cited: Davies et al. (2005, Chromosome Research, 13, 237-248). This technology can also help to identify translocations. It can be easily carried out with frozen biopsies or tumoral paraffin-included material. CGH results are expressed as the ratios of copy numbers in the tumoral material and in normal tissue. A threshold of 0.5 is been acknowledged to describe a gain or a loss. More this ratio is high, more the amplitude of the anomaly is important. Thus, an important anomaly is likely to have a real impact at the biological level. However, the chromosomal aberrations only represent a weak part of the origins of gene expression deregulation. This is why other technologies are necessary. CGH have another advantage, to certify presence of tumoral samples in the tumoral biopsy or biospecimen, and this whenever an aberration can be detected.
The second technology allowing a functional genomic analysis corresponds to the measurement of mRNA and microRNA. The determination of the expression level variation for these RNA is carried out by comparing the expression levels in a tumoral tissue and in the corresponding normal tissue. For instance, in case of colon adenocarcinoma, the corresponding normal tissue is the normal colic mucosal tissue. The gene expression analysis allows the study of the independent deregulations or deregulations due to chromosomal aberrations. Indeed, the regulation of the transformational activity of genes is complex and involves many levels of regulation: trans/cis transcription factors, promoters, chromatin regulation, and the like. Generally, all deregulations (over-expression or under-expression) are considered with a ratio tumour/normal of at least 2. This threshold called “fold change” can thus have a positive value >2 or a negative value <−2. The same concept applies to the microRNAs which play an important role in the post-transcriptional regulation of genes, therefore for the proteins expression. Technologies that can be used comprise northern analysis, mRNA or cDNA microarrays, RT-PCT (in particular quantitative RT-PCR) and the like. The level of transcription can be determined at the mRNA level or at the encoded protein level. Protein expression can be assessed by Western blotting, immunoassay, proteomics tools or mass spectrometry.
These two types of analyses, CGH and RNA expression determination can be supplemented by an analysis of the mutational status of genes. Indeed, the presence of mutation leading to a functional gain or loss has an important effect on biology of the tumour without being always connected to variations of gene expression or of gene copy number. Many mutations are known to have a direct effect on the activity of a treatment by inducing increased sensitivities or resistances. For example, the mutations in the tyrosine kinase domain of EGFR are often associated with sensitivity to the small molecules inhibiting EGFR, the mutations in KRAS gene are associated with resistance to the treatment by monoclonal antibodies targeting EGFR. In addition to mutational status, some SNP can also be detected. Indeed, SNP can be also associated to a functional gain or loss, a resistance or a toxicity for a drug. The mutational status can be determined by any method known in the art, for instance by sequencing, microsequencing or hybridization.
In short, high throughput genomic technologies can be used to characterize in the most exhaustive possible way the biological anomalies of a given tumour from an individual to be treated. The experimental data for each tumour are compiled in basic files being used for the application of the algorithms allowing calculation of a score for each drug. These files comprise the copy number of genes, the mutations, the fold-changes or the intensities of signals (proportional to the number of transcripts or to the number of gene copy) for normal tissue (Intensity 1 or I1) and for tumoral tissue (intensity 2 or I2). The functional genomic analysis allows the simultaneous measurement of 44,000 or more (for example 244,000) RNA sequences covering all the genome. Preferably, a filtration can be applied to retain only the probes having a ratio or fold-changes higher or lower than 2 and whose average of the intensities I1 and I2 is higher than 100 units of fluorescence (arbitrary units).
The term “molecular anomalies” refers herein to the gene expression differences (either mRNA, microRNA or protein expression), to a gain or loss of gene copy number, or to a mutation presence.
In a particular embodiment of the invention, the exhaustive characterization of the tumour is replaced by the characterization of the target genes of the drug database. In this embodiment, specific array can be prepared to determine the gene expression level of all the target genes of the database.
Drug Database
For the method of the invention, it is necessary to provide a database with a list of target genes for each drug of the database. As explained before, a target gene for a drug can be, without being limited thereto, any gene documented to be involved in the drug mechanism of action, to be involved in the drug metabolism, to have a modified gene expression in presence of the drug, to be associated with a drug resistance, to be associated with a drug toxicity. The database can be prepared based on the search in the public databases (such as CTD, DrugBank, PubMed, and the like) in order to identify the genes associated with each drug. For instance, the database can be built based on the CTD (The Comparative Toxicogenomics Database, See Worldwide Website: ctd.mdibl.org) data for a selection of drugs and their molecular targets (genes), restricted to the human species (ID 9606). These data can be crossed with genes' information from LocusLink (gene symbol, RefSeq NM, gene description). Finally, each drug/gene interaction in the database can be qualified from the available publications, to determine the type of interactions: some positive interactions (target, sensitivity, drug activator, drug carrier, toxicity reverser), some negative interactions (resistance, toxicity, drug metabolism, apoptosis, death).
The identified genes can have different roles and significances. Therefore, in a preferred embodiment, the target genes are classified into three categories: the major target genes, the minor target genes and the resistance genes. The identification of these genes from the public data (public literatures and data banks) and their classification in the three categories form an integral part of this invention. The major target genes are those which have been demonstrated to have a clear cause and effect link with the drug mechanism of action. For example, HER2 gene is regarded as major target gene for trastuzumab, VEGFA gene is regarded as major target gene for bevacizumab, and the like. A given drug can have one or more major target genes. This category also includes the genes known to be involved in the drug metabolization when drugs are known to become active only when an active metabolite is generated. The minor target genes are those which are found to be those whose level of regulation is modified in the presence of the drug, without a direct link with the drug mechanism of action. The resistance genes comprise genes known to induce a direct resistance to the drug but also genes associated with a major toxicity. For example, ERCC1 gene is a target gene of resistance for the use of platinum salts. For example, some cytochrome P450 isoforms are associated with a major toxicity.
In a particular embodiment of the invention, the considered target genes can only belong to the two following categories: the major target genes and the resistance genes.
A first drug database has been established by the inventors and is disclosed in Table 1. For some drugs, the target genes have been categorized.
The drug database can be incremented over the time, by categorizing target genes for a drug, and/or by adding new drug, new target genes and/or by including combination data (e.g. combination of drugs with radiotherapy or combination of drugs).
More complete is the drug database, more accurate is the prediction. However, the method for predicting the relative efficacy of drugs can be carried out as soon as a preliminary database is ready.
Algorithm
An algorithm has been indentified for calculating a score for each drug in consideration of the tumour characteristics and the genes known to be in relation with a drug. This calculation can be carried out by specific softwares by using of the scripts developed under R for instance, and allowing the determination of the frequencies and the association links between the file of target genes for the drugs and the file integrating the data of the genomic analysis resulting from the biological investigation from the tumour of the individual.
The algorithm can take into account the following parameter:
1) the whole percentage of deregulation of target genes of a drug. Therefore, the list of target genes for a given drug is compared with the list of deregulated genes in order to determine the percentage of deregulated genes for this drug. For instance, if 10 target genes have been identified for a given drug and, for a given tumour, 4 of the 10 target genes are found to be deregulated, then the percentage of deregulated genes for this drug is 40%.
2) the deregulation extent and sense (e.g., over- or under-expression) of the target genes defined by a Fold Change (Fc) and an average intensity (AvgInt). These parameters can be defined either as a whole for the target genes or by each category (e.g., major target genes, minor target genes and resistance target genes).
3) the presence of mutations in target genes known to have an effect on the given drug.
An algorithm is used to calculate a score for each drug of the database in consideration of the tumour characterization for the subject to be treated.
A first basic algorithm that can be used in the method is the following:
W
=
Pz
(
∑
C
F
c
>
2
)
n
C
F
c
>
2
wherein
W is the score for a given drug;
P is the percentage of target genes for the given drug which are deregulated in the tumour of the individual;
z is an optional multiplication coefficient associated to the presence of a mutation in a target gene;
Σ is sum;
Fc>2 is the Fold Change of each deregulated target gene for a given drug with a Fold Change higher than 2;
nCFc>2 refers to the number of target genes for the given drug with a Fold Change higher than 2.
In a particular embodiment of this algorithm, Fc>2 is the Fold Change of each over-expressed target gene for a given drug with a Fold Change higher than 2 and nCFc>2 can refer to the number of target genes for the given drug with a Fold Change higher than 2, or the number of over-expressed target genes for the given drug with a Fold Change higher than 2.
Of course, the algorithm can be more complex in order to take into account the category of the target genes (e.g., major target gene, minor target gene or resistance target gene), for instance by introducing a multiplication coefficient.
Such a more complex algorithm can be the following:
W
=
P
(
(
∑
CM
F
CM
)
n
1
CM
q
1
z
1
+
(
∑
Cm
F
Cm
)
n
2
Cm
q
2
z
2
-
(
∑
CR
F
CR
)
n
3
CR
q
3
z
3
)
wherein
W is the score for a given drug;
P is the percentage of target genes for the given drug which are deregulated in the tumour of the individual;
Σ is sum;
CM refers to major target gene for the given drug;
Cm refers to minor target gene for the given drug;
CR refers to resistance gene for the given drug;
- n1CM, n2Cm and n3CR respectively are the number of deregulated target genes with a defined threshold for major target genes, minor target genes and resistance genes;
FCM, FCm and FCR are the Fold change of each gene higher than the defined threshold for major target genes, minor target genes and resistance genes, respectively;
q1, q2 and q3 are multiplication coefficients for major target genes, minor target genes and resistance genes, respectively;
z1, z2 and z3 are optional multiplication coefficients associated to the presence of a mutation in a major target gene, a minor target gene and a resistance gene, respectively.
For instance, multiplication coefficients for the target genes can be comprised between 10 and 1,000 for major target genes, 0.1 and 10 for minor target genes and 10 to 1,000 for resistance genes. Other values for multiplication coefficients are not excluded.
The multiplication coefficients associated to a mutation are 1 when no mutation exists. Depending on the functional impact of the mutation, the coefficient z can be comprised between 10 and 1,000, for instance. Other values for multiplication coefficients associated to a mutation are not excluded.
In a preferred embodiment, the defined threshold is a Fold change of at least 2 or higher than 2. However, the consideration of a lower threshold is not excluded in the present method since a fold change of 1.5 can be significant for some genes.
In a particular embodiment, FCM, FCm and FCR can be the Fold Change of each over-expressed target gene for the given drug with the defined threshold and n1CM, n2Cm and n3CR can refer to the number of target genes for the given drug with the defined threshold, or the number of over-expressed target genes for the given drug with the defined threshold.
In an alternative complex algorithm, the formulae can be the following:
W
=
P
CM
(
∑
CM
F
CM
)
n
1
CM
q
1
z
1
+
P
Cm
(
∑
Cm
F
Cm
)
n
2
Cm
q
2
z
2
-
P
CR
(
∑
CR
F
CR
)
n
3
CR
q
3
z
3
wherein the meaning of W, Σ, CM, Cm, CR, FCM, FCm, FCR, q1, q2, q3, z1, z2 and z3 are the same than the previous algorithm and PCM, PCm and PCR are the percentage of genes for the given drug which are deregulated in the tumour of the individual for major target genes, minor target genes and resistance genes, respectively.
Similarly, in a preferred embodiment, the defined threshold is a Fold change of at least 2 or higher than 2. However, the consideration of a lower threshold is not excluded in the present method since a fold change of 1.5 can be significant for some genes.
In a particular embodiment, FCM, FCm and FCR can be the Fold Change of each over-expressed target gene for the given drug with the defined threshold and n1CM, n2Cm and n3CR can refer to the number of target genes for the given drug with the defined threshold, or the number of over-expressed target genes for the given drug with the defined threshold.
In a particular embodiment, the algorithm can take into account the average intensity or intensity variation. This parameter is indicative of the transcription level of genes. Indeed, it can be considered that for a same Fold Change of 2, a gene deregulation can have a different weight depending on the intensity of the transcription, for instance 200/100 in comparison to 200,000/100,000.
Accordingly, a still more complex algorithm can be one of the followings:
W
=
P
(
(
∑
CM
F
CM
×
Int
CM
)
n
1
CM
q
1
z
1
+
(
∑
Cm
F
Cm
×
Int
Cm
)
n
2
Cm
q
2
z
2
-
(
∑
CR
F
CR
×
Int
CR
)
n
3
CR
q
3
z
3
)
W
=
P
CM
(
∑
CM
F
CM
×
Int
CM
)
n
1
CM
q
1
z
1
+
P
Cm
(
∑
Cm
F
Cm
×
Int
Cm
)
n
2
Cm
q
2
z
2
-
P
CR
(
∑
CR
F
CR
×
Int
CR
)
n
3
CR
q
3
z
3
wherein the meaning of W, Σ, CM, Cm, CR, FCM, FCm, FCR, q1, q2, q3, z1, z2 and z3, and if present PCM, PCm and PCR, are the same than the previous algorithm and IntCM, IntCm and IntCR are the intensity for major target genes, minor target genes and resistance genes, respectively. “Int” can be the intensity of the gene transcription in the tumour sample, the difference of the gene transcription between the tumour sample and the normal sample from the individual.
In an additional embodiment, the method can be focused on the major target genes and the resistance genes, without taking into account of the minor target genes. In this embodiment, the algorithm could be one of the followings:
W
=
P
(
(
∑
CM
F
CM
)
n
1
CM
q
1
z
1
-
(
∑
CR
F
CR
)
n
3
CR
q
3
z
3
)
W
=
P
CM
(
∑
CM
F
CM
)
n
1
CM
q
1
z
1
-
P
CR
(
∑
CR
F
CR
)
n
3
CR
q
3
z
3
W
=
P
(
(
∑
CM
F
CM
×
Int
CM
)
n
1
CM
q
1
z
1
-
(
∑
CR
F
CR
×
Int
CR
)
n
3
CR
q
3
z
3
)
W
=
P
CM
(
∑
CM
F
CM
×
Int
CM
)
n
1
CM
q
1
z
1
-
P
CR
(
∑
CR
F
CR
×
Int
CR
)
n
3
CR
q
3
z
3
wherein the meaning of W, Σ, CM, CR, FCM, FCR, q1, q3, z1 and z3, and if present PCM, PCR, IntCM, and IntCR are the same than the previous algorithms.
Preferably, the selected algorithm is validated with two models: a retrospective model (e.g., tumours for which chemotherapies have been performed and for which the response to treatments is known); and a prospective model allowing the evaluation of the efficacy of a particular treatment in relation with the score.
During the algorithm validation tests, some variables can be refined, in particular the multiplication coefficients, the consideration of the average intensity or not, the threshold of the fold change. In addition, during this step, one can determine if it is preferable to use CGH or functional genomic analysis or both.
The method also considers other variants of the algorithm that could be proposed, the final objective staying to calculate a score for each drug based on the characteristic of the tumour of the individual to be treated, in particular on the biologic and genetic anomalies of the tumour.
Further aspects and advantages of this invention will be disclosed in the following examples, which should be regarded as illustrative and not limiting the scope of this invention.
EXAMPLES
Example 1
At diagnosis, 70% of lung cancers are in late stages. They are non operable with a poor clinical outcome.
The method of the present invention has been used in a patient case to help the practitioner to choose the most appropriate treatment.
The patient was a male Caucasian of 58 years old. He suffered of a non-small cell lung carcinoma (NSCLC), cT4, N0, M1. Nine therapeutic lines have been used, namely cisplatin-Gemzar, taxotere, navelbine, taxol-carboplatin, mediastinal radiotherapy, IRESSA, alimta, tarceva and HKI 272 (pan Her inhibitor). For HKI 272, the patient has been included in a clinical trial.
HKI 272 began in October 2005. FIG. 1 show NMR of mediastinal lymph node (C1) and adrenal node (C2). HKI was efficient; the patient remained in the study almost three years. However, after 37 months of HKI 272, a disease progression was observed (FIG. 2). New subclavious metastasis appeared. This is one of the biggest problems in oncology today; even if there is initial response, a secondary resistance to treatment often occurs. Accordingly, the decision to stop HKI 272 treatment was taken since new metastasis occurred. It is important to mention that practitioners considered at that time that HKI 272 was the last therapeutic line available for this patient.
Subclavious metastasis was resected and used for complete molecular profiling. The features of the profiling were:
- 1—comparison tumoral tissue versus normal lung tissue (T vs N);
- 2—Comparative genome hybridzation (CGH) (T vs N);
- 3—Gene expression (GE) comparison (T vs N);
- 4—microRNA (miRNA) profiling (T vs N);
- 5—Sequencing of genes including EGFR, p53, CTNNB1, AKT1, BRAF, KRAS, HRAS, NRAS, PIK3CA, FBXW7, EGFR, ERBB2, KIT, NOTCH1, PTEN, STK11, TP53, APC, MET, RB1, FGFR2, FGFR3, JAK2, TSC1, TSC2, CDKN2A, CDKN2A, TOP1, TOP2A, PDGFRA, VHL, CDK4, JAK1, TYK.
- 6—No relevant mutations were found in any of these genes (for example no mutation of EGFR or other genes). Therefore mutations did not impact algorithm for this patient. Only relevant results obtained with gene expression were used.
Then, the algorithm of the present invention was applied on these data in order to predict the drug efficacy. A score for each drug was calculated based on the collected data. The algorithm used was the following:
W
=
Pz
(
∑
C
F
c
>
2
)
n
C
F
c
>
2
wherein
W is the score for a given drug;
P is the percentage of target genes for the given drug which are deregulated in the tumour of the individual;
z is 1 because, in this example, no mutation was detected;
Σ is sum;
Fc>2 is the Fold Change of each deregulated target gene for a given drug with a Fold Change higher than 2;
nCFc>2 refers to the number of target genes for the given drug with a Fold Change higher than 2.
Table 2 shows the calculated scores. It can be observed that the drugs used in the previous therapeutic lines were associated with low scores, namely 108 for cisplatine, 70 for gemzar, 77 for taxotere, 147 for taxol, 82 for carboplatin, 66 for Iressa, and 73 for Alimta.
On December 2008, HKI 272 was stopped and a treatment with a combination of Xeloda (3 600 mg/day, from Day 1 to Day 14, every 21 days) and Lapatinib (1 250 mg/day) began. At the beginning of this treatment, the patient showed a rapid disease progression and demonstrated a degraded health. Lapatinib, an anti-HER1 and -HER2 inhibitor, was justified, even if no mutation was detected in EGFR, because EGF overexpressed 15 folds in the patient and it was needed to continue HKI 272. Indeed, overexpression of EGF in the tumor induces a constant activation of EGFR, that is why it appeared logic to assure the transition from HKI272 to another anti EGFR in order to cover the same spectra. Xeloda (score 555) was selected based on algorithm's score.
The disease was stable but recurrential paralysis was observed. Accordingly, in February 2009, it was decided to add Thiotepa which showed the highest algorithm score (score 713). After two months of treatment with the combination Xeloda (3 600 mg/day, 5 days by week, 3 weeks on 4 weeks), Lapatinib (1 250 mg/day) and Thiotepa (15-30 mg/day, Days 1 and 2, every 4 weeks), the disease was stable (FIG. 3). The disease was still stable for eleven months (FIG. 4), no more recurrential paralysis occurred and the patient showed a good general status.
In addition, the present method allows the determination of future therapeutic combinations. Indeed, during cancer treatment, resistance often appears. At least three others drugs showed high scores and can be used in case of resistance to the combination Xeloda, Lapatinib and Thiotepa, namely fotemustine (score 627), rituximab (score 761) and trabectidin (score 376).
By using the present method for selecting drugs, unexpected results were obtained. Indeed, without the score predicting the potential efficacy of a drug for a particular patient, the practitioner would not select both Xeloda and Thiotepa. Indeed, there is no indication for these drugs in lung cancer, in particular NSCLC. The present method allowed reaching fourteen months of stability with a good general status for the patient, whereas the vital prognosis was only of few weeks at the initiation of the treatment with the combination of Xeloda and Thiotepa.
In conclusion, the present example proves the value of the method of the present invention to help the practitioner to select appropriate drugs based on the individual data.
Retrospectively, the use of the new predicting method clearly demonstrated that all previous therapeutic lines, totally inefficient, were associated with a very low predictive score, as described. This is exactly the purpose of this innovative method, to be able to provide a predictive determination of the efficacy of drugs, and in this example, there is perfect validation of the concept, since all used inefficient drugs are linked with low score.
Other patients experiment the new procedure, and the high added value of the present method is to demonstrate that each patient needs a unique combination of drugs. The method appears therefore extremely relevant in the area of individualized selection of treatments.
Example 2
The patient was 64 years old. He suffered of a bronchial adenocarcinoma T4 with bones and pleural metastases. Two therapeutic lines have been used, namely cisplatin-Alimta and Tarceva. The first therapeutic line was associated with disease progression and the second was inefficient and led to a rapid progression.
A biopsy of normal bronchial mucosa and a tumoral biopsy were carried out and used for mutational analysis by sequencing, CGH, microRNAs analysis and Genome expression analysis.
CGH profile comprised numerous alteration (loss or gain), proving the tumoral status of the biopsy.
Mutational analysis including the genes as listed in Example 1 results in the identification of a mutation G464V in BRAF gene (B-Raf proto-oncogene serine/threonine-protein kinase, GeneID 673). This mutation is postulated to be activating with intrinsic mitotic signalisation. Therefore, a treatment with sorafenib could be contemplated.
Based on Genome Expression analysis, scores have been calculated as detailed in Example 1 and are shown in the following table only for some relevant drugs.
|
Avg
Avg
|
Target
Found
Found Targets List
Abs
Abs (FC)
|
Chemical
Genes
Target Genes List
Targets
(with fold-changes)
(FC)
UP-REG
Score
|
|
|
TIPIFARNIB
4
ABCB1 CYP3A4 CYP3A5
2
CYP3A4 (17.99)
20.73
20.73
1036
|
(Zarnestra)
UGT1A1
(2 + 0)
CYP3A5 (23.46)
|
(50.0%)
|
BEVACIZUMAB
1
VEGFA
1
VEGFA (2.30, 7.27,
4.58
4.58
457
|
(Avastin)
(1 + 0)
4.15)
|
(100.0%)
|
AFLIBERCEPT
1
VEGFA
1
VEGFA (2.30, 7.27,
4.58
4.58
457
|
(VEGF Trap)
(1 + 0)
4.15)
|
(100.0%)
|
IFOSFAMIDE
11
BCL2, CASP9, CYP2A6,
4
CYP3A4 (17.99)
14.82
20.73
376
|
(Cyfos, Holoxan,
CYP2B6, CYP3A4, CYP3A5,
(2 + 2)
CYP3A5 (23.46)
|
1000, IFEX,
DNMT1, GSTM1, GSTP1,
(36.4%)
BCL2 (−4.42) CYP2B6 (−13.41)
|
Ifex/Mesnex Kit,
GSTT1, SLC34A1
|
Ifosfamide/Mesna Kit,
|
Isoendoxan, Mitoxana,
|
Naxamide)
|
ECTEINASCIDIN 743
4
CCNA2 CCNB1 CCNB2 E2F1
3
CCNA2 (4.55) CCNB1
4.24
4.24
317
|
(Trabectedin, ET-743,
(3 + 0)
(2.95) CCNB2 (5.21)
|
Yondelis)
(75.0%)
|
VINORELBINE
7
CASP3 CDKN2A PTGS2
3
PTGS2 (17.97)
7.46
10.16
290
|
(Navelbine, Navelbine
RALBP1 RBM17 SLC29A1
(2 + 1)
SLC29A1 (2.36)
|
Base)
TUBB2A
(42.9%)
TUBB2A (−2.05)
|
—
—
—
—
—
—
—
—
|
PEMETREXED
10
DHFR FAS FPGS GART GGH
4
DHFR (2.40, 2.26)
3.91
3.91
156
|
(Alimta)
RBM17 SLC19A1 TP53 TYMP
(4 + 0)
GART (3.29) SLC19A1
|
TYMS
(40.0%)
(4.68) TYMS (5.32)
|
—
—
—
—
—
—
—
—
|
GEFITINIB
57
ABCG2 ADORA1 AKT1 AREG
18
AREG (6.94) CYP3A4
6.69
7.42
143
|
(Iressa, Irressat,
AVEN CASP3 CGRRF1
(11 + 7)
(17.99) CYP3A5 (23.46)
|
Tarceva)
COL4A3BP CORO1C CYP1A2
(31.6%)
DUSP3 (3.18) EPOR
|
CYP2C19 CYP2C9 CYP2D6
(2.02, 2.11) IFI6 (3.79)
|
CYP2F1 CYP3A4 CYP3A5
NPTX2 (2.77) PHLDA2
|
DUSP3 DUSP9 E2F1 EGF
(5.98) PLBD1 (8.04) SKI
|
EGFR EPOR EPS15 ERBB2
(2.09) TYMS (5.32)
|
EREG ESR1 FGF6 GADD45A
CYP2C9 (−2.94) CYP2F1
|
GADD45G GARS GCLC GNB2
(−27.19, −7.80) EGF (−2.04)
|
GUCY2D HBEGF IFI6 IGFBP3
EGFR (−3.99)
|
IL8 LEPR MAPK1 MAPK3 MLH1
GADD45G (−3.12) GCLC
|
NFKB1 NPTX2 NRL OSMR
(−2.59) LEPR (−6.56)
|
PARP1 PHLDA2 PLBD1 PTEN
|
QSOX1 RBM7 RPA1 SFN SKI
|
TGFA TNFRSF1B TYMS
|
—
—
—
—
—
—
—
—
|
CISPLATIN
403
A2M ABCB1 ABCC1 ABCC2
137
ABHD2 (2.30, 2.58)
5.94
5.17
80
|
(Abiplatin,
ABCC5 ABHD11 ABHD2 ABR
(63 + 71 + 3)
ADAM10 (2.01) BACH1
|
Biocisplatinum,
ACSL3 ADAM10 ADFP
(34.0%)
(2.09) BAX (2.02) BBC3
|
Briplatin, Carboquone,
ADORA2B AHCYL1 AKAP12
(2.35) BCAM (2.00)
|
Cis Pt II, Cismaplat,
AKR1B1 AKT1 AKT2 AKT3 ALB
BIRC2 (2.06) BIRC3
|
Cisplatine, Cisplatyl,
ANXA1 APEX1 ARF6 ARHGEF6
(4.00) BIRC5 (12.70)
|
Citoplationo,
ARID5B ARMCX2 ASS1 ASTN1
CCNE1 (3.18) CDKN1A
|
Lederplatin, Neoplatin,
ATP6V1G2 AXL B3GALT4
(2.33) CILP (4.39)
|
Plastin, Platamine,
BACH1 BAX BBC3 BCAM
CNTNAP2 (20.81)
|
Platiblastin, Platidiam,
BCAS4 BCL2 BCL2L1 BCL2L12
CYP3A4 (17.99) DAB2
|
Platinex, Platinol,
BIRC2 BIRC3 BIRC5 BMP7
(2.33) DKK1 (51.55)
|
Platinol-AQ,
BTG2 C11ORF68 C11ORF9
ETV4 (2.96) FADS1
|
Platinoxan, Randa)
C19ORF2 C4ORF29 C7ORF16
(2.31, 2.17) FANCC
|
CA2 CALCB CASP2 CASP3
(2.05) FEN1 (2.99, 3.13)
|
CASP8 CASP9 CAT CAV1
FOS (32.01) GDF15
|
CCDC85B CCNE1 CCNG2
(14.33) GLRX2 (2.53)
|
CD151 CD55 CDC40 CDH3
GSTM3 (2.04) HHEX
|
CDKL5 CDKN1A CDKN2AIP
(3.59) HPCAL1 (2.96)
|
CELSR2 CES2 CFHR1 CFLAR
IFI30 (2.79) JUN (2.41)
|
CIAPIN1 CIDEB CILP CKMT1B
KLK3 (2.11) LANCL1
|
CLU CNTF CNTNAP2 COL11A2
(2.60) LAPTM4B (3.54,
|
COL4A5 CORO1C CREBBP
3.75) MAP2K6 (2.32)
|
CTAGE4 CTDSP1 CTH
MED21 (2.11) MEST
|
CTNNAL1 CYCS CYP2C9
(8.01) MMP15 (3.00)
|
CYP3A4 D6S2723E DAB2
MMP16 (3.26) NCOA3
|
DDIT3 DDR1 DENND4A
(2.54) NMI (2.13) NMU
|
DEPDC6 DIABLO DKK1 DMBT1
(2.49) NR4A1 (3.47)
|
DPYD DRAP1 DST EDN2
NUDT1 (2.01) PDXK
|
EDNRA EGFR ELMO2 EMP3
(3.48, 2.73, 2.41)
|
ENPP2 EP300 ERBB2 ERCC1
PMAIP1 (3.68) PRKCI
|
ERCC2 ETV4 F8A3 FADD
(2.83, 2.64) PTGS2
|
FADS1 FAM129A FAM13A1
(17.97) PXDN (3.61,
|
FAM46A FANCC FANCG FAS
4.00) RNASET2 (2.15)
|
FASLG FASN FEN1 FGF7
RNF34 (2.28) SDC2
|
FGF9 FGFR2 FGFR3 FKBP2
(3.25) SLC29A1 (2.36)
|
FMOD FOS FOSL1 FOXC1
SP1 (2.15, 2.24) SPON1
|
FTLL1 GADD45A GALNT7
(2.57) STEAP1 (2.90,
|
GARS GAS1 GCLC GCLM
3.34, 2.83) STYX (2.41)
|
GCNT1 GCNT2 GDF15 GLRX2
TANK (2.02) TERT
|
GMPPA GOLGA8A GOLGA8B
(2.54) TP53I3 (3.40)
|
GOLSYN GPAA1 GPX3 GSTM1
TPI1 (2.88) TRAM1
|
GSTM2 GSTM3 GSTO1 GSTP1
(2.56) TRIB3 (2.05, 2.13)
|
GSTT1 GUCY1B3 GUK1 HERV-
TYMS (5.32) UPK1B
|
FRD HHEX HIF1A HLA-A HLA-
(2.08) VEGFA (2.30,
|
DPA3 HLA-G HNRNPA1
7.27, 4.15)
|
HPCAL1 HSD17B8 HSPB1
A2M (−7.98) ABCC5 (−2.30,
|
HSPE1 HTRA2 ICAM1 ID4 IFI30
−2.38) ANXA1 (−2.14)
|
IFITM1 IGFBP3 IGFBP5
ARHGEF6 (−2.10)
|
IL13RA1 IL1B IL1R1 IL4R IL6
ARID5B (−2.58, −2.20, −2.04)
|
ITGA9 ITGAE ITGB4 ITPA JUN
BCL2 (−4.42) BTG2
|
KCNA5 KCNK1 KLF2 KLK1
(−2.33) CA2 (−3.62)
|
KLK10 KLK11 KLK12 KLK15
CDH3 (−4.12) CELSR2 (−2.39)
|
KLK2 KLK3 KLK4 KLK5 KLK6
CES2 (−2.61)
|
KLK7 KLK8 KLK9 KRT17
CIDEB (−2.19) CLU (−8.31)
|
KRT19 KRT4 LANCL1
COL4A5 (−2.74)
|
LAPTM4B LASS4 LEPREL1
CTNNAL1 (−4.41)
|
LIMCH1 LOH11CR2A LTBP1
CYP2C9 (−2.94) DDR1 (−2.50,
|
M6PRBP1 MACF1 MAD2L2
−2.46) DMBT1 (−31.82)
|
MAGED2 MAL MAP2K6 MCM2
DPYD (−4.02, −3.55)
|
MED1 MED21 MEST MGMT
DST (−3.08, −14.93)
|
MLL MMP10 MMP15 MMP16
EGFR (−3.99) FAM129A
|
MMP3 MPO MPP2 MRPS27
(−11.54, −14.34) FGF7 (−6.10,
|
MT1A MT1F MT2A MT3 MVP
−6.45, −2.30) FGF9
|
MYC NAB1 NAIP NCOA3
(−2.12) FGFR2 (−15.60, −8.81)
|
NDUFS8 NEAT1 NEDD9 NMI
8.81) FGFR3 (−3.11, −7.43)
|
NMU NOTCH2 NOTCH4 NR1I2
FMOD (−2.27)
|
NR4A1 NTHL1 NUDT1 OPTN
FOXC1 (−3.90, −4.46)
|
P4HA2 PAFAH1B3 PAPPA2
GAS1 (−2.36) GCLC (−2.59)
|
PARD6A PARP1 PAX8 PBX1
GCLM (−3.92)
|
PCNA PDIA3 PDXK PFDN5
GOLGA8A (−3.47, −2.17)
|
PFKFB4 PFKP PGK1 PHIP
GOLSYN (−3.18) GSTM2
|
PHLDA1 PLP2 PMAIP1 PMPCA
(−3.53) HLA-A (−2.18)
|
PMS2L11 POLA1 POP4 PPIE
ID4 (−2.25) ITGA9 (−2.61)
|
PPP1R1B PPP3CB PRKCI
KLK10 (−5.32, −12.20)
|
PRKDC PRNP PRODH PROS1
KLK11 (−51.60) KLK12 (−21.92)
|
PSMB10 PTEN PTGS1 PTGS2
KRT19 (−2.14)
|
PTK2 PXDN QSOX1 RAB40B
KRT4 (−11.12) LASS4 (−2.24)
|
RAD21 RALB RALBP1 RASSF1
LIMCH1 (−2.87)
|
RB1 RBCK1 RBM9 RBP1 RELA
LTBP1 (−2.35) MACF1 (−2.02)
|
RHOC RING1 RNASET2 RNF34
MAL (−12.81)
|
RPL21 RPL36 RPL6 RPS14
MMP10 (−62.97) MT3 (−13.83,
|
RPS18 RPS4Y2 RPS5 RRAGD
−2.32) NAIP (−2.67)
|
RUNX3 RXRB SCRN1 SDC2
PBX1 (−3.32, −3.26)
|
SERPINB4 SERPINE2 SFN
PHIP (−2.01) PHLDA1 (−3.12,
|
SH2B3 SH3BGRL3 SLC15A1
−2.49) PPP1R1B (−3.30)
|
SLC20A1 SLC29A1 SLC2A1
PTGS1 (−4.87)
|
SLC31A1 SLC39A7 SLC6A12
RRAGD (−2.48) RUNX3
|
SLC7A11 SLC7A8 SLPI
(−4.02) SERPINB4 (−7.72)
|
SNAP29 SNAPC3 SNRPA
SLC31A1 (−2.78, −2.75,
|
SOCS1 SOCS2 SOD2 SOD3
−2.79) SLPI (−10.90,
|
SP1 SP100 SP110 SPINT2
−12.82) SOD3 (−5.07)
|
SPON1 SPTLC2 STEAP1 STYX
SWAP70 (−2.00)
|
SULT1A1 SULT1A2 SWAP70
TF (−4.25, −4.55)
|
SYNJ2 TANK TERT TF TFAP2A
TNFSF10 (−3.01)
|
TFB1M TGFA TGFB1 TLR2
TUBB2A (−2.05) UCP2 (−2.53)
|
TMSL6 TNF TNFAIP3 TNFSF10
UGT1A6 (−16.01, −24.90)
|
TNFSF13 TP53 TP53I3 TP73
VAV3 (−7.76)
|
TPI1 TRADD TRAM1 TRAP1
WFDC2 (−14.33, −12.71)
|
TRIB3 TRIP13 TSPAN12
XPA (−2.62) XRCC1 (−2.80)
|
TUBA1A TUBB2A TXN
BCAS4 (2.21, −2.07)
|
TXNDC13 TXNRD1 TYMP
CYCS (−2.70, 2.03)
|
TYMS UCP2 UGDH UGT1A1
PRNP (−4.40, 2.43)
|
UGT1A3 UGT1A6 UMPS
|
UPK1B USP14 VAPAVAV3
|
VEGFA VPS52 WDR46 WFDC2
|
WWC1 XIAP XPA XRCC1
|
XRCC5 XRCC6 YARS ZFP36L1
|
ZFP36L2 ZNF192 ZNRD1
|
|
Accordingly, it can be observed that the drugs used in the two therapeutic lines, which did not provide therapeutic efficacy are associated with low scores, namely 80 for cisplatine, 156 for alimta and 143 for Tarceva. Accordingly, the method of the invention should avoid the choice of such treatments.
Since January 2010, Vinorelbine, associated with a score of 290, has been selected for treating the patient. At the beginning, the patient has a very worsened general status. Three months later, the disease was stable, then progressed. In conclusion, although the drug associated with the best score has not been selected, the selected drug showed efficacy, conferring three months survival.
Example 3
A patient was diagnosed in May 2007 for a primary bronchial adenocarcinoma with bilateral pulmonary metastases and asymptomatic cerebral metastases. A surgical treatment has been carried out in November 2008 and two therapeutic lines have been used, namely thirteen cycles of cisplatin-gemcitabin for the first line and Alimta for the second one. The first line was associated with a partial response followed by a disease progression and the second line was only associated with a disease progression.
A normal bronchial biopsy and a pulmonary metastasis biopsy were carried out and used for mutational analysis by sequencing, CGH, microRNAs analysis and Genome expression analysis.
CGH profile comprised numerous aberrations (loss and gain throughout the genome) demonstrating the tumoral status of the biopsy.
Mutational analysis including the genes as listed in Example 1 did not lead to the identification of any mutation.
Based on Genome Expression analysis, scores have been calculated as detailed in Example 1 and are shown in the following table only for some relevant drugs.
|
Avg
|
Abs
|
Avg
(FC)
|
Target
Found
Found Targets List (with
Abs
UP-
|
Chemical
Genes
Target Genes List
Targets
fold-changes)
(FC)
REG
Score
|
|
|
CARBOPLATIN
16
ALB BAX BCL2 BCL2L12 BIRC2
6
ALB (84.71) BAX (2.03)
16.14
29.85
559
|
(Paraplatin,
CASP3 CASP9 DCT DPYD ERBB2 FAS
(3 + 3)
PTGS2 (2.81)
|
Paraplatin-AQ)
PARP1 PCNA PTGS2 RBM17 TYMS
(37.5%)
CASP3 (−2.56) DPYD (−2.07)
|
FAS (−2.69)
|
BEVACIZUMAB
1
VEGFA
1
VEGFA (3.18, 3.55, 4.81,
3.84
3.84
384
|
(Avastin)
(1 + 0)
3.82)
|
(100.0%)
|
AFLIBERCEPT
1
VEGFA
1
VEGFA (3.18, 3.55, 4.81,
3.84
3.84
384
|
(VEGF Trap)
(1 + 0)
3.82)
|
(100.0%)
|
CEDIRANIB
2
FLT1 FLT4
1
FLT1 (4.36, 5.59)
4.98
4.98
248
|
(Recentin)
(1 + 0)
|
(50.0%)
|
AXITINIB
6
FLT1 FLT4 KDR KIT PDGFRA PDGFRB
3
FLT1 (4.36, 5.59)
4.68
4.68
234
|
(3 + 0)
PDGFRA (4.21, 3.56)
|
(50.0%)
PDGFRB (5.18)
|
CAMPTOTHECIN
57
ABCB1 AGRN ALB ANXA4 BAX BCL2
16
AGRN (2.26, 2.29, 2.11)
8.40
14.18
199
|
BID BIRC5 BRCA1 BRCA2 CAB39
(8 + 8)
ALB (84.71) BAX (2.03)
|
CASP2 CASP3 CCNB1 CDK2 CDKN1A
(28.1%)
LGALS1 (3.09) PLK3
|
CEACAM1 CEBPZ CTSB CYCS DPYD
(2.10) PPP1R1B (5.31)
|
EI24 EP300 EPM2AIP1 FDXR GSTP1
THBS1 (10.46, 9.80)
|
HNRNPC IL1B IL8 JUN LGALS1
VEGFA (3.18, 3.55, 4.81,
|
MAP2K3 MAP3K5 MAPK9 MAPT
3.82)
|
MDM2 NCK2 PARP1 PLK3 PPP1R1B
ABCB1 (−2.74) CASP3 (−2.56)
|
PRC1 RAD51 RB1 RBL1 RBL2 SDC1
DPYD (−2.07) FDXR
|
TAP1 TAX1BP3 THBS1 TNFSF9 TOP1
(−4.08) GSTP1 (−2.04)
|
TP53 TP53I3 TP53TG1 TYMS VEGFA
MDM2 (−2.46) TAP1 (−2.71)
|
XIAP
TP53TG1 (−2.28)
|
VINORELBINE
7
CASP3 CDKN2A PTGS2 RALBP1
4
CDKN2A (9.83, 6.61)
4.12
4.64
198
|
(Navelbine,
RBM17 SLC29A1 TUBB2A
(3 + 1)
PTGS2 (2.81) TUBB2A
|
Navelbine Base)
(57.1%)
(2.88)
|
CASP3 (−2.56)
|
GEMCITABINE
158
AGPAT2 ALDH1A3 ALDH6A1 ANAPC1
48
ANTXR1 (2.23, 2.64, 3.53)
6.60
6.60
129
|
(DDFC, DFDC,
ANK3 ANKRD1 ANTXR1 ARF1 ATF3
(31 + 17)
BAX (2.03) CLIC4 (2.63,
|
GEO, Gemcin,
BAIAP1 BAX BCL2 BCL2L1 BCL2L11
(30.4%)
2.54, 2.54) CTHRC1
|
Gemcitabina,
BCL6 BIRC2 BIRC3 BIRC5 BNIP3L
(19.05) DLG2 (3.80) ETV1
|
Gemcitabine,
C15ORF15 C1ORF144 C4ORF18
(3.09, 3.19) GAL3ST1
|
HCl, Gemcitabine
CASP3 CCL20 CCND1 CCNG2 CD40
(5.88) GAS1 (2.17) GPC3
|
hydrochloride,
CDA CDH1 CDKN1A CEBPB CKB
(3.00) HOXB2 (2.95, 2.38)
|
Gemcitabinum,
CLIC4 CMPK COX3 CSRP2 CTHRC1
IFIT1 (2.11) IL6 (2.67)
|
Gemtro, Gemzar)
CXCL1 CXCL2 CXCL3 CYP24A1 DDIT4
JAM3 (2.13, 2.01) KLF8
|
DHX9 DLG2 DNCH1 DPYD EDN2
(3.81) KRT8 (2.56, 2.55)
|
EGFR EGR1 ETV1 EVI2B FBXO25
MAF (2.66, 2.91) NEDD9
|
FGG FOSL2 FXYD3 GAL3ST1 GAS1
(3.66) NEU1 (2.80) NNMT
|
GLRX GPC3 GTF2A1 HDAC9 HIF1A
(3.15) NRP1 (2.03, 3.00,
|
HIST1H4B HIST1H4C HOXB2 HSPA1L
2.60) PLAU (9.25) RGS2
|
HSPA5 IFIT1 IL6 INSIG1 IQGAP1
(3.75) SCD (3.76, 3.04,
|
IRAK2 IRF3 ITSN2 JAM3 KCTD12 KLF8
3.90) SLC2A3 (4.22, 7.94)
|
KRT8 LARP5 LIFR LRRC28 LYZ MAF
SPP1 (70.93)
|
MAGEA10 MAGEC1 MAP17 MARCKS
TNFRSF11B (12.11, 8.17)
|
MARS MDM2 MGMT MXI1 MYB
TYRP1 (13.30) VEGFA
|
NCBP1 NEDD9 NEU1 NFKB2 NFKBIE
(3.18, 3.55, 4.81, 3.82)
|
NNMT NPEPPS NR4A3 NRG1 NRP1
WBP5 (2.13) ZNF274
|
P2RY5 PAQR8 PARP1 PCSK9 PDPK1
(3.73) ZNF521 (2.79)
|
PJA2 PLAU PPFIA4 PPP1R15A PSAT1
ANK3 (−3.59, −3.38, −3.62)
|
PTEN PTGS1 PTPN11 RAB8A RBM17
BIRC3 (−2.27)CASP3 (−2.56)
|
RELA RGS2 RNF149 RPL37 RRAGD
CCL20 (−10.90)
|
RRM1 SAT SCD SLC25A29 SLC29A1
CD40 (−2.36) CXCL1 (−47.43)
|
SLC2A14 SLC2A3 SLC43A3 SLITRK2
CXCL2 (−2.14, −5.83)
|
SPP1 SYNCRIP TCOF1 TERT TGFB2
CXCL3 (−4.04)
|
TNF TNFAIP3 TNFRSF11B TP53
CYP24A1 (−2.10) DPYD (−2.07)
|
TP53BP1 TP53INP1 TRAF1 TUBE1
FXYD3 (−2.79)
|
TYMP TYMS TYRP1 UBE2C UGGT2
HDAC9 (−4.09) LYZ (−7.83)
|
VEGFA VGF VLDLR WBP5 WNT5A
MDM2 (−2.46)
|
XIAP ZNF274 ZNF449 ZNF521
MGMT (−2.34) MYB (−8.21)
|
NRG1 (−2.47, −3.36)
|
CISPLATIN
403
A2M ABCB1 ABCC1 ABCC2 ABCC5
112
A2M (2.45) ABCC2 (4.03,
5.94
4.76
80
|
(Abiplatin,
ABHD11 ABHD2 ABR ACSL3 ADAM10
(68 + 43 + 1)
3.37) AKAP12 (2.40)
|
Biocisplatinum,
ADFP ADORA2B AHCYL1 AKAP12
(27.8%)
AKT3 (3.10) ALB (84.71)
|
Briplatin,
AKR1B1 AKT1 AKT2 AKT3 ALB ANXA1
BAX (2.03) CA2 (2.50)
|
Carboquone, Cis
APEX1 ARF6 ARHGEF6 ARID5B
CCNE1 (3.72) CILP (3.81)
|
Pt II, Cismaplat,
ARMCX2 ASS1 ASTN1 ATP6V1G2 AXL
COL11A2 (21.07) DAB2
|
Cisplatine,
B3GALT4 BACH1 BAX BBC3 BCAM
(2.64) DKK1 (6.38)
|
Cisplatyl,
BCAS4 BCL2 BCL2L1 BCL2L12 BIRC2
EDNRA (2.53, 2.37)
|
Citoplationo,
BIRC3 BIRC5 BMP7 BTG2 C11ORF68
ENPP2 (2.36) ERCC2
|
Lederplatin,
C11ORF9 C19ORF2 C4ORF29
(2.03) FADS1 (3.44, 3.92)
|
Neoplatin,
C7ORF16 CA2 CALCB CASP2 CASP3
FANCC (2.22) FASN
|
Plastin,
CASP8 CASP9 CAT CAV1 CCDC85B
(2.36) FGF7 (2.19, 3.31,
|
Platamine,
CCNE1 CCNG2 CD151 CD55 CDC40
2.06, 2.66) FMOD (2.38)
|
Platiblastin,
CDH3 CDKL5 CDKN1A CDKN2AIP
GARS (2.10) GAS1 (2.17)
|
Platidiam,
CELSR2 CES2 CFHR1 CFLAR
GCNT1 (2.06) GDF15
|
Platinex, Platinol,
CIAPIN1 CIDEB CILP CKMT1B CLU
(3.10) GPX3 (2.08)
|
Platinol-AQ,
CNTF CNTNAP2 COL11A2 COL4A5
GSTM1 (4.71) GSTM3
|
Platinoxan,
CORO1C CREBBP CTAGE4 CTDSP1
(5.35, 5.57) GUCY1B3
|
Randa)
CTH CTNNAL1 CYCS CYP2C9
(2.65) HHEX (2.27)
|
CYP3A4 D6S2723E DAB2 DDIT3 DDR1
HPCAL1 (2.54) ICAM1
|
DENND4A DEPDC6 DIABLO DKK1
(5.72) ID4 (2.59) IGFBP3
|
DMBT1 DPYD DRAP1 DST EDN2
(2.97, 2.56) IGFBP5 (3.91,
|
EDNRA EGFR ELMO2 EMP3 ENPP2
2.60, 2.94) IL13RA1 (2.10,
|
EP300 ERBB2 ERCC1 ERCC2 ETV4
2.42) IL1R1 (2.41, 2.24)
|
F8A3 FADD FADS1 FAM129A
IL6 (2.67) ITGA9 (3.20,
|
FAM13A1 FAM46A FANCC FANCG
4.54) KLK8 (4.87) LIMCH1
|
FAS FASLG FASN FEN1 FGF7 FGF9
(2.71, 2.26) LTBP1 (2.86)
|
FGFR2 FGFR3 FKBP2 FMOD FOS
MACF1 (3.18, 3.43) MAL
|
FOSL1 FOXC1 FTLL1 GADD45A
(2.83) MEST (5.64)
|
GALNT7 GARS GAS1 GCLC GCLM
MMP15 (3.05) MMP16
|
GCNT1 GCNT2 GDF15 GLRX2 GMPPA
(3.43) NEDD9 (3.66)
|
GOLGA8A GOLGA8B GOLSYN GPAA1
PAFAH1B3 (2.04) PAX8
|
GPX3 GSTM1 GSTM2 GSTM3 GSTO1
(2.17) PFKFB4 (2.76)
|
GSTP1 GSTT1 GUCY1B3 GUK1
PPP1R1B (5.31) PRKCI
|
HERV-FRD HHEX HIF1A HLA-A HLA-
(2.31, 2.39) PRODH
|
DPA3 HLA-G HNRNPA1 HPCAL1
(3.77) PTGS2 (2.81)
|
HSD17B8 HSPB1 HSPE1 HTRA2
PXDN (10.10, 19.71)
|
ICAM1 ID4 IFI30 IFITM1 IGFBP3
SCRN1 (2.76) SDC2
|
IGFBP5 IL13RA1 IL1B IL1R1 IL4R IL6
(3.16) SERPINE2 (2.63)
|
ITGA9 ITGAE ITGB4 ITPA JUN KCNA5
SLC39A7 (3.59) SPINT2
|
KCNK1 KLF2 KLK1 KLK10 KLK11
(2.47) SPON1 (2.80)
|
KLK12 KLK15 KLK2 KLK3 KLK4 KLK5
STYX (2.12) SWAP70
|
KLK6 KLK7 KLK8 KLK9 KRT17 KRT19
(2.36) TGFB1 (2.40)
|
KRT4 LANCL1 LAPTM4B LASS4
TRIB3 (8.75) TUBB2A
|
LEPREL1 LIMCH1 LOH11CR2A LTBP1
(2.88) VEGFA (3.18, 3.55,
|
M6PRBP1 MACF1 MAD2L2 MAGED2
4.81, 3.82) WWC1 (2.43)
|
MAL MAP2K6 MCM2 MED1 MED21
ABCB1 (−2.74) ABHD2 (−2.82,
|
MEST MGMT MLL MMP10 MMP15
−2.33, −2.55)
|
MMP16 MMP3 MPO MPP2 MRPS27
ADORA2B (−4.27) BIRC3
|
MT1A MT1F MT2A MT3 MVP MYC
(−2.27) CASP3 (−2.56)
|
NAB1 NAIP NCOA3 NDUFS8 NEAT1
CES2 (−2.08) CLU (−4.24)
|
NEDD9 NMI NMU NOTCH2 NOTCH4
COL4A5 (−3.24) DMBT1
|
NR1I2 NR4A1 NTHL1 NUDT1 OPTN
(−34.95) DPYD (−2.07) FAS
|
P4HA2 PAFAH1B3 PAPPA2 PARD6A
(−2.69) FGFR2 (−4.25, −4.25)
|
PARP1 PAX8 PBX1 PCNA PDIA3
FGFR3 (−2.10, −2.89)
|
PDXK PFDN5 PFKFB4 PFKP PGK1
FOXC1 (−2.51, −3.13)
|
PHIP PHLDA1 PLP2 PMAIP1 PMPCA
GCLC (−2.03) GCLM
|
PMS2L11 POLA1 POP4 PPIE
(−3.16, −2.98) GOLSYN (−3.36)
|
PPP1R1B PPP3CB PRKCI PRKDC
GSTP1 (−2.04) HLA-
|
PRNP PRODH PROS1 PSMB10 PTEN
A (−2.16, −2.37) HLA-G (−2.84)
|
PTGS1 PTGS2 PTK2 PXDN QSOX1
KLK10 (−3.75, −5.35)
|
RAB40B RAD21 RALB RALBP1
KLK11 (−10.49) KLK3 (−9.01)
|
RASSF1 RB1 RBCK1 RBM9 RBP1
KRT17 (−3.10) KRT4
|
RELA RHOC RING1 RNASET2 RNF34
(−4.61) MGMT (−2.34)
|
RPL21 RPL36 RPL6 RPS14 RPS18
MMP10 (−12.00) MT3 (−8.76)
|
RPS4Y2 RPS5 RRAGD RUNX3 RXRB
NAB1 (−2.03)
|
SCRN1 SDC2 SERPINB4 SERPINE2
NEAT1 (−2.29, −2.02) NMU
|
SFN SH2B3 SH3BGRL3 SLC15A1
(−7.07) PMAIP1 (−3.07)
|
SLC20A1 SLC29A1 SLC2A1 SLC31A1
PSMB10 (−3.25)
|
SLC39A7 SLC6A12 SLC7A11 SLC7A8
SERPINB4 (−71.70)
|
SLPI SNAP29 SNAPC3 SNRPA SOCS1
SLC31A1 (−2.06) SLPI (−17.09,
|
SOCS2 SOD2 SOD3SP1 SP100
−28.09) SOD2 (−2.54)
|
SP110 SPINT2 SPON1 SPTLC2
TF (−15.98, −17.72)
|
STEAP1 STYX SULT1A1 SULT1A2
TNFSF10 (−3.33) UGT1A6
|
SWAP70 SYNJ2 TANK TERT TF
(−8.88, −8.56) UPK1B (−28.60)
|
TFAP2A TFB1M TGFA TGFB1 TLR2
VAV3 (−4.99, −3.12)
|
TMSL6 TNF TNFAIP3 TNFSF10
WFDC2 (−20.20, −15.05)
|
TNFSF13 TP53 TP53I3 TP73 TPI1
DST (2.30, 2.14, 2.36, −2.86)
|
TRADD TRAM1 TRAP1 TRIB3 TRIP13
|
TSPAN12 TUBA1A TUBB2A TXN
|
TXNDC13 TXNRD1 TYMP TYMS UCP2
|
UGDH UGT1A1 UGT1A3 UGT1A6
|
UMPS UPK1B USP14 VAPA VAV3
|
VEGFA VPS52 WDR46 WFDC2 WWC1
|
XIAP XPA XRCC1 XRCC5 XRCC6
|
YARS ZFP36L ZFP36L2 ZNF192
|
ZNRD1
|
PEMETREXED
10
DHFR FAS FPGS GART GGH RBM17
1
FAS (−2.69)
2.69
0.00
0
|
(Alimta)
SLC19A1 TP53 TYMP TYMS
(0 + 1)
|
(10.0%)
|
|
First of all, the scores associated with the drugs used in the first and second therapeutic lines are low (Gemcitabin=129; cisplatine=80 and Alimta=0). Those scores are consistent with the observed clinical data.
However, based on this score table, avastin associated with a score of 384 has been selected. The treatment has begun in January 2010 and a major response has been observed after two treatment cycles, as showed with the scanners of FIG. 5. This major response validates the present method and the unquestionable benefit for the patient.
Example 4
The patient was 59 years old. He suffered of a non small cell bronchial carcinoma with adrenal metastases. Two therapeutic lines have been used, namely three cycles of cisplatin-Alimta and three cycles of taxotere-cisplatine-avastin. These therapeutic lines were associated with a first step of stabilization and then a step of disease progression.
Normal and tumoral bronchial biopsies were carried out and used for mutational analysis by sequencing, CGH, microRNAs analysis and Genome expression analysis.
CGH profile is shown in FIG. 6 and comprises chromosomal aberrations in chromosome 11.
Mutational analysis including the genes as listed in Example 1 did not lead to the identification of any mutation.
Based on Genome Expression analysis, scores have been calculated as detailed in Example 1 and are shown in the following table only for some relevant drugs.
|
Avg
|
Ab
|
Found Targets List
Avg
(FC)
|
Target
Found
(with fold-
Abs
UP-
|
Chemical
Genes
Target Genes List
Targets
changes)
(FC)
REG
Score
|
|
|
ECTEINASCIDIN
4
CCNA2 CCNB1 CCNB2 E2F1
4
CCNA2 (7.13)
5.13
5.13
512
|
743
(4 + 0)
CCNB1 (4.52)
|
(Trabectedin, ET-
(100.0%)
CCNB2 (4.00) E2F1
|
743, Yondelis)
(4.85)
|
GEMTUZUMAB
1
CD33
1
CD33 (2.02, 2.63)
2.33
2.33
232
|
(Mylotarg)
(1 + 0)
|
(100.0%)
|
HYDROXYUREA
26
BAX C13ORF34 CASP3 CCNA2 CCNB1
11
CCNA2 (7.13)
4.45
4.67
179
|
(Biosupressin,
CCND1 CCND2 CCND3 CCNE1 CCNG1
(10 + 1)
CCNB1 (4.52)
|
Droxia, Hidrix,
CDC25C CDCA8 CDKN1A CKS2 EDN3 FAS
(42.3%)
CCNE1 (2.56)
|
Hydrea, Hydreia,
KPNA2 MECOM PRC1 PSRC1 RRM1 RRM2
CDCA8 (4.40)
|
Hydura, Hydurea,
RUNX1 SNCA TP53 UBE2C
CDKN1A (2.35)
|
Litaler, Litalir,
KPNA2 (2.00)
|
Onco-Carbide,
PRC1 (3.28)
|
Oxyurea,
PSRC1 (2.71)
|
Ureaphil)
RRM2 (14.29, 5.77)
|
UBE2C (7.67)
|
BAX (−2.32)
|
—
—
—
—
—
—
—
—
|
DOCETAXEL
43
ABCB1 ABCC1 ABCC2 BAX BCL2 BCL2L1
15
ABCC1 (2.14)
3.56
3.87
107
|
(Taxotere)
BIRC5 BUB1B CASP3 CCNB1 CFLAR CSF2
(12 + 3)
ABCC2 (2.58, 3.19)
|
CYP19A1 CYP1B1 CYP3A4 DPYD ERBB2
(34.9%)
BIRC5 (8.83)
|
F2R GSTP1 HIF1A HRAS IL6 MAD2L1
BUB1B (8.66)
|
MAPK1 MAPK3 MDM2 PARP1 PGR POR
CCNB1 (4.52)
|
PTGS2 RAF1 RB1 SKP2 TNF TNFRSF10B
CYP1B1 (2.39) IL6
|
TP53 TUBB TUBB1 TYMP TYMS UMPS
(2.79) MAD2L1
|
VEGFA XIAP
(2.68) PTGS2 (3.78,
|
2.77) SKP2 (2.18)
|
TNFRSF10B (2.35)
|
TYMS (3.72)
|
BAX (−2.32) BCL2 (−2.35)
|
VEGFA (−2.35)
|
—
—
—
—
—
—
—
—
|
PEMETREXED
10
DHFR FAS FPGS GART GGH RBM17
3
DHFR (2.02, 2.20,
2.94
2.94
88
|
(Alimta)
SLC19A1 TP53 TYMP TYMS
(3 + 0)
2.69, 3.12)
|
(30.0%)
SLC19A1 (2.59)
|
TYMS (3.72)
|
—
—
—
—
—
—
—
—
|
VINORELBINE
7
CASP3 CDKN2A PTGS2 RALBP1 RBM17
2
CDKN2A (2.42,
2.87
2.87
81
|
(Navelbine,
SLC29A1 TUBB2A
(2 + 0)
2.51) PTGS2 (3.78,
|
Navelbine Base)
(28.6%)
2.77)
|
—
—
—
—
—
—
—
—
|
CISPLATIN
403
A2M ABCB1 ABCC1 ABCC2 ABCC5
59
ABCC1 (2.14)
4.23
5.04
48
|
(Abiplatin,
ABHD11 ABHD2 ABR ACSL3 ADAM10
(39 + 19 + 1)
ABCC2 (2.58, 3.19)
|
Biocisplatinum,
ADFP ADORA2B AHCYL1 AKAP12 AKR1B1
(14.6%)
BIRC3 (4.02) BIRC5
|
Briplatin,
AKT1 AKT2 AKT3 ALB ANXA1 APEX1 ARF6
(8.83) CA2 (2.25)
|
Carboquone, Cis Pt
ARHGEF6 ARID5B ARMCX2 ASS1 ASTN1
CCNE1 (2.56)
|
II, Cismaplat,
ATP6V1G2 AXL B3GALT4 BACH1 BAX
CDH3 (2.23)
|
Cisplatine, Cisplatyl
BBC3 BCAM BCAS4 BCL2 BCL2L1
CDKN1A (2.35)
|
Citoplationo,
BCL2L12 BIRC2 BIRC3 BIRC5 BMP7 BTG2
CREBBP (2.16)
|
Lederplatin,
C11ORF68 C11ORF9 C19ORF2 C4ORF29
CYP2C9 (2.09)
|
Neoplatin, Plastin,
C7ORF16 CA2 CALCB CASP2 CASP3
DDIT3 (2.09) DKK1
|
Platamine,
CASP8 CASP9 CAT CAV1 CCDC85B
(14.15) ETV4 (2.22)
|
Platiblastin,
CCNE1 CCNG2 CD151 CD55 CDC40 CDH3
FADS1 (2.84, 3.87)
|
Platidiam, Platinex
CDKL5 CDKN1A CDKN2AIP CELSR2 CES2
FEN1 (2.52, 2.70)
|
Platinol
CFHR1 CFLAR CIAPIN1 CIDEB CILP
FGFR3 (2.26, 3.09)
|
Platinol-AQ,
CKMT1B CLU CNTF CNTNAP2 COL11A2
ICAM1 (3.90)
|
Platinoxan, Randa)
COL4A5 CORO1C CREBBP CTAGE4
IGFBP5 (2.04) IL1B
|
CTDSP1 CTH CTNNAL1 CYCS CYP2C9
(4.60) IL6 (2.79)
|
CYP3A4 D6S2723E DAB2 DDIT3 DDR1
KRT17 (3.17)
|
DENND4A DEPDC6 DIABLO DKK1 DMBT1
MAP2K6 (3.28)
|
DPYD DRAP1 DST EDN2 EDNRA EGFR
MCM2 (3.84) MEST
|
ELMO2 EMP3 ENPP2 EP300 ERBB2
(2.74) MMP10
|
ERCC1 ERCC2 ETV4 F8A3 FADD FADS1
(70.58) MYC (2.42)
|
FAM129A FAM13A1 FAM46A FANCC
PAFAH1B3 (2.10)
|
FANCG FAS FASLG FASN FEN1 FGF7
PHLDA1 (2.20)
|
FGF9 FGFR2 FGFR3 FKBP2 FMOD FOS
PTGS2 (3.78, 2.77)
|
FOSL1 FOXC1 FTLL1 GADD45A GALNT7
PXDN (2.31)
|
GARS GAS1 GCLC GCLM GCNT1 GCNT2
SERPINB4 (2.63)
|
GDF15 GLRX2 GMPPA GOLGA8A
SFN (2.66)
|
GOLGA8B GOLSYN GPAA1 GPX3 GSTM1
SLC7A11 (2.22)
|
GSTM2 GSTM3 GSTO1 GSTP1 GSTT1
SOD2 (3.28)
|
GUCY1B3 GUK1 HERV-FRD HHEX HIF1A
SPON1 (2.86)
|
HLA-A HLA-DPA3 HLA-G HNRNPA1
TRIB3 (6.70)
|
HPCAL1 HSD17B8 HSPB1 HSPE1 HTRA2
TXNRD1 (2.49)
|
ICAM1 ID4 IFI30 IFITM1 IGFBP3 IGFBP5
TYMS (3.72)
|
IL13RA1 IL1B IL1R1 IL4R IL6 ITGA9 ITGAE
UGT1A6 (2.26,
|
ITGB4 ITPA JUN KCNA5 KCNK1 KLF2
2.11)
|
KLK1 KLK10 KLK11 KLK12 KLK15 KLK2
BAX (−2.32) BBC3 (−2.27)
|
KLK3 KLK4 KLK5 KLK6 KLK7 KLK8 KLK9
BCAM (−2.07)
|
KRT17 KRT19 KRT4 LANCL1 LAPTM4B
BCL2 (−2.35)
|
LASS4 LEPREL1 LIMCH1 LOH11CR2A
CASP8 (−3.17)
|
LTBP1 M6PRBP1 MACF1 MAD2L2
CD55 (−4.47) CILP
|
MAGED2 MAL MAP2K6 MCM2 MED1
(−2.53) FOS (−2.24)
|
MED21 MEST MGMT MLL MMP10 MMP15
KLK3 (−2.46) KRT4
|
MMP16 MMP3 MPO MPP2 MRPS27 MT1A
(−4.87) LEPREL1 (−2.15)
|
MT1F MT2A MT3 MVP MYC NAB1 NAIP
LIMCH1 (−2.07)
|
NCOA3 NDUFS8 NEAT1 NEDD9 NMI NMU
MLL (−2.34)
|
NOTCH2 NOTCH4 NR1I2 NR4A1 NTHL1
PRNP (−2.27)
|
NUDT1 OPTN P4HA2 PAFAH1B3 PAPPA2
PTGS1 (−2.24) SLPI
|
PARD6A PARP1 PAX8 PBX1 PCNA PDIA3
(−2.68, −2.32) SOD3
|
PDXK PFDN5 PFKFB4 PFKP PGK1 PHIP
(−2.54) SP100 (−2.51,
|
PHLDA1 PLP2 PMAIP1 PMPCA PMS2L11
−2.24) VEGFA
|
POLA1 POP4 PPIE PPP1R1B PPP3CB
(−2.35)
|
PRKCI PRKDC PRNP PRODH PROS1
DST (−3.26, 3.55)
|
PSMB10 PTEN PTGS1 PTGS2 PTK2 PXDN
|
QSOX1 RAB40B RAD21 RALB RALBP1
|
RASSF1 RB1 RBCK1 RBM9 RBP1 RELA
|
RHOC RING1 RNASET2 RNF34 RPL21
|
RPL36 RPL6 RPS14 RPS18 RPS4Y2 RPS5
|
RRAGD RUNX3 RXRB SCRN1 SDC2
|
SERPINB4 SERPINE2 SFN SH2B3
|
SH3BGRL3 SLC15A1 SLC20A1 SLC29A1
|
SLC2A1 SLC31A1 SLC39A7 SLC6A12
|
SLC7A11 SLC7A8 SLPI SNAP29 SNAPC3
|
SNRPA SOCS1 SOCS2 SOD2 SOD3 SP1
|
SP100 SP110 SPINT2 SPON1 SPTLC2
|
STEAP1 STYX SULT1A1 SULT1A2
|
SWAP70 SYNJ2 TANK TERT TF TFAP2A
|
TFB1M TGFA TGFB1 TLR2 TMSL6 TNF
|
TNFAIP3 TNFSF10 TNFSF13 TP53 TP53I3
|
TP73 TPI1 TRADD TRAM1 TRAP1 TRIB3
|
TRIP13 TSPAN12 TUBA1A TUBB2A TXN
|
TXNDC13 TXNRD1 TYMP TYMS UCP2
|
UGDH UGT1A1 UGT1A3 UGT1A6 UMPS
|
UPK1B USP14 VAPA VAV3 VEGFA VPS52
|
WDR46 WFDC2 WWC1 XIAP XPA XRCC1
|
XRCC5 XRCC6 YARS ZFP36L1 ZFP36L2
|
ZNF192 ZNRD1
|
—
—
—
—
—
—
—
—
|
BEVACIZUMAB
1
VEGFA
1
VEGFA (−2.35)
2.35
0.00
0
|
(Avastin)
(0 + 1)
|
(100.0%)
|
|
Accordingly, the following scores are associated with the drugs of the first and second therapeutic lines: cisplatine (48), Alimta (88), taxotere (107) and avastin (0). Those scores are consistent with the clinical data.
However, other drugs are associated with better scores, for instance Trabectedin (512), Gemtuzumab (232) and hydroxyuea (179).
Example 5
The patient suffered of a rhabdomyosarcoma with pulmonary metastases, proving that the present method is efficient to predict the therapeutic efficacy in any type of tumors. This is an evolutive metastatic disease derived from a fibromixoid sarcoma of a buttock muscle.
This initial tumor has been resected by curative surgery in 2006. Subsequently, the patient developed pleural mesothelial metastases in 2007. After six cycles of treatment with a combination of Alimta and cisplatine, with a really poor response, the patient was subjected to a pleuralectomy. A novel pulmonary metastatic lesion was then detected with complex location prohibiting any surgery.
Normal muscle biopsy and pulmonary metastasis biopsy were carried out and used for mutational analysis by sequencing, CGH and Genome expression analysis.
CGH profile showed an important amplification of chromosome 16. It corresponds to an amplification of the PDGA locus.
Mutational analysis including the genes as listed in Example 1 did not lead to the identification of any mutation.
Based on Genome Expression analysis, scores have been calculated as detailed in Example 1 and are shown in the following table only for some relevant drugs.
|
Avg
|
Target
Found
Found Targets List (with fold-
Avg
Abs (FC)
|
Chemical
Genes
Target Genes List
Targets
changes)
Abs (FC)
UP-REG
Score
|
|
|
VINORELBINE
6
CDKN2A PTGS2
1
CDKN2A (48.68)
48.68
48.68
811
|
(Navelbine,
RALBP1 RBM17
(1 + 0)
|
Navelbine
SLC29A1 TUBB2A
(16.7%)
|
Base)
|
TEGAFUR
5
CDA CYP2A6
1
TYMS (16.61)
16.61
16.61
332
|
(UFT)
DPYD TP53 TYMS
(1 + 0)
|
(20.0%)
|
NILOTINIB
5
ABL1 BCR KIT
2
BCR (5.91) PDGFRA (11.97, 10.80,
8.10
8.10
324
|
(Ketek)
PDGFRA PDGFRB
(2 + 0)
8.13)
|
(40.0%)
|
|
Remarkably, Nilotinib is associated with a high score of 324 and is known to be active on the pathway of PDGFRA and PDGFRB. Accordingly, the inventors studied more precisely the PDGF pathway and obtained the following results.
|
Primary seq.
Fold
|
name
Sequence Description
Change
Intensity 1
Intensity 2
Accession #
|
|
|
PDGFD
Platelet derived growth factor D
18.6
114.8
2142.4
NM_025208
|
PDGFRA
Platelet derived growth factor receptor, alpha
12.0
2072.6
24849.8
NM_006206
|
PDGFRA
Platelet derived growth factor receptor, alpha
10.8
819.6
8964.0
AA559881
|
PDGFRA
Platelet derived growth factor receptor, alpha
8.1
21.3
182.3
BC015186
|
PDGFA
Platelet derived growth factor alpha
7.7
591.2
4576.5
NM_002607
|
PDGFRL
Platelet derived growth factor receptor like
4.7
5397.2
25269.9
NM_006207
|
PDGFRB
Platelet derived growth factor receptor beta
3.2
3327.0
10558.3
NM_002609
|
PDGFC
Platelet derived growth factor C
1.1
23.1
23.7
NM_016205
|
PDGFC
Platelet derived growth factor C
−1.6
1028.7
615.7
NM_016205
|
PDGFB
Platelet derived growth factor beta
−3.7
375.2
101.8
NM_002608
|
|
A very significant activation can be observed.
CGH and Gene expression profiles corroborate to designate the PDGF pathway as an important driver of tumorogenesis for this lesion. Indeed, PDGF D is overexpressed 18 fold in tumor versus normal tissue and will activate receptor beta-beta. It is worthwhile to mention that PDGFRB is also overexpressed 3 fold. PDFGA is overexpressed 8 fold and receptor PDGFRA is overexpressed 10 fold.
Taken together, Nilotinib appears a good candidate of targeted therapies because it inhibits both receptors.
The patient is awaiting for regulatory authorization for Nilotinib treatment. His attending physician acknowledged this therapeutic choice.
In conclusion, the studied patients were all in therapeutic failure. For all of them, there was no more therapeutic choice, and their general status was prohibiting entering into clinical trials. Based upon written consentment and upon request of oncology doctors, this method was applied. The present method allows the association of low scores for the drugs used in the previous therapeutic lines, illustrating the good correlation between low scores and therapeutic efficiency. Retrospectively, experts may envision that use of inefficient drugs may have been avoided if such strategy would have been applied, saving time for the patient. It is important to note that the studied patients showed quite unique profiles, proving the potency of the concept for personalized medicine. Method can apply to any type of tumors as far as normal cells and tumoral cells of same histologic type can be compared for a patient. Another advantage is that the method can provide a solution with potential therapeutic benefit for all patients, whereas current methods based on companion tests can apply only for limited number of patients which harbour a given abnormality.
TABLE 1
|
|
Molecule
RefSeq
Description
Symbol
PMID
Interaction
|
|
METHOTREXATE
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
12576456, 15239124
drug efflux
|
member 1
|
METHOTREXATE
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
15718312
drug efflux
|
NM_019899; NM_019900
member 1
|
METHOTREXATE
NM_000392
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC2
11500505, 15864128
drug efflux
|
member 2
|
METHOTREXATE
NM_001105515; NM_005845
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC4
15454390
drug efflux
|
member 4
|
METHOTREXATE
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
17032904
drug efflux
|
METHOTREXATE
NM_000477
albumin
ALB
—
used as drug
|
carrier
|
METHOTREXATE
NM_001631
alkaline phosphatase, intestinal
ALPI
16598758
mesure drug
|
toxicity
|
METHOTREXATE
NM_004044
5-aminoimidazole-4-carboxamide ribonucleotide
ATIC
17410198
target
|
formyltransferase/IMP cyclohydrolase
|
METHOTREXATE
NM_000616
CD4 molecule
CD4
15476228
altered by MTX
|
METHOTREXATE
NM_001040059; NM_001251
CD68 molecule
CD68
15476228
altered by MTX
|
METHOTREXATE
NM_001145873; NM_001768; NM_171827
CD8a molecule
CD8A
15476228
altered by MTX
|
METHOTREXATE
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
12065438, 16837568
drug
|
metabolism
|
METHOTREXATE
NM_000791
dihydrofolate reductase
DHFR
14679136
resistance
|
METHOTREXATE
NM_012242
dickkopf homolog 1 (Xenopus laevis)
DKK1
17320366
unrelated
|
METHOTREXATE
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
15713801
hepatotoxicity
|
METHOTREXATE
NM_000201
intercellular adhesion molecule 1
ICAM1
15476228
altered by MTX
|
METHOTREXATE
NM_000584
interleukin 8
IL8
15476228
altered by MTX
|
METHOTREXATE
NM_002422
matrix metallopeptidase 3 (stromelysin 1,
MMP3
15476228
altered by MTX
|
progelatinase)
|
METHOTREXATE
NM_005957
5,10-methylenetetrahydrofolate reductase (NADPH)
MTHFR
17488658
polymorphisms
|
METHOTREXATE
NM_000254
5-methyltetrahydrofolate-homocysteine
MTR
16598758
polymorphisms
|
methyltransferase
|
METHOTREXATE
NM_000662
N-acetyltransferase 1 (arylamine N-acetyltransferase)
NAT1
16003948
target
|
METHOTREXATE
NM_003889; NM_022002; NM_033013
nuclear receptor subfamily 1, group I, member 2
NR1I2
12065438
|
METHOTREXATE
NM_002539
ornithine decarboxylase 1
ODC1
16598758
resistance
|
METHOTREXATE
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
17286800
apoptosis
|
marker
|
METHOTREXATE
NM_003981; NM_199413; NM_199414
protein regulator of cytokinesis 1
PRC1
17374387
|
METHOTREXATE
NM_000321
retinoblastoma 1
RB1
12972956, 14534726, 14679136
resistance
|
METHOTREXATE
NM_000450
selectin E
SELE
15476228
altered by MTX
|
METHOTREXATE
NM_194255
solute carrier family 19 (folate transporter), member 1
SLC19A1
14679136, 16505119, 17034785,
drug uptake
|
17410198
|
METHOTREXATE
NM_080669
solute carrier family 46 (folate transporter), member 1
SLC46A1
17475902
drug uptake
|
METHOTREXATE
NM_001001522; NM_003186
transgelin
TAGLN
17320366
unrelated
|
METHOTREXATE
NM_003254
TIMP metallopeptidase inhibitor 1
TIMP1
15476228
altered by MTX
|
METHOTREXATE
NM_001071
thymidylate synthetase
TYMS
15713801, 17410198
resistance
|
METHOTREXATE
NM_007019; NM_181799; NM_181800;
ubiquitin-conjugating enzyme E2C
UBE2C
17374387
|
NM_181801; NM_181802; NM_181803
|
METHOTREXATE
NM_000376; NM_001017535
vitamin D (1,25-dihydroxyvitamin D3) receptor
VDR
15713801
|
METHOTREXATE
NM_003882; NM_080838
WNT1 inducible signaling pathway protein 1
WISP1
17320366
unrelated
|
METHOTREXATE
NM_003392
wingless-type MMTV integration site family, member
WNT5A
17320366
unrelated
|
5A
|
PEMETREXED
NM_000791
dihydrofolate reductase
DHFR
—
target
|
PEMETREXED
NM_001018078; NM_004957
folylpolyglutamate synthase
FPGS
17575230
drug activation
|
PEMETREXED
NM_000819; NM_001136005; NM_001136006;
phosphoribosylglycinamide formyltransferase,
GART
—
target
|
NM_175085
phosphoribosylglycinamide synthetase,
|
phosphoribosylaminoimidazole synthetase
|
PEMETREXED
NM_003878
gamma-glutamyl hydrolase (conjugase,
GGH
17575230
|
folylpolygammaglutamyl hydrolase)
|
PEMETREXED
NM_001145547; NM_032905
RNA binding motif protein 17
RBM17
16061639
resistance
|
PEMETREXED
NM_194255
solute carrier family 19 (folate transporter), member 1
SLC19A1
16505119
drug uptake
|
PEMETREXED
NM_001113755; NM_001113756; NM_001953
thymidine phosphorylase
TYMP
17575230
|
PEMETREXED
NM_001071
thymidylate synthetase
TYMS
—
resistance
|
FLUDARABINE
NM_000022
adenosine deaminase
ADA
—
unrelated
|
FLUDARABINE
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
15059916, 15213310
resistance
|
FLUDARABINE
NM_001668; NM_178426; NM_178427
aryl hydrocarbon receptor nuclear translocator
ARNT
15213310
|
FLUDARABINE
NM_001127240; NM_001127241; NM_001127242;
BCL2 binding component 3
BBC3
16439685
|
NM_014417
|
FLUDARABINE
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
—
|
FLUDARABINE
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
11675354
|
FLUDARABINE
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
11675354
|
NM_033355; NM_033356; NM_033358
|
FLUDARABINE
NM_001237
cyclin A2
CCNA2
15059916
|
FLUDARABINE
NM_053056
cyclin D1
CCND1
15059916
altered by F-
|
ara-A
|
FLUDARABINE
NM_001238; NM_057182
cyclin E1
CCNE1
15059916
|
FLUDARABINE
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
16439685, 16
|
FLUDARABINE
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
15059916
altered by F-
|
ara-A
|
FLUDARABINE
NM_018947
cytochrome c, somatic
CYCS
15059916
death pathway
|
FLUDARABINE
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
15059916
death pathway
|
FLUDARABINE
—
—
ERK
15059916
resistance
|
FLUDARABINE
NM_000043; NM_152871; NM_152872;
Fas (TNF receptor superfamily, member 6)
FAS
11675354
|
NM_152873; NM_152874; NM_152875;
|
NM_152876; NM_152877
|
FLUDARABINE
NM_004864
growth differentiation factor 15
GDF15
16439677
|
FLUDARABINE
NM_001530; NM_181054
hypoxia inducible factor 1, alpha subunit (basic helix-
HIF1A
15213310
altered by F-
|
loop-helix transcription factor)
ara-A
|
FLUDARABINE
NM_003493
histone cluster 3, H3
HIST3H3
15059916
unrelated
|
FLUDARABINE
NM_175054
histone cluster 4, H4
HIST4H4
15059916
unrelated
|
FLUDARABINE
NM_002755
mitogen-activated protein kinase kinase 1
MAP2K1
15059916
resistance
|
FLUDARABINE
NM_030662
mitogen-activated protein kinase kinase 2
MAP2K2
15059916
|
FLUDARABINE
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
15213310
resistance
|
FLUDARABINE
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
15213310
resistance
|
FLUDARABINE
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
15059916
resistance
|
FLUDARABINE
NM_002592; NM_182649
proliferating cell nuclear antigen
PCNA
16439677
|
FLUDARABINE
—
—
PDCD8
15059916
|
FLUDARABINE
NM_016937
polymerase (DNA directed), alpha 1, catalytic subunit
POLA1
—
target
|
FLUDARABINE
NM_001033
ribonucleotide reductase M1
RRM1
—
target
|
FLUDARABINE
NM_007315; NM_139266
signal transducer and activator of transcription 1,
STAT1
—
altered by F-
|
91 kDa
ara-A
|
FLUDARABINE
NM_003844
tumor necrosis factor receptor superfamily, member
TNFRSF10A
14614459
|
10a
|
FLUDARABINE
NM_003842; NM_147187
tumor necrosis factor receptor superfamily, member
TNFRSF10B
14614459, 18092340
|
10b
|
FLUDARABINE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
16439677, 17226861, 18092340
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
FLUDARABINE
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
15213310
altered by F-
|
NM_001025369; NM_001025370;
ara-A
|
NM_001033756; NM_003376
|
FLUDARABINE
NM_001167
X-linked inhibitor of apoptosis
XIAP
15059916
altered by F-
|
ara-A
|
FLUDARABINE
NM_022470; NM_152240
zinc finger, matrin type 3
ZMAT3
16439685
|
FLUOROURACIL
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
12576456, 15239124
resistance
|
member 1
|
FLUOROURACIL
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
12576456
resistance
|
NM_019899; NM_019900
member 1
|
FLUOROURACIL
NM_032583; NM_033151; NM_145186
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC11
18310281
|
member 11
|
FLUOROURACIL
NM_001023587; NM_005688
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC5
19077464
resistance
|
member 5
|
FLUOROURACIL
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
12576456
|
FLUOROURACIL
NM_001608
acyl-Coenzyme A dehydrogenase, long chain
ACADL
15585135
|
FLUOROURACIL
NM_001116
adenylate cyclase 9
ADCY9
19219653
|
FLUOROURACIL
NM_001126
adenylosuccinate synthase
ADSS
15585135
|
FLUOROURACIL
NM_001130846; NM_001130847; NM_004208;
apoptosis-inducing factor, mitochondrion-associated, 1
AIFM1
16168113
death pathway
|
NM_145812; NM_145813
|
FLUOROURACIL
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
18794807
|
FLUOROURACIL
NM_001144
autocrine motility factor receptor
AMFR
16896004
|
FLUOROURACIL
NM_004037; NM_139156; NM_203404
adenosine monophosphate deaminase 2 (isoform L)
AMPD2
19219653
|
FLUOROURACIL
NM_000481
aminomethyltransferase
AMT
15585135
|
FLUOROURACIL
NM_012098
angiopoietin-like 2
ANGPTL2
17327601
altered by 5FU
|
FLUOROURACIL
NM_001657
amphiregulin
AREG
15067352
sensitivity
|
FLUOROURACIL
NM_001024226; NM_001024227; NM_001024228;
ADP-ribosylation factor 1
ARF1
18927307
|
NM_001658
|
FLUOROURACIL
NM_001697
ATP synthase, H+ transporting, mitochondrial F1
ATP5O
17327601
sensitivity
|
complex, O subunit
|
FLUOROURACIL
NM_000053; NM_001005918
ATPase, Cu++ transporting, beta polypeptide
ATP7B
18593893
|
FLUOROURACIL
NM_001188
BCL2-antagonist/killer 1
BAK1
18593893
|
FLUOROURACIL
NM_003658
BARX homeobox 2
BARX2
15585135
|
FLUOROURACIL
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
11062132, 15986848, 15996812,
death pathway
|
NM_138764; NM_138765
16168113, 18834353, 19015929
|
FLUOROURACIL
NM_033028
Bardet-Biedl syndrome 4
BBS4
16896004
|
FLUOROURACIL
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
14503796, 15940066, 15996812,
resistance
|
18949393, 19015929, 19084572
|
FLUOROURACIL
NM_001040668; NM_138639
BCL2-like 12 (proline rich)
BCL2L12
19015929
|
FLUOROURACIL
NM_004051; NM_203314; NM_203315
3-hydroxybutyrate dehydrogenase, type 1
BDH1
15585135
altered by 5FU
|
FLUOROURACIL
NM_003766
beclin 1, autophagy related
BECN1
16896004
|
FLUOROURACIL
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
15067352, 18714155
resistance
|
FLUOROURACIL
NM_016252
baculoviral IAP repeat-containing 6
BIRC6
18239605
|
FLUOROURACIL
NM_004052
BCL2/adenovirus E1B 19 kDa interacting protein 3
BNIP3
15067352
sensitivity
|
FLUOROURACIL
NM_004331
BCL2/adenovirus E1B 19 kDa interacting protein 3-like
BNIP3L
15067352
sensitivity
|
FLUOROURACIL
NM_033030; NM_197970
bol, boule-like (Drosophila)
BOLL
17327601
|
FLUOROURACIL
NM_001130914; NM_006806
BTG family, member 3
BTG3
16896004
|
FLUOROURACIL
NM_001007793; NM_004725
budding uninhibited by benzimidazoles 3 homolog
BUB3
15585135
altered by 5FU
|
(yeast)
|
FLUOROURACIL
—
—
C13ORF34
17374387
|
FLUOROURACIL
NM_001218; NM_206925
carbonic anhydrase XII
CA12
16896004
|
FLUOROURACIL
NM_001024649; NM_001746
calnexin
CANX
18678097
|
FLUOROURACIL
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
14757846
death pathway
|
FLUOROURACIL
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
12414664, 12414664, 18830594,
death pathway
|
14503796, 15585135, 16168113,
|
18608205, 18772588, 19084572
|
FLUOROURACIL
NM_001227; NM_033338; NM_033339;
caspase 7, apoptosis-related cysteine peptidase
CASP7
16168113
death pathway
|
NM_033340
|
FLUOROURACIL
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
12414664, 18830594, 15585135,
death pathway
|
NM_033355; NM_033356; NM_033358
16168113
|
FLUOROURACIL
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
12414664,
death pathway
|
15996812, 12414664, 18830594,
|
16168113, 19015929
|
FLUOROURACIL
NM_001237
cyclin A2
CCNA2
18383818
|
FLUOROURACIL
NM_053056
cyclin D1
CCND1
18930000
|
FLUOROURACIL
NM_001136017; NM_001136125; NM_001136126;
cyclin D3
CCND3
15067352, 18383818
resistance
|
NM_001760
|
FLUOROURACIL
NM_001238; NM_057182
cyclin E1
CCNE1
18930000
resistance
|
FLUOROURACIL
NM_057749
cyclin E2
CCNE2
15067352
|
FLUOROURACIL
NM_001761
cyclin F
CCNF
15067352
resistance
|
FLUOROURACIL
NM_004354
cyclin G2
CCNG2
15067352, 18754885
sensitivity
|
FLUOROURACIL
NM_001790; NM_022809
cell division cycle 25 homolog C (S. pombe)
CDC25C
19074854
|
FLUOROURACIL
NM_018101
cell division cycle associated 8
CDCA8
17374387
|
FLUOROURACIL
NM_001798; NM_052827
cyclin-dependent kinase 2
CDK2
18383818
|
FLUOROURACIL
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
15067352, 16168113, 18834353
sensitivity
|
FLUOROURACIL
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
18930000
|
FLUOROURACIL
NM_000076; NM_001122630; NM_001122631
cyclin-dependent kinase inhibitor 1C (p57, Kip2)
CDKN1C
15067352
sensitivity
|
FLUOROURACIL
NM_001114121; NM_001114122; NM_001274
CHK1 checkpoint homolog (S. pombe)
CHEK1
18698031
|
FLUOROURACIL
NM_020313
cytokine induced apoptosis inhibitor 1
CIAPIN1
18389626
|
FLUOROURACIL
NM_014430
cell death-inducing DFFA-like effector b
CIDEB
15585135
altered by 5FU
|
FLUOROURACIL
NM_001827
CDC28 protein kinase regulatory subunit 2
CKS2
17374387
|
FLUOROURACIL
NM_004859
clathrin, heavy chain (Hc)
CLTC
18927307
|
FLUOROURACIL
NM_001083914; NM_001329; NM_022802
C-terminal binding protein 2
CTBP2
18927307
|
FLUOROURACIL
NM_001332
catenin (cadherin-associated protein), delta 2 (neural
CTNND2
16896004
|
plakophilin-related arm-repeat protein)
|
FLUOROURACIL
NM_001905
CTP synthase
CTPS
19219653
|
FLUOROURACIL
NM_005231; NM_138565
cortactin
CTTN
15585135
altered by 5FU
|
FLUOROURACIL
NM_000762
cytochrome P450, family 2, subfamily A, polypeptide 6
CYP2A6
11376561
|
FLUOROURACIL
NM_001554
cysteine-rich, angiogenic inducer, 61
CYR61
15067352
resistance
|
FLUOROURACIL
NM_001098424; NM_004087
discs, large homolog 1 (Drosophila)
DLG1
18927307
|
FLUOROURACIL
NM_000110
dihydropyrimidine dehydrogenase
DPYD
15239142, 15737843, 15858133,
drug
|
15930747, 18600527, 16761622,
metabolism
|
18383874, 18443386,
|
18443386, 18299612, 18986760,
|
19020767, 15655543, 18619742,
|
18846242, 19093184, 19104657,
|
19105824, 19219653
|
FLUOROURACIL
NM_000798
dopamine receptor D5
DRD5
17327601
|
FLUOROURACIL
NM_012145
deoxythymidylate kinase (thymidylate kinase)
DTYMK
15067352
drug
|
metabolism
|
FLUOROURACIL
NM_001025248; NM_001025249; NM_001948
deoxyuridine triphosphatase
DUT
19015155
|
FLUOROURACIL
NM_001949
E2F transcription factor 3
E2F3
16896004
sensitivity
|
FLUOROURACIL
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15723263, 15737843, 15981280,
resistance
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
16098254, 18794807, 19217205
|
FLUOROURACIL
NM_001964
early growth response 1
EGR1
18757417
|
FLUOROURACIL
NM_014239
eukaryotic translation initiation factor 2B, subunit 2
EIF2B2
15585135
|
beta, 39 kDa
|
FLUOROURACIL
—
—
EIF3S3
15585135
|
FLUOROURACIL
NM_012155
echinoderm microtubule associated protein like 2
EML2
17327601
|
FLUOROURACIL
NM_001126123; NM_017512; NM_202758
enolase superfamily member 1
ENOSF1
18357371
|
FLUOROURACIL
NM_001098175; NM_001776
ectonucleoside triphosphate diphosphohydrolase 1
ENTPD1
19219653
|
FLUOROURACIL
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
15737843, 15940066, 18337622
resistance
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
FLUOROURACIL
NM_001042599; NM_005235
v-erb-a erythroblastic leukemia viral oncogene
ERBB4
16896004
|
homolog 4 (avian)
|
FLUOROURACIL
NM_001983; NM_202001
excision repair cross-complementing rodent repair
ERCC1
15737843, 17401013,
resistance
|
deficiency, complementation group 1 (includes
18448328, 15213713
|
overlapping antisense sequence)
|
FLUOROURACIL
NM_000400; NM_001130867
excision repair cross-complementing rodent repair
ERCC2
15213713, 17401013
|
deficiency, complementation group 2
|
FLUOROURACIL
NM_001034025; NM_006817
endoplasmic reticulum protein 29
ERP29
15585135
|
FLUOROURACIL
NM_001001998; NM_002685
exosome component 10
EXOSC10
18567802
|
FLUOROURACIL
NM_001993
coagulation factor III (thromboplastin, tissue factor)
F3
15067352
resistance
|
FLUOROURACIL
NM_000132; NM_019863
coagulation factor VIII, procoagulant component
F8
17327601
marker
|
microvessels
|
FLUOROURACIL
NM_004629
Fanconi anemia, complementation group G
FANCG
15067352
resistance
|
FLUOROURACIL
NM_000043; NM_152871; NM_152872;
Fas (TNF receptor superfamily, member 6)
FAS
15034078, 15585135, 19015929
death pathway
|
NM_152873; NM_152874; NM_152875;
|
NM_152876; NM_152877
|
FLUOROURACIL
NM_004111
flap structure-specific endonuclease 1
FEN1
15067352
resistance
|
FLUOROURACIL
NM_002009
fibroblast growth factor 7 (keratinocyte growth factor)
FGF7
18575591, 18708365, 15375550
resistance
|
FLUOROURACIL
NM_000141; NM_001144913; NM_001144914;
fibroblast growth factor receptor 2
FGFR2
18575591
|
NM_001144915; NM_001144916;
|
NM_001144917; NM_001144918;
|
NM_001144919; NM_022970
|
FLUOROURACIL
NM_022110
FK506 binding protein like
FKBPL
14503796
|
FLUOROURACIL
NM_001455; NM_201559
forkhead box O3
FOXO3
15067352
sensitivity
|
FLUOROURACIL
NM_001924
growth arrest and DNA-damage-inducible, alpha
GADD45A
15067352, 19003803
sensitivity
|
FLUOROURACIL
NM_000156; NM_138924
guanidinoacetate N-methyltransferase
GAMT
16896004
|
FLUOROURACIL
NM_000819; NM_001136005; NM_001136006;
phosphoribosylglycinamide formyltransferase,
GART
19219653
|
NM_175085
phosphoribosylglycinamide synthetase,
|
phosphoribosylaminoimidazole synthetase
|
FLUOROURACIL
NM_001145453; NM_005264; NM_145793
GDNF family receptor alpha 1
GFRA1
16896004
|
FLUOROURACIL
NM_005269
GLI family zinc finger 1
GLI1
18776995
|
FLUOROURACIL
NM_181077
golgi autoantigen, golgin subfamily a, 8A
GOLGA8A
17327601
|
FLUOROURACIL
NM_000852
glutathione S-transferase pi 1
GSTP1
15213713, 15737843
resistance
|
FLUOROURACIL
NM_000853
glutathione S-transferase theta 1
GSTT1
15585135
|
FLUOROURACIL
NM_000857
guanylate cyclase 1, soluble, beta 3
GUCY1B3
19219653
|
FLUOROURACIL
NM_005524
hairy and enhancer of split 1, (Drosophila)
HES1
19147571
|
FLUOROURACIL
NM_005340
histidine triad nucleotide binding protein 1
HINT1
15585135
|
FLUOROURACIL
NM_005320
histone cluster 1, H1d
HIST1H1D
15585135
|
FLUOROURACIL
NM_000189
hexokinase 2
HK2
18772588
|
FLUOROURACIL
—
—
HNRPC
15585135
|
FLUOROURACIL
NM_001540
heat shock 27 kDa protein 1
HSPB1
18949417, 19088045
|
FLUOROURACIL
NM_001541
heat shock 27 kDa protein 2
HSPB2
18757417
|
FLUOROURACIL
NM_002176
interferon, beta 1, fibroblast
IFNB1
18608205, 18695887
|
FLUOROURACIL
NM_000875
insulin-like growth factor 1 receptor
IGF1R
15499378
|
FLUOROURACIL
NM_001552
insulin-like growth factor binding protein 4
IGFBP4
16896004
|
FLUOROURACIL
NM_000634
interleukin 8 receptor, alpha
IL8RA
16098254
|
FLUOROURACIL
NM_001025242; NM_001025243; NM_001569
interleukin-1 receptor-associated kinase 1
IRAK1
15067352
resistance
|
FLUOROURACIL
—
—
JMJD2B
16896004
death pathway
|
FLUOROURACIL
NM_002229
jun B proto-oncogene
JUNB
18678097
|
FLUOROURACIL
NM_012289; NM_203500
kelch-like ECH-associated protein 1
KEAP1
18692501
|
FLUOROURACIL
NM_015443
KIAA1267
KIAA1267
18927307
|
FLUOROURACIL
NM_020853
KIAA1467
KIAA1467
16896004
|
FLUOROURACIL
NM_007054
kinesin family member 3A
KIF3A
16896004
|
FLUOROURACIL
NM_002266
karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
KPNA2
17374387
|
FLUOROURACIL
NM_004985; NM_033360
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
KRAS
15585135
|
FLUOROURACIL
NM_006499; NM_201543; NM_201544;
lectin, galactoside-binding, soluble, 8
LGALS8
17327601
|
NM_201545
|
FLUOROURACIL
NM_005573
lamin B1
LMNB1
15067352
resistance
|
FLUOROURACIL
NM_002355
mannose-6-phosphate receptor (cation dependent)
M6PR
15585135
|
FLUOROURACIL
NR_002819; NR_002819; NR_002819;
metastasis associated lung adenocarcinoma transcript
MALAT1
18927307
|
NR_002819; NR_002819; NR_002819
1 (non-protein coding)
|
FLUOROURACIL
NM_006785; NM_173844
mucosa associated lymphoid tissue lymphoma
MALT1
15067352
resistance
|
translocation gene 1
|
FLUOROURACIL
NM_002754
mitogen-activated protein kinase 13
MAPK13
15585135
|
FLUOROURACIL
NM_001123066; NM_001123067; NM_005910;
microtubule-associated protein tau
MAPT
16896004
|
NM_016834; NM_016835; NM_016841
|
FLUOROURACIL
NM_022132
methylcrotonoyl-Coenzyme A carboxylase 2 (beta)
MCCC2
18927307
|
FLUOROURACIL
NM_002393
Mdm4 p53 binding protein homolog (mouse)
MDM4
18678097
|
FLUOROURACIL
NM_015335
mediator complex subunit 13-like
MED13L
16896004
|
FLUOROURACIL
NM_014791
maternal embryonic leucine zipper kinase
MELK
16896004
|
FLUOROURACIL
NM_024042
meteorin, glial cell differentiation regulator
METRN
16896004
|
FLUOROURACIL
NM_002417
antigen identified by monoclonal antibody Ki-67
MKI67
15940066
sensitivity
|
FLUOROURACIL
NM_000249
mutL homolog 1, colon cancer, nonpolyposis
MLH1
18497967, 18949393
|
type 2 (E. coli)
|
FLUOROURACIL
NM_001127891; NM_004530
matrix metallopeptidase 2 (gelatinase A, 72 kDa
MMP2
18678097
|
gelatinase, 72 kDa type IV collagenase)
|
FLUOROURACIL
NM_001142418; NM_001142419; NM_001142420;
mortality factor 4 like 2
MORF4L2
18593893
|
NM_001142421; NM_001142422;
|
NM_001142423; NM_001142424;
|
NM_001142425; NM_001142426;
|
NM_001142427; NM_001142428; NM_001142429;
|
NM_001142430; NM_001142431;
|
NM_001142432; NM_012286
|
FLUOROURACIL
NM_000251
mutS homolog 2, colon cancer, nonpolyposis type 1
MSH2
18949393
|
(E. coli)
|
FLUOROURACIL
NM_005957
5,10-methylenetetrahydrofolate reductase (NADPH)
MTHFR
18633250, 19203896
|
FLUOROURACIL
NM_002467
v-myc myelocytomatosis viral oncogene homolog
MYC
15585135, 18802399
resistance
|
(avian)
|
FLUOROURACIL
NM_006311
nuclear receptor co-repressor 1
NCOR1
18927307
|
FLUOROURACIL
NM_004544
NADH dehydrogenase (ubiquinone) 1 alpha
NDUFA10
15585135
|
subcomplex, 10, 42 kDa
|
FLUOROURACIL
NM_001145412; NM_001145413; NM_006164
nuclear factor (erythroid-derived 2)-like 2
NFE2L2
18692501
|
FLUOROURACIL
NM_024522
Na+/K+ transporting ATPase interacting 1
NKAIN1
16896004
|
FLUOROURACIL
NM_020201
5′,3′-nucleotidase, mitochondrial
NT5M
19219653
|
FLUOROURACIL
NM_022731
nuclear casein kinase and cyclin-dependent kinase
NUCKS1
15585135
|
substrate 1
|
FLUOROURACIL
NM_001079524; NM_001079525; NM_006452
phosphoribosylaminoimidazole carboxylase,
PAICS
19219653
|
phosphoribosylaminoimidazole succinocarboxamide
|
synthetase
|
FLUOROURACIL
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
15996812, 16525653, 19084572
apoptosis
|
marker
|
FLUOROURACIL
NM_018908; NM_031501
protocadherin alpha 5
PCDHA5
15585135
|
FLUOROURACIL
NM_014891
PDGFA associated protein 1
PDAP1
15585135
|
FLUOROURACIL
NM_000926
progesterone receptor
PGR
15940066
|
FLUOROURACIL
NM_000944; NM_001130691; NM_001130692
protein phosphatase 3 (formerly 2B), catalytic subunit,
PPP3CA
15585135, 18927307
|
alpha isoform
|
FLUOROURACIL
NM_003981; NM_199413; NM_199414
protein regulator of cytokinesis 1
PRC1
17374387
altered by 5FU
|
FLUOROURACIL
NM_001081640; NM_006904
protein kinase, DNA-activated, catalytic polypeptide
PRKDC
18546291
|
FLUOROURACIL
NM_000311; NM_001080121; NM_001080122;
prion protein
PRNP
15386405
unrelated
|
NM_001080123; NM_183079
|
FLUOROURACIL
—
—
PSCD3
15585135
|
FLUOROURACIL
NM_002784
pregnancy specific beta-1-glycoprotein 9
PSG9
17327601
|
FLUOROURACIL
NM_001005290; NM_001032290; NM_001032291;
proline/serine-rich coiled-coil 1
PSRC1
17374387
unrelated
|
NM_032636
|
FLUOROURACIL
NM_000264; NM_001083602; NM_001083603;
patched homolog 1 (Drosophila)
PTCH1
18776995
|
NM_001083604; NM_001083605;
|
NM_001083606; NM_001083607
|
FLUOROURACIL
NM_012212
prostaglandin reductase 1
PTGR1
15585135
|
FLUOROURACIL
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
12414664, 18695918
|
G/H synthase and cyclooxygenase)
|
FLUOROURACIL
NM_002874
RAD23 homolog B (S. cerevisiae)
RAD23B
15067352
resistance
|
FLUOROURACIL
NM_005855
receptor (G protein-coupled) activity modifying protein 1
RAMP1
16896004
|
FLUOROURACIL
NM_000321
retinoblastoma 1
RB1
18383818, 18678097
|
FLUOROURACIL
NM_001135255; NM_001135256; NM_005610
retinoblastoma binding protein 4
RBBP4
18678097
|
FLUOROURACIL
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
19003803
|
(avian)
|
FLUOROURACIL
NM_001128617; NM_031922
RALBP1 associated Eps domain containing 1
REPS1
18927307
|
FLUOROURACIL
NM_025126; NM_194271
ring finger protein 34
RNF34
16270526
resistance
|
FLUOROURACIL
NM_000967; NM_001033853
ribosomal protein L3
RPL3
15585135
|
FLUOROURACIL
NM_001034
ribonucleotide reductase M2 polypeptide
RRM2
16896004
target
|
FLUOROURACIL
NM_001015055; NM_001015056; NM_033046
rhotekin
RTKN
15480428
resistance
|
FLUOROURACIL
NM_005980
S100 calcium binding protein P
S100P
18636193
|
FLUOROURACIL
NM_020974
signal peptide, CUB domain, EGF-like 2
SCUBE2
16896004
|
FLUOROURACIL
NM_001136528; NM_001136529; NM_001136530;
serpin peptidase inhibitor, clade E (nexin, plasminogen
SERPINE2
17327601
unrelated
|
NM_006216
activator inhibitor type 1), member 2
|
FLUOROURACIL
NM_006142
stratifin
SFN
15999354
|
FLUOROURACIL
NM_000193
sonic hedgehog homolog (Drosophila)
SHH
18776995
|
FLUOROURACIL
NM_001078174; NM_001078175; NM_001078176;
solute carrier family 29 (nucleoside transporters),
SLC29A1
18383843, 18992248
|
NM_001078177; NM_004955
member 1
|
FLUOROURACIL
NM_005631
smoothened homolog (Drosophila)
SMO
18776995
|
FLUOROURACIL
NM_003082
small nuclear RNA activating complex, polypeptide 1,
SNAPC1
15585135
|
43 kDa
|
FLUOROURACIL
NM_003090
small nuclear ribonucleoprotein polypeptide A′
SNRPA1
18927307
|
FLUOROURACIL
NM_003109; NM_138473
Sp1 transcription factor
SP1
18927307
|
FLUOROURACIL
NM_005417; NM_198291
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene
SRC
18794807
|
homolog (avian)
|
FLUOROURACIL
NM_003130; NM_198901
sorcin
SRI
18423116
|
FLUOROURACIL
NM_006282
serine/threonine kinase 4
STK4
18927307
|
FLUOROURACIL
NM_016169
suppressor of fused homolog (Drosophila)
SUFU
18776995
|
FLUOROURACIL
NM_030756
transcription factor 7-like 2 (T-cell specific, HMG-box)
TCF7L2
18678097
|
FLUOROURACIL
NM_005652
telomeric repeat binding factor 2
TERF2
15585135
|
FLUOROURACIL
NM_198253; NM_198255
telomerase reverse transcriptase
TERT
18396642
|
FLUOROURACIL
NM_003246
thrombospondin 1
THBS1
18757417
|
FLUOROURACIL
NM_018271
threonine synthase-like 2 (S. cerevisiae)
THNSL2
16896004
|
FLUOROURACIL
NM_004614
thymidine kinase 2, mitochondrial
TK2
19219653
|
FLUOROURACIL
NM_003265
toll-like receptor 3
TLR3
18779317
|
FLUOROURACIL
NM_021109
thymosin beta 4, X-linked
TMSB4X
16364925
|
FLUOROURACIL
—
—
TMSL8
15067352
|
FLUOROURACIL
NM_003842; NM_147187
tumor necrosis factor receptor superfamily, member
TNFRSF10B
17922852
death pathway
|
10b
|
FLUOROURACIL
NM_003810
tumor necrosis factor (ligand) superfamily, member 10
TNFSF10
19106633
|
FLUOROURACIL
NM_003808; NM_172087; NM_172088
tumor necrosis factor (ligand) superfamily, member 13
TNFSF13
18423122
|
FLUOROURACIL
NM_003286
topoisomerase (DNA) I
TOP1
18509181
|
FLUOROURACIL
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
18465341
|
FLUOROURACIL
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
15940066, 15999354, 16077963,
death pathway
|
NM_001126114; NM_001126115;
16168113, 18498133, 18600534,
|
NM_001126116; NM_001126117
18698031, 18779317, 18930000,
|
19015155, 12082016, 19106633
|
FLUOROURACIL
NM_001126240; NM_001126241; NM_001126242;
tumor protein p73
TP73
18714155
|
NM_005427
|
FLUOROURACIL
NM_000365; NM_001159287
triosephosphate isomerase 1
TPI1
18309519
|
FLUOROURACIL
NM_000367
thiopurine S-methyltransferase
TPMT
18927307
|
FLUOROURACIL
NM_006472
thioredoxin interacting protein
TXNIP
18930000
|
FLUOROURACIL
NM_001093771; NM_003330; NM_182729;
thioredoxin reductase 1
TXNRD1
19219653
|
NM_182742; NM_182743
|
FLUOROURACIL
NM_001113755; NM_001113756; NM_001953
thymidine phosphorylase
TYMP
15655543, 17454858
sensitivity
|
FLUOROURACIL
NM_001071
thymidylate synthetase
TYMS
15067352, 15213713, 15239142,
resistance
|
15737843, (following)
|
(following) 15788669, 18794807, 19020767, 15655543, 18633250, 18505590, 10482907, 18607850, 16168113, 17454858, 18425338, 18448328, 18490900, 18593893, 18383874,
|
18490900, 19105824, 18505590, 18600534, 18676755, 18722050, 19082493, 18661526, 18794807, 18986760, 18507058, 19074750, 19084572, 19219653, 19084572
|
FLUOROURACIL
NM_007019; NM_181799; NM_181800;
ubiquitin-conjugating enzyme E2C
UBE2C
17374387
|
NM_181801; NM_181802; NM_181803
|
FLUOROURACIL
NM_000463
UDP glucuronosyltransferase 1 family, polypeptide A1
UGT1A1
18797458
|
FLUOROURACIL
NM_000373
uridine monophosphate synthetase
UMPS
19020767, 19020740, 19082440,
|
19084572
|
FLUOROURACIL
NM_003362; NM_080911
uracil-DNA glycosylase
UNG
18714155
|
FLUOROURACIL
NM_003364; NM_181597
uridine phosphorylase 1
UPP1
15067352
sensitivity
|
FLUOROURACIL
NM_145052
uracil phosphoribosyltransferase (FUR1) homolog
UPRT
18575323
sensitivity
|
(S. cerevisiae)
|
FLUOROURACIL
NM_004182; NM_153477
ubiquitously-expressed transcript
UXT
15585135
|
FLUOROURACIL
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
18494554
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
FLUOROURACIL
—
—
WBSCR1
15585135
|
FLUOROURACIL
NM_017523; NM_199139
XIAP associated factor 1
XAF1
15843754
sensitivity
|
FLUOROURACIL
NM_021141
X-ray repair complementing defective repair in Chinese
XRCC5
18546291
|
hamster cells 5 (double-strand-break rejoining)
|
FLUOROURACIL
NM_001469
X-ray repair complementing defective repair in Chinese
XRCC6
18546291
|
hamster cells 6
|
FLUOROURACIL
NM_024493
zinc finger with KRAB and SCAN domains 3
ZKSCAN3
18519692
|
FLUOROURACIL
NM_001005368; NM_006973
zinc finger protein 32
ZNF32
17327601
|
FLUOROURACIL
NM_024762
zinc finger protein 552
ZNF552
16896004
|
FLUOROURACIL
NM_144690
zinc finger protein 582
ZNF582
17327601
|
FLUOROURACIL
NM_005089
zinc finger (CCCH type), RNA-binding motif and
ZRSR2
17327601
|
serine/arginine rich 2
|
CAPECITABINE
NM_001024649; NM_001746
calnexin
CANX
18678097
drug activation
|
CAPECITABINE
NM_001025194; NM_001025195; NM_001266
carboxylesterase 1 (monocyte/macrophage serine
CES1
15687373
drug activation
|
esterase 1)
|
CAPECITABINE
NM_003869; NM_198061
carboxylesterase 2 (intestine, liver)
CES2
15687373, 18473752
drug activation
|
CAPECITABINE
NM_024922
carboxylesterase 3
CES3
15687373
reverse toxicity
|
CAPECITABINE
NM_000110
dihydropyrimidine dehydrogenase
DPYD
18846242
|
CAPECITABINE
NM_002229
jun B proto-oncogene
JUNB
18678097
|
CAPECITABINE
NM_002393
Mdm4 p53 binding protein homolog (mouse)
MDM4
18678097
|
CAPECITABINE
NM_001127891; NM_004530
matrix metallopeptidase 2 (gelatinase A, 72 kDa
MMP2
18678097
|
gelatinase, 72 kDa type IV collagenase)
|
CAPECITABINE
NM_000321
retinoblastoma 1
RB1
18678097
|
CAPECITABINE
NM_001135255; NM_001135256; NM_005610
retinoblastoma binding protein 4
RBBP4
18678097
|
CAPECITABINE
NM_030756
transcription factor 7-like 2 (T-cell specific, HMG-box)
TCF7L2
18678097
|
CAPECITABINE
NM_001071
thymidylate synthetase
TYMS
—
resistance
|
GEMCITABINE
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
15770523
death pathway
|
NM_138764; NM_138765
|
GEMCITABINE
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
15770523
resistance
|
GEMCITABINE
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
15770523
death pathway
|
GEMCITABINE
NM_001785
cytidine deaminase
CDA
18728667
|
GEMCITABINE
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
15770523
sensitivity
|
GEMCITABINE
—
—
CMPK
—
sensitivity
|
GEMCITABINE
—
cytochrome c oxidase III
COX3
17428446
|
GEMCITABINE
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
15770523
altered by
|
DFDC
|
GEMCITABINE
NM_002613; NM_031268
3-phosphoinositide dependent protein kinase-1
PDPK1
16782806
resistance
|
GEMCITABINE
NM_001145547; NM_032905
RNA binding motif protein 17
RBM17
16061639
resistance
|
GEMCITABINE
NM_001033
ribonucleotide reductase M1
RRM1
—
resistance
|
GEMCITABINE
NM_001078174; NM_001078175; NM_001078176;
solute carrier family 29 (nucleoside transporters),
SLC29A1
18383843, 18490900,
drug uptake
|
NM_001078177; NM_004955
member 1
18728667, 18452103, 18992248,
|
18992248, 18383843
|
GEMCITABINE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
12082016
unrelated
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
GEMCITABINE
NM_001113755; NM_001113756; NM_001953
thymidine phosphorylase
TYMP
18728667
|
GEMCITABINE
NM_001071
thymidylate synthetase
TYMS
—
resistance
|
CYCLOPHOSPHAMIDE
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
12576456
resistance
|
member 1
|
CYCLOPHOSPHAMIDE
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
12576456
resistance
|
NM_019899; NM_019900
member 1
|
CYCLOPHOSPHAMIDE
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
12576456
resistance
|
CYCLOPHOSPHAMIDE
NM_001101
actin, beta
ACTB
12167460
|
CYCLOPHOSPHAMIDE
NM_000689
aldehyde dehydrogenase 1 family, member A1
ALDH1A1
12513786, 17403535, 17502835,
|
18496131
|
CYCLOPHOSPHAMIDE
NM_000690
aldehyde dehydrogenase 2 family (mitochondrial)
ALDH2
17403535
|
CYCLOPHOSPHAMIDE
NM_000691; NM_001135167; NM_001135168
aldehyde dehydrogenase 3 family, memberA1
ALDH3A1
18496131
|
CYCLOPHOSPHAMIDE
NM_001629
arachidonate 5-lipoxygenase-activating protein
ALOX5AP
17403535
|
CYCLOPHOSPHAMIDE
NM_001144
autocrine motility factor receptor
AMFR
16896004
|
CYCLOPHOSPHAMIDE
NM_001146
angiopoietin 1
ANGPT1
17403535
|
CYCLOPHOSPHAMIDE
NM_012068
activating transcription factor 5
ATF5
17403535
|
CYCLOPHOSPHAMIDE
NM_004323
BCL2-associated athanogene
BAG1
16322899
sensitivity
|
CYCLOPHOSPHAMIDE
NM_033028
Bardet-Biedl syndrome 4
BBS4
16896004
|
CYCLOPHOSPHAMIDE
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
11723234, 14503796, 15940066,
sensitivity
|
16322899
|
CYCLOPHOSPHAMIDE
NM_003766
beclin 1, autophagy related
BECN1
16896004
|
CYCLOPHOSPHAMIDE
NM_001197
BCL2-interacting killer (apoptosis-inducing)
BIK
17403535
|
CYCLOPHOSPHAMIDE
NM_001725
bactericidal/permeability-increasing protein
BPI
17403535
|
CYCLOPHOSPHAMIDE
NM_001130914; NM_006806
BTG family, member 3
BTG3
16896004
|
CYCLOPHOSPHAMIDE
NM_001007793; NM_004725
budding uninhibited by benzimidazoles 3 homolog
BUB3
16322899
sensitivity
|
(yeast)
|
CYCLOPHOSPHAMIDE
—
—
C13ORF27
17403535
|
CYCLOPHOSPHAMIDE
NM_001218; NM_206925
carbonic anhydrase XII
CA12
16896004
|
CYCLOPHOSPHAMIDE
NM_000067
carbonic anhydrase II
CA2
17403535
|
CYCLOPHOSPHAMIDE
NM_001223; NM_033292; NM_033293;
caspase 1, apoptosis-related cysteine peptidase
CASP1
17403535
|
NM_033294; NM_033295
(interleukin 1, beta, convertase)
|
CYCLOPHOSPHAMIDE
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
11723234, 14503796, 16675587
death pathway
|
CYCLOPHOSPHAMIDE
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
11723234
death pathway
|
CYCLOPHOSPHAMIDE
NM_005893
calicin
CCIN
17475930
|
CYCLOPHOSPHAMIDE
NM_005201
chemokine (C-C motif) receptor 8
CCR8
17403535
|
CYCLOPHOSPHAMIDE
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
16322899
sensitivity
|
CYCLOPHOSPHAMIDE
NM_001865
cytochrome c oxidase subunit VIIa polypeptide 2 (liver)
COX7A2
17403535
|
CYCLOPHOSPHAMIDE
NM_003650
cystatin F (leukocystatin)
CST7
17403535
|
CYCLOPHOSPHAMIDE
NM_001012329; NM_020248
catenin, beta interacting protein 1
CTNNBIP1
16322899
resistance
|
CYCLOPHOSPHAMIDE
NM_001332
catenin (cadherin-associated protein), delta 2 (neural
CTNND2
16896004
|
plakophilin-related arm-repeat protein)
|
CYCLOPHOSPHAMIDE
NM_004390; NM_148979
cathepsin H
CTSH
17403535
|
CYCLOPHOSPHAMIDE
—
—
CTSL
17403535
|
CYCLOPHOSPHAMIDE
NM_000104
cytochrome P450, family 1, subfamily B, polypeptide 1
CYP1B1
12167460
|
CYCLOPHOSPHAMIDE
—
—
CYP2B1
11933215, 16
|
CYCLOPHOSPHAMIDE
NM_000767
cytochrome P450, family 2, subfamily B, polypeptide 6
CYP2B6
10919648, 12498089, 11389073,
drug activation
|
12872138, 15248218,
|
15769884, 18633247, 18212249,
|
16322899, 17502835,
|
17502835, 16183265, 12872138,
|
18496131
|
CYCLOPHOSPHAMIDE
NM_000769
cytochrome P450, family 2, subfamily C, polypeptide
CYP2C19
15248218, 16116487, 17502835,
|
19
18496131
|
CYCLOPHOSPHAMIDE
NM_000771
cytochrome P450, family 2, subfamily C, polypeptide 9
CYP2C9
10991840, 18496131
|
CYCLOPHOSPHAMIDE
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
17502835, 18496131
|
CYCLOPHOSPHAMIDE
NM_000777
cytochrome P450, family 3, subfamily A, polypeptide 5
CYP3A5
17502835, 18496131
|
CYCLOPHOSPHAMIDE
NM_006094; NM_024767; NM_182643
deleted in liver cancer 1
DLC1
17403535
|
CYCLOPHOSPHAMIDE
NM_005494; NM_058246
DnaJ (Hsp40) homolog, subfamily B, member 6
DNAJB6
17475930
|
CYCLOPHOSPHAMIDE
NM_014934; NM_198968
DAZ interacting protein 1
DZIP1
17403535
|
CYCLOPHOSPHAMIDE
NM_001949
E2F transcription factor 3
E2F3
16896004
|
CYCLOPHOSPHAMIDE
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15981280
resistance
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
CYCLOPHOSPHAMIDE
NM_001412
eukaryotic translation initiation factor 1A, X-linked
EIF1AX
16322899
resistance
|
CYCLOPHOSPHAMIDE
NM_004095
eukaryotic translation initiation factor 4E binding
EIF4EBP1
16322899
resistance
|
protein 1
|
CYCLOPHOSPHAMIDE
NM_001135554; NM_001135555; NM_001431
erythrocyte membrane protein band 4.1-like 2
EPB41L2
17403535
|
CYCLOPHOSPHAMIDE
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
15834928, 15940066, 17010609
resistance
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
CYCLOPHOSPHAMIDE
NM_001042599; NM_005235
v-erb-a erythroblastic leukemia viral oncogene
ERBB4
16896004
|
homolog 4 (avian)
|
CYCLOPHOSPHAMIDE
NM_001136154; NM_001136155; NM_004449;
v-ets erythroblastosis virus E26 oncogene homolog
ERG
17403535
|
NM_182918
(avian)
|
CYCLOPHOSPHAMIDE
NM_000125; NM_001122740; NM_001122741;
estrogen receptor 1
ESR1
16322899
|
NM_001122742
|
CYCLOPHOSPHAMIDE
NM_001040275; NM_001040276; NM_001437
estrogen receptor 2 (ER beta)
ESR2
16322899
|
CYCLOPHOSPHAMIDE
NM_001993
coagulation factor III (thromboplastin, tissue factor)
F3
17403535
|
CYCLOPHOSPHAMIDE
NM_022110
FK506 binding protein like
FKBPL
14503796
|
CYCLOPHOSPHAMIDE
NM_003088
fascin homolog 1, actin-bundling protein
FSCN1
17403535
|
(Strongylocentrotus purpuratus)
|
CYCLOPHOSPHAMIDE
NM_002037; NM_153047; NM_153048
FYN oncogene related to SRC, FGR, YES
FYN
17403535
|
CYCLOPHOSPHAMIDE
NM_000156; NM_138924
guanidinoacetate N-methyltransferase
GAMT
16896004
|
CYCLOPHOSPHAMIDE
NM_001143830; NM_005256; NM_177553
growth arrest-specific 2
GAS2
17475930
|
CYCLOPHOSPHAMIDE
NM_001145453; NM_005264; NM_145793
GDNF family receptor alpha 1
GFRA1
16896004
|
CYCLOPHOSPHAMIDE
NM_000824
glycine receptor, beta
GLRB
17403535
|
CYCLOPHOSPHAMIDE
NM_018841
guanine nucleotide binding protein (G protein), gamma
GNG12
17403535
|
12
|
CYCLOPHOSPHAMIDE
NM_001039847; NM_001039848; NM_002085
glutathione peroxidase 4 (phospholipid
GPX4
17475930
|
hydroperoxidase)
|
CYCLOPHOSPHAMIDE
NM_145740
glutathione S-transferase alpha 1
GSTA1
12516103, 18496131
polymorphisms
|
CYCLOPHOSPHAMIDE
NM_000852
glutathione S-transferase pi 1
GSTP1
18496131
|
CYCLOPHOSPHAMIDE
NM_001520
general transcription factor IIIC, polypeptide 1, alpha
GTF3C1
16322899
resistance
|
220 kDa
|
CYCLOPHOSPHAMIDE
NM_002140; NM_031262; NM_031263
heterogeneous nuclear ribonucleoprotein K
HNRNPK
17475930
|
CYCLOPHOSPHAMIDE
NM_002162
intercellular adhesion molecule 3
ICAM3
17403535
|
CYCLOPHOSPHAMIDE
NM_001552
insulin-like growth factor binding protein 4
IGFBP4
16896004
|
CYCLOPHOSPHAMIDE
NM_000575
interleukin 1, alpha
IL1A
16636934
|
CYCLOPHOSPHAMIDE
NM_001137673; NM_004516; NM_012218;
interleukin enhancer binding factor 3, 90 kDa
ILF3
16322899
resistance
|
NM_017620; NM_153464
|
CYCLOPHOSPHAMIDE
NM_005544
insulin receptor substrate 1
IRS1
16322899
sensitivity
|
CYCLOPHOSPHAMIDE
—
—
JMJD2B
16896004
|
CYCLOPHOSPHAMIDE
NM_014867
kelch repeat and BTB (POZ) domain containing 11
KBTBD11
17403535
|
CYCLOPHOSPHAMIDE
NM_020853
KIAA1467
KIAA1467
16896004
|
CYCLOPHOSPHAMIDE
NM_007054
kinesin family member 3A
KIF3A
16896004
|
CYCLOPHOSPHAMIDE
NM_002305
lectin, galactoside-binding, soluble, 1
LGALS1
17403535
|
CYCLOPHOSPHAMIDE
NM_000240
monoamine oxidase A
MAOA
17403535
|
CYCLOPHOSPHAMIDE
NM_001315; NM_139012; NM_139013;
mitogen-activated protein kinase 14
MAPK14
16322899
sensitivity
|
NM_139014
|
CYCLOPHOSPHAMIDE
NM_001123066; NM_001123067; NM_005910;
microtubule-associated protein tau
MAPT
16896004
unrelated
|
NM_016834; NM_016835; NM_016841
|
CYCLOPHOSPHAMIDE
NM_002356
myristoylated alanine-rich protein kinase C substrate
MARCKS
17403535
|
CYCLOPHOSPHAMIDE
NM_199072
MyoD family inhibitor domain containing
MDFIC
17403535
|
CYCLOPHOSPHAMIDE
NM_015335
mediator complex subunit 13-like
MED13L
16896004
|
CYCLOPHOSPHAMIDE
NM_014791
maternal embryonic leucine zipper kinase
MELK
16896004
|
CYCLOPHOSPHAMIDE
NM_024042
meteorin, glial cell differentiation regulator
METRN
16896004
|
CYCLOPHOSPHAMIDE
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
15741301, 17403535
resistance
|
CYCLOPHOSPHAMIDE
NM_002417
antigen identified by monoclonal antibody Ki-67
MKI67
15940066
|
CYCLOPHOSPHAMIDE
NM_001031666; NM_001031809; NM_006138
membrane-spanning 4-domains, subfamily A, member
MS4A3
17403535
|
3 (hematopoietic cell-specific)
|
CYCLOPHOSPHAMIDE
NM_002463
myxovirus (influenza virus) resistance 2 (mouse)
MX2
17403535
|
CYCLOPHOSPHAMIDE
NM_004536; NM_022892
NLR family, apoptosis inhibitory protein
NAIP
16322899
BIRC1—
|
sensitivity
|
CYCLOPHOSPHAMIDE
—
—
NK4
17403535
|
CYCLOPHOSPHAMIDE
NM_024522
Na+/K+ transporting ATPase interacting 1
NKAIN1
16896004
|
CYCLOPHOSPHAMIDE
NM_002564; NM_176071; NM_176072
purinergic receptor P2Y, G-protein coupled, 2
P2RY2
17403535
|
CYCLOPHOSPHAMIDE
NM_007203; NM_147150
PALM2-AKAP2 readthrough transcript
PALM2-
17403535
|
AKAP2
|
CYCLOPHOSPHAMIDE
NM_000926
progesterone receptor
PGR
15940066
|
CYCLOPHOSPHAMIDE
NM_003311
pleckstrin homology-like domain, family A, member 2
PHLDA2
17403535
|
CYCLOPHOSPHAMIDE
NM_000302
procollagen-lysine 1,2-oxoglutarate 5-dioxygenase 1
PLOD1
16322899
resistance
|
CYCLOPHOSPHAMIDE
NM_001084
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
PLOD3
16322899
resistance
|
CYCLOPHOSPHAMIDE
NM_000941
P450 (cytochrome) oxidoreductase
POR
10919648
|
CYCLOPHOSPHAMIDE
NM_002777
proteinase 3
PRTN3
17403535
|
CYCLOPHOSPHAMIDE
NM_002790
proteasome (prosome, macropain) subunit, alpha type, 5
PSMA5
17475930
|
CYCLOPHOSPHAMIDE
NM_005855
receptor (G protein-coupled) activity modifying protein 1
RAMP1
16896004, 17403535
|
CYCLOPHOSPHAMIDE
NM_001008710; NM_001008711; NM_001008712;
RNA binding protein with multiple splicing
RBPMS
17403535
|
NM_006867
|
CYCLOPHOSPHAMIDE
NM_002934
ribonuclease, RNase A family, 2 (liver, eosinophil-
RNASE2
17403535
|
derived neurotoxin)
|
CYCLOPHOSPHAMIDE
NM_006570
Ras-related GTP binding A
RRAGA
17403535
|
CYCLOPHOSPHAMIDE
NM_001102669; NM_012250
related RAS viral (r-ras) oncogene homolog 2
RRAS2
17403535
|
CYCLOPHOSPHAMIDE
NM_001034
ribonucleotide reductase M2 polypeptide
RRM2
16896004
resistance
|
CYCLOPHOSPHAMIDE
NM_016434; NM_032957
regulator of telomere elongation helicase 1
RTEL1
17475930
|
CYCLOPHOSPHAMIDE
NM_005980
S100 calcium binding protein P
S100P
17403535
|
CYCLOPHOSPHAMIDE
NM_020974
signal peptide, CUB domain, EGF-like 2
SCUBE2
16896004
|
CYCLOPHOSPHAMIDE
NM_003118
secreted protein, acidic, cysteine-rich (osteonectin)
SPARC
17403535
|
CYCLOPHOSPHAMIDE
NM_003132
spermidine synthase
SRM
16322899
resistance
|
CYCLOPHOSPHAMIDE
NM_021978
suppression of tumorigenicity 14 (colon carcinoma)
ST14
16322899
resistance
|
CYCLOPHOSPHAMIDE
NM_013233
serine threonine kinase 39 (STE20/SPS1 homolog,
STK39
16322899
sensitivity
|
yeast)
|
CYCLOPHOSPHAMIDE
NM_018271
threonine synthase-like 2 (S. cerevisiae)
THNSL2
16896004
|
CYCLOPHOSPHAMIDE
NM_014220
transmembrane 4 L six family member 1
TM4SF1
17403535
|
CYCLOPHOSPHAMIDE
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
18465341
|
CYCLOPHOSPHAMIDE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
15940066
death pathway
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
CYCLOPHOSPHAMIDE
NM_024762
zinc finger protein 552
ZNF552
16896004
|
IFOSFAMIDE
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
11723234
|
IFOSFAMIDE
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
11723234
death pathway
|
IFOSFAMIDE
NM_000762
cytochrome P450, family 2, subfamily A, polypeptide 6
CYP2A6
12136253
drug activation
|
IFOSFAMIDE
NM_000767
cytochrome P450, family 2, subfamily B, polypeptide 6
CYP2B6
15875221
drug activation
|
IFOSFAMIDE
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
12136253, 15821045, 15875221
drug activation
|
IFOSFAMIDE
NM_000777
cytochrome P450, family 3, subfamily A, polypeptide 5
CYP3A5
15821045, 15875221
drug activation
|
IFOSFAMIDE
NM_001130823; NM_001379
DNA (cytosine-5-)-methyltransferase 1
DNMT1
—
|
IFOSFAMIDE
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
12868187
polymorphism/
|
toxicity
|
IFOSFAMIDE
NM_000852
glutathione S-transferase pi 1
GSTP1
12868187
polymorphism/
|
toxicity
|
IFOSFAMIDE
NM_000853
glutathione S-transferase theta 1
GSTT1
12868187
polymorphism/
|
toxicity
|
MELPHALAN
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
11115505
resistance
|
NM_019899; NM_019900
member 1
|
MELPHALAN
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16373717
|
MELPHALAN
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
14757846
death pathway
|
MELPHALAN
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16951922
death pathway
|
MELPHALAN
NM_001785
cytidine deaminase
CDA
10830723
resistance
|
MELPHALAN
NM_000136
Fanconi anemia, complementation group C
FANCC
16243825
|
MELPHALAN
NM_004629
Fanconi anemia, complementation group G
FANCG
16243825
|
MELPHALAN
NM_145740
glutathione S-transferase alpha 1
GSTA1
15779864
unrelated
|
MELPHALAN
NM_000852
glutathione S-transferase pi 1
GSTP1
15779864, 27
unrelated
|
MELPHALAN
NM_000201
intercellular adhesion molecule 1
ICAM1
16025434
|
MELPHALAN
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
16025434
|
MELPHALAN
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
16025434
|
MELPHALAN
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
16039682
unrelated
|
MELPHALAN
NM_002413
microsomal glutathione S-transferase 2
MGST2
15779864
resistance
|
MELPHALAN
NM_006788
ralA binding protein 1
RALBP1
—
resistance
|
MELPHALAN
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
16025434
|
MELPHALAN
NM_001071
thymidylate synthetase
TYMS
10482907
|
CARMUSTINE
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
15239124
resistance
|
member 1
|
CARMUSTINE
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
12653207
resistance
|
NM_019899; NM_019900
member 1
|
CARMUSTINE
NM_005159
actin, alpha, cardiac muscle 1
ACTC1
15980968
|
CARMUSTINE
NM_001615
actin, gamma 2, smooth muscle, enteric
ACTG2
15980968
|
CARMUSTINE
NM_001102; NM_001130004; NM_001130005
actinin, alpha 1
ACTN1
15980968
|
CARMUSTINE
NM_003815; NM_207191; NM_207194;
ADAM metallopeptidase domain 15
ADAM15
15980968
|
NM_207195; NM_207196; NM_207197
|
CARMUSTINE
NM_005099
ADAM metallopeptidase with thrombospondin type 1
ADAMTS4
15980968
|
motif, 4
|
CARMUSTINE
NM_001099733; NM_001117
adenylate cyclase activating polypeptide 1 (pituitary)
ADCYAP1
15980968
|
CARMUSTINE
NM_000679
adrenergic, alpha-1B-, receptor
ADRA1B
15980968
|
CARMUSTINE
NM_000029
angiotensinogen (serpin peptidase inhibitor, clade A,
AGT
11034089
|
member 8)
|
CARMUSTINE
—
—
AGTRL1
15980968
|
CARMUSTINE
NM_001626
v-akt murine thymoma viral oncogene homolog 2
AKT2
15980968
|
CARMUSTINE
NM_000031
aminolevulinate, delta-, dehydratase
ALAD
15980968
|
CARMUSTINE
NM_001039130; NM_001039131; NM_001141
arachidonate 15-lipoxygenase, type B
ALOX15B
15980968
|
CARMUSTINE
NM_000479
anti-Mullerian hormone
AMH
15980968
|
CARMUSTINE
NM_005883
adenomatosis polyposis coli 2
APC2
15980968
|
CARMUSTINE
NM_001169
aquaporin 8
AQP8
15980968
|
CARMUSTINE
—
—
ARGBP2
15980968
|
CARMUSTINE
NM_005731; NM_152862
actin related protein 2/3 complex, subunit 2, 34 kDa
ARPC2
15980968
|
CARMUSTINE
NM_001136215; NM_003976; NM_057090;
artemin
ARTN
15980968
|
NM_057091; NM_057160
|
CARMUSTINE
NM_004192
acetylserotonin O-methyltransferase-like
ASMTL
15980968
|
CARMUSTINE
NM_152296
ATPase, Na+/K+ transporting, alpha 3 polypeptide
ATP1A3
15980968
|
CARMUSTINE
NM_000705
ATPase, H+/K+ exchanging, beta polypeptide
ATP4B
15980968
|
CARMUSTINE
NM_001001975; NM_001687
ATP synthase, H+ transporting, mitochondrial F1
ATP5D
15980968
|
complex, delta subunit
|
CARMUSTINE
NM_001694
ATPase, H+ transporting, lysosomal 16 kDa,
ATP6V0C
15980968
|
V0 subunit c
|
CARMUSTINE
NM_007245; NM_145714; NM_148414;
ataxin 2-like
ATXN2L
15980968
|
NM_148415; NM_148416
|
CARMUSTINE
NM_000706
arginine vasopressin receptor 1A
AVPR1A
15980968
|
CARMUSTINE
NM_004776
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,
B4GALT5
15980968
|
polypeptide 5
|
CARMUSTINE
NM_001144888; NM_006340; NM_017450;
BAI1-associated protein 2
BAIAP2
15980968
|
NM_017451
|
CARMUSTINE
NM_003933
BAI1-associated protein 3
BAIAP3
15980968
|
CARMUSTINE
NM_003921
B-cell CLL/lymphoma 10
BCL10
15980968
|
CARMUSTINE
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
16187019
resistance
|
CARMUSTINE
NM_001191; NM_138578
BCL2-like 1
BCL2L1
16187019
|
CARMUSTINE
NM_003766
beclin 1, autophagy related
BECN1
15980968
|
CARMUSTINE
NM_001003398; NM_001714
bicaudal D homolog 1 (Drosophila)
BICD1
15980968
|
CARMUSTINE
NM_001715
B lymphoid tyrosine kinase
BLK
15980968
|
CARMUSTINE
NM_001719
bone morphogenetic protein 7
BMP7
15980968
|
CARMUSTINE
NM_001519; NM_145685
BRF1 homolog, subunit of RNA polymerase III
BRF1
15980968
|
transcription initiation factor IIIB (S. cerevisiae)
|
CARMUSTINE
NM_001215
carbonic anhydrase VI
CA6
15980968
|
CARMUSTINE
NM_001740; NM_007087; NM_007088
calbindin 2
CALB2
15980968
|
CARMUSTINE
NM_002982
chemokine (C-C motif) ligand 2
CCL2
15980968
|
CARMUSTINE
NM_001039490; NM_004357; NM_139029;
CD151 molecule (Raph blood group)
CD151
15980968
|
NM_139030
|
CARMUSTINE
NM_001040059; NM_001251
CD68 molecule
CD68
15980968
|
CARMUSTINE
NM_001783; NM_021601
CD79a molecule, immunoglobulin-associated alpha
CD79A
15980968
|
CARMUSTINE
NM_005191
CD80 molecule
CD80
15980968
|
CARMUSTINE
NM_001790; NM_022809
cell division cycle 25 homolog C (S. pombe)
CDC25C
15735757
|
CARMUSTINE
NM_001260
cyclin-dependent kinase 8
CDK8
15980968
|
CARMUSTINE
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
15735757
resistance
|
CARMUSTINE
NM_005193
caudal type homeobox 4
CDX4
15980968
|
CARMUSTINE
NM_001815
carcinoembryonic antigen-related cell adhesion
CEACAM3
15980968
|
molecule 3
|
CARMUSTINE
NM_005194
CCAAT/enhancer binding protein (C/EBP), beta
CEBPB
15980968
|
CARMUSTINE
NM_001114121; NM_001114122; NM_001274
CHK1 checkpoint homolog (S. pombe)
CHEK1
15735757
|
CARMUSTINE
NM_000741
cholinergic receptor, muscarinic 4
CHRM4
15980968
|
CARMUSTINE
NM_000749
cholinergic receptor, nicotinic, beta 3
CHRNB3
15980968
|
CARMUSTINE
NM_005199
cholinergic receptor, nicotinic, gamma
CHRNG
15980968
|
CARMUSTINE
NM_001824
creatine kinase, muscle
CKM
15980968
altered by
|
CNU
|
CARMUSTINE
NM_001835; NM_007098
clathrin, heavy chain-like 1
CLTCL1
15980968
|
CARMUSTINE
NM_003632
contactin associated protein 1
CNTNAP1
15980968
|
CARMUSTINE
NM_001851; NM_078485
collagen, type IX, alpha 1
COL9A1
15980968
|
CARMUSTINE
NM_005205
cytochrome c oxidase subunit VIa polypeptide 2
COX6A2
15980968
|
CARMUSTINE
NM_004378
cellular retinoic acid binding protein 1
CRABP1
15980968
|
CARMUSTINE
NM_000755; NM_004003
carnitine acetyltransferase
CRAT
15980968
|
CARMUSTINE
NM_001887
crystallin, beta B1
CRYBB1
15980968
|
CARMUSTINE
NM_001900
cystatin D
CST5
15980968
|
CARMUSTINE
NM_001142544; NM_001330
cardiotrophin 1
CTF1
15980968
|
CARMUSTINE
NM_003798
catenin (cadherin-associated protein), alpha-like 1
CTNNAL1
15980968
|
CARMUSTINE
NM_000103; NM_031226
cytochrome P450, family 19, subfamily A, polypeptide 1
CYP19A1
15980968
|
CARMUSTINE
NM_004762; NM_017456
cytohesin 1
CYTH1
15980968
|
CARMUSTINE
NM_003587
DEAH (Asp-Glu-Ala-His) box polypeptide 16
DHX16
15980968
|
CARMUSTINE
NM_001374
deoxyribonuclease I-like 2
DNASE1L2
15980968
|
CARMUSTINE
NM_004421
dishevelled, dsh homolog 1 (Drosophila)
DVL1
15980968
|
CARMUSTINE
NM_001393
extracellular matrix protein 2, female organ and
ECM2
15980968
|
adipocyte specific
|
CARMUSTINE
NM_001404
eukaryotic translation elongation factor 1 gamma
EEF1G
15980968
|
CARMUSTINE
NM_001414
eukaryotic translation initiation factor 2B, subunit 1
EIF2B1
15980968
|
alpha, 26 kDa
|
CARMUSTINE
NM_002212; NM_181466; NM_181468
eukaryotic translation initiation factor 6
EIF6
15980968
|
CARMUSTINE
NM_000120; NM_001136018
epoxide hydrolase 1, microsomal (xenobiotic)
EPHX1
15980968
resistance ?
|
CARMUSTINE
NM_004451
estrogen-related receptor alpha
ESRRA
15980968
|
CARMUSTINE
NM_004456; NM_152998
enhancer of zeste homolog 2 (Drosophila)
EZH2
15980968
|
CARMUSTINE
NM_000138
fibrillin 1
FBN1
15980968
|
CARMUSTINE
NM_000801; NM_054014
FK506 binding protein 1A, 12 kDa
FKBP1A
15980968
|
CARMUSTINE
NM_001018676; NM_001018677; NM_002027
farnesyltransferase, CAAX box, alpha
FNTA
15980968
|
CARMUSTINE
NM_001454
forkhead box J1
FOXJ1
15980968
|
CARMUSTINE
NM_002032
ferritin, heavy polypeptide 1
FTH1
15980968
|
CARMUSTINE
NM_000146
ferritin, light polypeptide
FTL
15980968
|
CARMUSTINE
NM_002037; NM_153047; NM_153048
FYN oncogene related to SRC, FGR, YES
FYN
15980968
|
CARMUSTINE
NM_000807; NM_001114175
gamma-aminobutyric acid (GABA) A receptor, alpha 2
GABRA2
15980968
|
CARMUSTINE
NM_000811
gamma-aminobutyric acid (GABA) A receptor, alpha 6
GABRA6
15980968
|
CARMUSTINE
NM_000156; NM_138924
guanidinoacetate N-methyltransferase
GAMT
15980968
|
CARMUSTINE
NM_000805
gastrin
GAST
15980968
|
CARMUSTINE
NM_003643
glial cells missing homolog 1 (Drosophila)
GCM1
15980968
|
CARMUSTINE
NM_001493
GDP dissociation inhibitor 1
GDI1
15980968
|
CARMUSTINE
NM_001115156; NM_001494
GDP dissociation inhibitor 2
GDI2
15980968
|
CARMUSTINE
NM_001131019; NM_002055
glial fibrillary acidic protein
GFAP
15980968
|
CARMUSTINE
NM_004122; NM_198407
growth hormone secretagogue receptor
GHSR
15980968
|
CARMUSTINE
NM_000406; NM_001012763
gonadotropin-releasing hormone receptor
GNRHR
15980968
|
CARMUSTINE
NM_004486
golgi autoantigen, golgin subfamily a, 2
GOLGA2
15980968
|
CARMUSTINE
NM_002078
golgi autoantigen, golgin subfamily a, 4
GOLGA4
15980968
|
CARMUSTINE
NM_000407
glycoprotein Ib (platelet), beta polypeptide
GP1BB
15980968
|
CARMUSTINE
NM_005298
G protein-coupled receptor 25
GPR25
15980968
|
CARMUSTINE
NM_001506
G protein-coupled receptor 32
GPR32
15980968
|
CARMUSTINE
NM_005302
G protein-coupled receptor 37 (endothelin receptor
GPR37
15980968
|
type B-like)
|
CARMUSTINE
NM_003608
G protein-coupled receptor 65
GPR65
15980968
|
CARMUSTINE
NM_001030002; NM_005310
growth factor receptor-bound protein 7
GRB7
15980968
|
CARMUSTINE
NM_002087
granulin
GRN
15980968
|
CARMUSTINE
NM_000637
glutathione reductase
GSR
—
target
|
CARMUSTINE
NM_145740
glutathione S-transferase alpha 1
GSTA1
8395980
unrelated
|
CARMUSTINE
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
8395980
unrelated
|
CARMUSTINE
NM_000849
glutathione S-transferase mu 3 (brain)
GSTM3
15247628, 8395980
resistance
|
CARMUSTINE
NM_000852
glutathione S-transferase pi 1
GSTP1
16899598, 8395980
unrelated
|
CARMUSTINE
NM_002096
general transcription factor IIF, polypeptide 1, 74 kDa
GTF2F1
15980968
|
CARMUSTINE
NM_002105
H2A histone family, member X
H2AFX
15980968
|
CARMUSTINE
—
—
HADHSC
15980968
|
CARMUSTINE
NM_001040427; NM_005326
hydroxyacylglutathione hydrolase
HAGH
15980968
|
CARMUSTINE
NM_005334
host cell factor C1 (VP16-accessory protein)
HCFC1
15980968
|
CARMUSTINE
NM_005517
high-mobility group nucleosomal binding domain 2
HMGN2
15980968
|
CARMUSTINE
NM_000545
HNF1 homeobox A
HNF1A
15980968
|
CARMUSTINE
NM_002141
homeobox A4
HOXA4
15980968
|
CARMUSTINE
NM_003259
intercellular adhesion molecule 5, telencephalin
ICAM5
15980968
|
CARMUSTINE
NM_000202; NM_006123
iduronate 2-sulfatase
IDS
15980968
|
CARMUSTINE
NM_003897
immediate early response 3
IER3
15980968
|
CARMUSTINE
NM_001099856; NM_001099857; NM_001145255;
inhibitor of kappa light polypeptide gene enhancer in B-
IKBKG
15980968
|
NM_003639
cells, kinase gamma
|
CARMUSTINE
NM_001567
inositol polyphosphate phosphatase-like 1
INPPL1
15980968
|
CARMUSTINE
NM_005542; NM_198336; NM_198337
insulin induced gene 1
INSIG1
15980968
|
CARMUSTINE
NM_005543
insulin-like 3 (Leydig cell)
INSL3
15980968
|
CARMUSTINE
NM_005544
insulin receptor substrate 1
IRS1
15980968
|
CARMUSTINE
NM_005545; NM_201526
immunoglobulin superfamily containing leucine-rich
ISLR
15980968
|
repeat
|
CARMUSTINE
NM_002204; NM_005501
integrin, alpha 3 (antigen CD49C, alpha 3 subunit of
ITGA3
15980968
|
VLA-3 receptor)
|
CARMUSTINE
NM_002215
inter-alpha (globulin) inhibitor H1
ITIH1
15980968
|
CARMUSTINE
NM_000238; NM_172056; NM_172057
potassium voltage-gated channel, subfamily H (eag-
KCNH2
15980968
|
related), member 2
|
CARMUSTINE
NM_004984
kinesin family member 5A
KIF5A
15980968
|
CARMUSTINE
NM_000422
keratin 17
KRT17
15980968
|
CARMUSTINE
NM_002277
keratin 31
KRT31
15980968
|
CARMUSTINE
NM_005558
ladinin 1
LAD1
15980968
|
CARMUSTINE
NM_002287; NM_021706
leukocyte-associated immunoglobulin-like receptor 1
LAIR1
15980968
|
CARMUSTINE
NM_000228; NM_001017402; NM_001127641
laminin, beta 3
LAMB3
15980968
|
CARMUSTINE
NM_002316
LIM homeobox transcription factor 1, beta
LMX1B
15980968
|
CARMUSTINE
NM_005576
lysyl oxidase-like 1
LOXL1
15980968
|
CARMUSTINE
NM_002319
leucine-rich repeats and calponin homology (CH)
LRCH4
15980968
|
domain containing 4
|
CARMUSTINE
NM_006152
lymphoid-restricted membrane protein
LRMP
15980968
|
CARMUSTINE
NM_001013836; NM_001013837; NM_003550
MAD1 mitotic arrest deficient-like 1 (yeast)
MAD1L1
15980968
|
CARMUSTINE
NM_004579
mitogen-activated protein kinase kinase kinase kinase 2
MAP4K2
15980968
|
CARMUSTINE
NM_002753; NM_138980; NM_138981;
mitogen-activated protein kinase 10
MAPK10
15980968
|
NM_138982
|
CARMUSTINE
NM_000429
methionine adenosyltransferase I, alpha
MAT1A
15980968
|
CARMUSTINE
NM_001012333; NM_001012334; NM_002391
midkine (neurite growth-promoting factor 2)
MDK
15980968
|
CARMUSTINE
NM_004774
mediator complex subunit 1
MED1
15980968
|
CARMUSTINE
NM_001098270; NM_002409
mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-
MGAT3
15980968
|
acetylglucosaminyltransferase
|
CARMUSTINE
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
15319033,
resistance
|
15833865, 16039682, 15814657,
|
16899598, 16033832
|
CARMUSTINE
NM_002445; NM_138715; NM_138716
macrophage scavenger receptor 1
MSR1
15980968
|
CARMUSTINE
NM_002457
mucin 2, oligomeric mucus/gel-forming
MUC2
15980968
|
CARMUSTINE
NM_002461
mevalonate (diphospho) decarboxylase
MVD
15980968
|
CARMUSTINE
NM_004997
myosin binding protein H
MYBPH
15980968
|
CARMUSTINE
NM_002468
myeloid differentiation primary response gene (88)
MYD88
15980968
|
CARMUSTINE
NM_002478
myogenic differentiation 1
MYOD1
15980968
|
CARMUSTINE
NM_002479
myogenin (myogenic factor 4)
MYOG
15980968
|
CARMUSTINE
NM_002494
NADH dehydrogenase (ubiquinone) 1, subcomplex
NDUFC1
15980968
|
unknown, 1, 6 kDa
|
CARMUSTINE
NM_002509
NK2 homeobox 2
NKX2-2
15980968
|
CARMUSTINE
NM_002517
neuronal PAS domain protein 1
NPAS1
15980968
|
CARMUSTINE
NM_005286
neuropeptides B/W receptor 2
NPBWR2
15980968
|
CARMUSTINE
NM_004558
neurturin
NRTN
15980968
|
CARMUSTINE
NM_002542; NM_016819; NM_016820;
8-oxoguanine DNA glycosylase
OGG1
11181913
|
NM_016821; NM_016826; NM_016827;
|
NM_016828; NM_016829
|
CARMUSTINE
NM_006189
olfactory marker protein
OMP
15980968
|
CARMUSTINE
NM_001018049; NM_002571
progestagen-associated endometrial protein
PAEP
15980968
|
CARMUSTINE
NM_003466; NM_013951; NM_013952;
paired box 8
PAX8
15980968
|
NM_013953; NM_013992
|
CARMUSTINE
NM_002586
pre-B-cell leukemia homeobox 2
PBX2
15980968
|
CARMUSTINE
NM_000281
pterin-4 alpha-carbinolamine dehydratase/dimerization
PCBD1
15980968
|
cofactor of hepatocyte nuclear factor 1 alpha
|
CARMUSTINE
NM_002588; NM_032402; NM_032403
protocadherin gamma subfamily C, 3
PCDHGC3
15980968
|
CARMUSTINE
NM_002593
procollagen C-endopeptidase enhancer
PCOLCE
15980968
|
CARMUSTINE
NM_005017
phosphate cytidylyltransferase 1, choline, alpha
PCYT1A
15980968
|
CARMUSTINE
NM_001018053; NM_006212
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2
PFKFB2
15980968
|
CARMUSTINE
NM_000289
phosphofructokinase, muscle
PFKM
15980968
|
CARMUSTINE
NM_005022
profilin 1
PFN1
15980968
|
CARMUSTINE
NM_001114172; NM_003629
phosphoinositide-3-kinase, regulatory subunit 3
PIK3R3
15980968
|
(gamma)
|
CARMUSTINE
NR_023383; NR_023383; NR_023383;
postmeiotic segregation increased 2-like 11
PMS2L11
15980968
|
NR_023383; NR_023383; NR_023383;
pseudogene
|
NR_023383; NR_023383; NR_023383
|
CARMUSTINE
NM_002695
polymerase (RNA) II (DNA directed) polypeptide E,
POLR2E
15980968
|
25 kDa
|
CARMUSTINE
NM_002707; NM_177983
protein phosphatase 1G (formerly 2C), magnesium-
PPM1G
15980968
|
dependent, gamma isoform
|
CARMUSTINE
NM_003981; NM_199413; NM_199414
protein regulator of cytokinesis 1
PRC1
17374387
|
CARMUSTINE
NM_000948
prolactin
PRL
15980968
|
CARMUSTINE
NM_002762
protamine 2
PRM2
15980968
|
CARMUSTINE
NM_001145368; NM_001145369; NM_001145370;
protein tyrosine phosphatase, non-receptor type 3
PTPN3
15980968
|
NM_001145371; NM_001145372;
|
NM_002829
|
CARMUSTINE
NM_002864
pregnancy-zone protein
PZP
15980968
|
CARMUSTINE
NM_005053
RAD23 homolog A (S. cerevisiae)
RAD23A
15980968
|
CARMUSTINE
NM_002875; NM_133487
RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)
RAD51
15980968
|
CARMUSTINE
—
—
RAD9
15980968
|
CARMUSTINE
NM_002901
reticulocalbin 1, EF-hand calcium binding domain
RCN1
15980968
|
CARMUSTINE
NM_001012720; NM_001012722; NM_002921
retinal G protein coupled receptor
RGR
15980968
|
CARMUSTINE
NM_002930
Ras-like without CAAX 2
RIT2
15980968
|
CARMUSTINE
NM_002937; NM_194431
ribonuclease, RNase A family, 4
RNASE4
15980968
|
CARMUSTINE
NM_002688
septin 5
sept-05
15980968
|
CARMUSTINE
NM_005066
splicing factor proline/glutamine-rich (polypyrimidine
SFPQ
15980968
|
tract binding protein associated)
|
CARMUSTINE
NM_000023; NM_001135697
sarcoglycan, alpha (50 kDa dystrophin-associated
SGCA
15980968
|
glycoprotein)
|
CARMUSTINE
NM_005412
serine hydroxymethyltransferase 2 (mitochondrial)
SHMT2
15980968
|
CARMUSTINE
NM_000451; NM_006883
short stature homeobox
SHOX
15980968
|
CARMUSTINE
—
—
SIAT1
15980968
|
CARMUSTINE
NM_003049
solute carrier family 10 (sodium/bile acid cotransporter
SLC10A1
15980968
|
family), member 1
|
CARMUSTINE
NM_006517
solute carrier family 16, member 2 (monocarboxylic
SLC16A2
15980968
|
acid transporter 8)
|
CARMUSTINE
NM_003459
solute carrier family 30 (zinc transporter), member 3
SLC30A3
15980968
|
CARMUSTINE
NM_001043
solute carrier family 6 (neurotransmitter transporter,
SLC6A2
15980968
|
noradrenalin), member 2
|
CARMUSTINE
NM_021094; NM_134431
solute carrier organic anion transporter family, member
SLCO1A2
15980968
|
1A2
|
CARMUSTINE
NM_003076; NM_139071
SWI/SNF related, matrix associated, actin dependent
SMARCD1
15980968
|
regulator of chromatin, subfamily d, member 1
|
CARMUSTINE
NM_003080
sphingomyelin phosphodiesterase 2, neutral
SMPD2
15980968
|
membrane (neutral sphingomyelinase)
|
CARMUSTINE
NM_003082
small nuclear RNA activating complex, polypeptide 1,
SNAPC1
15980968
|
43 kDa
|
CARMUSTINE
NM_001039697
small nuclear RNA activating complex, polypeptide 3,
SNAPC3
15980968
|
50 kDa
|
CARMUSTINE
NM_003087
synuclein, gamma (breast cancer-specific protein 1)
SNCG
15980968
|
CARMUSTINE
NM_003092; NM_198220
small nuclear ribonucleoprotein polypeptide B″
SNRPB2
15980968
|
CARMUSTINE
NM_003745
suppressor of cytokine signaling 1
SOCS1
17374387
|
CARMUSTINE
NM_005876
SPEG complex locus
SPEG
15980968
|
CARMUSTINE
NM_001017418
small proline-rich protein 2B
SPRR2B
15980968
|
CARMUSTINE
NM_003134
signal recognition particle 14 kDa (homologous Alu
SRP14
15980968
|
RNA binding protein)
|
CARMUSTINE
NM_003140
sex determining region Y
SRY
15980968
|
CARMUSTINE
NM_003034
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
ST8SIA1
15980968
|
sialyltransferase 1
|
CARMUSTINE
NM_003473
signal transducing adaptor molecule (SH3 domain and
STAM
15980968
|
ITAM motif) 1
|
CARMUSTINE
NM_000351
steroid sulfatase (microsomal), isozyme S
STS
15980968
|
CARMUSTINE
NM_052874
syntaxin 1B
STX1B
15980968
|
CARMUSTINE
NM_001127396; NM_006949
syntaxin binding protein 2
STXBP2
15980968
|
CARMUSTINE
NM_003182; NM_013996; NM_013997;
tachykinin, precursor 1
TAC1
15980968
|
NM_013998
|
CARMUSTINE
NM_003206; NM_198392
transcription factor 21
TCF21
15980968
|
CARMUSTINE
—
—
TEGT
15980968
|
CARMUSTINE
NM_198253; NM_198255
telomerase reverse transcriptase
TERT
18021753
|
CARMUSTINE
NM_001105192; NM_005078; NM_020908
transducin-like enhancer of split 3 (E(sp1) homolog,
TLE3
15980968
|
Drosophila)
|
CARMUSTINE
NM_002546
tumor necrosis factor receptor superfamily, member
TNFRSF11B
15980968
|
11b
|
CARMUSTINE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
15735757
resistance
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
CARMUSTINE
NM_005658
TNF receptor-associated factor 1
TRAF1
15980968
|
CARMUSTINE
NM_001025234; NM_001025235; NM_001025236;
tetraspanin 4
TSPAN4
15980968
|
NM_001025237; NM_001025238;
|
NM_001025239; NM_003271
|
CARMUSTINE
NM_178014
tubulin, beta
TUBB
15980968
|
CARMUSTINE
NM_001070
tubulin, gamma 1
TUBG1
15980968
|
CARMUSTINE
NM_001128174; NM_003360
UDP glycosyltransferase 8
UGT8
15980968
|
CARMUSTINE
NM_002911
UPF1 regulator of nonsense transcripts homolog
UPF1
15980968
|
(yeast)
|
CARMUSTINE
NM_003378
VGF nerve growth factor inducible
VGF
15980968
|
CARMUSTINE
NM_001077269; NM_003387
WAS/WASL interacting protein family, member 1
WIPF1
15980968
|
CARMUSTINE
NM_003405
tyrosine 3-monooxygenase/tryptophan 5-
YWHAH
15980968
|
monooxygenase activation protein, eta polypeptide
|
CARMUSTINE
NM_003443
zinc finger and BTB domain containing 17
ZBTB17
15980968
|
CARMUSTINE
NM_001010972; NM_003461
zyxin
ZYX
15980968
|
FOTEMUSTINE
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
12970393, 16039682, 12970393
resistance
|
FOTEMUSTINE
NM_001093771; NM_003330; NM_182729;
thioredoxin reductase 1
TXNRD1
—
target
|
NM_182742; NM_182743
|
CARBOPLATIN
NM_000477
albumin
ALB
—
unrelated
|
CARBOPLATIN
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
15576332, 15996812
death pathway
|
NM_138764; NM_138765
|
CARBOPLATIN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
15996812,
resistance
|
15996812, 17404015, 15576332
|
CARBOPLATIN
NM_001040668; NM_138639
BCL2-like 12 (proline rich)
BCL2L12
15576332
|
CARBOPLATIN
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
10815900
|
CARBOPLATIN
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
15576332
death pathway
|
CARBOPLATIN
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
15996812, 17404015, 15576332
death pathway
|
CARBOPLATIN
NM_001129889; NM_001922
dopachrome tautomerase (dopachrome delta-
DCT
15897911
resistance
|
isomerase, tyrosine-related protein 2)
|
CARBOPLATIN
NM_000043; NM_152871; NM_152872;
Fas (TNF receptor superfamily, member 6)
FAS
15576332
death pathway
|
NM_152873; NM_152874; NM_152875;
|
NM_152876; NM_152877
|
CARBOPLATIN
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
15996812
altered by
|
platin
|
CARBOPLATIN
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
18089846
|
G/H synthase and cyclooxygenase)
|
CARBOPLATIN
NM_001145547; NM_032905
RNA binding motif protein 17
RBM17
16061639
resistance
|
CISPLATIN
NM_000014
alpha-2-macroglobulin
A2M
16773208
|
CISPLATIN
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
15650019, 15756446, 15802814,
resistance
|
member 1
15990222,
|
15990222, 15650019, 15239124
|
CISPLATIN
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
15448748, 15756446, 15802814,
resistance
|
NM_019899; NM_019900
member 1
18695918
|
CISPLATIN
NM_000392
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC2
15688364, 8797578, 15756446,
resistance
|
member 2
15985617, 18695918
|
CISPLATIN
NM_001023587; NM_005688
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC5
15882455
resistance
|
member 5
|
CISPLATIN
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
15981204, 18071906
resistance
|
CISPLATIN
NM_001626
v-akt murine thymoma viral oncogene homolog 2
AKT2
18071906
resistance
|
CISPLATIN
NM_005465; NM_181690
v-akt murine thymoma viral oncogene homolog 3
AKT3
18071906
resistance
|
(protein kinase B, gamma)
|
CISPLATIN
NM_000477
albumin
ALB
16773208
drug carrier
|
CISPLATIN
NM_001641; NM_080648; NM_080649
APEX nuclease (multifunctional DNA repair enzyme) 1
APEX1
16373707
resistance
|
CISPLATIN
NM_001699; NM_021913
AXL receptor tyrosine kinase
AXL
16061661
resistance
|
CISPLATIN
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
14512787, 14601052, 16009487
death pathway
|
NM_138764; NM_138765
|
CISPLATIN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
14512787, 15917659,
resistance
|
15981204, 14601052, 16009487,
|
17404015
|
CISPLATIN
NM_001191; NM_138578
BCL2-like 1
BCL2L1
15917659, 15981204, 14601052,
resistance
|
16020667
|
CISPLATIN
NM_001040668; NM_138639
BCL2-like 12 (proline rich)
BCL2L12
17404015
sensitivity
|
CISPLATIN
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
14601052,
resistance
|
14654915, 16142363, 10815900
|
CISPLATIN
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
14654915, 16391810
resistance
|
CISPLATIN
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
14601052, 15917659, 16382892,
resistance
|
15970709, 11911975, 15981204,
|
15981204, 16142363, 14654915,
|
11911975
|
CISPLATIN
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
14757846
death pathway
|
CISPLATIN
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16009487, 15863139, 14512787,
death pathway
|
18071906
|
CISPLATIN
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
16009487, 18071906
death pathway
|
NM_033355; NM_033356; NM_033358
|
CISPLATIN
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
16009487, 17404015
death pathway
|
CISPLATIN
NM_001752
catalase
CAT
10754530, 15930895
altered by
|
platin
|
CISPLATIN
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
11099651, 12807743, 14601052
resistance
|
CISPLATIN
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
14601052
resistance
|
CISPLATIN
NM_020313
cytokine induced apoptosis inhibitor 1
CIAPIN1
18389626
|
CISPLATIN
NM_001831; NM_203339
clusterin
CLU
15955107
resistance
|
CISPLATIN
NM_000614
ciliary neurotrophic factor
CNTF
16898872
|
CISPLATIN
NM_001079846; NM_004380
CREB binding protein
CREBBP
17498666
|
CISPLATIN
NM_018947
cytochrome c, somatic
CYCS
16009487
death pathway
|
CISPLATIN
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
15650019
unrelated
|
CISPLATIN
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
16391810
death pathway
|
CISPLATIN
NM_000110
dihydropyrimidine dehydrogenase
DPYD
15737843
resistance
|
CISPLATIN
NM_001956
endothelin 2
EDN2
16898872
|
CISPLATIN
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15723263, 15737843, 18337622
resistance
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
CISPLATIN
NM_001429
E1A binding protein p300
EP300
17498666
|
CISPLATIN
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
15737843, 18337622
resistance
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
CISPLATIN
NM_001983; NM_202001
excision repair cross-complementing rodent repair
ERCC1
15737843
resistance
|
deficiency, complementation group 1 (includes
|
overlapping antisense sequence)
|
CISPLATIN
NM_000400; NM_001130867
excision repair cross-complementing rodent repair
ERCC2
15882455
resistance
|
deficiency, complementation group 2
|
CISPLATIN
NM_001079675; NM_001986
ets variant 4
ETV4
16061661
resistance
|
CISPLATIN
NM_003824
Fas (TNFRSF6)-associated via death domain
FADD
16009487
death pathway
|
CISPLATIN
NM_000136
Fanconi anemia, complementation group C
FANCC
16243825
|
CISPLATIN
NM_004629
Fanconi anemia, complementation group G
FANCG
16061661, 16243825
resistance
|
CISPLATIN
NM_000043; NM_152871; NM_152872;
Fas (TNF receptor superfamily, member 6)
FAS
16009487, 17305640
death pathway
|
NM_152873; NM_152874; NM_152875;
|
NM_152876; NM_152877
|
CISPLATIN
NM_000639
Fas ligand (TNF superfamily, member 6)
FASLG
16009487
death pathway
|
CISPLATIN
NM_002009
fibroblast growth factor 7 (keratinocyte growth factor)
FGF7
18708365
|
CISPLATIN
NM_000142; NM_022965
fibroblast growth factor receptor 3
FGFR3
12066199
|
CISPLATIN
NM_005438
FOS-like antigen 1
FOSL1
15756446, 16061661
sensitivity
|
CISPLATIN
NM_001924
growth arrest and DNA-damage-inducible, alpha
GADD45A
19003803
|
CISPLATIN
NM_004864
growth differentiation factor 15
GDF15
16898872
|
CISPLATIN
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
12851839
polymorphisms
|
CISPLATIN
NM_000849
glutathione S-transferase mu 3 (brain)
GSTM3
11081456
polymorphisms
|
CISPLATIN
NM_000852
glutathione S-transferase pi 1
GSTP1
14678959, 15239142, 15279901,
resistance
|
15737843, 2747627
|
CISPLATIN
NM_000853
glutathione S-transferase theta 1
GSTT1
12851839
polymorphisms
|
CISPLATIN
NM_000858; NM_001159390; NM_001159391
guanylate kinase 1
GUK1
16898872
|
CISPLATIN
NM_001530; NM_181054
hypoxia inducible factor 1, alpha subunit (basic helix-
HIF1A
16532342, 17498666
resistance
|
loop-helix transcription factor)
|
CISPLATIN
NM_001540
heat shock 27 kDa protein 1
HSPB1
19088045
|
CISPLATIN
NM_002157
heat shock 10 kDa protein 1 (chaperonin 10)
HSPE1
16394183
resistance
|
CISPLATIN
NM_013247; NM_145074
HtrA serine peptidase 2
HTRA2
15863139
death pathway
|
CISPLATIN
NM_003641
interferon induced transmembrane protein 1 (9-27)
IFITM1
16898872
sensitivity
|
CISPLATIN
NM_000598; NM_001013398
insulin-like growth factor binding protein 3
IGFBP3
16061661
sensitivity
|
CISPLATIN
NM_000418; NM_001008699
interleukin 4 receptor
IL4R
14678968
|
CISPLATIN
NM_002207
integrin, alpha 9
ITGA9
12066199
|
CISPLATIN
NM_000213; NM_001005619; NM_001005731
integrin, beta 4
ITGB4
12066199
altered by
|
platin
|
CISPLATIN
NM_002228
jun oncogene
JUN
16898872
altered by
|
platin
|
CISPLATIN
NM_002276
keratin 19
KRT19
16061661
sensitivity
|
CISPLATIN
NM_002272
keratin 4
KRT4
16061661
sensitivity
|
CISPLATIN
NM_024552
LAG1 homolog, ceramide synthase 4
LASS4
15756446
unrelated
|
CISPLATIN
NM_004526
minichromosome maintenance complex component 2
MCM2
16061661
resistance
|
CISPLATIN
NM_004774
mediator complex subunit 1
MED1
15650019
sensitivity
|
CISPLATIN
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
15015788, 2766459, 7562019,
resistance
|
15809756, 16043385, 16039682,
|
16043385
|
CISPLATIN
NM_002425
matrix metallopeptidase 10 (stromelysin 2)
MMP10
12066199
altered by
|
platin
|
CISPLATIN
NM_002428
matrix metallopeptidase 15 (membrane-inserted)
MMP15
12066199
altered by
|
platin
|
CISPLATIN
NM_005941; NM_022564
matrix metallopeptidase 16 (membrane-inserted)
MMP16
12066199
altered by
|
platin
|
CISPLATIN
NM_015084
mitochondrial ribosomal protein S27
MRPS27
15756446
sensitivity
|
CISPLATIN
NM_005946
metallothionein 1A
MT1A
12680227
resistance
|
CISPLATIN
NM_005953
metallothionein 2A
MT2A
12680227, 16394183
resistance
|
CISPLATIN
NM_005954
metallothionein 3
MT3
16061661, 16898872
resistance
|
CISPLATIN
NM_005115; NM_017458
major vault protein
MVP
15802814
resistance
|
CISPLATIN
NM_004536; NM_022892
NLR family, apoptosis inhibitory protein
NAIP
11911975, 11911975, 14654915
|
CISPLATIN
NM_006534; NM_181659
nuclear receptor coactivator 3
NCOA3
15650019
|
CISPLATIN
NM_004557
Notch homolog 4 (Drosophila)
NOTCH4
16898872
|
CISPLATIN
NM_003889; NM_022002; NM_033013
nuclear receptor subfamily 1, group I, member 2
NR1I2
15650019
resistance
|
CISPLATIN
NM_002528
nth endonuclease III-like 1 (E. coli)
NTHL1
16898872
resistance
|
CISPLATIN
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
16009487, 18
altered by
|
platin
|
CISPLATIN
NM_002592; NM_182649
proliferating cell nuclear antigen
PCNA
11099651
|
CISPLATIN
NM_005313
protein disulfide isomerase family A, member 3
PDIA3
15756446
|
CISPLATIN
NM_002624; NM_145897
prefoldin subunit 5
PFDN5
16898872
|
CISPLATIN
NM_000291
phosphoglycerate kinase 1
PGK1
15756446
sensitivity
|
CISPLATIN
NM_021127
phorbol-12-myristate-13-acetate-induced protein 1
PMAIP1
17216584
|
CISPLATIN
NM_001081640; NM_006904
protein kinase, DNA-activated, catalytic polypeptide
PRKDC
18546291
|
CISPLATIN
NM_000311; NM_001080121; NM_001080122;
prion protein
PRNP
15386405
|
NM_001080123; NM_183079
|
CISPLATIN
NM_000314
phosphatase and tensin homolog
PTEN
11707646
sensitivity
|
CISPLATIN
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
15517878, 18695918
resistance
|
G/H synthase and cyclooxygenase)
|
CISPLATIN
NM_005607; NM_153831
PTK2 protein tyrosine kinase 2
PTK2
16391810
resistance
|
CISPLATIN
NM_006788
ralA binding protein 1
RALBP1
—
resistance
|
CISPLATIN
NM_000321
retinoblastoma 1
RB1
14704340
|
CISPLATIN
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
19003803
|
(avian)
|
CISPLATIN
NM_001042678; NM_001042679; NM_175744
ras homolog gene family, member C
RHOC
16898872
|
CISPLATIN
NM_015414; NM_033643
ribosomal protein L36
RPL36
16394183
resistance
|
CISPLATIN
NM_001009
ribosomal protein S5
RPS5
16898872
|
CISPLATIN
NM_001031680; NM_004350
runt-related transcription factor 3
RUNX3
15756676
|
CISPLATIN
NM_006142
stratifin
SFN
15999354
|
CISPLATIN
NM_001078174; NM_001078175; NM_001078176;
solute carrier family 29 (nucleoside transporters),
SLC29A1
18728667
drug import
|
NM_001078177; NM_004955
member 1
|
CISPLATIN
NM_001859
solute carrier family 31 (copper transporters), member 1
SLC31A1
15985617
|
CISPLATIN
NM_003745
suppressor of cytokine signaling 1
SOCS1
17374387
unrelated
|
CISPLATIN
NM_021102
serine peptidase inhibitor, Kunitz type, 2
SPINT2
15756446
|
CISPLATIN
NM_198253; NM_198255
telomerase reverse transcriptase
TERT
18021753
|
CISPLATIN
NM_001063
transferrin
TF
16773208
|
CISPLATIN
NM_003808; NM_172087; NM_172088
tumor necrosis factor (ligand) superfamily, member 13
TNFSF13
18423122
|
CISPLATIN
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
12807743, 14562046, 15578696,
sensitivity
|
NM_001126114; NM_001126115;
15990222, 12082016, 17555331,
|
NM_001126116; NM_001126117
15990222, 16020667, 15999354,
|
16077963, 16211088, 17216584,
|
17498666, 17555331
|
CISPLATIN
NM_001126240; NM_001126241; NM_001126242;
tumor protein p73
TP73
14678968, 17076661
sensitivity
|
NM_005427
|
CISPLATIN
NM_000365; NM_001159287
triosephosphate isomerase 1
TPI1
18309519
|
CISPLATIN
NM_014294
translocation associated membrane protein 1
TRAM1
16061661
sensitivity
|
CISPLATIN
NM_016292
TNF receptor-associated protein 1
TRAP1
16061661
resistance
|
CISPLATIN
NM_006009
tubulin, alpha 1a
TUBA1A
16898872
resistance
|
CISPLATIN
NM_003329
thioredoxin
TXN
10754530
resistance
|
CISPLATIN
NM_001071
thymidylate synthetase
TYMS
10482907, 15737843
resistance
|
CISPLATIN
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
17498666
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
CISPLATIN
NM_001167
X-linked inhibitor of apoptosis
XIAP
11911975, 16142363, 15863139,
resistance
|
14654915, 15981204, 14601052,
|
16391810, 16391810, 15863139,
|
18071906
|
CISPLATIN
NM_000380
xeroderma pigmentosum, complementation group A
XPA
15882455
|
CISPLATIN
NM_006297
X-ray repair complementing defective repair in Chinese
XRCC1
15882455
|
hamster cells 1
|
CISPLATIN
NM_021141
X-ray repair complementing defective repair in Chinese
XRCC5
12384553, 18546291
|
hamster cells 5 (double-strand-break rejoining)
|
CISPLATIN
NM_001469
X-ray repair complementing defective repair in Chinese
XRCC6
18546291
polymorphisms
|
hamster cells 6
|
CISPLATIN
NM_004926
zinc finger protein 36, C3H type-like 1
ZFP36L1
15880358
altered by
|
platin
|
OXALIPLATIN
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
18790786, 19147571
|
OXALIPLATIN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
16024531
resistance
|
OXALIPLATIN
NM_001191; NM_138578
BCL2-like 1
BCL2L1
16024531
resistance
|
OXALIPLATIN
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16004971, 16004971, 16024531,
altered by
|
19147571
oxaliplatin
|
OXALIPLATIN
NM_001237
cyclin A2
CCNA2
15204521
altered by
|
oxaliplatin
|
OXALIPLATIN
NM_031966
cyclin B1
CCNB1
15204521
altered by
|
oxaliplatin
|
OXALIPLATIN
NM_053056
cyclin D1
CCND1
19147571
|
OXALIPLATIN
NM_001238; NM_057182
cyclin E1
CCNE1
15204521
altered by
|
oxaliplatin
|
OXALIPLATIN
NM_001785
cytidine deaminase
CDA
18728667
|
OXALIPLATIN
NM_001130829; NM_001786; NM_033379
cell division cycle 2, G1 to S and G2 to M
CDC2
15204521, 16024531
altered by
|
oxaliplatin
|
OXALIPLATIN
NM_001798; NM_052827
cyclin-dependent kinase 2
CDK2
15204521
altered by
|
oxaliplatin
|
OXALIPLATIN
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
15204521
altered by
|
oxaliplatin
|
OXALIPLATIN
NM_001025248; NM_001025249; NM_001948
deoxyuridine triphosphatase
DUT
19015155
|
OXALIPLATIN
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
16098254
polymorphism
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
OXALIPLATIN
NM_001983; NM_202001
excision repair cross-complementing rodent repair
ERCC1
15655543, 17401013,
resistance
|
deficiency, complementation group 1 (includes
18448328, 15213713
|
overlapping antisense sequence)
|
OXALIPLATIN
NM_000400; NM_001130867
excision repair cross-complementing rodent repair
ERCC2
15213713, 15655543, 17401013
|
deficiency, complementation group 2
|
OXALIPLATIN
NM_001160030; NM_001160031; NM_002019
fms-related tyrosine kinase 1 (vascular endothelial
FLT1
18790786
|
growth factor/vascular permeability factor receptor)
|
OXALIPLATIN
—
—
FRAP1
19147571
|
OXALIPLATIN
NM_000852
glutathione S-transferase pi 1
GSTP1
15213713, 15655543, 17401013
resistance
|
OXALIPLATIN
NM_005524
hairy and enhancer of split 1, (Drosophila)
HES1
19147571
|
OXALIPLATIN
NM_000634
interleukin 8 receptor, alpha
IL8RA
16098254
|
OXALIPLATIN
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
18790786
|
OXALIPLATIN
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
18790786
|
OXALIPLATIN
NM_002467
v-myc myelocytomatosis viral oncogene homolog
MYC
15204521
sensitivity
|
(avian)
|
OXALIPLATIN
NM_015331
nicastrin
NCSTN
19147571
|
OXALIPLATIN
NM_017617
Notch homolog 1, translocation-associated
NOTCH1
19147571
|
(Drosophila)
|
OXALIPLATIN
NM_001024628; NM_001024629; NM_003873
neuropilin 1
NRP1
18790786
|
OXALIPLATIN
NM_002632
placental growth factor
PGF
18790786
|
OXALIPLATIN
NM_000021; NM_007318
presenilin 1
PSEN1
19147571
|
OXALIPLATIN
NM_000321
retinoblastoma 1
RB1
15204521
altered by
|
oxaliplatin
|
OXALIPLATIN
NM_005980
S100 calcium binding protein P
S100P
18636193
|
OXALIPLATIN
NM_003109; NM_138473
Sp1 transcription factor
SP1
19015155
|
OXALIPLATIN
NM_005417; NM_198291
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene
SRC
18790786
|
homolog (avian)
|
OXALIPLATIN
NM_003286
topoisomerase (DNA) I
TOP1
18509181
|
OXALIPLATIN
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
19015155
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
OXALIPLATIN
NM_001113755; NM_001113756; NM_001953
thymidine phosphorylase
TYMP
18728667
|
OXALIPLATIN
NM_001071
thymidylate synthetase
TYMS
15213713, 18448328, 19074750
resistance
|
OXALIPLATIN
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
18790786
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
OXALIPLATIN
NM_005429
vascular endothelial growth factor C
VEGFC
18790786
|
BUSULFAN
NM_145740
glutathione S-transferase alpha 1
GSTA1
10437668, 10570028, 8886613,
drug
|
12429583, 15779864
metabolism
|
BUSULFAN
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
15142875, 8886613
unrelated
|
BUSULFAN
NM_000852
glutathione S-transferase pi 1
GSTP1
15779864, 8886613
unrelated
|
BUSULFAN
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
16039682
unrelated
|
BUSULFAN
NM_002413
microsomal glutathione S-transferase 2
MGST2
15779864
resistance
|
PROCARBAZINE
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
16033832
|
DACARBAZINE
NM_001641; NM_080648; NM_080649
APEX nuclease (multifunctional DNA repair enzyme) 1
APEX1
16373707
resistance
|
DACARBAZINE
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
15577328
|
DACARBAZINE
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
17410615
death pathway
|
DACARBAZINE
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
17410615
|
NM_033355; NM_033356; NM_033358
|
DACARBAZINE
NM_001775
CD38 molecule
CD38
11583285, 14669796, 16078447
unrelated
|
DACARBAZINE
NM_001781
CD69 molecule
CD69
14669796, 17973783
unrelated
|
DACARBAZINE
NM_000499
cytochrome P450, family 1, subfamily A, polypeptide 1
CYP1A1
11751525
drug activation
|
DACARBAZINE
NM_000761
cytochrome P450, family 1, subfamily A, polypeptide 2
CYP1A2
11751525
drug activation
|
DACARBAZINE
NM_000799
erythropoietin
EPO
15743794
resistance
|
DACARBAZINE
NM_024013
interferon, alpha 1
IFNA1
11583285, 16078447
therapy
|
DACARBAZINE
NM_000605
interferon, alpha 2
IFNA2
14669796, 17973783
therapy
|
DACARBAZINE
NM_000584
interleukin 8
IL8
12939465, 15123733,
altered by
|
15026559, 12939465,
DTIC
|
15026559, 15123733, 12939465
|
DACARBAZINE
NM_002198
interferon regulatory factor 1
IRF1
17973783
unrelated
|
DACARBAZINE
NM_005921
mitogen-activated protein kinase kinase kinase 1
MAP3K1
15123733
|
DACARBAZINE
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
15123733
|
DACARBAZINE
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
15123733
|
DACARBAZINE
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
12787138
|
DACARBAZINE
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
10751609, 12170182, 15870882,
resistance
|
14562026
|
DACARBAZINE
NM_002689
polymerase (DNA directed), alpha 2 (70 kD subunit)
POLA2
—
|
DACARBAZINE
NM_006516
solute carrier family 2 (facilitated glucose transporter),
SLC2A1
17520257
resistance
|
member 1
|
DACARBAZINE
NM_003810
tumor necrosis factor (ligand) superfamily, member 10
TNFSF10
17410615
therapy
|
DACARBAZINE
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
12939465, 15123733, 15026559,
|
NM_001025369; NM_001025370;
12939465, 15026559, 12939465,
|
NM_001033756; NM_003376
15123733, 15026559, 15123733,
|
12939465
|
TEMOZOLOMIDE
NM_000029
angiotensinogen (serpin peptidase inhibitor, clade A,
AGT
11034089
resistance
|
member 8)
|
TEMOZOLOMIDE
—
—
AKT
—
resistance
|
TEMOZOLOMIDE
NM_004052
BCL2/adenovirus E1B 19 kDa interacting protein 3
BNIP3
—
resistance
|
TEMOZOLOMIDE
NM_001129889; NM_001922
dopachrome tautomerase (dopachrome delta-
DCT
15897911
|
isomerase, tyrosine-related protein 2)
|
TEMOZOLOMIDE
NM_002006
fibroblast growth factor 2 (basic)
FGF2
—
resistance
|
TEMOZOLOMIDE
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
—
sensitivity
|
NM_001145340; NM_002392;
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
TEMOZOLOMIDE
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
15319033, 15486188,
resistance
|
15758010, 15814657, 15833865,
|
16039682, 15865885, 16075413
|
TEMOZOLOMIDE
NM_001015052; NM_001015054; NM_002434
N-methylpurine-DNA glycosylase
MPG
15299078, 15299078, 16024643
sensitivity
|
TEMOZOLOMIDE
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
17638900
|
enhancer in B-cells inhibitor, alpha
|
TEMOZOLOMIDE
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
15867241
resistance
|
TEMOZOLOMIDE
NM_021127
phorbol-12-myristate-13-acetate-induced protein 1
PMAIP1
17216584
unrelated
|
TEMOZOLOMIDE
NM_002690
polymerase (DNA directed), beta
POLB
16024643
resistance
|
TEMOZOLOMIDE
NM_007195
polymerase (DNA directed) iota
POLI
16024643
unrelated
|
TEMOZOLOMIDE
NM_013274
polymerase (DNA directed), lambda
POLL
16024643
unrelated
|
TEMOZOLOMIDE
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
17638900
|
G/H synthase and cyclooxygenase)
|
TEMOZOLOMIDE
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
17638900
|
(avian)
|
TEMOZOLOMIDE
NM_000636; NM_001024465; NM_001024466
superoxide dismutase 2, mitochondrial
SOD2
17638900
|
TEMOZOLOMIDE
NM_198253; NM_198255
telomerase reverse transcriptase
TERT
18021753
|
TEMOZOLOMIDE
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
17638900
|
TEMOZOLOMIDE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
17216584
resistance
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
TEMOZOLOMIDE
NM_001167
X-linked inhibitor of apoptosis
XIAP
17638900
|
THIOTEPA
NM_004322; NM_032989
BCL2-associated agonist of cell death
BAD
10822281
|
THIOTEPA
NM_001188
BCL2-antagonist/killer 1
BAK1
10822281
|
THIOTEPA
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
10822281
|
NM_138764; NM_138765
|
THIOTEPA
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
10822281
|
THIOTEPA
NM_001191; NM_138578
BCL2-like 1
BCL2L1
10822281
|
THIOTEPA
NM_000767
cytochrome P450, family 2, subfamily B, polypeptide 6
CYP2B6
15769884
|
THIOTEPA
NM_145740
glutathione S-transferase alpha 1
GSTA1
7712478
polymorphism
|
THIOTEPA
NM_000846
glutathione S-transferase alpha 2
GSTA2
7712478
polymorphism
|
THIOTEPA
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
7712478
polymorphism
|
THIOTEPA
NM_000852
glutathione S-transferase pi 1
GSTP1
10334868, 7712478
polymorphism
|
THIOTEPA
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
16039682
unrelated
|
THIOTEPA
NM_002542; NM_016819; NM_016820;
8-oxoguanine DNA glycosylase
OGG1
11431349, 11
|
NM_016821; NM_016826; NM_016827;
|
NM_016828; NM_016829
|
ECTEINASCIDIN
NM_001237
cyclin A2
CCNA2
—
|
743
|
ECTEINASCIDIN
NM_031966
cyclin B1
CCNB1
—
|
743
|
ECTEINASCIDIN
NM_004701
cyclin B2
CCNB2
—
|
743
|
ECTEINASCIDIN
NM_005225
E2F transcription factor 1
E2F1
—
|
743
|
DOCETAXEL
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
15239124, 15239142
resistance
|
member 1
|
DOCETAXEL
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
15239124
resistance
|
NM_019899; NM_019900
member 1
|
DOCETAXEL
NM_000392
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC2
15849751
resistance
|
member 2
|
DOCETAXEL
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
—
resistance
|
DOCETAXEL
NM_001191; NM_138578
BCL2-like 1
BCL2L1
16080463
resistance
|
DOCETAXEL
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16224667, 19
resistance
|
DOCETAXEL
NM_001211
budding uninhibited by benzimidazoles 1 homolog beta
BUB1B
18691855
|
(yeast)
|
DOCETAXEL
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
15970518
death pathway
|
DOCETAXEL
NM_031966
cyclin B1
CCNB1
—
|
DOCETAXEL
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
16080463
unrelated
|
DOCETAXEL
NM_000103; NM_031226
cytochrome P450, family 19, subfamily A, polypeptide 1
CYP19A1
15623590
|
DOCETAXEL
NM_000104
cytochrome P450, family 1, subfamily B, polypeptide 1
CYP1B1
18187806
drug
|
metabolism
|
DOCETAXEL
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
15239142
drug
|
metabolism
|
DOCETAXEL
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
15567936, 15834928, 17010609
unrelated
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
DOCETAXEL
NM_000852
glutathione S-transferase pi 1
GSTP1
15239142
resistance
|
DOCETAXEL
NM_001530; NM_181054
hypoxia inducible factor 1, alpha subunit (basic helix-
HIF1A
17498666
altered by
|
loop-helix transcription factor)
docetaxel
|
DOCETAXEL
NM_001130442; NM_005343; NM_176795
v-Ha-ras Harvey rat sarcoma viral oncogene homolog
HRAS
15970518
resistance
|
DOCETAXEL
NM_000600
interleukin 6 (interferon, beta 2)
IL6
15623590
altered by
|
docetaxel
|
DOCETAXEL
NM_002358
MAD2 mitotic arrest deficient-like 1 (yeast)
MAD2L1
18691855
|
DOCETAXEL
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
15970518
resistance
|
DOCETAXEL
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
15970518
resistance
|
DOCETAXEL
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
16080190
|
NM_001145340; NM_002392;
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
DOCETAXEL
NR_022009; NR_022009; NR_022009;
Prader-Willi/Angelman region-1
PAR1
16052512
|
NR_022009; NR_022009; NR_022009;
|
NR_022009
|
DOCETAXEL
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
15970518
altered by
|
docetaxel
|
DOCETAXEL
NM_000926
progesterone receptor
PGR
15623590
|
DOCETAXEL
NM_000941
P450 (cytochrome) oxidoreductase
POR
15239142
unrelated
|
DOCETAXEL
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
15623590
resistance
|
G/H synthase and cyclooxygenase)
|
DOCETAXEL
NM_002880
v-raf-1 murine leukemia viral oncogene homolog 1
RAF1
15970518
unrelated
|
DOCETAXEL
NM_000321
retinoblastoma 1
RB1
15297405
|
DOCETAXEL
NM_005983; NM_032637
S-phase kinase-associated protein 2 (p45)
SKP2
18644126
unrelated
|
DOCETAXEL
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
15623590
|
DOCETAXEL
NM_003842; NM_147187
tumor necrosis factor receptor superfamily, member
TNFRSF10B
17922852
|
10b
|
DOCETAXEL
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
15297405, 15970518, 15970518,
|
NM_001126114; NM_001126115;
16080190, 16080190, 17369602
|
NM_001126116; NM_001126117
|
DOCETAXEL
NM_178014
tubulin, beta
TUBB
15239142, 16080190
target/resistance
|
DOCETAXEL
NM_030773
tubulin, beta 1
TUBB1
—
target/resistance
|
DOCETAXEL
NM_001071
thymidylate synthetase
TYMS
19074750
|
DOCETAXEL
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
17498666
altered by
|
NM_001025369; NM_001025370;
docetaxel
|
NM_001033756; NM_003376
|
DOCETAXEL
NM_001167
X-linked inhibitor of apoptosis
XIAP
19102932
|
PACLITAXEL
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
10617675, 15239142, 15650019,
resistance
|
member 1
15901749, 15990222, 15252144,
|
15990222, 15650019, 16322897,
|
18433974
|
PACLITAXEL
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
15548710
resistance
|
NM_019899; NM_019900
member 1
|
PACLITAXEL
NM_000392
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC2
15645438, 15849751
resistance
|
member 2
|
PACLITAXEL
NM_001130846; NM_001130847; NM_004208;
apoptosis-inducing factor, mitochondrion-associated, 1
AIFM1
16168113
death pathway
|
NM_145812; NM_145813
|
PACLITAXEL
NM_001354; NM_205845
aldo-keto reductase family 1, member C2 (dihydrodiol
AKR1C2
16322897
unrelated
|
dehydrogenase 2; bile acid binding protein; 3-alpha
|
hydroxysteroid dehydrogenase, type III)
|
PACLITAXEL
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
16211241, 16782806, 18071906
resistance
|
PACLITAXEL
NM_001626
v-akt murine thymoma viral oncogene homolog 2
AKT2
18071906
resistance
|
PACLITAXEL
NM_005465; NM_181690
v-akt murine thymoma viral oncogene homolog 3
AKT3
18071906
resistance
|
(protein kinase B, gamma)
|
PACLITAXEL
NM_001144
autocrine motility factor receptor
AMFR
16896004
|
PACLITAXEL
NM_001160; NM_013229; NM_181861;
apoptotic peptidase activating factor 1
APAF1
14749477
death pathway
|
NM_181868; NM_181869
|
PACLITAXEL
NM_004312
arrestin 3, retinal (X-arrestin)
ARR3
16322897
|
PACLITAXEL
NM_018136
asp (abnormal spindle) homolog, microcephaly
ASPM
17374387
|
associated (Drosophila)
|
PACLITAXEL
NM_003600; NM_198433; NM_198434;
aurora kinase A
AURKA
17374387
resistance
|
NM_198435; NM_198436; NM_198437
|
PACLITAXEL
NM_004322; NM_032989
BCL2-associated agonist of cell death
BAD
10822281, 16413505
death pathway
|
PACLITAXEL
NM_001188
BCL2-antagonist/killer 1
BAK1
10822281
|
PACLITAXEL
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
10822281, 16051289, 16168113
death pathway
|
NM_138764; NM_138765
|
PACLITAXEL
NM_033028
Bardet-Biedl syndrome 4
BBS4
16896004
|
PACLITAXEL
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
10822281, 12086014, 16168113,
resistance
|
16243823, 16275990, 16322897
|
PACLITAXEL
NM_001191; NM_138578
BCL2-like 1
BCL2L1
10822281, 14749477, 16051289,
resistance
|
16243823,
|
16275990, 11468182, 16080463
|
PACLITAXEL
NM_003766
beclin 1, autophagy related
BECN1
16896004
|
PACLITAXEL
NM_001196; NM_197966; NM_197967
BH3 interacting domain death agonist
BID
14749477
unrelated
|
PACLITAXEL
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
14749477, 16243823
unrelated
|
PACLITAXEL
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
14749477, 16243823
resistance
|
PACLITAXEL
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
14749477, 15970709, 16170024,
resistance
|
16202317, 16211241, 16373717
|
PACLITAXEL
NM_001719
bone morphogenetic protein 7
BMP7
16322897
|
PACLITAXEL
NM_001130914; NM_006806
BTG family, member 3
BTG3
16896004
|
PACLITAXEL
NM_001211
budding uninhibited by benzimidazoles 1 homolog beta
BUB1B
18691855
resistance
|
(yeast)
|
PACLITAXEL
—
—
C7ORF23
15556294
|
PACLITAXEL
NM_001218; NM_206925
carbonic anhydrase XII
CA12
16896004
unrelated
|
PACLITAXEL
NM_001033952; NM_001033953; NM_001741
calcitonin-related polypeptide alpha
CALCA
16222118
|
PACLITAXEL
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
10822281, 12086014, 16051289,
death pathway
|
16168113, 16170024, 16413505,
|
18071906
|
PACLITAXEL
NM_001227; NM_033338; NM_033339;
caspase 7, apoptosis-related cysteine peptidase
CASP7
14749477, 16168113
death pathway
|
NM_033340
|
PACLITAXEL
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
14749477, 16051289, 16168113,
death pathway
|
NM_033355; NM_033356; NM_033358
18071906
|
PACLITAXEL
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
14749477, 16168113, 16170024
death pathway
|
PACLITAXEL
NM_001753
caveolin 1, caveolae protein, 22 kDa
CAV1
16322897
altered by
|
paclitaxel
|
PACLITAXEL
NM_031966
cyclin B1
CCNB1
16356831
sensitivity/
|
resistance
|
PACLITAXEL
NM_053056
cyclin D1
CCND1
16243823
sensitivity/
|
unrelated
|
PACLITAXEL
NM_002389; NM_153826; NM_172350;
CD46 molecule, complement regulatory protein
CD46
16322897
|
NM_172351; NM_172352; NM_172353;
|
NM_172354; NM_172355; NM_172356;
|
NM_172357; NM_172358; NM_172359;
|
NM_172360; NM_172361
|
PACLITAXEL
NM_001025079; NM_001777; NM_198793
CD47 molecule
CD47
16322897
|
PACLITAXEL
NM_001785
cytidine deaminase
CDA
18728667
|
PACLITAXEL
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
16168113, 16413505
sensitivity
|
PACLITAXEL
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
16080463
resistance
|
PACLITAXEL
NM_001831; NM_203339
clusterin
CLU
16308731, 16
resistance
|
PACLITAXEL
NM_006565
CCCTC-binding factor (zinc finger protein)
CTCF
16322897
|
PACLITAXEL
NM_001332
catenin (cadherin-associated protein), delta 2 (neural
CTNND2
16896004
|
plakophilin-related arm-repeat protein)
|
PACLITAXEL
NM_001912; NM_145918
cathepsin L1
CTSL1
16322897
|
PACLITAXEL
NM_001008540; NM_003467
chemokine (C—X—C motif) receptor 4
CXCR4
16322897
|
PACLITAXEL
NM_006564
chemokine (C—X—C motif) receptor 6
CXCR6
16322897
|
PACLITAXEL
NM_020311
chemokine (C—X—C motif) receptor 7
CXCR7
16322897
|
PACLITAXEL
NM_018947
cytochrome c, somatic
CYCS
14749477, 16051289, 16413505
death pathway
|
PACLITAXEL
NM_000103; NM_031226
cytochrome P450, family 19, subfamily A, polypeptide 1
CYP19A1
14691014
|
PACLITAXEL
NM_000767
cytochrome P450, family 2, subfamily B, polypeptide 6
CYP2B6
14977870
|
PACLITAXEL
NM_000770
cytochrome P450, family 2, subfamily C, polypeptide 8
CYP2C8
12464242, 12401345, 16124035,
drug
|
15239142, 15933212, 15901749
metabolism
|
PACLITAXEL
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
12065438, 15650019, 15901749
drug
|
metabolism
|
PACLITAXEL
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
14749477
sensitivity
|
PACLITAXEL
NM_000110
dihydropyrimidine dehydrogenase
DPYD
18506536, 18630517
|
PACLITAXEL
NM_001949
E2F transcription factor 3
E2F3
16896004
|
PACLITAXEL
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15723263, 16211241, 16413505
resistance
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
PACLITAXEL
NM_001042599; NM_005235
v-erb-a erythroblastic leukemia viral oncogene
ERBB4
16896004
|
homolog 4 (avian)
|
PACLITAXEL
NM_000043; NM_152871; NM_152872;
Fas (TNF receptor superfamily, member 6)
FAS
16051289
sensitivity
|
NM_152873; NM_152874; NM_152875;
|
NM_152876; NM_152877
|
PACLITAXEL
NM_000639
Fas ligand (TNF superfamily, member 6)
FASLG
16051289
sensitivity
|
PACLITAXEL
NM_001135821; NM_001135822; NM_002004
farnesyl diphosphate synthase (farnesyl
FDPS
16322897
|
pyrophosphate synthetase,
|
dimethylallyltranstransferase, geranyltranstransferase)
|
PACLITAXEL
NM_002032
ferritin, heavy polypeptide 1
FTH1
16322897
|
PACLITAXEL
NM_000146
ferritin, light polypeptide
FTL
16322897
|
PACLITAXEL
NM_002569
furin (paired basic amino acid cleaving enzyme)
FURIN
16322897
|
PACLITAXEL
NM_001136007; NM_001136008; NM_001136009;
FXYD domain containing ion transport regulator 3
FXYD3
16322897
|
NM_001136010; NM_001136011;
|
NM_001136012; NM_005971;
|
NM_021910
|
PACLITAXEL
NM_001924
growth arrest and DNA-damage-inducible, alpha
GADD45A
16322897
sensitivity
|
PACLITAXEL
NM_000156; NM_138924
guanidinoacetate N-methyltransferase
GAMT
16896004
|
PACLITAXEL
NM_001145453; NM_005264; NM_145793
GDNF family receptor alpha 1
GFRA1
16896004
|
PACLITAXEL
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
12851839
resistance
|
PACLITAXEL
NM_000851
glutathione S-transferase mu 5
GSTM5
16322897
resistance
|
PACLITAXEL
NM_000852
glutathione S-transferase pi 1
GSTP1
15239142
resistance
|
PACLITAXEL
NM_000853
glutathione S-transferase theta 1
GSTT1
12851839
resistance
|
PACLITAXEL
NM_001530; NM_181054
hypoxia inducible factor 1, alpha subunit (basic helix-
HIF1A
17498666
|
loop-helix transcription factor)
|
PACLITAXEL
NM_000201
intercellular adhesion molecule 1
ICAM1
16243823
altered by
|
paclitaxel
|
PACLITAXEL
NM_006332
interferon, gamma-inducible protein 30
IFI30
16322897
|
PACLITAXEL
NM_000875
insulin-like growth factor 1 receptor
IGF1R
15499378
|
PACLITAXEL
NM_001552
insulin-like growth factor binding protein 4
IGFBP4
16896004
|
PACLITAXEL
NM_002213
integrin, beta 5
ITGB5
16322897
|
PACLITAXEL
—
—
JMJD2B
16896004
|
PACLITAXEL
NM_002228
jun oncogene
JUN
15585644
altered by
|
paclitaxel
|
PACLITAXEL
NM_020853
KIAA1467
KIAA1467
16896004
|
PACLITAXEL
NM_007054
kinesin family member 3A
KIF3A
16896004
|
PACLITAXEL
NM_002274; NM_153490
keratin 13
KRT13
16322897
|
PACLITAXEL
NM_002358
MAD2 mitotic arrest deficient-like 1 (yeast)
MAD2L1
18691855
|
PACLITAXEL
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
16051289, 16211241, 16413505
|
PACLITAXEL
NM_001315; NM_139012; NM_139013;
mitogen-activated protein kinase 14
MAPK14
16051289
death pathway
|
NM_139014
|
PACLITAXEL
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
16051289, 16211241, 16413505
|
PACLITAXEL
NM_002750; NM_139046; NM_139047;
mitogen-activated protein kinase 8
MAPK8
16051289
death pathway
|
NM_139049
|
PACLITAXEL
NM_001135044; NM_002752; NM_139068;
mitogen-activated protein kinase 9
MAPK9
16051289
death pathway
|
NM_139069; NM_139070
|
PACLITAXEL
NM_001123066; NM_001123067; NM_005910;
microtubule-associated protein tau
MAPT
16896004
resistance
|
NM_016834; NM_016835; NM_016841
|
PACLITAXEL
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
14749477
resistance
|
PACLITAXEL
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
13130078
resistance
|
NM_001145340; NM_002392;
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
PACLITAXEL
NM_004774
mediator complex subunit 1
MED1
15650019
|
PACLITAXEL
NM_015335
mediator complex subunit 13-like
MED13L
16896004
|
PACLITAXEL
NM_014791
maternal embryonic leucine zipper kinase
MELK
16896004
|
PACLITAXEL
NM_024042
meteorin, glial cell differentiation regulator
METRN
16896004
|
PACLITAXEL
NM_004994
matrix metallopeptidase 9 (gelatinase B, 92 kDa
MMP9
16243823
|
gelatinase, 92 kDa type IV collagenase)
|
PACLITAXEL
NM_175617
metallothionein 1E
MT1E
16322897
unrelated
|
PACLITAXEL
NM_005953
metallothionein 2A
MT2A
16322897
unrelated
|
PACLITAXEL
NM_002467
v-myc myelocytomatosis viral oncogene homolog
MYC
16243823, 18802399
death pathway
|
(avian)
|
PACLITAXEL
NM_000662
N-acetyltransferase 1 (arylamine N-acetyltransferase)
NAT1
15015580, 17564303
altered by
|
paclitaxel
|
PACLITAXEL
NM_006534; NM_181659
nuclear receptor coactivator 3
NCOA3
15650019
|
PACLITAXEL
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
16243823
altered by
|
enhancer in B-cells 1
paclitaxel
|
PACLITAXEL
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
16243823
sensitivity
|
enhancer in B-cells inhibitor, alpha
|
PACLITAXEL
NM_024522
Na+/K+ transporting ATPase interacting 1
NKAIN1
16896004
|
PACLITAXEL
NM_003889; NM_022002; NM_033013
nuclear receptor subfamily 1, group I, member 2
NR1I2
14977870, 15864135, 15650019,
resistance
|
15650019, 12065438, 15864135
|
PACLITAXEL
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
14749477, 15585644,
altered by
|
18071906, 15585644
paclitaxel
|
PACLITAXEL
NM_002613; NM_031268
3-phosphoinositide dependent protein kinase-1
PDPK1
16782806
resistance
|
PACLITAXEL
NM_000304; NM_153321; NM_153322
peripheral myelin protein 22
PMP22
16322897
|
PACLITAXEL
NM_000941
P450 (cytochrome) oxidoreductase
POR
15239142
unrelated
|
PACLITAXEL
NM_003981; NM_199413; NM_199414
protein regulator of cytokinesis 1
PRC1
17374387
|
PACLITAXEL
NM_000314
phosphatase and tensin homolog
PTEN
11707646, 15548710
resistance/
|
mutation
|
PACLITAXEL
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
16127422, 16243823, 16831230
sensitivity/
|
G/H synthase and cyclooxygenase)
resistance
|
PACLITAXEL
NM_005855
receptor (G protein-coupled) activity modifying protein 1
RAMP1
16896004
|
PACLITAXEL
NM_000321
retinoblastoma 1
RB1
15138593
altered by
|
paclitaxel
|
PACLITAXEL
NM_005611
retinoblastoma-like 2 (p130)
RBL2
15585644
unrelated
|
PACLITAXEL
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
15291876, 16243823
resistance
|
(avian)
|
PACLITAXEL
NM_000449; NM_001025603
regulatory factor X, 5 (influences HLA class II
RFX5
16322897
|
expression)
|
PACLITAXEL
NM_000984
ribosomal protein L23a
RPL23A
16322897
|
PACLITAXEL
NM_001003; NM_213725
ribosomal protein, large, P1
RPLP1
16322897
|
PACLITAXEL
NM_001034
ribonucleotide reductase M2 polypeptide
RRM2
16896004
|
PACLITAXEL
NM_001015055; NM_001015056; NM_033046
rhotekin
RTKN
15480428
|
PACLITAXEL
NM_005980
S100 calcium binding protein P
S100P
16322897, 18636193
sensitivity
|
PACLITAXEL
NM_020974
signal peptide, CUB domain, EGF-like 2
SCUBE2
16896004
|
PACLITAXEL
NM_003130; NM_198901
sorcin
SRI
18423116
|
PACLITAXEL
NM_198253; NM_198255
telomerase reverse transcriptase
TERT
18021753
|
PACLITAXEL
NM_003225
trefoil factor 1
TFF1
16322897
|
PACLITAXEL
NM_018271
threonine synthase-like 2 (S. cerevisiae)
THNSL2
16896004
|
PACLITAXEL
NM_003842; NM_147187
tumor necrosis factor receptor superfamily, member
TNFRSF10B
17922852
altered by
|
10b
paclitaxel
|
PACLITAXEL
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
16322897
altered by
|
paclitaxel
|
PACLITAXEL
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
15990222, 15990222, 12082016,
unrelated
|
NM_001126114; NM_001126115;
16168113, 16413505
|
NM_001126116; NM_001126117
|
PACLITAXEL
NM_178014
tubulin, beta
TUBB
15239142
target/resistance
|
PACLITAXEL
NM_030773
tubulin, beta 1
TUBB1
—
target ?
|
PACLITAXEL
NM_001113755; NM_001113756; NM_001953
thymidine phosphorylase
TYMP
18506536, 18630517
|
PACLITAXEL
NM_001071
thymidylate synthetase
TYMS
10482907, 16168113, 18630517
unrelated
|
PACLITAXEL
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
16243823, 17498666
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
PACLITAXEL
NM_001167
X-linked inhibitor of apoptosis
XIAP
16243823, 16356831, 18071906
resistance
|
PACLITAXEL
NM_024762
zinc finger protein 552
ZNF552
16896004
|
VINBLASTINE
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
11355955, 8917702, 15725475,
resistance
|
member 1
15466210, 15640379, 15824923,
|
16221533
|
VINBLASTINE
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
16156793
resistance
|
NM_019899; NM_019900
member 1
|
VINBLASTINE
NM_000392
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC2
15849751, 9525973, 15849751
resistance
|
member 2
|
VINBLASTINE
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
14757846
|
VINBLASTINE
NM_001556
inhibitor of kappa light polypeptide gene enhancer in B-
IKBKB
17029595
altered by VB
|
cells, kinase beta
|
VINBLASTINE
NM_002228
jun oncogene
JUN
12221076
resistance
|
VINBLASTINE
NM_002750; NM_139046; NM_139047;
mitogen-activated protein kinase 8
MAPK8
12221076
death pathway
|
NM_139049
|
VINBLASTINE
NM_001135044; NM_002752; NM_139068;
mitogen-activated protein kinase 9
MAPK9
12221076
death pathway
|
NM_139069; NM_139070
|
VINBLASTINE
NM_002467
v-myc myelocytomatosis viral oncogene homolog
MYC
18802399
|
(avian)
|
VINBLASTINE
NM_001136022; NM_004554
nuclear factor of activated T-cells, cytoplasmic,
NFATC4
17044076
|
calcineurin-dependent 4
|
VINBLASTINE
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
17029595
|
enhancer in B-cells inhibitor, alpha
|
VINBLASTINE
NM_006788
ralA binding protein 1
RALBP1
—
resistance
|
VINBLASTINE
NM_003842; NM_147187
tumor necrosis factor receptor superfamily, member
TNFRSF10B
17922852
|
10b
|
VINBLASTINE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
12221076
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
VINBLASTINE
NM_001069
tubulin, beta 2A
TUBB2A
—
unrelated
|
VINCRISTINE
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
10617675, 11934808,
resistance
|
member 1
15239124, 16038730, 15645438,
|
16925584
|
VINCRISTINE
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
10900222, 15581632, 15896345,
resistance
|
NM_019899; NM_019900
member 1
16042792, 15896345, 10900222,
|
15044619, 12067707
|
VINCRISTINE
NM_000392
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC2
15896345
resistance
|
member 2
|
VINCRISTINE
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
16740780
resistance
|
VINCRISTINE
NM_001160; NM_013229; NM_181861;
apoptotic peptidase activating factor 1
APAF1
16001973
death pathway
|
NM_181868; NM_181869
|
VINCRISTINE
NM_000039
apolipoprotein A-I
APOA1
16001973
|
VINCRISTINE
NM_018136
asp (abnormal spindle) homolog, microcephaly
ASPM
17374387
|
associated (Drosophila)
|
VINCRISTINE
NM_003600; NM_198433; NM_198434;
aurora kinase A
AURKA
17374387
resistance
|
NM_198435; NM_198436; NM_198437
|
VINCRISTINE
NM_004322; NM_032989
BCL2-associated agonist of cell death
BAD
16001973
death pathway
|
VINCRISTINE
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
16001973
death pathway
|
NM_138764; NM_138765
|
VINCRISTINE
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
16001973
resistance
|
VINCRISTINE
NM_001223; NM_033292; NM_033293;
caspase 1, apoptosis-related cysteine peptidase
CASP1
16001973
|
NM_033294; NM_033295
(interleukin 1, beta, convertase)
|
VINCRISTINE
NM_001230; NM_032974; NM_032977
caspase 10, apoptosis-related cysteine peptidase
CASP10
16001973
|
VINCRISTINE
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
16001973
death pathway
|
VINCRISTINE
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16001973
death pathway
|
VINCRISTINE
NM_001225; NM_033306
caspase 4, apoptosis-related cysteine peptidase
CASP4
16001973
|
VINCRISTINE
NM_001136109; NM_001136110; NM_001136111;
caspase 5, apoptosis-related cysteine peptidase
CASP5
16001973
|
NM_001136112; NM_004347
|
VINCRISTINE
NM_001226; NM_032992
caspase 6, apoptosis-related cysteine peptidase
CASP6
16001973
death pathway
|
VINCRISTINE
NM_001227; NM_033338; NM_033339;
caspase 7, apoptosis-related cysteine peptidase
CASP7
16001973
death pathway
|
NM_033340
|
VINCRISTINE
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
16001973
death pathway
|
NM_033355; NM_033356; NM_033358
|
VINCRISTINE
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
16001973
death pathway
|
VINCRISTINE
NM_001752
catalase
CAT
11178967
|
VINCRISTINE
NM_005194
CCAAT/enhancer binding protein (C/EBP), beta
CEBPB
16001973
|
VINCRISTINE
NM_001025194; NM_001025195; NM_001266
carboxylesterase 1 (monocyte/macrophage serine
CES1
16001973
|
esterase 1)
|
VINCRISTINE
NM_000492
cystic fibrosis transmembrane conductance regulator
CFTR
16038730
|
(ATP-binding cassette sub-family C, member 7)
|
VINCRISTINE
NM_020313
cytokine induced apoptosis inhibitor 1
CIAPIN1
18389626
|
VINCRISTINE
NM_001916
cytochrome c-1
CYC1
16001973
death pathway
|
VINCRISTINE
NM_005225
E2F transcription factor 1
E2F1
16001973
|
VINCRISTINE
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
16001973
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
VINCRISTINE
NM_003824
Fas (TNFRSF6)-associated via death domain
FADD
16001973
|
VINCRISTINE
NM_012306
Fas apoptotic inhibitory molecule 2
FAIM2
16001973
|
VINCRISTINE
NM_002046
glyceraldehyde-3-phosphate dehydrogenase
GAPDH
16001973
|
VINCRISTINE
NM_001498
glutamate-cysteine ligase, catalytic subunit
GCLC
10900222
|
VINCRISTINE
NM_002061
glutamate-cysteine ligase, modifier subunit
GCLM
10900222
|
VINCRISTINE
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
15044619, 15713801
resistance
|
VINCRISTINE
NM_000852
glutathione S-transferase pi 1
GSTP1
10900222
|
VINCRISTINE
NM_016315
GULP, engulfment adaptor PTB domain containing 1
GULP1
16001973
|
VINCRISTINE
NM_001130442; NM_005343; NM_176795
v-Ha-ras Harvey rat sarcoma viral oncogene homolog
HRAS
16001973
resistance
|
VINCRISTINE
NM_000415
islet amyloid polypeptide
IAPP
16001973
|
VINCRISTINE
NM_000618; NM_001111283; NM_001111284;
insulin-like growth factor 1 (somatomedin C)
IGF1
16740780
|
NM_001111285
|
VINCRISTINE
NM_000875
insulin-like growth factor 1 receptor
IGF1R
16001973
resistance
|
VINCRISTINE
NM_000600
interleukin 6 (interferon, beta 2)
IL6
16001973
unrelated
|
VINCRISTINE
NM_005572; NM_170707; NM_170708
lamin A/C
LMNA
16001973
|
VINCRISTINE
NM_005573
lamin B1
LMNB1
16001973
resistance
|
VINCRISTINE
NM_003010
mitogen-activated protein kinase kinase 4
MAP2K4
16001973
altered by
|
vincristine
|
VINCRISTINE
NM_003188; NM_145331; NM_145332;
mitogen-activated protein kinase kinase kinase 7
MAP3K7
16001973
|
NM_145333
|
VINCRISTINE
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
16001973
|
VINCRISTINE
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
16001973
|
NM_001145340; NM_002392;
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
VINCRISTINE
NM_001130926; NM_001130927; NM_001130928;
myocyte enhancer factor 2A
MEF2A
16001973
|
NM_005587
|
VINCRISTINE
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
16033832
|
VINCRISTINE
NM_002467
v-myc myelocytomatosis viral oncogene homolog
MYC
16001973
|
(avian)
|
VINCRISTINE
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
15744361, 16001973
resistance
|
enhancer in B-cells 1
|
VINCRISTINE
NM_006025
26 serine protease
P11
16001973
|
VINCRISTINE
—
—
PCAF
16001973
|
VINCRISTINE
NM_003981; NM_199413; NM_199414
protein regulator of cytokinesis 1
PRC1
17374387
|
VINCRISTINE
NM_000311; NM_001080121; NM_001080122;
prion protein
PRNP
15386405
|
NM_001080123; NM_183079
|
VINCRISTINE
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
18695918
|
G/H synthase and cyclooxygenase)
|
VINCRISTINE
NM_004103; NM_173174; NM_173175;
PTK2B protein tyrosine kinase 2 beta
PTK2B
11478917
|
NM_173176
|
VINCRISTINE
NM_006264; NM_080683; NM_080684;
protein tyrosine phosphatase, non-receptor type 13
PTPN13
16001973
|
NM_080685
(APO-1/CD95 (Fas)-associated phosphatase)
|
VINCRISTINE
NM_006788
ralA binding protein 1
RALBP1
—
|
VINCRISTINE
NM_000965; NM_016152
retinoic acid receptor, beta
RARB
17608728
|
VINCRISTINE
NM_001145547; NM_032905
RNA binding motif protein 17
RBM17
16061639
resistance
|
VINCRISTINE
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
15744361
resistance
|
(avian)
|
VINCRISTINE
NM_002944
c-ros oncogene 1, receptor tyrosine kinase
ROS1
16001973
|
VINCRISTINE
NM_001031680; NM_004350
runt-related transcription factor 3
RUNX3
15756676
|
VINCRISTINE
NM_006516
solute carrier family 2 (facilitated glucose transporter),
SLC2A1
17520257
|
member 1
|
VINCRISTINE
NM_005633
son of sevenless homolog 1 (Drosophila)
SOS1
16001973
|
VINCRISTINE
NM_003130; NM_198901
sorcin
SRI
18423116
|
VINCRISTINE
NM_007315; NM_139266
signal transducer and activator of transcription 1,
STAT1
16001973
|
91 kDa
|
VINCRISTINE
NM_005419
signal transducer and activator of transcription 2,
STAT2
16001973
|
113 kDa
|
VINCRISTINE
NM_003150; NM_139276; NM_213662
signal transducer and activator of transcription 3
STAT3
16001973
|
(acute-phase response factor)
|
VINCRISTINE
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
16001973
synergistic
|
effects
|
VINCRISTINE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
12082016, 16001973, 17555331
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
VINCRISTINE
NM_000365; NM_001159287
triosephosphate isomerase 1
TPI1
18309519
|
VINCRISTINE
NM_001069
tubulin, beta 2A
TUBB2A
—
target?
|
VINCRISTINE
NM_001071
thymidylate synthetase
TYMS
15713801
|
VINCRISTINE
NM_000376; NM_001017535
vitamin D (1,25-dihydroxyvitamin D3) receptor
VDR
15713801
|
VINCRISTINE
NM_001079539; NM_005080
X-box binding protein 1
XBP1
17353921
|
VINFLUNINE
NM_030773
tubulin, beta 1
TUBB1
—
target
|
VINDESINE
NM_030773
tubulin, beta 1
TUBB1
—
target
|
VINORELBINE
NM_006788
ralA binding protein 1
RALBP1
—
resistance
|
VINORELBINE
NM_001145547; NM_032905
RNA binding motif protein 17
RBM17
16061639
resistance
|
VINORELBINE
NM_001078174; NM_001078175; NM_001078176;
solute carrier family 29 (nucleoside transporters),
SLC29A1
18452103
resistance
|
NM_001078177; NM_004955
member 1
|
VINORELBINE
NM_001069
tubulin, beta 2A
TUBB2A
—
target
|
EPOTHILONES
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
12517783
death pathway
|
NM_138764; NM_138765
|
EPOTHILONES
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
12517783
resistance
|
EPOTHILONES
NM_001191; NM_138578
BCL2-like 1
BCL2L1
12517783
|
EPOTHILONES
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
12517783
altered by
|
epothilone
|
EPOTHILONES
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
12517783
altered by
|
epothilone
|
EPOTHILONES
—
—
TUBA1
—
|
EPOTHILONES
—
—
TUBA2
—
|
EPOTHILONES
—
—
TUBA3
—
|
EPOTHILONES
—
—
TUBA6
—
|
EPOTHILONES
NM_018943
tubulin, alpha 8
TUBA8
—
|
EPOTHILONES
NM_030773
tubulin, beta 1
TUBB1
—
target?
|
EPOTHILONES
NM_001069
tubulin, beta 2A
TUBB2A
—
target?
|
EPOTHILONES
NM_006088
tubulin, beta 2C
TUBB2C
—
target?
|
EPOTHILONES
NM_006086
tubulin, beta 3
TUBB3
—
target?
|
EPOTHILONES
NM_006087
tubulin, beta 4
TUBB4
—
target?
|
EPOTHILONES
NM_020040
tubulin, beta polypeptide 4, member Q
TUBB4Q
—
target?
|
EPOTHILONES
NM_001167
X-linked inhibitor of apoptosis
XIAP
12517783
altered by
|
epothilone
|
DOXORUBICIN
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
11355955, 15765123, 11313874,
resistance
|
member 1
17947497, (following)
|
(following) 8917702, 15725475, 15861398, 15239142, 15501994, 15501994, 16579640, 15501994, 17526808, 15736412, 15861398, 15946544, 15967469, 16223781,
|
16322897, 16044152, 15765123, 16356834, 16499877, 16544145, 16544145, 18510171, 18560228, 17852453, 16579640, 17085340, 17483874, 8917702, 17526808, 17947497,
|
17947497, 17526808, 18461970, 8917702
|
DOXORUBICIN
—
—
ABCB1A
15695394
resistance
|
DOXORUBICIN
NM_000443; NM_018849; NM_018850
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB4
11313874, 12926078, 16579640
resistance
|
member 4
|
DOXORUBICIN
NM_178559
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB5
15899824
resistance
|
member 5
|
DOXORUBICIN
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
11560771, 12504668, 15473893,
resistance
|
NM_019899; NM_019900
member 1
15473893, 12067707, 11560771,
|
10900222, 12657726, 17940500,
|
15548710, 15581632, 15880572,
|
15946544, 16331495, 17352253,
|
17852453, 18560228, 17940500
|
DOXORUBICIN
NM_001144070; NM_003786
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC3
15695394, 15884115, 15901850,
resistance
|
member 3
18463201
|
DOXORUBICIN
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
17273774, 17938326, 18382425
resistance
|
DOXORUBICIN
NM_023038; NM_033274
ADAM metallopeptidase domain 19 (meltrin beta)
ADAM19
18510171
|
DOXORUBICIN
NM_007038
ADAM metallopeptidase with thrombospondin type 1
ADAMTS5
16404146
|
motif, 5
|
DOXORUBICIN
NM_000687; NM_001161766
adenosylhomocysteinase
AHCY
18510171
|
DOXORUBICIN
NM_001130846; NM_001130847; NM_004208;
apoptosis-inducing factor, mitochondrion-associated, 1
AIFM1
16168113
|
NM_145812; NM_145813
|
DOXORUBICIN
NM_006066; NM_153326
aldo-keto reductase family 1, member A1 (aldehyde
AKR1A1
18322072
drug
|
reductase)
metabolism
|
DOXORUBICIN
NM_001354; NM_205845
aldo-keto reductase family 1, member C2 (dihydrodiol
AKR1C2
18322072
|
dehydrogenase 2; bile acid binding protein; 3-alpha
|
hydroxysteroid dehydrogenase, type III)
|
DOXORUBICIN
NM_003739
aldo-keto reductase family 1, member C3 (3-alpha
AKR1C3
18635746
drug
|
hydroxysteroid dehydrogenase, type II)
metabolism
|
DOXORUBICIN
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
15494689, 16168102, 17359293,
resistance
|
16059641, 16168102, 16438844,
|
16740780, 16782806, 17339365,
|
17359293, 17935137,
|
17935137, 16168102, 18071906
|
DOXORUBICIN
NM_001626
v-akt murine thymoma viral oncogene homolog 2
AKT2
18071906
resistance
|
DOXORUBICIN
NM_005465; NM_181690
v-akt murine thymoma viral oncogene homolog 3
AKT3
18071906
resistance
|
(protein kinase B, gamma)
|
DOXORUBICIN
NM_000477
albumin
ALB
17378599, 17378599, 16211657
used as drug
|
carrier
|
DOXORUBICIN
NM_001144
autocrine motility factor receptor
AMFR
16896004
|
DOXORUBICIN
NM_001146
angiopoietin 1
ANGPT1
15763944
resistance
|
DOXORUBICIN
NM_007347
adaptor-related protein complex 4, epsilon 1 subunit
AP4E1
16044152
|
DOXORUBICIN
NM_001160; NM_013229; NM_181861;
apoptotic peptidase activating factor 1
APAF1
15939500, 16001973, 15939500
death pathway
|
NM_181868; NM_181869
|
DOXORUBICIN
NM_001142930; NM_001142931; NM_006595
apoptosis inhibitor 5
API5
16322897
|
DOXORUBICIN
NM_000039
apolipoprotein A-I
APOA1
16001973
|
DOXORUBICIN
NM_000484; NM_001136016; NM_001136129;
amyloid beta (A4) precursor protein
APP
17608641
resistance
|
NM_001136130; NM_001136131;
|
NM_201413; NM_201414
|
DOXORUBICIN
NM_004706; NM_198977; NM_199002
Rho guanine nucleotide exchange factor (GEF) 1
ARHGEF1
16404146
|
DOXORUBICIN
NM_014786
Rho guanine nucleotide exchange factor (GEF) 17
ARHGEF17
16404146
|
DOXORUBICIN
NM_006407
ADP-ribosylation-like factor 6 interacting protein 5
ARL6IP5
16430862
|
DOXORUBICIN
NM_001675; NM_182810
activating transcription factor 4 (tax-responsive
ATF4
16298333
|
enhancer element B67)
|
DOXORUBICIN
NM_000051; NM_138292
ataxia telangiectasia mutated
ATM
15489221
|
DOXORUBICIN
NM_003945
ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit
ATP6V0E1
16579640
|
e1
|
DOXORUBICIN
NM_001185
alpha-2-glycoprotein 1, zinc-binding
AZGP1
16404146
|
DOXORUBICIN
NM_001497
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,
B4GALT1
16404146
|
polypeptide 1
|
DOXORUBICIN
NM_001011545; NM_001186; NM_206866
BTB and CNC homology 1, basic leucine zipper
BACH1
16322897
|
transcription factor 1
|
DOXORUBICIN
NM_004322; NM_032989
BCL2-associated agonist of cell death
BAD
16001973, 16438844, 16705698,
|
16843435, 17359293
|
DOXORUBICIN
NM_004323
BCL2-associated athanogene
BAG1
16322899
|
DOXORUBICIN
NM_001188
BCL2-antagonist/killer 1
BAK1
11313874, 15917298
|
DOXORUBICIN
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
14601052, 15456408, 15492826,
|
NM_138764; NM_138765
15576332, 15939500, 15985719,
|
16001973, 17404015, 16168113,
|
16322301, 16705698, 17542780,
|
17959036,
|
17959036, 17339365, 17542780,
|
17922852
|
DOXORUBICIN
NM_001127240; NM_001127241; NM_001127242;
BCL2 binding component 3
BBC3
16439685
|
NM_014417
|
DOXORUBICIN
NM_152618
Bardet-Biedl syndrome 12
BBS12
16044152
|
DOXORUBICIN
NM_033028
Bardet-Biedl syndrome 4
BBS4
16896004
|
DOXORUBICIN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
14601052, 15897917, 15571967,
|
15576332,
|
(following) 15939500, 15985719, 16001973, 17404015, 18560228, 16168113, 16322301, 17541305, 16450387, 16322899, 16705698, 16890185, 17542780, 17959036,
|
17959036, 17542780, 16890185, 18325115
|
DOXORUBICIN
NM_001114735; NM_004049
BCL2-related protein A1
BCL2A1
16572199
|
DOXORUBICIN
NM_001191; NM_138578
BCL2-like 1
BCL2L1
14601052, 15781649, 11468182,
|
15911101, 15939500, 15939500,
|
18560228, 16843435, 17912235,
|
17922852, 16843435, 17923112
|
DOXORUBICIN
NM_006538; NM_138621; NM_207002
BCL2-like 11 (apoptosis facilitator)
BCL2L11
17339365
|
DOXORUBICIN
NM_001040668; NM_138639
BCL2-like 12 (proline rich)
BCL2L12
15576332, 17404015
|
DOXORUBICIN
NM_003766
beclin 1, autophagy related
BECN1
16718815, 16896004
|
DOXORUBICIN
NM_001196; NM_197966; NM_197967
BH3 interacting domain death agonist
BID
15812552, 15870702, 16705698,
|
16868541
|
DOXORUBICIN
NM_001197
BCL2-interacting killer (apoptosis-inducing)
BIK
16007125, 16705698
|
DOXORUBICIN
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
14601052, 14666661, 15359644,
|
15571967, 15571967, 14666661,
|
17521628
|
DOXORUBICIN
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
12926068, 12948851, 15899819,
|
15911101, 16705698, 17521628
|
DOXORUBICIN
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
11911975, 16086872, 16364925,
|
16108013, 11911975, 17124180,
|
16108013, 14601052, 16086872,
|
16086872, 17521628, 16108013,
|
17124180
|
DOXORUBICIN
NM_016252
baculoviral IAP repeat-containing 6
BIRC6
17521628
|
DOXORUBICIN
NM_022161; NM_139317
baculoviral IAP repeat-containing 7
BIRC7
17521628
|
DOXORUBICIN
NM_033341
baculoviral IAP repeat-containing 8
BIRC8
17521628
|
DOXORUBICIN
NM_007294; NM_007295; NM_007296;
breast cancer 1, early onset
BRCA1
10344722
|
NM_007297; NM_007298; NM_007299;
|
NM_007300; NM_007302; NM_007303;
|
NM_007304; NM_007305
|
DOXORUBICIN
NM_000059
breast cancer 2, early onset
BRCA2
10344722
|
DOXORUBICIN
NM_001731
B-cell translocation gene 1, anti-proliferative
BTG1
16705698
|
DOXORUBICIN
NM_006763
BTG family, member 2
BTG2
16705698
|
DOXORUBICIN
NM_001130914; NM_006806
BTG family, member 3
BTG3
16896004
|
DOXORUBICIN
NM_001211
budding uninhibited by benzimidazoles 1 homolog beta
BUB1B
15870702
|
(yeast)
|
DOXORUBICIN
NM_001007793; NM_004725
budding uninhibited by benzimidazoles 3 homolog
BUB3
16322899
|
(yeast)
|
DOXORUBICIN
—
—
C21ORF87
16044152
|
DOXORUBICIN
—
—
C5ORF13
16044152
|
DOXORUBICIN
—
—
C7ORF23
15556294, 15556294, 18510171
|
DOXORUBICIN
NM_001218; NM_206925
carbonic anhydrase XII
CA12
16896004
|
DOXORUBICIN
NM_020247
chaperone, ABC1 activity of bc1 complex
CABC1
16404146
|
homolog (S. pombe)
|
DOXORUBICIN
NM_004342; NM_033138; NM_033139;
caldesmon 1
CALD1
16044152
|
NM_033140; NM_033157
|
DOXORUBICIN
NM_014289
calpain 6
CAPN6
16404146
|
DOXORUBICIN
NM_001223; NM_033292; NM_033293;
caspase 1, apoptosis-related cysteine peptidase
CASP1
16001973
|
NM_033294; NM_033295
(interleukin 1, beta, convertase)
|
DOXORUBICIN
NM_001230; NM_032974; NM_032977
caspase 10, apoptosis-related cysteine peptidase
CASP10
16001973
|
DOXORUBICIN
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
14757846, 15917298, 16001973,
|
17013758
|
DOXORUBICIN
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
15456408, 15557793, 15571967,
|
15578696,
|
(following) 15812552, 15870702, 15939500, 15981920, 15985719,
|
15985719, 16962673, 17437844, 15456408, 16364925, 17085670, 17088416, 16909308, 15680309, 15981920, 19106633, 15571967, 15578696, 16823846, 16843435, 15868924, 18508926,
|
16001973, 15576332, 16705698, 15939500, 16168113, 16364925, 16823846, 16843435, 16868541, 16890185, 16909308, 16962673, 17013758, 17085670, 17088416, 17285121,
|
17437844, 17542780, 17935137, 17935137, 17542780, 16024631, 18246814, 15897917, 17285121, 16890185, 17651020, 17959036,
|
17959036, 15557793, 18071906, 15555623, 17653088, 18246814, 18278454, 18508926, 19106633
|
DOXORUBICIN
NM_001225; NM_033306
caspase 4, apoptosis-related cysteine peptidase
CASP4
16001973
|
DOXORUBICIN
NM_001136109; NM_001136110; NM_001136111;
caspase 5, apoptosis-related cysteine peptidase
CASP5
16001973
|
NM_001136112; NM_004347
|
DOXORUBICIN
NM_001226; NM_032992
caspase 6, apoptosis-related cysteine peptidase
CASP6
15870702, 16001973, 17437844,
|
17922852, 17437844
|
DOXORUBICIN
NM_001227; NM_033338; NM_033339;
caspase 7, apoptosis-related cysteine peptidase
CASP7
15870702, 16001973, 16705698,
|
NM_033340
16024631, 16168113, 16298333,
|
17653088, 19106633
|
DOXORUBICIN
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
15812552, 15870702, 15897917,
|
NM_033355; NM_033356; NM_033358
16024631, 15981920, 16001973,
|
16168113, 16705698, 16868541,
|
17013758, 17437844, 17437844,
|
18508926, 15868924, 17970047,
|
18071906, 18508926
|
DOXORUBICIN
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
15812552, 15870702, 15939500,
|
15981920,
|
(following) 15981920, 15868924, 18508926, 17437844, 16001973, 15576332, 15939500, 16168113, 16311509, 16311509, 15557793, 17935137, 17653088, 15555623, 16364925,
|
16705698, 17013758, 17285121, 17339365, 17404015, 17437844, 17651020, 17651020, 17285121, 16024631, 16364925, 17935137, 18508926
|
DOXORUBICIN
NM_001757
carbonyl reductase 1
CBR1
18635746
drug
|
metabolism
|
DOXORUBICIN
NM_002982
chemokine (C-C motif) ligand 2
CCL2
12908082
|
DOXORUBICIN
NM_001237
cyclin A2
CCNA2
16036217, 16284694, 16537896,
|
17390037
|
DOXORUBICIN
NM_031966
cyclin B1
CCNB1
15141020, 16537896, 16928833,
|
17320279, 17893511
|
DOXORUBICIN
NM_053056
cyclin D1
CCND1
16036217
|
DOXORUBICIN
NM_001759
cyclin D2
CCND2
16928833
|
DOXORUBICIN
NM_001238; NM_057182
cyclin E1
CCNE1
16036217
|
DOXORUBICIN
NM_000610; NM_001001389; NM_001001390;
CD44 molecule (Indian blood group)
CD44
16705698
|
NM_001001391; NM_001001392
|
DOXORUBICIN
NM_001130829; NM_001786; NM_033379
cell division cycle 2, G1 to S and G2 to M
CDC2
15870702, 16036217, 16537896,
|
17320279, 17320279, 15141020
|
DOXORUBICIN
NM_001790; NM_022809
cell division cycle 25 homolog C (S. pombe)
CDC25C
17320279, 19074854
sensitivity
|
DOXORUBICIN
NM_001098533; NM_001160367; NM_052987;
cyclin-dependent kinase 10
CDK10
16404146
|
NM_052988
|
DOXORUBICIN
NM_001798; NM_052827
cyclin-dependent kinase 2
CDK2
15823547, 16036217
|
DOXORUBICIN
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
14601052, 15141020, 15492826,
|
15601469,
|
(following) 15781256, 15823547, 16168113, 16537896, 17974990, 15601469, 15555623, 19074854, 17682292, 17653088, 15781256, 16909308, 17079232,
|
17653088, 16705698, 16439685, 17682292, 17893511, 17974990, 18269916, 19074854
|
DOXORUBICIN
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
16322899, 16705698, 17893511,
|
16036217, 17935137
|
DOXORUBICIN
NM_000077; NM_058195; NM_058197
cyclin-dependent kinase inhibitor 2A (melanoma, p16,
CDKN2A
16705698
|
inhibits CDK4)
|
DOXORUBICIN
NM_005194
CCAAT/enhancer binding protein (C/EBP), beta
CEBPB
16001973
|
DOXORUBICIN
NM_001042426; NM_001809
centromere protein A
CENPA
15870702
|
DOXORUBICIN
NM_001025194; NM_001025195; NM_001266
carboxylesterase 1 (monocyte/macrophage serine
CES1
16001973
|
esterase 1)
|
DOXORUBICIN
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
14601052, 16
|
DOXORUBICIN
NM_000492
cystic fibrosis transmembrane conductance regulator
CFTR
17762173
|
(ATP-binding cassette sub-family C, member 7)
|
DOXORUBICIN
NM_001114121; NM_001114122; NM_001274
CHK1 checkpoint homolog (S. pombe)
CHEK1
15489221, 15870702, 16036217,
|
17085670, 17088865, 17088865,
|
17085670, 17320279, 18698031
|
DOXORUBICIN
NM_001005735; NM_007194; NM_145862
CHK2 checkpoint homolog (S. pombe)
CHEK2
15489221, 17085670, 17320279
|
DOXORUBICIN
NM_001278
conserved helix-loop-helix ubiquitous kinase
CHUK
18463201
|
DOXORUBICIN
NM_020313
cytokine induced apoptosis inhibitor 1
CIAPIN1
18389626
|
DOXORUBICIN
NM_013324; NM_145071
cytokine inducible SH2-containing protein
CISH
16044152
|
DOXORUBICIN
NM_021101
claudin 1
CLDN1
16404146
|
DOXORUBICIN
NM_002956; NM_198240
CAP-GLY domain containing linker protein 1
CLIP1
16404146
|
DOXORUBICIN
NM_001294
cleft lip and palate associated transmembrane protein 1
CLPTM1
16243817
|
DOXORUBICIN
NM_001831; NM_203339
clusterin
CLU
16322897
|
DOXORUBICIN
NM_030582; NM_130444; NM_130445
collagen, type XVIII, alpha 1
COL18A1
17627616
|
DOXORUBICIN
—
cytochrome c oxidase II
COX2
16278810
|
DOXORUBICIN
NM_001031847; NM_001876
carnitine palmitoyltransferase 1A (liver)
CPT1A
16283381
|
DOXORUBICIN
NM_001079846; NM_004380
CREB binding protein
CREBBP
17498666
|
DOXORUBICIN
NM_001142407; NM_001142408; NM_001142417;
cysteine-rich secretory protein 2
CRISP2
16404146
|
NM_001142435; NM_003296
|
DOXORUBICIN
NM_000394
crystallin, alpha A
CRYAA
16322897
|
DOXORUBICIN
NM_001885
crystallin, alpha B
CRYAB
16322897
|
DOXORUBICIN
NM_001897
chondroitin sulfate proteoglycan 4
CSPG4
16404146
|
DOXORUBICIN
NM_001901
connective tissue growth factor
CTGF
16579640
|
DOXORUBICIN
NM_001012329; NM_020248
catenin, beta interacting protein 1
CTNNBIP1
16322899
|
DOXORUBICIN
NM_001332
catenin (cadherin-associated protein), delta 2 (neural
CTNND2
16896004
|
plakophilin-related arm-repeat protein)
|
DOXORUBICIN
NM_001908; NM_147780; NM_147781;
cathepsin B
CTSB
16705698, 17378599
|
NM_147782; NM_147783
|
DOXORUBICIN
NM_001909
cathepsin D
CTSD
18566016
|
DOXORUBICIN
NM_001911
cathepsin G
CTSG
16458935
|
DOXORUBICIN
NM_002993
chemokine (C—X—C motif) ligand 6 (granulocyte
CXCL6
16404146
|
chemotactic protein 2)
|
DOXORUBICIN
NM_001916
cytochrome c-1
CYC1
16001973
|
DOXORUBICIN
NM_018947
cytochrome c, somatic
CYCS
16001973, 16705698, 16331251,
|
16749863, 16868541
|
DOXORUBICIN
NM_000499
cytochrome P450, family 1, subfamily A, polypeptide 1
CYP1A1
15377855
|
DOXORUBICIN
NM_000785
cytochrome P450, family 27, subfamily B, polypeptide 1
CYP27B1
17716971
|
DOXORUBICIN
NM_000767
cytochrome P450, family 2, subfamily B, polypeptide 6
CYP2B6
16322899
|
DOXORUBICIN
NM_001141969; NM_001141970; NM_001350
death-domain associated protein
DAXX
12948851
|
DOXORUBICIN
—
—
DDEF1
16404146
|
DOXORUBICIN
NM_004083
DNA-damage-inducible transcript 3
DDIT3
16298333, 17912235
|
DOXORUBICIN
NM_001134709; NM_003472
DEK oncogene
DEK
16579640
|
DOXORUBICIN
NM_004717
diacylglycerol kinase, iota
DGKI
16404146
|
DOXORUBICIN
NM_001930; NM_013406; NM_013407
deoxyhypusine synthase
DHPS
16404146
|
DOXORUBICIN
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
12948851, 17521628
|
DOXORUBICIN
NM_014421
dickkopf homolog 2 (Xenopus laevis)
DKK2
16404146
|
DOXORUBICIN
NM_001539
DnaJ (Hsp40) homolog, subfamily A, member 1
DNAJA1
16579640
|
DOXORUBICIN
NM_001130823; NM_001379
DNA (cytosine-5-)-methyltransferase 1
DNMT1
17124180
|
DOXORUBICIN
NM_001935
dipeptidyl-peptidase 4
DPP4
15753397
|
DOXORUBICIN
NM_014208
dentin sialophosphoprotein
DSPP
16404146
|
DOXORUBICIN
NM_012145
deoxythymidylate kinase (thymidylate kinase)
DTYMK
18413751
|
DOXORUBICIN
NM_005225
E2F transcription factor 1
E2F1
16001973
|
DOXORUBICIN
NM_001949
E2F transcription factor 3
E2F3
16896004
|
DOXORUBICIN
NM_004092
enoyl Coenzyme A hydratase, short chain, 1,
ECHS1
15492826
|
mitochondrial
|
DOXORUBICIN
NM_030796
EGFR-coamplified and overexpressed protein
ECOP
18510171
|
DOXORUBICIN
NM_001955
endothelin 1
EDN1
17974986
|
DOXORUBICIN
NM_001406
ephrin-B3
EFNB3
16322897
|
DOXORUBICIN
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
16969495
|
DOXORUBICIN
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15981280, 16001973, 17938326,
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
17974986
|
DOXORUBICIN
NM_001964
early growth response 1
EGR1
17330857
|
DOXORUBICIN
NM_006709; NM_025256
euchromatic histone-lysine N-methyltransferase 2
EHMT2
17124180
|
DOXORUBICIN
NM_001412
eukaryotic translation initiation factor 1A, X-linked
EIF1AX
16322899
|
DOXORUBICIN
NM_032025
eukaryotic translation initiation factor 2A, 65 kDa
EIF2A
16298333
|
DOXORUBICIN
NM_004095
eukaryotic translation initiation factor 4E binding
EIF4EBP1
16322899
|
protein 1
|
DOXORUBICIN
NM_001429
E1A binding protein p300
EP300
10344722, 17498666, 10344722
|
DOXORUBICIN
NM_004431
EPH receptor A2
EPHA2
16900372
|
DOXORUBICIN
NM_001040458; NM_016442
endoplasmic reticulum aminopeptidase 1
ERAP1
16404146
|
DOXORUBICIN
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
15486187, 15834928, 16168102,
|
homolog 2, neuro/glioblastoma derived oncogene
17010609
|
homolog (avian)
|
DOXORUBICIN
NM_001005915; NM_001982
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB3
16168102
|
homolog 3 (avian)
|
DOXORUBICIN
NM_001042599; NM_005235
v-erb-a erythroblastic leukemia viral oncogene
ERBB4
16896004
|
homolog 4 (avian)
|
DOXORUBICIN
NM_000125; NM_001122740; NM_001122741;
estrogen receptor 1
ESR1
16322899
|
NM_001122742
|
DOXORUBICIN
NM_001040275; NM_001040276; NM_001437
estrogen receptor 2 (ER beta)
ESR2
16322899, 16900372
|
DOXORUBICIN
NM_001987
ets variant 6
ETV6
15217836
|
DOXORUBICIN
NM_001993
coagulation factor III (thromboplastin, tissue factor)
F3
18246814, 18278454, 18325115
|
DOXORUBICIN
NM_000131; NM_019616
coagulation factor VII (serum prothrombin conversion
F7
18325115
|
accelerator)
|
DOXORUBICIN
NM_003824
Fas (TNFRSF6)-associated via death domain
FADD
16001973, 16705698, 17970047
|
DOXORUBICIN
NM_012306
Fas apoptotic inhibitory molecule 2
FAIM2
16001973
|
DOXORUBICIN
NM_000043; NM_152871; NM_152872;
Fas (TNF receptor superfamily, member 6)
FAS
15763944,
|
NM_152873; NM_152874; NM_152875;
15763944, 15576332, 17088865,
|
NM_152876; NM_152877
16705698, 15981920, 17088865,
|
17404015, 17970047
|
DOXORUBICIN
NM_000639
Fas ligand (TNF superfamily, member 6)
FASLG
15763944, 15763944, 17088865,
|
15981920, 17088865
|
DOXORUBICIN
NM_000569; NM_001127592; NM_001127593;
Fc fragment of IgG, low affinity IIIa, receptor (CD16a)
FCGR3A
17852453
|
NM_001127595; NM_001127596
|
DOXORUBICIN
NM_004462
farnesyl-diphosphate farnesyltransferase 1
FDFT1
16322897
|
DOXORUBICIN
NM_001039492; NM_001450; NM_201555;
four and a half LIM domains 2
FHL2
17682292
|
NM_201557
|
DOXORUBICIN
NM_001145775; NM_001145776; NM_001145777;
FK506 binding protein 5
FKBP5
15571967
|
NM_004117
|
DOXORUBICIN
NM_012181
FK506 binding protein 8, 38 kDa
FKBP8
16404146
|
DOXORUBICIN
NM_002026; NM_054034; NM_212474;
fibronectin 1
FN1
17703109
|
NM_212475; NM_212476; NM_212478;
|
NM_212482
|
DOXORUBICIN
NM_000802; NM_016724; NM_016725;
folate receptor 1 (adult)
FOLR1
15634643, 16404146
|
NM_016729; NM_016730; NM_016731
|
DOXORUBICIN
NM_005252
v-fos FBJ murine osteosarcoma viral oncogene
FOS
16900372
|
homolog
|
DOXORUBICIN
NM_001454
forkhead box J1
FOXJ1
16044152
|
DOXORUBICIN
NM_002015
forkhead box O1
FOXO1
17935137
|
DOXORUBICIN
NM_001455; NM_201559
forkhead box O3
FOXO3
17935137
|
DOXORUBICIN
NM_000510; NM_001018080
follicle stimulating hormone, beta polypeptide
FSHB
17028438
|
DOXORUBICIN
NM_000146
ferritin, light polypeptide
FTL
12644586
|
DOXORUBICIN
NM_177478
ferritin mitochondrial
FTMT
12644586
|
DOXORUBICIN
NM_002033
fucosyltransferase 4 (alpha (1,3) fucosyltransferase,
FUT4
17852453
|
myeloid-specific)
|
DOXORUBICIN
NM_000402; NM_001042351
glucose-6-phosphate dehydrogenase
G6PD
16404146
|
DOXORUBICIN
NM_006705
growth arrest and DNA-damage-inducible, gamma
GADD45G
16404146
|
DOXORUBICIN
NM_000156; NM_138924
guanidinoacetate N-methyltransferase
GAMT
16896004
|
DOXORUBICIN
NM_002046
glyceraldehyde-3-phosphate dehydrogenase
GAPDH
16001973
|
DOXORUBICIN
NM_002049
GATA binding protein 1 (globin transcription factor 1)
GATA1
14623254, 17097070
|
DOXORUBICIN
NM_001498
glutamate-cysteine ligase, catalytic subunit
GCLC
10900222, 11560771
|
DOXORUBICIN
NM_002061
glutamate-cysteine ligase, modifier subunit
GCLM
10900222
|
DOXORUBICIN
NM_004864
growth differentiation factor 15
GDF15
16705698
|
DOXORUBICIN
NM_001135031; NM_004188
growth factor independent 1B transcription repressor
GFI1B
16322897
|
DOXORUBICIN
NM_001145453; NM_005264; NM_145793
GDNF family receptor alpha 1
GFRA1
16896004
|
DOXORUBICIN
NM_006708
glyoxalase I
GLO1
16085563
|
DOXORUBICIN
NM_000406; NM_001012763
gonadotropin-releasing hormone receptor
GNRHR
17943530
|
DOXORUBICIN
NM_000174
glycoprotein IX (platelet)
GP9
16404146
|
DOXORUBICIN
NM_000581; NM_201397
glutathione peroxidase 1
GPX1
15473893
|
DOXORUBICIN
NM_002093
glycogen synthase kinase 3 beta
GSK3B
17339365
|
DOXORUBICIN
NM_145740
glutathione S-transferase alpha 1
GSTA1
16890185
|
DOXORUBICIN
NM_001512
glutathione S-transferase alpha 4
GSTA4
18225754
|
DOXORUBICIN
NM_000852
glutathione S-transferase pi 1
GSTP1
10900222, 14623254, 15448748,
resistance
|
15946544, 16356834,
|
16579640, 15533597, 14623254,
|
18225754
|
DOXORUBICIN
NM_001520
general transcription factor IIIC, polypeptide 1, alpha
GTF3C1
16322899
|
220 kDa
|
DOXORUBICIN
NM_016315
GULP, engulfment adaptor PTB domain containing 1
GULP1
16001973
|
DOXORUBICIN
NM_002105
H2A histone family, member X
H2AFX
15489221, 15489221, 16432175
|
DOXORUBICIN
NM_000184
hemoglobin, gamma G
HBG2
17097070
|
DOXORUBICIN
NM_001525
hypocretin (orexin) receptor 1
HCRTR1
16404146
|
DOXORUBICIN
NM_004964
histone deacetylase 1
HDAC1
17124180
|
DOXORUBICIN
NM_000410; NM_139003; NM_139004;
hemochromatosis
HFE
16823846
|
NM_139006; NM_139007; NM_139008;
|
NM_139009; NM_139010; NM_139011
|
DOXORUBICIN
NM_000601; NM_001010931; NM_001010932;
hepatocyte growth factor (hepapoietin A; scatter factor)
HGF
15688034, 16
|
NM_001010933; NM_001010934
|
DOXORUBICIN
NM_001530; NM_181054
hypoxia inducible factor 1, alpha subunit (basic helix-
HIF1A
16532342, 17498666, 17912235
|
loop-helix transcription factor)
|
DOXORUBICIN
NM_003526
histone cluster 1, H2bc
HIST1H2BC
16322897
|
DOXORUBICIN
NM_002123
major histocompatibility complex, class II, DQ beta 1
HLA-
16322897, 16404146
|
DQB1
|
DOXORUBICIN
NM_021983
major histocompatibility complex, class II, DR beta 4
HLA-
16322897
|
DRB4
|
DOXORUBICIN
NM_015980
HMP19 protein
HMP19
16044152
|
DOXORUBICIN
NM_005968; NM_031203
heterogeneous nuclear ribonucleoprotein M
HNRNPM
16928833
|
DOXORUBICIN
NM_001130442; NM_005343; NM_176795
v-Ha-ras Harvey rat sarcoma viral oncogene homolog
HRAS
16001973
|
DOXORUBICIN
NM_005114
heparan sulfate (glucosamine) 3-O-sulfotransferase 1
HS3ST1
16044152
|
DOXORUBICIN
NM_001017963; NM_005348
heat shock protein 90 kDa alpha (cytosolic), class A
HSP90AA1
17680992
|
member 1
|
DOXORUBICIN
NM_002154
heat shock 70 kDa protein 4
HSPA4
16311509
|
DOXORUBICIN
NM_005347
heat shock 70 kDa protein 5 (glucose-regulated protein,
HSPA5
16298333, 17680992
|
78 kDa)
|
DOXORUBICIN
NM_006597; NM_153201
heat shock 70 kDa protein 8
HSPA8
16579640, 16579640, 17680992
|
DOXORUBICIN
NM_004134
heat shock 70 kDa protein 9 (mortalin)
HSPA9
17680992
|
DOXORUBICIN
NM_001540
heat shock 27 kDa protein 1
HSPB1
17680992
|
DOXORUBICIN
NM_002156; NM_199440
heat shock 60 kDa protein 1 (chaperonin)
HSPD1
17680992
|
DOXORUBICIN
NM_002775
HtrA serine peptidase 1
HTRA1
16243817
|
DOXORUBICIN
NM_031407
HECT, UBA and WWE domain containing 1
HUWE1
16404146
|
DOXORUBICIN
NM_000415
islet amyloid polypeptide
IAPP
16001973
|
DOXORUBICIN
NM_024013
interferon, alpha 1
IFNA1
17959036
|
DOXORUBICIN
NM_000618; NM_001111283; NM_001111284;
insulin-like growth factor 1 (somatomedin C)
IGF1
16740780
|
NM_001111285
|
DOXORUBICIN
NM_000875
insulin-like growth factor 1 receptor
IGF1R
16001973
|
DOXORUBICIN
NM_001552
insulin-like growth factor binding protein 4
IGFBP4
16896004
|
DOXORUBICIN
NM_001556
inhibitor of kappa light polypeptide gene enhancer in B-
IKBKB
15899819, 18463201
|
cells, kinase beta
|
DOXORUBICIN
NM_001099856; NM_001099857; NM_001145255;
inhibitor of kappa light polypeptide gene enhancer in B-
IKBKG
17890907
|
NM_003639
cells, kinase gamma
|
DOXORUBICIN
NM_000600
interleukin 6 (interferon, beta 2)
IL6
16001973
|
DOXORUBICIN
NM_000584
interleukin 8
IL8
12908082, 15899819, 18510171
|
DOXORUBICIN
NM_001137673; NM_004516; NM_012218;
interleukin enhancer binding factor 3, 90 kDa
ILF3
16322899
|
NM_017620; NM_153464
|
DOXORUBICIN
NM_005544
insulin receptor substrate 1
IRS1
16322899
|
DOXORUBICIN
NM_002226; NM_145159
jagged 2
JAG2
16404146
|
DOXORUBICIN
—
—
JMJD2B
16896004
|
DOXORUBICIN
NM_002228
jun oncogene
JUN
15585644, 15880572, 18645001
|
DOXORUBICIN
NM_000238; NM_172056; NM_172057
potassium voltage-gated channel, subfamily H (eag-
KCNH2
16086867
|
related), member 2
|
DOXORUBICIN
NM_002242
potassium inwardly-rectifying channel, subfamily J,
KCNJ13
16404146
|
member 13
|
DOXORUBICIN
NM_018658; NM_170741; NM_170742
potassium inwardly-rectifying channel, subfamily J,
KCNJ16
16404146
|
member 16
|
DOXORUBICIN
NM_002035
3-ketodihydrosphingosine reductase
KDSR
16322897
|
DOXORUBICIN
NM_003685
KH-type splicing regulatory protein
KHSRP
16404146
|
DOXORUBICIN
NM_020853
KIAA1467
KIAA1467
16896004
|
DOXORUBICIN
NM_007054
kinesin family member 3A
KIF3A
16896004
|
DOXORUBICIN
NM_016270
Kruppel-like factor 2 (lung)
KLF2
18510171
|
DOXORUBICIN
NM_000224; NM_199187
keratin 18
KRT18
16928833
|
DOXORUBICIN
NM_002306
lectin, galactoside-binding, soluble, 3
LGALS3
16322897
|
DOXORUBICIN
NM_001098268; NM_002312; NM_206937
ligase IV, DNA, ATP-dependent
LIG4
18508926
|
DOXORUBICIN
NM_001113546; NM_001113547; NM_016357
LIM domain and actin binding 1
LIMA1
16044152
|
DOXORUBICIN
NM_005572; NM_170707; NM_170708
lamin A/C
LMNA
16001973
|
DOXORUBICIN
NM_005573
lamin B1
LMNB1
16001973
|
DOXORUBICIN
NM_002349
lymphocyte antigen 75
LY75
16404146
|
DOXORUBICIN
NM_002358
MAD2 mitotic arrest deficient-like 1 (yeast)
MAD2L1
15870702
|
DOXORUBICIN
NM_002755
mitogen-activated protein kinase kinase 1
MAP2K1
17974986
|
DOXORUBICIN
NM_030662
mitogen-activated protein kinase kinase 2
MAP2K2
17974986
|
DOXORUBICIN
NM_002756; NM_145109
mitogen-activated protein kinase kinase 3
MAP2K3
15870702
|
DOXORUBICIN
NM_003010
mitogen-activated protein kinase kinase 4
MAP2K4
15870702, 16001973
|
DOXORUBICIN
NM_002758
mitogen-activated protein kinase kinase 6
MAP2K6
15870702
|
DOXORUBICIN
NM_003188; NM_145331; NM_145332;
mitogen-activated protein kinase kinase kinase 7
MAP3K7
16001973
|
NM_145333
|
DOXORUBICIN
NM_005204
mitogen-activated protein kinase kinase kinase 8
MAP3K8
16322897
|
DOXORUBICIN
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
15557793, 16001973, 17526808,
|
17974986, 15557793, 18468633,
|
18468633, 18468633, 15557793
|
DOXORUBICIN
NM_001315; NM_139012; NM_139013;
mitogen-activated protein kinase 14
MAPK14
15494689, 16843435, 15557793,
|
NM_139014
15870702, 16322899, 16843435
|
DOXORUBICIN
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
15557793, 16059641, 16928833,
|
17526808, 17974986, 18468633,
|
15557793, 18468633, 18468633,
|
15557793
|
DOXORUBICIN
NM_002750; NM_139046; NM_139047;
mitogen-activated protein kinase 8
MAPK8
15494689, 15870702, 15880572,
|
NM_139049
15917298, 15917298, 16890185,
|
16868541, 16890185
|
DOXORUBICIN
NM_001135044; NM_002752; NM_139068;
mitogen-activated protein kinase 9
MAPK9
15494689, 15557793, 15557793,
|
NM_139069; NM_139070
15585644, 15585644
|
DOXORUBICIN
NM_001123066; NM_001123067; NM_005910;
microtubule-associated protein tau
MAPT
16896004
|
NM_016834; NM_016835; NM_016841
|
DOXORUBICIN
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
17935137
|
DOXORUBICIN
NM_005918
malate dehydrogenase 2, NAD (mitochondrial)
MDH2
16322897
|
DOXORUBICIN
NM_001012333; NM_001012334; NM_002391
midkine (neurite growth-promoting factor 2)
MDK
16322897
|
DOXORUBICIN
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
16001973, 17935137, 17959036,
|
NM_001145340; NM_002392;
17959036, 19074854, 17653088
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
DOXORUBICIN
NM_015335
mediator complex subunit 13-like
MED13L
16896004
|
DOXORUBICIN
NM_001130926; NM_001130927; NM_001130928;
myocyte enhancer factor 2A
MEF2A
16001973
|
NM_005587
|
DOXORUBICIN
NM_014791
maternal embryonic leucine zipper kinase
MELK
16896004
|
DOXORUBICIN
NM_006838
methionyl aminopeptidase 2
METAP2
16404146
|
DOXORUBICIN
NM_024042
meteorin, glial cell differentiation regulator
METRN
16896004
|
DOXORUBICIN
NM_001114614; NM_005928
milk fat globule-EGF factor 8 protein
MFGE8
16404146
|
DOXORUBICIN
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
16356834
|
DOXORUBICIN
NM_005933
myeloid/lymphoid or mixed-lineage leukemia (trithorax
MLL
16322897
|
homolog, Drosophila)
|
DOXORUBICIN
NM_004529
myeloid/lymphoid or mixed-lineage leukemia (trithorax
MLLT3
16404146
|
homolog, Drosophila); translocated to, 3
|
DOXORUBICIN
NM_000902; NM_007287; NM_007288;
membrane metallo-endopeptidase
MME
16997790
|
NM_007289
|
DOXORUBICIN
NM_002421
matrix metallopeptidase 1 (interstitial collagenase)
MMP1
11313874
|
DOXORUBICIN
NM_001127891; NM_004530
matrix metallopeptidase 2 (gelatinase A, 72 kDa
MMP2
16458935
|
gelatinase, 72 kDa type IV collagenase)
|
DOXORUBICIN
NM_018135
mitochondrial ribosomal protein S18A
MRPS18A
16404146
|
DOXORUBICIN
NM_000179
mutS homolog 6 (E. coli)
MSH6
16404146
|
DOXORUBICIN
NM_005950
metallothionein 1G
MT1G
16579640
|
DOXORUBICIN
NR_001447; NR_001447; NR_001447;
metallothionein 1L (gene/pseudogene)
MT1L
16579640
|
NR_001447; NR_001447; NR_001447
|
DOXORUBICIN
NM_005953
metallothionein 2A
MT2A
16579640
|
DOXORUBICIN
NM_000254
5-methyltetrahydrofolate-homocysteine
MTR
16322897
|
methyltransferase
|
DOXORUBICIN
NM_014751
metastasis suppressor 1
MTSS1
16243817
|
DOXORUBICIN
NM_005115; NM_017458
major vault protein
MVP
17575109
|
DOXORUBICIN
NM_002467
v-myc myelocytomatosis viral oncogene homolog
MYC
15911101, 16001973, 11585056,
|
(avian)
18606404, 18802399
|
DOXORUBICIN
NM_004536; NM_022892
NLR family, apoptosis inhibitory protein
NAIP
11911975, 15911101, 16322899,
|
DOXORUBICIN
NM_002485
nibrin
NBN
17521628 15489221
|
DOXORUBICIN
NM_004146
NADH dehydrogenase (ubiquinone) 1 beta
NDUFB7
16404146
|
subcomplex, 7, 18 kDa
|
DOXORUBICIN
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
15555623, 15571967, 15870702,
|
enhancer in B-cells 1
15905586, 16001973, 16322301,
|
17912235, 18463201
|
DOXORUBICIN
NM_001077493; NM_001077494; NM_002502
nuclear factor of kappa light polypeptide gene
NFKB2
17890907
|
enhancer in B-cells 2 (p49/p100)
|
DOXORUBICIN
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
15571967, 15870702, 15899819,
|
enhancer in B-cells inhibitor, alpha
17542780, 17935137, 17935137,
|
15899819, 17542780, 18463201
|
DOXORUBICIN
NM_002508
nidogen 1
NID1
17703109
|
DOXORUBICIN
NM_024522
Na+/K+ transporting ATPase interacting 1
NKAIN1
16896004
|
DOXORUBICIN
NM_002511
neuromedin B receptor
NMBR
16404146
|
DOXORUBICIN
NM_004741
nucleolar and coiled-body phosphoprotein 1
NOLC1
17129415
|
DOXORUBICIN
NM_000625
nitric oxide synthase 2, inducible
NOS2
15695394, 15695394, 18463201,
|
18463201
|
DOXORUBICIN
NM_002135; NM_173157
nuclear receptor subfamily 4, group A, member 1
NR4A1
16322897
|
DOXORUBICIN
NM_013936
olfactory receptor, family 12, subfamily D, member 2
OR12D2
16404146
|
DOXORUBICIN
NM_012369
olfactory receptor, family 2, subfamily F, member 1
OR2F1
16404146
|
DOXORUBICIN
NM_000916
oxytocin receptor
OXTR
11313874
|
DOXORUBICIN
NM_006025
26 serine protease
P11
16001973
|
DOXORUBICIN
NM_012226; NM_016318; NM_170682;
purinergic receptor P2X, ligand-gated ion channel, 2
P2RX2
16404146
|
NM_170683; NM_174872; NM_174873
|
DOXORUBICIN
NM_004154; NM_176796; NM_176797;
pyrimidinergic receptor P2Y, G-protein coupled, 6
P2RY6
16044152
|
NM_176798
|
DOXORUBICIN
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
15456408, 15557793, 15585644,
|
15753397,
|
(following) 15870702, 15981920, 16311509, 16311509, 17651020, 16890185, 15557793, 18071906, 15585644, 16843435, 16962673, 15555623, 17285121, 17935137, 17959036,
|
16843435, 16890185, 16962673, 17285121, 17339365, 17418594, 17651020, 17935137, 17959036
|
DOXORUBICIN
NM_002583
PRKC, apoptosis, WT1, regulator
PAWR
12948851
|
DOXORUBICIN
NM_000280; NM_001127612; NM_001604
paired box 6
PAX6
16404146
|
DOXORUBICIN
—
—
PCAF
16001973
|
DOXORUBICIN
NM_002592; NM_182649
proliferating cell nuclear antigen
PCNA
16322897, 16537896
|
DOXORUBICIN
NM_004708
programmed cell death 5
PDCD5
16579640
|
DOXORUBICIN
NM_002613; NM_031268
3-phosphoinositide dependent protein kinase-1
PDPK1
16782806
|
DOXORUBICIN
NM_002653
paired-like homeodomain 1
PITX1
16404146
|
DOXORUBICIN
NM_001145031; NM_002658
plasminogen activator, urokinase
PLAU
12908082, 15557793, 16356834
|
DOXORUBICIN
NM_000302
procollagen-lysine 1,2-oxoglutarate 5-dioxygenase 1
PLOD1
16322899
|
DOXORUBICIN
NM_001084
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
PLOD3
16322899
|
DOXORUBICIN
NM_021127
phorbol-12-myristate-13-acetate-induced protein 1
PMAIP1
17653088
|
DOXORUBICIN
NM_021173
polymerase (DNA-directed), delta 4
POLD4
16404146
|
DOXORUBICIN
NM_013382
protein-O-mannosyltransferase 2
POMT2
16404146
|
DOXORUBICIN
NM_000941
P450 (cytochrome) oxidoreductase
POR
15942634, 16322897
|
DOXORUBICIN
NM_006238; NM_177435
peroxisome proliferator-activated receptor delta
PPARD
16404146
|
DOXORUBICIN
NM_005155; NM_138717
palmitoyl-protein thioesterase 2
PPT2
16404146
|
DOXORUBICIN
NM_002730; NM_207518
protein kinase, cAMP-dependent, catalytic, alpha
PRKACA
16404146
|
DOXORUBICIN
NM_002737
protein kinase C, alpha
PRKCA
16087181, 16579994
|
DOXORUBICIN
NM_006254; NM_212539
protein kinase C, delta
PRKCD
15917298
|
DOXORUBICIN
NM_001081640; NM_006904
protein kinase, DNA-activated, catalytic polypeptide
PRKDC
18508926
|
DOXORUBICIN
NM_000948
prolactin
PRL
18681966
|
DOXORUBICIN
NM_000311; NM_001080121; NM_001080122;
prion protein
PRNP
15386405
|
NM_001080123; NM_183079
|
DOXORUBICIN
NM_000312
protein C (inactivator of coagulation factors Va and
PROC
17172434
|
VIIIa)
|
DOXORUBICIN
NM_006404
protein C receptor, endothelial (EPCR)
PROCR
17172434
|
DOXORUBICIN
NM_001143937; NM_002786; NM_148976
proteasome (prosome, macropain) subunit, alpha type, 1
PSMA1
17346995
|
DOXORUBICIN
NM_002787
proteasome (prosome, macropain) subunit, alpha type, 2
PSMA2
17346995
|
DOXORUBICIN
NM_002788; NM_152132
proteasome (prosome, macropain) subunit, alpha type, 3
PSMA3
17346995
|
DOXORUBICIN
NM_001102667; NM_001102668; NM_002789
proteasome (prosome, macropain) subunit, alpha type, 4
PSMA4
17346995
|
DOXORUBICIN
NM_002790
proteasome (prosome, macropain) subunit, alpha type, 5
PSMA5
17346995
|
DOXORUBICIN
NM_002791
proteasome (prosome, macropain) subunit, alpha type, 6
PSMA6
17346995
|
DOXORUBICIN
NM_002792
proteasome (prosome, macropain) subunit, alpha type, 7
PSMA7
17346995
|
DOXORUBICIN
NM_002794
proteasome (prosome, macropain) subunit, beta type, 2
PSMB2
17346995
|
DOXORUBICIN
NM_002795
proteasome (prosome, macropain) subunit, beta type, 3
PSMB3
17346995
|
DOXORUBICIN
NM_002799
proteasome (prosome, macropain) subunit, beta type, 7
PSMB7
17346995
|
DOXORUBICIN
NM_000314
phosphatase and tensin homolog
PTEN
11707646, 15548710, 16438844,
|
17330857, 17359293, 17935137,
|
17935137, 16438844, 17359293
|
DOXORUBICIN
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
15501994, 16127422, 18498876
|
G/H synthase and cyclooxygenase)
|
DOXORUBICIN
NM_005607; NM_153831
PTK2 protein tyrosine kinase 2
PTK2
15870702, 16168102
|
DOXORUBICIN
NM_004103; NM_173174; NM_173175;
PTK2B protein tyrosine kinase 2 beta
PTK2B
16168102
|
NM_173176
|
DOXORUBICIN
NM_006264; NM_080683; NM_080684;
protein tyrosine phosphatase, non-receptor type 13
PTPN13
16001973
|
NM_080685
(APO-1/CD95 (Fas)-associated phosphatase)
|
DOXORUBICIN
NM_001161440; NM_002842
protein tyrosine phosphatase, receptor type, H
PTPRH
16044152
|
DOXORUBICIN
NM_002875; NM_133487
RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)
RAD51
10344722, 17351394
|
DOXORUBICIN
NM_006788
ralA binding protein 1
RALBP1
15386349, 15950949, 16087181,
resistance
|
16579994, 17273774
|
DOXORUBICIN
NM_005855
receptor (G protein-coupled) activity modifying protein 1
RAMP1
16896004
|
DOXORUBICIN
NM_000965; NM_016152
retinoic acid receptor, beta
RARB
17608728
|
DOXORUBICIN
NM_000321
retinoblastoma 1
RB1
15141020, 16537896
|
DOXORUBICIN
NM_002895; NM_183404
retinoblastoma-like 1 (p107)
RBL1
16537896
|
DOXORUBICIN
NM_005611
retinoblastoma-like 2 (p130)
RBL2
15585644, 16537896
|
DOXORUBICIN
NM_001145547; NM_032905
RNA binding motif protein 17
RBM17
16061639
resistance
|
DOXORUBICIN
NM_001008710; NM_001008711; NM_001008712;
RNA binding protein with multiple splicing
RBPMS
16404146
|
NM_006867
|
DOXORUBICIN
NM_002908
v-rel reticuloendotheliosis viral oncogene homolog
REL
15870702, 16404146, 17890907
|
(avian)
|
DOXORUBICIN
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
15555623, 15571967, 15823547,
|
(avian)
15899819,
|
(following) 15905586, 15911101, 16322301, 17097285, 17097285, 15870702, 17542780, 17890907, 18269916, 18463201, 18463201, 17542780
|
DOXORUBICIN
NM_006509
v-rel reticuloendotheliosis viral oncogene homolog B
RELB
17890907
|
DOXORUBICIN
NM_002927; NM_144766
regulator of G-protein signaling 13
RGS13
16404146
|
DOXORUBICIN
NM_016321
Rh family, C glycoprotein
RHCG
16404146
|
DOXORUBICIN
NM_002944
c-ros oncogene 1, receptor tyrosine kinase
ROS1
16001973
|
DOXORUBICIN
NM_001034
ribonucleotide reductase M2 polypeptide
RRM2
16896004
|
DOXORUBICIN
NM_001001890; NM_001122607; NM_001754
runt-related transcription factor 1
RUNX1
15217836
|
DOXORUBICIN
NM_001031680; NM_004350
runt-related transcription factor 3
RUNX3
15756676
|
DOXORUBICIN
NM_002970
spermidine/spermine N1-acetyltransferase 1
SAT1
16322897
|
DOXORUBICIN
NM_001039
sodium channel, nonvoltage-gated 1, gamma
SCNN1G
15564131
|
DOXORUBICIN
NM_020974
signal peptide, CUB domain, EGF-like 2
SCUBE2
16896004
|
DOXORUBICIN
NM_004892
SEC22 vesicle trafficking protein homolog
SEC22B
16404146
|
B (S. cerevisiae)
|
DOXORUBICIN
NM_000602
serpin peptidase inhibitor, clade E (nexin, plasminogen
SERPINE1
15870702, 16705698
|
activator inhibitor type 1), member 1
|
DOXORUBICIN
NM_001235
serpin peptidase inhibitor, clade H (heat shock protein
SERPINH1
17680992
|
47), member 1, (collagen binding protein 1)
|
DOXORUBICIN
NM_005983; NM_032637
S-phase kinase-associated protein 2 (p45)
SKP2
17893511
|
DOXORUBICIN
NM_033125
solute carrier family 22 (organic cation/carnitine
SLC22A16
15963465
|
transporter), member 16
|
DOXORUBICIN
NM_003060
solute carrier family 22 (organic cation/carnitine
SLC22A5
16283381
|
transporter), member 5
|
DOXORUBICIN
NM_001078174; NM_001078175; NM_001078176;
solute carrier family 29 (nucleoside transporters),
SLC29A1
18452103
|
NM_001078177; NM_004955
member 1
|
DOXORUBICIN
NM_018976
solute carrier family 38, member 2
SLC38A2
16044152
|
DOXORUBICIN
NM_000453
solute carrier family 5 (sodium iodide symporter),
SLC5A5
15671536
|
member 5
|
DOXORUBICIN
NM_003047
solute carrier family 9 (sodium/hydrogen exchanger),
SLC9A1
15729714
|
member 1
|
DOXORUBICIN
NM_003062
slit homolog 3 (Drosophila)
SLIT3
16404146
|
DOXORUBICIN
NM_001003652; NM_001135937; NM_005901
SMAD family member 2
SMAD2
18606404
|
DOXORUBICIN
NM_001145102; NM_001145103; NM_001145104;
SMAD family member 3
SMAD3
18606404
|
NM_005902
|
DOXORUBICIN
NM_005359
SMAD family member 4
SMAD4
18606404
|
DOXORUBICIN
NM_005904
SMAD family member 7
SMAD7
18606404
|
DOXORUBICIN
NM_006306
structural maintenance of chromosomes 1A
SMC1A
15489221
|
DOXORUBICIN
NM_000454
superoxide dismutase 1, soluble
SOD1
16579640
|
DOXORUBICIN
NM_000636; NM_001024465; NM_001024466
superoxide dismutase 2, mitochondrial
SOD2
14660625, 10969820, 18384434
|
DOXORUBICIN
NM_005633
son of sevenless homolog 1 (Drosophila)
SOS1
16001973
|
DOXORUBICIN
NM_003109; NM_138473
Sp1 transcription factor
SP1
17108358, 17124180
|
DOXORUBICIN
NM_003118
secreted protein, acidic, cysteine-rich (osteonectin)
SPARC
15870702
|
DOXORUBICIN
NM_020126
sphingosine kinase 2
SPHK2
17974990
|
DOXORUBICIN
NM_003130; NM_198901
sorcin
SRI
18423116
|
DOXORUBICIN
NM_003132
spermidine synthase
SRM
16322899
|
DOXORUBICIN
NM_017857
slingshot homolog 3 (Drosophila)
SSH3
16404146
|
DOXORUBICIN
NM_021978
suppression of tumorigenicity 14 (colon carcinoma)
ST14
16322899
|
DOXORUBICIN
NM_007315; NM_139266
signal transducer and activator of transcription 1,
STAT1
16001973, 17072862
|
91 kDa
|
DOXORUBICIN
NM_005419
signal transducer and activator of transcription 2,
STAT2
16001973
|
113 kDa
|
DOXORUBICIN
NM_003150; NM_139276; NM_213662
signal transducer and activator of transcription 3
STAT3
16001973, 17920763
|
(acute-phase response factor)
|
DOXORUBICIN
NM_013233
serine threonine kinase 39 (STE20/SPS1 homolog,
STK39
16322899
|
yeast)
|
DOXORUBICIN
NM_001145454; NM_005563; NM_203399;
stathmin 1
STMN1
16458935
|
NM_203401
|
DOXORUBICIN
NM_004177
syntaxin 3
STX3
16322897
|
DOXORUBICIN
NM_001001522; NM_003186
transgelin
TAGLN
15870702
|
DOXORUBICIN
NM_001136139; NM_003200
transcription factor 3 (E2A immunoglobulin enhancer
TCF3
16886622
|
binding factors E12/E47)
|
DOXORUBICIN
NM_198253; NM_198255
telomerase reverse transcriptase
TERT
16077987, 18396642, 18560228
|
DOXORUBICIN
NM_003225
trefoil factor 1
TFF1
16579640
|
DOXORUBICIN
NM_000660
transforming growth factor, beta 1
TGFB1
17418594, 18606404
|
DOXORUBICIN
NM_004613; NM_198951
transglutaminase 2 (C polypeptide, protein-glutamine-
TGM2
15870702, 17073438
|
gamma-glutamyltransferase)
|
DOXORUBICIN
NM_000361
thrombomodulin
THBD
17172434
|
DOXORUBICIN
NM_003246
thrombospondin 1
THBS1
16962673
|
DOXORUBICIN
NM_018271
threonine synthase-like 2 (S. cerevisiae)
THNSL2
16896004
|
DOXORUBICIN
NM_022037; NM_022173
TIA1 cytotoxic granule-associated RNA binding protein
TIA1
16404146
|
DOXORUBICIN
NM_021025
T-cell leukemia homeobox 3
TLX3
16404146
|
DOXORUBICIN
NM_021109
thymosin beta 4, X-linked
TMSB4X
16364925
|
DOXORUBICIN
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
12908082, 15823547, 15899819,
|
16001973, 17651020
|
DOXORUBICIN
NM_003844
tumor necrosis factor receptor superfamily, member
TNFRSF10A
16098063, 17437844, 16364925,
|
10a
17437844, 17437844, 15897917
|
DOXORUBICIN
NM_003842; NM_147187
tumor necrosis factor receptor superfamily, member
TNFRSF10B
16364925, 17922852, 15897917,
|
10b
17922852, 16098063, 17922852,
|
16705698
|
DOXORUBICIN
NM_001065
tumor necrosis factor receptor superfamily, member 1A
TNFRSF1A
17651020
|
DOXORUBICIN
NM_001066
tumor necrosis factor receptor superfamily, member 1B
TNFRSF1B
17651020
|
DOXORUBICIN
NM_001039664; NM_003790; NM_148965;
tumor necrosis factor receptor superfamily, member 25
TNFRSF25
16705698
|
NM_148966; NM_148967; NM_148970
|
DOXORUBICIN
NM_003810
tumor necrosis factor (ligand) superfamily, member 10
TNFSF10
16364925, 19106633
|
DOXORUBICIN
NM_014765
translocase of outer mitochondrial membrane 20
TOMM20
16322897
|
homolog (yeast)
|
DOXORUBICIN
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
11470519, 15239142, 15486187,
|
15753397, 15765123, 16969495,
|
17351394
|
DOXORUBICIN
NM_001068
topoisomerase (DNA) II beta 180 kDa
TOP2B
16239602, 16957942
|
DOXORUBICIN
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
15141020, 17124180, 15489221,
|
NM_001126114; NM_001126115;
15578696,
|
NM_001126116; NM_001126117
|
(following) 15671536, 19106633, 15763944, 15781256, 15823547, 15823547, 15601469, 16211088, 15939500, 16001973, 16404146, 15939500, 17959036, 16168113, 16432175,
|
16537896, 15781256, 17959036, 17339365, 17912235, 16108013, 10969820, 12082016, 15555623, 15601469, 17285121, 19074854, 17088865, 15763944, 15671536, 16826403,
|
17079232, 17085670, 17088865, 17124180, 17285121, 17369602, 15578696, 17555331, 17608641, 17653088, 17682292, 17893511, 17912235, 17959036, 18269916, 18510171,
|
18698031, 19074854, 19106633
|
DOXORUBICIN
NM_001126240; NM_001126241; NM_001126242;
tumor protein p73
TP73
17716971
|
NM_005427
|
DOXORUBICIN
NM_000365; NM_001159287
triosephosphate isomerase 1
TPI1
18309519
|
DOXORUBICIN
NM_016292
TNF receptor-associated protein 1
TRAP1
17680992
|
DOXORUBICIN
NM_001656; NM_033227; NM_033228
tripartite motif-containing 23
TRIM23
16404146
|
DOXORUBICIN
NM_005762
tripartite motif-containing 28
TRIM28
17079232
|
DOXORUBICIN
NM_001003827; NM_021616; NM_130389;
tripartite motif-containing 34
TRIM34
16404146
|
NM_130390
|
DOXORUBICIN
—
—
TRP53
16013437
|
DOXORUBICIN
NM_000370
tocopherol (alpha) transfer protein
TTPA
16404146
|
DOXORUBICIN
NM_006000
tubulin, alpha 4a
TUBA4A
16322897
|
DOXORUBICIN
NM_178014
tubulin, beta
TUBB
16579640
|
DOXORUBICIN
NM_006087
tubulin, beta 4
TUBB4
16322897
|
DOXORUBICIN
NM_001071
thymidylate synthetase
TYMS
10482907, 16168113
|
DOXORUBICIN
NM_003358
UDP-glucose ceramide glucosyltransferase
UGCG
16404146, 18245173
|
DOXORUBICIN
NM_021139
UDP glucuronosyltransferase 2 family, polypeptide B4
UGT2B4
16404146
|
DOXORUBICIN
NM_003364; NM_181597
uridine phosphorylase 1
UPP1
18510171
|
DOXORUBICIN
NM_006004
ubiquinol-cytochrome c reductase hinge protein
UQCRH
18510171
|
DOXORUBICIN
NM_000376; NM_001017535
vitamin D (1,25-dihydroxyvitamin D3) receptor
VDR
17716971
|
DOXORUBICIN
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
16900372, 17431384, 17498666,
|
NM_001025369; NM_001025370;
17627616, 17627616, 17498666,
|
NM_001033756; NM_003376
17912235, 18494554
|
DOXORUBICIN
NM_001167
X-linked inhibitor of apoptosis
XIAP
11911975, 11911975, 16211302,
|
12948851, 14601052, 15897917,
|
15359644, 15911101, 17521628,
|
18071906
|
DOXORUBICIN
NM_006887
zinc finger protein 36, C3H type-like 2
ZFP36L2
16322897
|
DOXORUBICIN
NM_022470; NM_152240
zinc finger, matrin type 3
ZMAT3
16439685
|
DOXORUBICIN
NM_003453; NM_197968
zinc finger, MYM-type 2
ZMYM2
16579640
|
DOXORUBICIN
NM_006963
zinc finger protein 22 (KOX 15)
ZNF22
16404146
|
DOXORUBICIN
NM_024762
zinc finger protein 552
ZNF552
16896004
|
EPIRUBICIN
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
12576456
resistance
|
member 1
|
EPIRUBICIN
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
12576456, 12657726
resistance
|
NM_019899; NM_019900
member 1
|
EPIRUBICIN
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
12576456
resistance
|
EPIRUBICIN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
14503796
|
EPIRUBICIN
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16188142
resistance
|
EPIRUBICIN
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
14503796, 15996160
death pathway
|
EPIRUBICIN
NM_001270
chromodomain helicase DNA binding protein 1
CHD1
—
|
EPIRUBICIN
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
18768436
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
EPIRUBICIN
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
18768436
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
EPIRUBICIN
NM_001005915; NM_001982
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB3
18768436
|
homolog 3 (avian)
|
EPIRUBICIN
NM_022110
FK506 binding protein like
FKBPL
14503796
|
EPIRUBICIN
NM_005980
S100 calcium binding protein P
S100P
18636193
|
EPIRUBICIN
NM_000636; NM_001024465; NM_001024466
superoxide dismutase 2, mitochondrial
SOD2
9569045
|
EPIRUBICIN
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
18465341
target
|
MITOXANTRONE
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
15239124
resistance
|
member 1
|
MITOXANTRONE
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
15239124, 15640379, 15695404,
resistance
|
15703302, 15875186, 17032904,
|
16636798, 17032904
|
MITOXANTRONE
NM_130847
angiomotin like 1
AMOTL1
16044152
|
MITOXANTRONE
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
15359644
|
MITOXANTRONE
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
12948851
|
MITOXANTRONE
—
—
C4ORF28
16044152
|
MITOXANTRONE
NM_007359
cancer susceptibility candidate 3
CASC3
16044152
|
MITOXANTRONE
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
14757846
|
MITOXANTRONE
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
12948851
|
MITOXANTRONE
NM_001226; NM_032992
caspase 6, apoptosis-related cysteine peptidase
CASP6
12948851
|
MITOXANTRONE
NM_001227; NM_033338; NM_033339;
caspase 7, apoptosis-related cysteine peptidase
CASP7
12948851
|
NM_033340
|
MITOXANTRONE
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
12948851
|
NM_033355; NM_033356; NM_033358
|
MITOXANTRONE
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
12948851
|
MITOXANTRONE
NM_030809
cysteine-serine-rich nuclear protein 2
CSRNP2
16044152
|
MITOXANTRONE
NM_001141969; NM_001141970; NM_001350
death-domain associated protein
DAXX
12948851
|
MITOXANTRONE
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
12948851
|
MITOXANTRONE
NM_001144774; NM_001144775; NM_001144776;
ELAV (embryonic lethal, abnormal vision, Drosophila)-
ELAVL4
16044152
|
NM_001144777; NM_021952
like 4 (Hu antigen D)
|
MITOXANTRONE
NM_021814
ELOVL family member 5, elongation of long chain fatty
ELOVL5
16044152
|
acids (FEN1/Elo2, SUR4/Elo3-like, yeast)
|
MITOXANTRONE
NM_001135554; NM_001135555; NM_001431
erythrocyte membrane protein band 4.1-like 2
EPB41L2
16044152
|
MITOXANTRONE
NM_000875
insulin-like growth factor 1 receptor
IGF1R
15499378
|
MITOXANTRONE
NM_024337
iroquois homeobox 1
IRX1
16044152
|
MITOXANTRONE
NM_000426; NM_001079823
laminin, alpha 2
LAMA2
16044152
|
MITOXANTRONE
NM_001143944; NM_181336
LEM domain containing 2
LEMD2
16044152
|
MITOXANTRONE
NM_001161572; NM_001161573; NM_001161574;
v-maf musculoaponeurotic fibrosarcoma oncogene
MAFF
16044152
|
NM_012323; NM_152878
homolog F (avian)
|
MITOXANTRONE
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
17575151
variant allelic/
|
NM_001145340; NM_002392;
resistance
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
MITOXANTRONE
NM_002583
PRKC, apoptosis, WT1, regulator
PAWR
12948851
|
MITOXANTRONE
NM_000965; NM_016152
retinoic acid receptor, beta
RARB
17608728
altered by
|
mitox
|
MITOXANTRONE
NM_002890; NM_022650
RAS p21 protein activator (GTPase activating protein) 1
RASA1
16044152
|
MITOXANTRONE
NM_001145547; NM_032905
RNA binding motif protein 17
RBM17
16061639
resistance
|
MITOXANTRONE
NM_021244
Ras-related GTP binding D
RRAGD
16044152
|
MITOXANTRONE
NM_003014
secreted frizzled-related protein 4
SFRP4
16044152
|
MITOXANTRONE
NM_032379; NM_032943; NM_206927;
synaptotagmin-like 2
SYTL2
16044152
|
NM_206928; NM_206929; NM_206930
|
MITOXANTRONE
NM_145274
transmembrane protein 99
TMEM99
16044152
|
MITOXANTRONE
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
—
target
|
MITOXANTRONE
NM_001167
X-linked inhibitor of apoptosis
XIAP
12948851, 15359644
|
BLEOMYCIN
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
10815900
|
BLEOMYCIN
NM_000386
bleomycin hydrolase
BLMH
12082022
resistance
|
BLEOMYCIN
NM_001752
catalase
CAT
10751631
unrelated
|
BLEOMYCIN
NM_000234
ligase I, DNA, ATP-dependent
LIG1
—
unrelated
|
BLEOMYCIN
NM_002311; NM_013975
ligase III, DNA, ATP-dependent
LIG3
—
resistance
|
BLEOMYCIN
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
18695918
|
G/H synthase and cyclooxygenase)
|
BLEOMYCIN
NM_003745
suppressor of cytokine signaling 1
SOCS1
17374387
resistance
|
BLEOMYCIN
NM_006297
X-ray repair complementing defective repair in Chinese
XRCC1
12082022
resistance
|
hamster cells 1
|
BLEOMYCIN
NM_021141
X-ray repair complementing defective repair in Chinese
XRCC5
12384553
|
hamster cells 5 (double-strand-break rejoining)
|
MITOMYCIN
NM_000691; NM_001135167; NM_001135168
aldehyde dehydrogenase 3 family, memberA1
ALDH3A1
15905174
resistance
|
MITOMYCIN
NM_000484; NM_001136016; NM_001136129;
amyloid beta (A4) precursor protein
APP
12760830
|
NM_001136130; NM_001136131;
|
NM_201413; NM_201414
|
MITOMYCIN
NM_001675; NM_182810
activating transcription factor 4 (tax-responsive
ATF4
12760830
|
enhancer element B67)
|
MITOMYCIN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
15793875
|
MITOMYCIN
NM_001202; NM_130850; NM_130851
bone morphogenetic protein 4
BMP4
12760830
|
MITOMYCIN
NM_031966
cyclin B1
CCNB1
12760830
|
MITOMYCIN
NM_000611; NM_001127223; NM_001127225;
CD59 molecule, complement regulatory protein
CD59
17045307
|
NM_001127226; NM_001127227;
|
NM_203329; NM_203330; NM_203331
|
MITOMYCIN
NM_001785
cytidine deaminase
CDA
18728667
|
MITOMYCIN
NM_001964
early growth response 1
EGR1
12760830
|
MITOMYCIN
NM_004431
EPH receptor A2
EPHA2
12760830
|
MITOMYCIN
—
—
GRP58
—
sensitivity
|
MITOMYCIN
NM_000852
glutathione S-transferase pi 1
GSTP1
15239142
resistance
|
MITOMYCIN
NM_002117
major histocompatibility complex, class I, C
HLA-C
12760830
|
MITOMYCIN
NM_000234
ligase I, DNA, ATP-dependent
LIG1
12760830
|
MITOMYCIN
NM_012325
microtubule-associated protein, RP/EB family, member 1
MAPRE1
12760830
|
MITOMYCIN
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
16039682
sensitivity
|
MITOMYCIN
NM_004995
matrix metallopeptidase 14 (membrane-inserted)
MMP14
12760830
|
MITOMYCIN
NM_002505; NM_021705
nuclear transcription factor Y, alpha
NFYA
12760830
|
MITOMYCIN
NM_000903; NM_001025433; NM_001025434
NAD(P)H dehydrogenase, quinone 1
NQO1
15239142
drug activation
|
MITOMYCIN
NM_000941
P450 (cytochrome) oxidoreductase
POR
15239142
drug activation
|
MITOMYCIN
NM_000311; NM_001080121; NM_001080122;
prion protein
PRNP
12760830
|
NM_001080123; NM_183079
|
MITOMYCIN
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
15793875
|
G/H synthase and cyclooxygenase)
|
MITOMYCIN
NM_000321
retinoblastoma 1
RB1
15617745
|
MITOMYCIN
NM_002893
retinoblastoma binding protein 7
RBBP7
12760830
|
MITOMYCIN
NM_002916; NM_181573
replication factor C (activator 1) 4, 37 kDa
RFC4
12760830
|
MITOMYCIN
NM_001006
ribosomal protein S3A
RPS3A
12760830
|
MITOMYCIN
NM_001031680; NM_004350
runt-related transcription factor 3
RUNX3
15756676
|
MITOMYCIN
NM_006713
SUB1 homolog (S. cerevisiae)
SUB1
12760830
|
MITOMYCIN
NM_198253; NM_198255
telomerase reverse transcriptase
TERT
—
resistance
|
MITOMYCIN
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
12082016
sensitivity
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
MITOMYCIN
NM_001113755; NM_001113756; NM_001953
thymidine phosphorylase
TYMP
18728667
|
HYDROXYUREA
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
16005713
death pathway
|
NM_138764; NM_138765
|
HYDROXYUREA
—
—
C13ORF34
17374387
|
HYDROXYUREA
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16005713
death pathway
|
HYDROXYUREA
NM_001237
cyclin A2
CCNA2
11468187
|
HYDROXYUREA
NM_031966
cyclin B1
CCNB1
11468187
|
HYDROXYUREA
NM_053056
cyclin D1
CCND1
11468187
altered by HU
|
HYDROXYUREA
NM_001759
cyclin D2
CCND2
11468187
altered by HU
|
HYDROXYUREA
NM_001136017; NM_001136125; NM_001136126;
cyclin D3
CCND3
11468187
altered by HU
|
NM_001760
|
HYDROXYUREA
NM_001238; NM_057182
cyclin E1
CCNE1
11468187
|
HYDROXYUREA
NM_004060; NM_199246
cyclin G1
CCNG1
16005713
altered by HU
|
HYDROXYUREA
NM_001790; NM_022809
cell division cycle 25 homolog C (S. pombe)
CDC25C
19074854
|
HYDROXYUREA
NM_018101
cell division cycle associated 8
CDCA8
17374387
|
HYDROXYUREA
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
16005713
resistance
|
HYDROXYUREA
NM_001827
CDC28 protein kinase regulatory subunit 2
CKS2
17374387
|
HYDROXYUREA
NM_000114; NM_207032; NM_207033;
endothelin 3
EDN3
15020278
altered by HU
|
NM_207034
|
HYDROXYUREA
NM_000043; NM_152871; NM_152872;
Fas (TNF receptor superfamily, member 6)
FAS
16005713
altered by HU
|
NM_152873; NM_152874; NM_152875;
|
NM_152876; NM_152877
|
HYDROXYUREA
NM_002266
karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
KPNA2
17374387
|
HYDROXYUREA
NM_003981; NM_199413; NM_199414
protein regulator of cytokinesis 1
PRC1
17374387
|
HYDROXYUREA
NM_001005290; NM_001032290; NM_001032291;
proline/serine-rich coiled-coil 1
PSRC1
17374387
|
NM_032636
|
HYDROXYUREA
NM_001033
ribonucleotide reductase M1
RRM1
—
unrelated
|
HYDROXYUREA
NM_001034
ribonucleotide reductase M2 polypeptide
RRM2
—
resistance
|
HYDROXYUREA
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
16005713
death pathway
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
HYDROXYUREA
NM_007019; NM_181799; NM_181800;
ubiquitin-conjugating enzyme E2C
UBE2C
17374387
|
NM_181801; NM_181802; NM_181803
|
CAMPTOTHECIN
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
10692111
resistance
|
member 1
|
CAMPTOTHECIN
NM_198576
agrin
AGRN
17374387
|
CAMPTOTHECIN
NM_000477
albumin
ALB
10803926, 17378599
used as a drug
|
carrier
|
CAMPTOTHECIN
NM_001153
annexin A4
ANXA4
17374387
|
CAMPTOTHECIN
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
15665116, 17555331
|
NM_138764; NM_138765
|
CAMPTOTHECIN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
10692111
|
CAMPTOTHECIN
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16061681
|
CAMPTOTHECIN
NM_007294; NM_007295; NM_007296;
breast cancer 1, early onset
BRCA1
10344722
|
NM_007297; NM_007298; NM_007299;
|
NM_007300; NM_007302; NM_007303;
|
NM_007304; NM_007305
|
CAMPTOTHECIN
NM_000059
breast cancer 2, early onset
BRCA2
10344722
|
CAMPTOTHECIN
NM_001130849; NM_001130850; NM_016289
calcium binding protein 39
CAB39
17374387
|
CAMPTOTHECIN
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
14757846
|
CAMPTOTHECIN
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16273314, 16962673, 16962673
|
CAMPTOTHECIN
NM_031966
cyclin B1
CCNB1
16061681
|
CAMPTOTHECIN
NM_001798; NM_052827
cyclin-dependent kinase 2
CDK2
15141020
|
CAMPTOTHECIN
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
11741290, 9673414, 17555331
|
CAMPTOTHECIN
NM_001024912; NM_001712
carcinoembryonic antigen-related cell adhesion
CEACAM1
17374387
|
molecule 1 (biliary glycoprotein)
|
CAMPTOTHECIN
NM_005760
CCAAT/enhancer binding protein (C/EBP), zeta
CEBPZ
17374387
|
CAMPTOTHECIN
NM_001908; NM_147780; NM_147781;
cathepsin B
CTSB
17378599
|
NM_147782; NM_147783
|
CAMPTOTHECIN
NM_001007277; NM_004879
etoposide induced 2.4 mRNA
EI24
17374387
|
CAMPTOTHECIN
NM_001429
E1A binding protein p300
EP300
10344722
|
CAMPTOTHECIN
NM_014805
EPM2A (laforin) interacting protein 1
EPM2AIP1
17374387
|
CAMPTOTHECIN
NM_004110; NM_024417
ferredoxin reductase
FDXR
17374387
|
CAMPTOTHECIN
NM_000852
glutathione S-transferase pi 1
GSTP1
15500952, 15500952, 14732228
|
CAMPTOTHECIN
NM_001077442; NM_001077443; NM_004500;
heterogeneous nuclear ribonucleoprotein C (C1/C2)
HNRNPC
16960656
|
NM_031314
|
CAMPTOTHECIN
NM_000576
interleukin 1, beta
IL1B
16356833
|
CAMPTOTHECIN
NM_000584
interleukin 8
IL8
16356833
|
CAMPTOTHECIN
NM_002228
jun oncogene
JUN
15585644
|
CAMPTOTHECIN
NM_002756; NM_145109
mitogen-activated protein kinase kinase 3
MAP2K3
17374387
|
CAMPTOTHECIN
NM_005923
mitogen-activated protein kinase kinase kinase 5
MAP3K5
17374387
|
CAMPTOTHECIN
NM_001135044; NM_002752; NM_139068;
mitogen-activated protein kinase 9
MAPK9
15585644
|
NM_139069; NM_139070
|
CAMPTOTHECIN
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
17555331
|
NM_001145340; NM_002392;
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
CAMPTOTHECIN
NM_001004720; NM_001004722; NM_003581
NCK adaptor protein 2
NCK2
17374387
|
CAMPTOTHECIN
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
11741290, 15585644, 16962673,
|
15585644, 16962673
|
CAMPTOTHECIN
NM_004073
polo-like kinase 3 (Drosophila)
PLK3
17374387
|
CAMPTOTHECIN
NM_032192; NM_181505
protein phosphatase 1, regulatory (inhibitor) subunit 1B
PPP1R1B
16061638
|
CAMPTOTHECIN
NM_003981; NM_199413; NM_199414
protein regulator of cytokinesis 1
PRC1
17374387
|
CAMPTOTHECIN
NM_002875; NM_133487
RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae)
RAD51
10344722
|
CAMPTOTHECIN
NM_000321
retinoblastoma 1
RB1
14704340, 15585644
|
CAMPTOTHECIN
NM_002895; NM_183404
retinoblastoma-like 1 (p107)
RBL1
15585644
|
CAMPTOTHECIN
NM_005611
retinoblastoma-like 2 (p130)
RBL2
15585644
|
CAMPTOTHECIN
NM_001006946; NM_002997
syndecan 1
SDC1
17374387
|
CAMPTOTHECIN
NM_000593
transporter 1, ATP-binding cassette, sub-family B
TAP1
17374387
|
(MDR/TAP)
|
CAMPTOTHECIN
NM_014604
Tax1 (human T-cell leukemia virus type I) binding
TAX1BP3
17374387
|
protein 3
|
CAMPTOTHECIN
NM_003246
thrombospondin 1
THBS1
16962673
|
CAMPTOTHECIN
NM_003811
tumor necrosis factor (ligand) superfamily, member 9
TNFSF9
17374387
|
CAMPTOTHECIN
NM_003286
topoisomerase (DNA) I
TOP1
—
|
CAMPTOTHECIN
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
10692111, 11741290, 17555331,
|
NM_001126114; NM_001126115;
9673414, 9673414, 17555331,
|
NM_001126116; NM_001126117
12082016
|
CAMPTOTHECIN
NM_004881; NM_147184
tumor protein p53 inducible protein 3
TP53I3
17374387
|
CAMPTOTHECIN
NR_015381; NR_015381; NR_015381;
TP53 target 1 (non-protein coding)
TP53TG1
17374387
|
NR_015381; NR_015381; NR_015381;
|
NR_015381; NR_015381
|
CAMPTOTHECIN
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
16356833
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
CAMPTOTHECIN
NM_001167
X-linked inhibitor of apoptosis
XIAP
16061681, 16211302
|
TOPOTECAN
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
15695404, 15875186, 17032904,
resistance
|
17032904
|
TOPOTECAN
NM_001668; NM_178426; NM_178427
aryl hydrocarbon receptor nuclear translocator
ARNT
15930297
|
TOPOTECAN
NM_002105
H2A histone family, member X
H2AFX
16432175
|
TOPOTECAN
NM_001530; NM_181054
hypoxia inducible factor 1, alpha subunit (basic helix-
HIF1A
15930297
target
|
loop-helix transcription factor)
|
TOPOTECAN
NM_003286
topoisomerase (DNA) I
TOP1
—
target
|
TOPOTECAN
NM_052963
topoisomerase (DNA) I, mitochondrial
TOP1MT
—
target
|
TOPOTECAN
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
15930297
target
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
IRINOTECAN
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
12960109, 15655543, 15801936,
resistance
|
member 1
16815871
|
IRINOTECAN
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
15897249, 16815871, 18927307
resistance
|
NM_019899; NM_019900
member 1
|
IRINOTECAN
NM_000392
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC2
16815871, 18981587
resistance
|
member 2
|
IRINOTECAN
NM_001105515; NM_005845
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC4
15827327
resistance
|
member 4
|
IRINOTECAN
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
15239142, 15695404, 15655543,
resistance
|
15801936
|
IRINOTECAN
NM_032859
abhydrolase domain containing 13
ABHD13
18927307
|
IRINOTECAN
NM_198834; NM_198836; NM_198837;
acetyl-Coenzyme A carboxylase alpha
ACACA
18927307
|
NM_198838; NM_198839
|
IRINOTECAN
NM_023038; NM_033274
ADAM metallopeptidase domain 19 (meltrin beta)
ADAM19
18927307
|
IRINOTECAN
NM_001121; NM_016824; NM_019903
adducin 3 (gamma)
ADD3
15956246
|
IRINOTECAN
NM_018269
acireductone dioxygenase 1
ADI1
18927307
|
IRINOTECAN
NM_000029
angiotensinogen (serpin peptidase inhibitor, clade A,
AGT
18927307
|
member 8)
|
IRINOTECAN
NM_007202
A kinase (PRKA) anchor protein 10
AKAP10
15956246
|
IRINOTECAN
NM_000032; NM_001037967; NM_001037968
aminolevulinate, delta-, synthase 2
ALAS2
15956246
|
IRINOTECAN
NM_000477
albumin
ALB
18927307
|
IRINOTECAN
NM_000689
aldehyde dehydrogenase 1 family, member A1
ALDH1A1
15956246
|
IRINOTECAN
NM_001143668; NM_181847
adhesion molecule with Ig-like domain 2
AMIGO2
18927307
|
IRINOTECAN
NM_012098
angiopoietin-like 2
ANGPTL2
17327601
|
IRINOTECAN
NM_032217; NM_198889
ankyrin repeat domain 17
ANKRD17
18927307
|
IRINOTECAN
NM_015199
ankyrin repeat domain 28
ANKRD28
18927307
|
IRINOTECAN
NM_001003954; NM_004306
annexin A13
ANXA13
18927307
|
IRINOTECAN
NM_001155; NM_004033
annexin A6
ANXA6
15956246
|
IRINOTECAN
NM_001030006; NM_001282
adaptor-related protein complex 2, beta 1 subunit
AP2B1
18927307
|
IRINOTECAN
NM_000038; NM_001127510; NM_001127511
adenomatous polyposis coli
APC
15956246
|
IRINOTECAN
NM_001654
v-raf murine sarcoma 3611 viral oncogene homolog
ARAF
15956246
|
IRINOTECAN
NM_001657
amphiregulin
AREG
15723263
|
IRINOTECAN
NM_001024226; NM_001024227; NM_001024228;
ADP-ribosylation factor 1
ARF1
18927307
|
NM_001658
|
IRINOTECAN
NM_001030055; NM_001173
Rho GTPase activating protein 5
ARHGAP5
15956246
|
IRINOTECAN
NM_015313
Rho guanine nucleotide exchange factor (GEF) 12
ARHGEF12
18927307
|
IRINOTECAN
NM_152641
AT rich interactive domain 2 (ARID, RFX-like)
ARID2
18927307
|
IRINOTECAN
NM_002892; NM_023000; NM_023001
AT rich interactive domain 4A (RBP1-like)
ARID4A
15956246
|
IRINOTECAN
—
—
ARL6IP2
18927307
|
IRINOTECAN
—
—
ARL7
18927307
|
IRINOTECAN
NM_014154; NM_015396; NM_213654
armadillo repeat containing 8
ARMC8
18927307
|
IRINOTECAN
NM_000046; NM_198709
arylsulfatase B
ARSB
18927307
|
IRINOTECAN
NM_001030287; NM_001040619; NM_001674;
activating transcription factor 3
ATF3
15956246
|
NM_004024
|
IRINOTECAN
NM_001131028; NM_031482
ATG10 autophagy related 10 homolog (S. cerevisiae)
ATG10
15956246
|
IRINOTECAN
NM_001697
ATP synthase, H+ transporting, mitochondrial F1
ATP5O
17327601
|
complex, O subunit
|
IRINOTECAN
NM_001003803; NM_001003805; NM_015684
ATP synthase, H+ transporting, mitochondrial F0
ATP5S
18927307
|
complex, subunit s (factor B)
|
IRINOTECAN
NM_001141972; NM_080650
ATP binding domain 4
ATPBD4
18927307
|
IRINOTECAN
NM_000489; NM_138270
alpha thalassemia/mental retardation syndrome X-
ATRX
18927307
|
linked (RAD54 homolog, S. cerevisiae)
|
IRINOTECAN
NM_004217
aurora kinase B
AURKB
15956246
|
IRINOTECAN
NM_012342
BMP and activin membrane-bound inhibitor homolog
BAMBI
18927307
|
(Xenopus laevis)
|
IRINOTECAN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
18949393
|
IRINOTECAN
NM_001024808; NM_020993
B-cell CLL/lymphoma 7A
BCL7A
15956246
|
IRINOTECAN
NM_004326
B-cell CLL/lymphoma 9
BCL9
15956246
|
IRINOTECAN
NM_004327; NM_021574
breakpoint cluster region
BCR
18927307
|
IRINOTECAN
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
15956246, 16373703
|
IRINOTECAN
—
—
BM1_06115
18927307
|
IRINOTECAN
NM_181809
bone morphogenetic protein 8a
BMP8A
15956246
|
IRINOTECAN
NM_033030; NM_197970
bol, boule-like (Drosophila)
BOLL
17327601
|
IRINOTECAN
NM_014962; NM_181443
BTB (POZ) domain containing 3
BTBD3
18927307
|
IRINOTECAN
NM_004336
budding uninhibited by benzimidazoles 1 homolog
BUB1
15956246
|
(yeast)
|
IRINOTECAN
—
—
C11ORF80
18927307
|
IRINOTECAN
—
—
C14ORF118
18927307
|
IRINOTECAN
—
—
C15ORF5
18927307
|
IRINOTECAN
—
—
C16ORF87
18927307
|
IRINOTECAN
—
—
C1ORF43
18927307
|
IRINOTECAN
—
—
C5ORF28
18927307
|
IRINOTECAN
—
—
C7ORF44
18927307
|
IRINOTECAN
—
—
C9ORF100
18927307
|
IRINOTECAN
—
—
C9ORF126
18927307
|
IRINOTECAN
—
—
C9ORF25
18927307
|
IRINOTECAN
NM_012295
calcineurin binding protein 1
CABIN1
18927307
|
IRINOTECAN
NM_001003406; NM_021096
calcium channel, voltage-dependent, T type, alpha 1I
CACNA1I
18927307
|
subunit
|
IRINOTECAN
NM_001225; NM_033306
caspase 4, apoptosis-related cysteine peptidase
CASP4
15956246
|
IRINOTECAN
NM_019083
coiled-coil domain containing 76
CCDC76
18927307
|
IRINOTECAN
NM_001237
cyclin A2
CCNA2
15956246
|
IRINOTECAN
NM_004701
cyclin B2
CCNB2
15956246
|
IRINOTECAN
NM_001761
cyclin F
CCNF
15956246
|
IRINOTECAN
NM_004354
cyclin G2
CCNG2
18927307
|
IRINOTECAN
NM_001295
chemokine (C-C motif) receptor 1
CCR1
15956246
|
IRINOTECAN
NM_004367; NM_031409
chemokine (C-C motif) receptor 6
CCR6
15956246
|
IRINOTECAN
NM_001009186; NM_001762
chaperonin containing TCP1, subunit 6A (zeta 1)
CCT6A
18927307
|
IRINOTECAN
NM_001025079; NM_001777; NM_198793
CD47 molecule
CD47
18927307
|
IRINOTECAN
NM_001252
CD70 molecule
CD70
15956246
|
IRINOTECAN
NM_005191
CD80 molecule
CD80
15956246
|
IRINOTECAN
NM_001130829; NM_001786; NM_033379
cell division cycle 2, G1 to S and G2 to M
CDC2
15956246
|
IRINOTECAN
NM_004358; NM_021872; NM_021873
cell division cycle 25 homolog B (S. pombe)
CDC25B
15956246
|
IRINOTECAN
NM_003718; NM_031267
cell division cycle 2-like 5 (cholinesterase-related cell
CDC2L5
15956246
|
division controller)
|
IRINOTECAN
NM_003607; NM_014826
CDC42 binding protein kinase alpha (DMPK-like)
CDC42BPA
18927307
|
IRINOTECAN
NM_001794
cadherin 4, type 1, R-cadherin (retinal)
CDH4
18927307
|
IRINOTECAN
NM_003936
cyclin-dependent kinase 5, regulatory subunit 2 (p39)
CDK5R2
15956246
|
IRINOTECAN
NM_001145306; NM_001259
cyclin-dependent kinase 6
CDK6
18927307
|
IRINOTECAN
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
15132777
|
IRINOTECAN
NM_001130851; NM_005192
cyclin-dependent kinase inhibitor 3
CDKN3
15956246
|
IRINOTECAN
NM_016952
Cdon homolog (mouse)
CDON
18927307
|
IRINOTECAN
NM_001813
centromere protein E, 312 kDa
CENPE
15956246, 18927307
|
IRINOTECAN
NM_016343
centromere protein F, 350/400ka (mitosin)
CENPF
15956246
|
IRINOTECAN
—
—
CENTG2
18927307
|
IRINOTECAN
NM_032142
centrosomal protein 192 kDa
CEP192
18927307
|
IRINOTECAN
NM_025114
centrosomal protein 290 kDa
CEP290
18927307
|
IRINOTECAN
NM_001025194; NM_001025195; NM_001266
carboxylesterase 1 (monocyte/macrophage serine
CES1
15100172, 15239142
|
esterase 1)
|
IRINOTECAN
NM_003869; NM_198061
carboxylesterase 2 (intestine, liver)
CES2
10728672, 12171891, 11716702,
|
12171903,
|
(following) 12171891, 15592324, 16203781, 11716702, 15475733, 14581373, 15100172, 15592324, 15655543, 16033949, 16203781
|
IRINOTECAN
NM_024922
carboxylesterase 3
CES3
15100172
|
IRINOTECAN
NM_001270
chromodomain helicase DNA binding protein 1
CHD1
15956246
|
IRINOTECAN
NM_001130675; NM_004362
calmegin
CLGN
18927307
|
IRINOTECAN
NM_004859
clathrin, heavy chain (Hc)
CLTC
18927307
|
IRINOTECAN
NM_017649; NM_199076; NM_199077
cyclin M2
CNNM2
18927307
|
IRINOTECAN
NM_001130103; NM_005203; NM_080798;
collagen, type XIII, alpha 1
COL13A1
18927307
|
NM_080799; NM_080800; NM_080801;
|
NM_080802; NM_080803; NM_080804;
|
NM_080805; NM_080806; NM_080807;
|
NM_080808; NM_080809; NM_080810;
|
NM_080811; NM_080812;
|
NM_080813; NM_080814; NM_080815
|
IRINOTECAN
NM_000092
collagen, type IV, alpha 4
COL4A4
18927307
|
IRINOTECAN
NM_001848
collagen, type VI, alpha 1
COL6A1
15956246
|
IRINOTECAN
NM_203495; NM_203497
COMM domain containing 6
COMMD6
15956246
|
IRINOTECAN
NM_001098398; NM_004371
coatomer protein complex, subunit alpha
COPA
18927307
|
IRINOTECAN
NM_001873
carboxypeptidase E
CPE
18927307
|
IRINOTECAN
NM_001079846; NM_004380
CREB binding protein
CREBBP
15956246, 18927307
|
IRINOTECAN
NM_016441
cysteine rich transmembrane BMP regulator 1
CRIM1
18927307
|
(chordin-like)
|
IRINOTECAN
NM_020991; NM_022644; NM_022645
chorionic somatomammotropin hormone 2
CSH2
18927307
|
IRINOTECAN
NM_001083914; NM_001329; NM_022802
C-terminal binding protein 2
CTBP2
18927307
|
IRINOTECAN
NM_001902; NM_153742
cystathionase (cystathionine gamma-lyase)
CTH
18927307
|
IRINOTECAN
NM_001008895; NM_003589
cullin 4A
CUL4A
18927307
|
IRINOTECAN
NM_000609; NM_001033886; NM_199168
chemokine (C—X—C motif) ligand 12 (stromal cell-
CXCL12
18927307
|
derived factor 1)
|
IRINOTECAN
NM_000761
cytochrome P450, family 1, subfamily A, polypeptide 2
CYP1A2
11901092
unrelated
|
IRINOTECAN
NM_000762
cytochrome P450, family 2, subfamily A, polypeptide 6
CYP2A6
11901092
|
IRINOTECAN
NM_000767
cytochrome P450, family 2, subfamily B, polypeptide 6
CYP2B6
11901092
|
IRINOTECAN
NM_000769
cytochrome P450, family 2, subfamily C, polypeptide
CYP2C19
11901092
|
19
|
IRINOTECAN
NM_000770
cytochrome P450, family 2, subfamily C, polypeptide 8
CYP2C8
11901092
unrelated
|
IRINOTECAN
NM_000771
cytochrome P450, family 2, subfamily C, polypeptide 9
CYP2C9
11901092
unrelated
|
IRINOTECAN
NM_000106; NM_001025161
cytochrome P450, family 2, subfamily D, polypeptide 6
CYP2D6
11901092
|
IRINOTECAN
NM_000773
cytochrome P450, family 2, subfamily E, polypeptide 1
CYP2E1
11901092
|
IRINOTECAN
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
11901092, 15100172, 15239142,
drug
|
15523087, 15655543
metabolism
|
IRINOTECAN
NM_000777
cytochrome P450, family 3, subfamily A, polypeptide 5
CYP3A5
15897249
drug
|
metabolism
|
IRINOTECAN
NM_001142936; NM_139179
diacylglycerol lipase, beta
DAGLB
18927307
|
IRINOTECAN
NM_014881
DNA cross-link repair 1A (PSO2 homolog, S. cerevisiae)
DCLRE1A
15956246
|
IRINOTECAN
NM_006400
dynactin 2 (p50)
DCTN2
18927307
|
IRINOTECAN
NM_000107
damage-specific DNA binding protein 2, 48 kDa
DDB2
15956246
|
IRINOTECAN
NM_030637
DDHD domain containing 1
DDHD1
18927307
|
IRINOTECAN
NM_001039711; NM_001039712; NM_032998
death effector domain containing
DEDD
18927307
|
IRINOTECAN
NM_004084
defensin, alpha 1
DEFA1
15956246
|
IRINOTECAN
NM_001144823; NM_005848
DENN/MADD domain containing 4A
DENND4A
15956246
|
IRINOTECAN
NM_003677
density-regulated protein
DENR
18927307
|
IRINOTECAN
NM_001145208; NM_018369
DEP domain containing 1B
DEPDC1B
18927307
|
IRINOTECAN
NM_022720
DiGeorge syndrome critical region gene 8
DGCR8
18927307
|
IRINOTECAN
NM_176815
dihydrofolate reductase-like 1
DHFRL1
18927307
|
IRINOTECAN
NM_001146114; NM_001146115; NM_015151;
DIP2 disco-interacting protein 2 homolog A
DIP2A
18927307
|
NM_206889; NM_206890; NM_206891
(Drosophila)
|
IRINOTECAN
NM_006094; NM_024767; NM_182643
deleted in liver cancer 1
DLC1
18927307
|
IRINOTECAN
NM_001098424; NM_004087
discs, large homolog 1 (Drosophila)
DLG1
18927307
|
IRINOTECAN
NM_001934; NM_138281
distal-less homeobox 4
DLX4
18927307
|
IRINOTECAN
NM_004943
dystrophia myotonica, WD repeat containing
DMWD
15956246
|
IRINOTECAN
—
—
DNMT2
15956246
|
IRINOTECAN
NM_001039589; NM_001384
DPH2 homolog (S. cerevisiae)
DPH2
18927307
|
IRINOTECAN
NM_000110
dihydropyrimidine dehydrogenase
DPYD
15956246
|
IRINOTECAN
NM_000798
dopamine receptor D5
DRD5
17327601
|
IRINOTECAN
NM_004147
developmentally regulated GTP binding protein 1
DRG1
15897249
|
IRINOTECAN
NM_001144769; NM_001144770; NM_001144771;
dystonin
DST
18927307
|
NM_001723; NM_015548;
|
NM_020388; NM_183380
|
IRINOTECAN
NM_004418
dual specificity phosphatase 2
DUSP2
15956246
|
IRINOTECAN
NM_001396; NM_101395; NM_130436;
dual-specificity tyrosine-(Y)-phosphorylation regulated
DYRK1A
15956246
|
NM_130437; NM_130438
kinase 1A
|
IRINOTECAN
NM_003583; NM_006482
dual-specificity tyrosine-(Y)-phosphorylation regulated
DYRK2
15956246
|
kinase 2
|
IRINOTECAN
—
—
EBI2
15956246
|
IRINOTECAN
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15723263
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
IRINOTECAN
NM_001964
early growth response 1
EGR1
15956246
|
IRINOTECAN
NM_001013703
eukaryotic translation initiation factor 2 alpha kinase 4
EIF2AK4
18927307
|
IRINOTECAN
NM_012155
echinoderm microtubule associated protein like 2
EML2
17327601
|
IRINOTECAN
NM_001428
enolase 1, (alpha)
ENO1
18927307
|
IRINOTECAN
NM_001429
E1A binding protein p300
EP300
15956246
|
IRINOTECAN
NM_031308
epiplakin 1
EPPK1
18927307
|
IRINOTECAN
NM_001042599; NM_005235
v-erb-a erythroblastic leukemia viral oncogene
ERBB4
15956246
|
homolog 4 (avian)
|
IRINOTECAN
NM_015064; NM_178037; NM_178038;
ELKS/RAB6-interacting/CAST family member 1
ERC1
18927307
|
NM_178039; NM_178040
|
IRINOTECAN
NM_001432
epiregulin
EREG
18927307
|
IRINOTECAN
NM_005239
v-ets erythroblastosis virus E26 oncogene homolog 2
ETS2
15956246
|
(avian)
|
IRINOTECAN
NM_001987
ets variant 6
ETV6
15956246
|
IRINOTECAN
NM_001037126; NM_021807
exocyst complex component 4
EXOC4
18927307
|
IRINOTECAN
NM_000132; NM_019863
coagulation factor VIII, procoagulant component
F8
17327601
|
IRINOTECAN
NM_001040442; NM_001130958; NM_001445
fatty acid binding protein 6, ileal
FABP6
18927307
|
IRINOTECAN
—
—
FAM152A
18927307
|
IRINOTECAN
NM_001040020; NM_014888
family with sequence similarity 3, member C
FAM3C
18927307
|
IRINOTECAN
—
—
FAM44A
18927307
|
IRINOTECAN
NM_004629
Fanconi anemia, complementation group G
FANCG
15956246
|
IRINOTECAN
NM_005687
phenylalanyl-tRNA synthetase, beta subunit
FARSB
18927307
|
IRINOTECAN
NM_000639
Fas ligand (TNF superfamily, member 6)
FASLG
15897249
|
IRINOTECAN
NM_015962
FCF1 small subunit (SSU) processome component
FCF1
18927307
|
homolog (S. cerevisiae)
|
IRINOTECAN
NM_002006
fibroblast growth factor 2 (basic)
FGF2
15956246
|
IRINOTECAN
NM_002010
fibroblast growth factor 9 (glia-activating factor)
FGF9
18927307
|
IRINOTECAN
NM_002026; NM_054034; NM_212474;
fibronectin 1
FN1
15956246, 18927307
|
NM_212475; NM_212476; NM_212478;
|
NM_212482
|
IRINOTECAN
NM_005252
v-fos FBJ murine osteosarcoma viral oncogene
FOS
15956246
|
homolog
|
IRINOTECAN
NM_001114171; NM_006732
FBJ murine osteosarcoma viral oncogene homolog B
FOSB
15956246
|
IRINOTECAN
NM_032892
FERM domain containing 5
FRMD5
18927307
|
IRINOTECAN
NM_001080432
fat mass and obesity associated
FTO
18927307
|
IRINOTECAN
NM_001465; NM_199335
FYN binding protein (FYB-120/130)
FYB
18927307
|
IRINOTECAN
—
—
G1P3
18927307
|
IRINOTECAN
NM_001002295; NM_002051
GATA binding protein 3
GATA3
15956246
|
IRINOTECAN
NM_004864
growth differentiation factor 15
GDF15
15956246
|
IRINOTECAN
NM_001032364; NM_001032365; NM_005265;
gamma-glutamyltransferase 1
GGT1
18927307
|
NM_013430
|
IRINOTECAN
NM_000165
gap junction protein, alpha 1, 43 kDa
GJA1
18927307
|
IRINOTECAN
NM_000167; NM_001128127; NM_203391
glycerol kinase
GK
18927307
|
IRINOTECAN
NM_006541
glutaredoxin 3
GLRX3
18927307
|
IRINOTECAN
NM_006572
guanine nucleotide binding protein (G protein), alpha
GNA13
18927307
|
13
|
IRINOTECAN
NM_181077
golgi autoantigen, golgin subfamily a, 8A
GOLGA8A
17327601
|
IRINOTECAN
NM_015590; NM_182679
G patch domain containing 4
GPATCH4
18927307
|
IRINOTECAN
NM_002084
glutathione peroxidase 3 (plasma)
GPX3
15956246
|
IRINOTECAN
NM_002105
H2A histone family, member X
H2AFX
15956246
|
IRINOTECAN
NM_001945
heparin-binding EGF-like growth factor
HBEGF
15723263
|
IRINOTECAN
NM_000559
hemoglobin, gamma A
HBG1
18927307
|
IRINOTECAN
NM_005334
host cell factor C1 (VP16-accessory protein)
HCFC1
18927307
|
IRINOTECAN
NM_173497; NM_182765
HECT domain containing 2
HECTD2
18927307
|
IRINOTECAN
NM_018063
helicase, lymphoid-specific
HELLS
18927307
|
IRINOTECAN
NM_005524
hairy and enhancer of split 1, (Drosophila)
HES1
19147571
|
IRINOTECAN
NM_003512
histone cluster 1, H2ac
HIST1H2AC
15956246
|
IRINOTECAN
NM_003542
histone cluster 1, H4c
HIST1H4C
18927307
|
IRINOTECAN
NM_005514
major histocompatibility complex, class I, B
HLA-B
18927307
|
IRINOTECAN
NM_002124
major histocompatibility complex, class II, DR beta 1
HLA-
18927307
|
DRB1
|
IRINOTECAN
NM_021983
major histocompatibility complex, class II, DR beta 4
HLA-
18927307
|
DRB4
|
IRINOTECAN
NM_001142556; NM_001142557; NM_012484;
hyaluronan-mediated motility receptor (RHAMM)
HMMR
15956246
|
NM_012485
|
IRINOTECAN
NM_001002032; NM_001002033; NM_016185
hematological and neurological expressed 1
HN1
18927307
|
IRINOTECAN
—
—
HNRPA1
18927307
|
IRINOTECAN
—
—
HNRPD
18927307
|
IRINOTECAN
NM_031372
heterogeneous nuclear ribonucleoprotein D-like
HNRPDL
18927307
|
IRINOTECAN
NM_000412
histidine-rich glycoprotein
HRG
15956246
|
IRINOTECAN
NM_006041
heparan sulfate (glucosamine) 3-O-sulfotransferase
HS3ST3B1
18927307
|
3B1
|
IRINOTECAN
NM_014278
heat shock 70 kDa protein 4-like
HSPA4L
15956246
|
IRINOTECAN
—
—
HYPK
18927307
|
IRINOTECAN
NM_002166
inhibitor of DNA binding 2, dominant negative helix-
ID2
15956246
|
loop-helix protein
|
IRINOTECAN
NM_003641
interferon induced transmembrane protein 1 (9-27)
IFITM1
18927307
|
IRINOTECAN
NM_000618; NM_001111283; NM_001111284;
insulin-like growth factor 1 (somatomedin C)
IGF1
15956246
|
NM_001111285
|
IRINOTECAN
—
immunoglobulin heavy constant gamma 1 (G1m
IGHG1
18927307
|
marker)
|
IRINOTECAN
NM_000576
interleukin 1, beta
IL1B
15956246
|
IRINOTECAN
NM_000584
interleukin 8
IL8
15723263
|
IRINOTECAN
NM_032549
IMP2 inner mitochondrial membrane
IMMP2L
18927307
|
peptidase-like (S. cerevisiae)
|
IRINOTECAN
NM_001100169; NM_001100170; NM_006839
inner membrane protein, mitochondrial (mitofilin)
IMMT
18927307
|
IRINOTECAN
NM_019071; NM_198267
inhibitor of growth family, member 3
ING3
18927307
|
IRINOTECAN
NM_005542; NM_198336; NM_198337
insulin induced gene 1
INSIG1
18927307
|
IRINOTECAN
NM_002203
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2
ITGA2
18927307
|
receptor)
|
IRINOTECAN
NM_001144999; NM_001145000; NM_002210
integrin, alpha V (vitronectin receptor, alpha
ITGAV
15956246
|
polypeptide, antigen CD51)
|
IRINOTECAN
NM_000887
integrin, alpha X (complement component 3 receptor 4
ITGAX
15956246
|
subunit)
|
IRINOTECAN
NM_014288
integrin beta 3 binding protein (beta3-endonexin)
ITGB3BP
15956246
|
IRINOTECAN
NM_002228
jun oncogene
JUN
15956246
|
IRINOTECAN
NM_006559
KH domain containing, RNA binding, signal
KHDRBS1
18927307
|
transduction associated 1
|
IRINOTECAN
NM_001162893; NM_001162894; NM_001162895;
KIAA0040
KIAA0040
18927307
|
NM_014656
|
IRINOTECAN
NM_015443
KIAA1267
KIAA1267
18927307
|
IRINOTECAN
—
—
KIAA1333
18927307
|
IRINOTECAN
NM_033395
KIAA1731
KIAA1731
18927307
|
IRINOTECAN
NM_014875
kinesin family member 14
KIF14
18927307
|
IRINOTECAN
NM_004235
Kruppel-like factor 4 (gut)
KLF4
18927307
|
IRINOTECAN
NM_001206
Kruppel-like factor 9
KLF9
15956246
|
IRINOTECAN
NM_017644
kelch-like 24 (Drosophila)
KLHL24
18927307
|
IRINOTECAN
NM_001013406; NM_004912; NM_194454;
KRIT1, ankyrin repeat containing
KRIT1
18927307
|
NM_194455; NM_194456
|
IRINOTECAN
NM_000424
keratin 5
KRT5
15956246
|
IRINOTECAN
NM_030915
limb bud and heart development homolog (mouse)
LBH
18927307
|
IRINOTECAN
NM_006499; NM_201543; NM_201544;
lectin, galactoside-binding, soluble, 8
LGALS8
17327601
|
NM_201545
|
IRINOTECAN
—
—
LIM
18927307
|
IRINOTECAN
NM_032603
lysyl oxidase-like 3
LOXL3
18927307
|
IRINOTECAN
NM_024830
lysophosphatidylcholine acyltransferase 1
LPCAT1
18927307
|
IRINOTECAN
NM_032773
leucine-rich repeats and calponin homology (CH)
LRCH3
18927307
|
domain containing 3
|
IRINOTECAN
NM_002343
lactotransferrin
LTF
15956246
|
IRINOTECAN
NM_032860
LTV1 homolog (S. cerevisiae)
LTV1
18927307
|
IRINOTECAN
NM_002358
MAD2 mitotic arrest deficient-like 1 (yeast)
MAD2L1
15956246
|
IRINOTECAN
NM_002371; NM_022438; NM_022439;
mal, T-cell differentiation protein
MAL
15956246
|
NM_022440
|
IRINOTECAN
NR_002819; NR_002819; NR_002819;
metastasis associated lung adenocarcinoma transcript
MALAT1
18927307
|
NR_002819; NR_002819; NR_002819
1 (non-protein coding)
|
IRINOTECAN
NM_005434
mal, T-cell differentiation protein-like
MALL
15956246
|
IRINOTECAN
NM_005923
mitogen-activated protein kinase kinase kinase 5
MAP3K5
15956246
|
IRINOTECAN
NM_003618
mitogen-activated protein kinase kinase kinase kinase 3
MAP4K3
18927307
|
IRINOTECAN
NM_005885
membrane-associated ring finger (C3HC4) 6
MARCH6
18927307
|
IRINOTECAN
NM_002380; NM_030583
matrilin 2
MATN2
18927307
|
IRINOTECAN
NM_018834; NM_199189
matrin 3
MATR3
18927307
|
IRINOTECAN
NM_021038; NM_207292; NM_207293;
muscleblind-like (Drosophila)
MBNL1
18927307
|
NM_207294; NM_207295; NM_207296;
|
NM_207297
|
IRINOTECAN
NM_001025081; NM_001025090; NM_001025092;
myelin basic protein
MBP
18927307
|
NM_001025100; NM_001025101;
|
NM_002385
|
IRINOTECAN
NM_022132
methylcrotonoyl-Coenzyme A carboxylase 2 (beta)
MCCC2
18927307
|
IRINOTECAN
NM_001112732; NM_024979
MCF.2 cell line derived transforming sequence-like
MCF2L
15956246
|
IRINOTECAN
NM_005914; NM_182746
minichromosome maintenance complex component 4
MCM4
15956246
|
IRINOTECAN
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
15956246
|
NM_001145340; NM_002392;
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
IRINOTECAN
NM_014611
MDN1, midasin homolog (yeast)
MDN1
18927307
|
IRINOTECAN
NM_005121
mediator complex subunit 13
MED13
18927307
|
IRINOTECAN
NM_001145785
myocyte enhancer factor 2B
MEF2B
15956246
|
IRINOTECAN
NM_002412
O-6-methylguanine-DNA methyltransferase
MGMT
15239142
|
IRINOTECAN
NM_012064
major intrinsic protein of lens fiber
MIP
18927307
|
IRINOTECAN
NR_027350; XR_079513; XR_079513;
microRNA host gene 1 (non-protein coding)
MIRHG1
18927307
|
XR_079539; XR_079539; XR_079554;
|
XR_079554
|
IRINOTECAN
NM_173576
mohawk homeobox
MKX
18927307
|
IRINOTECAN
NM_000249
mutL homolog 1, colon cancer,
MLH1
18949393
|
nonpolyposis type 2 (E. coli)
|
IRINOTECAN
NM_004994
matrix metallopeptidase 9 (gelatinase B, 92 kDa
MMP9
15956246
|
gelatinase, 92 kDa type IV collagenase)
|
IRINOTECAN
NM_000250
myeloperoxidase
MPO
15956246
|
IRINOTECAN
NM_173496
membrane protein, palmitoylated 7 (MAGUK p55
MPP7
18927307
|
subfamily member 7)
|
IRINOTECAN
NM_016640
mitochondrial ribosomal protein S30
MRPS30
18927307
|
IRINOTECAN
NM_000251
mutS homolog 2, colon cancer, nonpolyposis type 1
MSH2
15956246, 18949393
|
(E. coli)
|
IRINOTECAN
NM_015440
methylenetetrahydrofolate dehydrogenase (NADP+
MTHFD1L
18927307
|
dependent) 1-like
|
IRINOTECAN
NM_006441
5,10-methenyltetrahydrofolate synthetase (5-
MTHFS
15956246
|
formyltetrahydrofolate cyclo-ligase)
|
IRINOTECAN
NM_002463
myxovirus (influenza virus) resistance 2 (mouse)
MX2
15956246
|
IRINOTECAN
NM_005964
myosin, heavy chain 10, non-muscle
MYH10
18927307
|
IRINOTECAN
NM_001085487
Myb-like, SWIRM and MPN domains 1
MYSM1
18927307
|
IRINOTECAN
NM_153029
NEDD4 binding protein 1
N4BP1
18927307
|
IRINOTECAN
NM_017940
neuroblastoma breakpoint family, member 1
NBPF1
18927307
|
IRINOTECAN
NM_006153
NCK adaptor protein 1
NCK1
15956246
|
IRINOTECAN
NM_003743; NM_147223; NM_147233
nuclear receptor coactivator 1
NCOA1
15956246
|
IRINOTECAN
NM_006311
nuclear receptor co-repressor 1
NCOR1
18927307
|
IRINOTECAN
NM_015331
nicastrin
NCSTN
19147571
|
IRINOTECAN
NM_002497
NIMA (never in mitosis gene a)-related kinase 2
NEK2
15956246
|
IRINOTECAN
NM_006018
niacin receptor 2
NIACR2
15956246
|
IRINOTECAN
NM_002508
nidogen 1
NID1
15956246
|
IRINOTECAN
NM_000903; NM_001025433; NM_001025434
NAD(P)H dehydrogenase, quinone 1
NQO1
18927307
|
IRINOTECAN
NM_006178
N-ethylmaleimide-sensitive factor
NSF
18927307
|
IRINOTECAN
NM_005124
nucleoporin 153 kDa
NUP153
18927307
|
IRINOTECAN
NM_001129897; NM_016359; NM_018454
nucleolar and spindle associated protein 1
NUSAP1
18927307
|
IRINOTECAN
NM_002547
oligophrenin 1
OPHN1
18927307
|
IRINOTECAN
NM_003999
oncostatin M receptor
OSMR
15956246
|
IRINOTECAN
NM_018440
phosphoprotein associated with glycosphingolipid
PAG1
18927307
|
microdomains 1
|
IRINOTECAN
NM_000919; NM_138766; NM_138821;
peptidylglycine alpha-amidating monooxygenase
PAM
18927307
|
NM_138822
|
IRINOTECAN
NM_175854
PAN3 poly(A) specific ribonuclease subunit homolog
PAN3
18927307
|
(S. cerevisiae)
|
IRINOTECAN
NM_016734
paired box 5
PAX5
18927307
|
IRINOTECAN
NM_001135254; NM_002584; NM_013945
paired box 7
PAX7
18927307
|
IRINOTECAN
—
—
PCAF
18927307
|
IRINOTECAN
NM_032151
pterin-4 alpha-carbinolamine dehydratase/dimerization
PCBD2
18927307
|
cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 2
|
IRINOTECAN
NM_002588; NM_032402; NM_032403
protocadherin gamma subfamily C, 3
PCDHGC3
15956246
|
IRINOTECAN
NM_001037339; NM_001037340; NM_001037341;
phosphodiesterase 4B, cAMP-specific
PDE4B
15956246
|
NM_002600
(phosphodiesterase E4 dunce homolog, Drosophila)
|
IRINOTECAN
NM_173582
phosphoglucomutase 2-like 1
PGM2L1
18927307
|
IRINOTECAN
NM_007350
pleckstrin homology-like domain, family A, member 1
PHLDA1
18927307
|
IRINOTECAN
NR_003700; NR_003700; NR_003700;
phosphatidylinositol 4-kinase, catalytic, alpha
PI4KAP2
15956246
|
NR_003700
pseudogene 2
|
IRINOTECAN
NM_178517
phosphatidylinositol glycan anchor biosynthesis, class W
PIGW
18927307
|
IRINOTECAN
NM_000930; NM_033011
plasminogen activator, tissue
PLAT
18927307
|
IRINOTECAN
NM_001134478; NM_153268
phosphatidylinositol-specific phospholipase C, X
PLCXD2
18927307
|
domain containing 2
|
IRINOTECAN
NM_001143821; NM_019012
pleckstrin homology domain containing, family A
PLEKHA5
18927307
|
member 5
|
IRINOTECAN
NM_024927
pleckstrin homology domain containing, family H (with
PLEKHH3
15956246
|
MyTH4 domain) member 3
|
IRINOTECAN
NM_005030
polo-like kinase 1 (Drosophila)
PLK1
15956246
|
IRINOTECAN
NM_006622
polo-like kinase 2 (Drosophila)
PLK2
15956246
|
IRINOTECAN
NM_004073
polo-like kinase 3 (Drosophila)
PLK3
15956246
|
IRINOTECAN
NM_021127
phorbol-12-myristate-13-acetate-induced protein 1
PMAIP1
15956246
|
IRINOTECAN
NM_006813
proline-rich nuclear receptor coactivator 1
PNRC1
18927307
|
IRINOTECAN
NM_015100; NM_145796; NM_207171
pogo transposable element with ZNF domain
POGZ
18927307
|
IRINOTECAN
NM_016218
polymerase (DNA directed) kappa
POLK
18927307
|
IRINOTECAN
NM_000941
P450 (cytochrome) oxidoreductase
POR
15239142
|
IRINOTECAN
NM_003620
protein phosphatase 1D magnesium-dependent, delta
PPM1D
18927307
|
isoform
|
IRINOTECAN
NM_000944; NM_001130691; NM_001130692
protein phosphatase 3 (formerly 2B), catalytic subunit,
PPP3CA
18927307
|
alpha isoform
|
IRINOTECAN
NM_001142353; NM_001142354; NM_021132
protein phosphatase 3 (formerly 2B), catalytic subunit,
PPP3CB
15956246
|
beta isoform
|
IRINOTECAN
NM_006251; NM_206907
protein kinase, AMP-activated, alpha 1 catalytic
PRKAA1
18927307
|
subunit
|
IRINOTECAN
NM_002737
protein kinase C, alpha
PRKCA
15723263
|
IRINOTECAN
NM_002738; NM_212535
protein kinase C, beta
PRKCB
15723263
|
IRINOTECAN
NM_006254; NM_212539
protein kinase C, delta
PRKCD
15723263
|
IRINOTECAN
NM_002740
protein kinase C, iota
PRKCI
15723263
|
IRINOTECAN
NM_001145848; NM_001145849; NM_001145850;
prominin 1
PROM1
15956246
|
NM_001145851; NM_001145852;
|
NM_006017
|
IRINOTECAN
NM_002784
pregnancy specific beta-1-glycoprotein 9
PSG9
17327601
|
IRINOTECAN
NM_004878
prostaglandin E synthase
PTGES
15956246
|
IRINOTECAN
NM_005607; NM_153831
PTK2 protein tyrosine kinase 2
PTK2
18927307
|
IRINOTECAN
NM_003463
protein tyrosine phosphatase type IVA, member 1
PTP4A1
18927307
|
IRINOTECAN
NM_006264; NM_080683; NM_080684;
protein tyrosine phosphatase, non-receptor type 13
PTPN13
15956246
|
NM_080685
(APO-1/CD95 (Fas)-associated phosphatase)
|
IRINOTECAN
NM_012411; NM_015967
protein tyrosine phosphatase, non-receptor type 22
PTPN22
15956246
|
(lymphoid)
|
IRINOTECAN
NM_001040712; NM_002839; NM_130391;
protein tyrosine phosphatase, receptor type, D
PTPRD
15956246
|
NM_130392; NM_130393
|
IRINOTECAN
NM_002841
protein tyrosine phosphatase, receptor type, G
PTPRG
18927307
|
IRINOTECAN
NM_002846
protein tyrosine phosphatase, receptor type, N
PTPRN
15956246
|
IRINOTECAN
NM_005052
ras-related C3 botulinum toxin substrate 3 (rho family,
RAC3
15956246
|
small GTP binding protein Rac3)
|
IRINOTECAN
NM_002874
RAD23 homolog B (S. cerevisiae)
RAD23B
15956246
|
IRINOTECAN
NM_002877; NM_133509; NM_133510
RAD51-like 1 (S. cerevisiae)
RAD51L1
18927307
|
IRINOTECAN
NM_002890; NM_022650
RAS p21 protein activator (GTPase activating protein) 1
RASA1
18927307
|
IRINOTECAN
NM_000321
retinoblastoma 1
RB1
15132777
|
IRINOTECAN
NM_005057
retinoblastoma binding protein 5
RBBP5
15956246
|
IRINOTECAN
NM_002895; NM_183404
retinoblastoma-like 1 (p107)
RBL1
15956246
|
IRINOTECAN
NM_001143941; NM_001143942; NM_153020
RNA binding motif protein 24
RBM24
18927307
|
IRINOTECAN
—
—
RBPSUH
18927307
|
IRINOTECAN
NM_021111
reversion-inducing-cysteine-rich protein with kazal
RECK
18927307
|
motifs
|
IRINOTECAN
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
15161687, 16685529
|
(avian)
|
IRINOTECAN
NM_001128617; NM_031922
RALBP1 associated Eps domain containing 1
REPS1
18927307
|
IRINOTECAN
NM_002915; NM_181558
replication factor C (activator 1) 3, 38 kDa
RFC3
15956246
|
IRINOTECAN
NM_002922
regulator of G-protein signaling 1
RGS1
15956246
|
IRINOTECAN
NM_015668
regulator of G-protein signaling 22
RGS22
18927307
|
IRINOTECAN
NM_021205
ras homolog gene family, member U
RHOU
18927307
|
IRINOTECAN
—
—
RNF12
18927307
|
IRINOTECAN
NM_000968
ribosomal protein L4
RPL4
18927307
|
IRINOTECAN
NM_001001890; NM_001122607; NM_001754
runt-related transcription factor 1
RUNX1
15956246
|
IRINOTECAN
NM_017654
sterile alpha motif domain containing 9
SAMD9
18927307
|
IRINOTECAN
NM_015474
SAM domain and HD domain 1
SAMHD1
18927307
|
IRINOTECAN
—
—
SCD4
18927307
|
IRINOTECAN
NM_002999
syndecan 4
SDC4
15956246
|
IRINOTECAN
NM_001077206; NM_001077207; NM_001077208;
SEC31 homolog A (S. cerevisiae)
SEC31A
18927307
|
NM_014933; NM_016211
|
IRINOTECAN
NM_006379
sema domain, immunoglobulin domain (Ig), short basic
SEMA3C
18927307
|
domain, secreted, (semaphorin) 3C
|
IRINOTECAN
NM_001100409; NM_015571
SUMO1/sentrin specific peptidase 6
SENP6
18927307
|
IRINOTECAN
NM_001136528; NM_001136529; NM_001136530;
serpin peptidase inhibitor, clade E (nexin, plasminogen
SERPINE2
17327601
|
NM_006216
activator inhibitor type 1), member 2
|
IRINOTECAN
NM_031459
sestrin 2
SESN2
15956246
|
IRINOTECAN
NM_015048
SET domain containing 1B
SETD1B
18927307
|
IRINOTECAN
NM_001080517
SET domain containing 5
SETD5
18927307
|
IRINOTECAN
NM_006142
stratifin
SFN
16373703
|
IRINOTECAN
NM_001145444; NM_001145445; NM_020706
splicing factor, arginine/serine-rich 15
SFRS15
18927307
|
IRINOTECAN
—
—
SGK
15956246, 18927307
|
IRINOTECAN
NM_152524
shugoshin-like 2 (S. pombe)
SGOL2
18927307
|
IRINOTECAN
NM_004696
solute carrier family 16, member 4 (monocarboxylic
SLC16A4
15956246
|
acid transporter 5)
|
IRINOTECAN
NM_194255
solute carrier family 19 (folate transporter), member 1
SLC19A1
18927307
|
IRINOTECAN
NM_030631
solute carrier family 25 (mitochondrial oxodicarboxylate
SLC25A21
18927307
|
carrier), member 21
|
IRINOTECAN
NM_021194
solute carrier family 30 (zinc transporter), member 1
SLC30A1
18927307
|
IRINOTECAN
NM_001130012; NM_004785
solute carrier family 9 (sodium/hydrogen exchanger),
SLC9A3R2
15956246
|
member 3 regulator 2
|
IRINOTECAN
NM_001145102; NM_001145103; NM_001145104;
SMAD family member 3
SMAD3
18927307
|
NM_005902
|
IRINOTECAN
NM_015295
structural maintenance of chromosomes flexible hinge
SMCHD1
18927307
|
domain containing 1
|
IRINOTECAN
NM_001122964; NM_020463
SMEK homolog 2, suppressor of mek1 (Dictyostelium)
SMEK2
18927307
|
IRINOTECAN
NM_018225
smu-1 suppressor of mec-8 and unc-52
SMU1
18927307
|
homolog (C. elegans)
|
IRINOTECAN
NM_020429; NM_181349
SMAD specific E3 ubiquitin protein ligase 1
SMURF1
18927307
|
IRINOTECAN
—
—
SNAG1
15956246
|
IRINOTECAN
NM_003090
small nuclear ribonucleoprotein polypeptide A′
SNRPA1
18927307
|
IRINOTECAN
NM_003109; NM_138473
Sp1 transcription factor
SP1
18927307
|
IRINOTECAN
NM_003121
Spi-B transcription factor (Spi-1/PU.1 related)
SPIB
15956246
|
IRINOTECAN
NM_007271
serine/threonine kinase 38
STK38
15956246
|
IRINOTECAN
NM_006282
serine/threonine kinase 4
STK4
15956246, 18927307
|
IRINOTECAN
NM_001017389; NM_001017390
sulfotransferase family, cytosolic, 1A, phenol-
SULT1A4
15956246
|
preferring, member 4
|
IRINOTECAN
NM_032184
synapse defective 1, Rho GTPase,
SYDE2
18927307
|
homolog 2 (C. elegans)
|
IRINOTECAN
NM_001135805; NM_001135806; NM_005639
synaptotagmin I
SYT1
18927307
|
IRINOTECAN
NM_003184
TAF2 RNA polymerase II, TATA box binding protein
TAF2
15956246
|
(TBP)-associated factor, 150 kDa
|
IRINOTECAN
NM_003192
tubulin folding cofactor C
TBCC
15956246
|
IRINOTECAN
NM_003205; NM_207036; NM_207037;
transcription factor 12
TCF12
18927307
|
NM_207038; NM_207040
|
IRINOTECAN
NM_030756
transcription factor 7-like 2 (T-cell specific, HMG-box)
TCF7L2
18927307
|
IRINOTECAN
NM_005653
transcription factor CP2
TFCP2
18927307
|
IRINOTECAN
NM_001032281; NM_006287
tissue factor pathway inhibitor (lipoprotein-associated
TFPI
18927307
|
coagulation inhibitor)
|
IRINOTECAN
NM_001128148; NM_003234
transferrin receptor (p90, CD71)
TFRC
18927307
|
IRINOTECAN
NM_001099691; NM_003236
transforming growth factor, alpha
TGFA
15723263
|
IRINOTECAN
NM_000358
transforming growth factor, beta-induced, 68 kDa
TGFBI
18927307
|
IRINOTECAN
NM_053055
thioesterase superfamily member 4
THEM4
18927307
|
IRINOTECAN
NM_024838
threonine synthase-like 1 (S. cerevisiae)
THNSL1
18927307
|
IRINOTECAN
NM_005119
thyroid hormone receptor associated protein 3
THRAP3
18927307
|
IRINOTECAN
NM_006288
Thy-1 cell surface antigen
THY1
15956246
|
IRINOTECAN
NM_052932
transmembrane protein 123
TMEM123
18927307
|
IRINOTECAN
NM_015012
transmembrane protein 41B
TMEM41B
15956246
|
IRINOTECAN
NM_021109
thymosin beta 4, X-linked
TMSB4X
16364925
|
IRINOTECAN
NM_007115
tumor necrosis factor, alpha-induced protein 6
TNFAIP6
15956246
|
IRINOTECAN
NM_005749
transducer of ERBB2, 1
TOB1
15956246
|
IRINOTECAN
NM_016272
transducer of ERBB2, 2
TOB2
15956246
|
IRINOTECAN
NM_003286
topoisomerase (DNA) I
TOP1
11914913, 15655543, 18509181
|
IRINOTECAN
NM_052963
topoisomerase (DNA) I, mitochondrial
TOP1MT
—
|
IRINOTECAN
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
15239142, 15956246
|
IRINOTECAN
NM_005802
topoisomerase I binding, arginine/serine-rich
TOPORS
15956246
|
IRINOTECAN
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
16373703
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
IRINOTECAN
NM_001135733; NM_033285
tumor protein p53 inducible nuclear protein 1
TP53INP1
18927307
|
IRINOTECAN
NM_000367
thiopurine S-methyltransferase
TPMT
18927307
|
IRINOTECAN
NM_007030
tubulin polymerization promoting protein
TPPP
18927307
|
IRINOTECAN
NM_012112
TPX2, microtubule-associated, homolog (Xenopus
TPX2
15956246
|
laevis)
|
IRINOTECAN
NM_003789
TNFRSF1A-associated via death domain
TRADD
15956246
|
IRINOTECAN
NM_005658
TNF receptor-associated factor 1
TRAF1
15956246
|
IRINOTECAN
NM_025195
tribbles homolog 1 (Drosophila)
TRIB1
18927307
|
IRINOTECAN
NM_021643
tribbles homolog 2 (Drosophila)
TRIB2
18927307
|
IRINOTECAN
NM_033017; NM_033091
tripartite motif-containing 4
TRIM4
18927307
|
IRINOTECAN
NM_015163; NM_052978
tripartite motif-containing 9
TRIM9
18927307
|
IRINOTECAN
NM_003318
TTK protein kinase
TTK
15956246
|
IRINOTECAN
NM_001113755; NM_001113756; NM_001953
thymidine phosphorylase
TYMP
17454858
|
IRINOTECAN
NM_001071
thymidylate synthetase
TYMS
10482907, 17454858
|
IRINOTECAN
NM_007019; NM_181799; NM_181800;
ubiquitin-conjugating enzyme E2C
UBE2C
15956246
|
NM_181801; NM_181802; NM_181803
|
IRINOTECAN
NM_006357; NM_182678
ubiquitin-conjugating enzyme E2E 3 (UBC4/5
UBE2E3
18927307
|
homolog, yeast)
|
IRINOTECAN
NM_058167; NM_194315; NM_194457;
ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog,
UBE2J2
18927307
|
NM_194458
yeast)
|
IRINOTECAN
NM_015984
ubiquitin carboxyl-terminal hydrolase L5
UCHL5
15956246
|
IRINOTECAN
NM_020121
UDP-glucose ceramide glucosyltransferase-like 2
UGCGL2
18927307
|
IRINOTECAN
NM_000463
UDP glucuronosyltransferase 1 family, polypeptide A1
UGT1A1
12960109, 15517893, 15523087,
|
15833930, 17898154, 15716465,
|
15655543, 15858133, 17898154,
|
18478930, 18300238, 18797458
|
IRINOTECAN
NM_019075
UDP glucuronosyltransferase 1 family, polypeptide
UGT1A10
15517893, 17898154, 15716465
|
A10
|
IRINOTECAN
NM_001072; NM_205862
UDP glucuronosyltransferase 1 family, polypeptide A6
UGT1A6
15716465
|
IRINOTECAN
NM_019077
UDP glucuronosyltransferase 1 family, polypeptide A7
UGT1A7
15833930, 15716465, 17898154
|
IRINOTECAN
NM_019076
UDP glucuronosyltransferase 1 family, polypeptide A8
UGT1A8
15833930, 18
|
IRINOTECAN
NM_021027
UDP glucuronosyltransferase 1 family, polypeptide A9
UGT1A9
15833930, 18
|
IRINOTECAN
NM_025217
UL16 binding protein 2
ULBP2
18927307
|
IRINOTECAN
NM_017886
unc-51-like kinase 4 (C. elegans)
ULK4
18927307
|
IRINOTECAN
NM_015306
ubiquitin specific peptidase 24
USP24
18927307
|
IRINOTECAN
—
—
VDP
18927307
|
IRINOTECAN
NM_013245
vacuolar protein sorting 4 homolog A (S. cerevisiae)
VPS4A
18927307
|
IRINOTECAN
NM_145206
vesicle transport through interaction with t-SNAREs
VTI1A
18927307
|
homolog 1A (yeast)
|
IRINOTECAN
NM_015045
wings apart-like homolog (Drosophila)
WAPAL
18927307
|
IRINOTECAN
NM_003941
Wiskott-Aldrich syndrome-like
WASL
18927307
|
IRINOTECAN
NM_015726
WD repeat domain 42A
WDR42A
18927307
|
IRINOTECAN
NM_016087; NM_057168
wingless-type MMTV integration site family, member
WNT16
18927307
|
16
|
IRINOTECAN
NM_015626; NM_134265
WD repeat and SOCS box-containing 1
WSB1
18927307
|
IRINOTECAN
NM_001100161; NM_001100162; NM_015024
exportin 7
XPO7
18927307
|
IRINOTECAN
NM_003401; NM_022406; NM_022550
X-ray repair complementing defective repair in Chinese
XRCC4
15956246
|
hamster cells 4
|
IRINOTECAN
NM_021141
X-ray repair complementing defective repair in Chinese
XRCC5
18927307
|
hamster cells 5 (double-strand-break rejoining)
|
IRINOTECAN
NM_005748
YY1 associated factor 2
YAF2
18927307
|
IRINOTECAN
NM_005433
v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1
YES1
15956246
|
IRINOTECAN
NM_015642
zinc finger and BTB domain containing 20
ZBTB20
18927307
|
IRINOTECAN
NM_020119; NM_024625
zinc finger CCCH-type, antiviral 1
ZC3HAV1
18927307
|
IRINOTECAN
NM_173798
zinc finger, CCHC domain containing 12
ZCCHC12
18927307
|
IRINOTECAN
NM_178566
zinc finger, DHHC-type containing 21
ZDHHC21
18927307
|
IRINOTECAN
NM_001143823; NM_003409
zinc finger protein 161 homolog (mouse)
ZFP161
18927307
|
IRINOTECAN
NM_006887
zinc finger protein 36, C3H type-like 2
ZFP36L2
15956246
|
IRINOTECAN
NM_003410
zinc finger protein, X-linked
ZFX
15956246
|
IRINOTECAN
NM_001032293; NM_001098507; NM_003457
zinc finger protein 207
ZNF207
18927307
|
IRINOTECAN
NM_001005368; NM_006973
zinc finger protein 32
ZNF32
17327601
|
IRINOTECAN
NM_001135215; NM_001135216; NM_030899;
zinc finger protein 323
ZNF323
18927307
|
NM_145909
|
IRINOTECAN
NM_022752
zinc finger protein 574
ZNF574
18927307
|
IRINOTECAN
NM_144690
zinc finger protein 582
ZNF582
17327601
|
IRINOTECAN
NM_024706
zinc finger protein 668
ZNF668
18927307
|
IRINOTECAN
NM_032268
zinc and ring finger 1
ZNRF1
18927307
|
IRINOTECAN
NM_005089
zinc finger (CCCH type), RNA-binding motif and
ZRSR2
17327601
|
serine/arginine rich 2
|
ETOPOSIDE
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
12969965, 15239124
resistance
|
member 1
|
ETOPOSIDE
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
10900222, 12067707, 15460906,
resistance
|
NM_019899; NM_019900
member 1
15617835,
|
15999103, 16156793, 10900222,
|
16156793
|
ETOPOSIDE
NM_000392
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC2
15751272, 15849751, 15849751
resistance
|
member 2
|
ETOPOSIDE
NM_001144070; NM_003786
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC3
15884115
resistance
|
member 3
|
ETOPOSIDE
NM_198576
agrin
AGRN
17374387
|
ETOPOSIDE
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
17935137
|
ETOPOSIDE
NM_000691; NM_001135167; NM_001135168
aldehyde dehydrogenase 3 family, memberA1
ALDH3A1
15905174
|
ETOPOSIDE
NM_001153
annexin A4
ANXA4
17374387
|
ETOPOSIDE
NM_001657
amphiregulin
AREG
15228094
|
ETOPOSIDE
NM_001675; NM_182810
activating transcription factor 4 (tax-responsive
ATF4
16298333
|
enhancer element B67)
|
ETOPOSIDE
NM_001188
BCL2-antagonist/killer 1
BAK1
15215046
|
ETOPOSIDE
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
15917659
|
ETOPOSIDE
NM_001191; NM_138578
BCL2-like 1
BCL2L1
11468182, 15215046, 15917659
|
ETOPOSIDE
NM_004050
BCL2-like 2
BCL2L2
14973057
|
ETOPOSIDE
NM_001197
BCL2-interacting killer (apoptosis-inducing)
BIK
16007125
|
ETOPOSIDE
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
10815900, 15050749, 14970392
|
ETOPOSIDE
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
14666661, 15050749
|
ETOPOSIDE
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
15917659, 16382892, 16322251,
|
16364925
|
ETOPOSIDE
NM_007294; NM_007295; NM_007296;
breast cancer 1, early onset
BRCA1
16417649
|
NM_007297; NM_007298; NM_007299;
|
NM_007300; NM_007302; NM_007303;
|
NM_007304; NM_007305
|
ETOPOSIDE
NM_001729
betacellulin
BTC
15228094
|
ETOPOSIDE
NM_001130849; NM_001130850; NM_016289
calcium binding protein 39
CAB39
17374387
|
ETOPOSIDE
NM_001033952; NM_001033953; NM_001741
calcitonin-related polypeptide alpha
CALCA
16222118
|
ETOPOSIDE
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
14757846
|
ETOPOSIDE
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
15215046, 16364925, 16844113,
|
16951922, 17935137, 18056177,
|
18056177, 16364925, 16844113,
|
16951922
|
ETOPOSIDE
NM_001227; NM_033338; NM_033339;
caspase 7, apoptosis-related cysteine peptidase
CASP7
16298333, 18056177
|
NM_033340
|
ETOPOSIDE
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
15215046, 16364925, 17935137,
|
18056177
|
ETOPOSIDE
NM_001237
cyclin A2
CCNA2
17390037
|
ETOPOSIDE
NM_004354
cyclin G2
CCNG2
18754885
|
ETOPOSIDE
NM_000610; NM_001001389; NM_001001390;
CD44 molecule (Indian blood group)
CD44
15215046
|
NM_001001391; NM_001001392
|
ETOPOSIDE
NM_001798; NM_052827
cyclin-dependent kinase 2
CDK2
16417649
|
ETOPOSIDE
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
14601052
|
ETOPOSIDE
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
17935137
|
ETOPOSIDE
NM_001024912; NM_001712
carcinoembryonic antigen-related cell adhesion
CEACAM1
17374387
|
molecule 1 (biliary glycoprotein)
|
ETOPOSIDE
NM_005760
CCAAT/enhancer binding protein (C/EBP), zeta
CEBPZ
17374387
|
ETOPOSIDE
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
14601052
|
ETOPOSIDE
NM_001114121; NM_001114122; NM_001274
CHK1 checkpoint homolog (S. pombe)
CHEK1
18698031
|
ETOPOSIDE
NM_020313
cytokine induced apoptosis inhibitor 1
CIAPIN1
18389626
|
ETOPOSIDE
NM_000785
cytochrome P450, family 27, subfamily B, polypeptide 1
CYP27B1
17716971
|
ETOPOSIDE
NM_000762
cytochrome P450, family 2, subfamily A, polypeptide 6
CYP2A6
8114683
unrelated
|
ETOPOSIDE
NM_000767
cytochrome P450, family 2, subfamily B, polypeptide 6
CYP2B6
8114683
unrelated
|
ETOPOSIDE
NM_000770
cytochrome P450, family 2, subfamily C, polypeptide 8
CYP2C8
8114683
unrelated
|
ETOPOSIDE
NM_000771
cytochrome P450, family 2, subfamily C, polypeptide 9
CYP2C9
8114683
unrelated
|
ETOPOSIDE
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
12969965, 17279585, 8114683
drug
|
metabolism
|
ETOPOSIDE
NM_000777
cytochrome P450, family 3, subfamily A, polypeptide 5
CYP3A5
12969965, 8114683
drug
|
metabolism
|
ETOPOSIDE
NM_004083
DNA-damage-inducible transcript 3
DDIT3
16298333
|
ETOPOSIDE
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
15228094, 16969495
|
ETOPOSIDE
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15228094
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
ETOPOSIDE
NM_001007277; NM_004879
etoposide induced 2.4 mRNA
EI24
17374387
|
ETOPOSIDE
NM_014805
EPM2A (laforin) interacting protein 1
EPM2AIP1
17374387
|
ETOPOSIDE
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
15228094
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
ETOPOSIDE
NM_001005915; NM_001982
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB3
15228094
|
homolog 3 (avian)
|
ETOPOSIDE
NM_001042599; NM_005235
v-erb-a erythroblastic leukemia viral oncogene
ERBB4
15228094
|
homolog 4 (avian)
|
ETOPOSIDE
NM_001432
epiregulin
EREG
15228094
|
ETOPOSIDE
NM_001987
ets variant 6
ETV6
15217836
|
ETOPOSIDE
NM_004110; NM_024417
ferredoxin reductase
FDXR
17374387
|
ETOPOSIDE
NM_002015
forkhead box O1
FOXO1
17935137
|
ETOPOSIDE
NM_001455; NM_201559
forkhead box O3
FOXO3
17935137
|
ETOPOSIDE
NM_001924
growth arrest and DNA-damage-inducible, alpha
GADD45A
19003803
|
ETOPOSIDE
NM_001498
glutamate-cysteine ligase, catalytic subunit
GCLC
10900222
|
ETOPOSIDE
NM_002061
glutamate-cysteine ligase, modifier subunit
GCLM
10900222
|
ETOPOSIDE
NM_000561; NM_146421
glutathione S-transferase mu 1
GSTM1
15713801
|
ETOPOSIDE
NM_000852
glutathione S-transferase pi 1
GSTP1
10900222, 12969965, 15999103,
|
15999103, 10900222
|
ETOPOSIDE
NM_001945
heparin-binding EGF-like growth factor
HBEGF
15228094
|
ETOPOSIDE
NM_005347
heat shock 70 kDa protein 5 (glucose-regulated protein,
HSPA5
16298333
|
78 kDa)
|
ETOPOSIDE
NM_000875
insulin-like growth factor 1 receptor
IGF1R
15499378
|
ETOPOSIDE
NM_002756; NM_145109
mitogen-activated protein kinase kinase 3
MAP2K3
17374387
|
ETOPOSIDE
NM_145185
mitogen-activated protein kinase kinase 7
MAP2K7
—
|
ETOPOSIDE
NM_005923
mitogen-activated protein kinase kinase kinase 5
MAP3K5
17374387
|
ETOPOSIDE
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
17935137
|
ETOPOSIDE
NM_001145336; NM_001145337; NM_001145339;
Mdm2 p53 binding protein homolog (mouse)
MDM2
17575151, 17935137
resistance
|
NM_001145340; NM_002392;
|
NM_006878; NM_006879; NM_006881;
|
NM_006882
|
ETOPOSIDE
NM_001004720; NM_001004722; NM_003581
NCK adaptor protein 2
NCK2
17374387
|
ETOPOSIDE
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
17935137
|
enhancer in B-cells inhibitor, alpha
|
ETOPOSIDE
NM_003889; NM_022002; NM_033013
nuclear receptor subfamily 1, group I, member 2
NR1I2
17279585
|
ETOPOSIDE
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
17935137, 17935137, 16844113
|
ETOPOSIDE
NM_004073
polo-like kinase 3 (Drosophila)
PLK3
17374387
|
ETOPOSIDE
NM_003981; NM_199413; NM_199414
protein regulator of cytokinesis 1
PRC1
17374387
|
ETOPOSIDE
NM_000311; NM_001080121; NM_001080122;
prion protein
PRNP
15386405
|
NM_001080123; NM_183079
|
ETOPOSIDE
NM_000314
phosphatase and tensin homolog
PTEN
17935137
|
ETOPOSIDE
NM_134424
RAD52 homolog (S. cerevisiae)
RAD52
16417649
|
ETOPOSIDE
NM_001142548; NM_003579
RAD54-like (S. cerevisiae)
RAD54L
16417649
|
ETOPOSIDE
NM_001145547; NM_032905
RNA binding motif protein 17
RBM17
16061639
resistance
|
ETOPOSIDE
NM_001001890; NM_001122607; NM_001754
runt-related transcription factor 1
RUNX1
15217836
|
ETOPOSIDE
NM_001031680; NM_004350
runt-related transcription factor 3
RUNX3
15756676
|
ETOPOSIDE
NM_005980
S100 calcium binding protein P
S100P
18636193
|
ETOPOSIDE
NM_001006946; NM_002997
syndecan 1
SDC1
17374387
|
ETOPOSIDE
NM_000593
transporter 1, ATP-binding cassette, sub-family B
TAP1
17374387
|
(MDR/TAP)
|
ETOPOSIDE
NM_014604
Tax1 (human T-cell leukemia virus type I) binding
TAX1BP3
17374387
|
protein 3
|
ETOPOSIDE
NM_001099691; NM_003236
transforming growth factor, alpha
TGFA
15228094
|
ETOPOSIDE
NM_021109
thymosin beta 4, X-linked
TMSB4X
16364925
|
ETOPOSIDE
NM_003844
tumor necrosis factor receptor superfamily, member
TNFRSF10A
16364925
|
10a
|
ETOPOSIDE
NM_003842; NM_147187
tumor necrosis factor receptor superfamily, member
TNFRSF10B
15964798, 16364925
|
10b
|
ETOPOSIDE
NM_003810
tumor necrosis factor (ligand) superfamily, member 10
TNFSF10
16364925
|
ETOPOSIDE
NM_003811
tumor necrosis factor (ligand) superfamily, member 9
TNFSF9
17374387
|
ETOPOSIDE
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
11470519, 11531262, 11676865,
|
12569090, 16969495, 17575151
|
ETOPOSIDE
NM_001068
topoisomerase (DNA) II beta 180 kDa
TOP2B
15322234, 16239602
|
ETOPOSIDE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
12082016, 15964798, 18698031
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
ETOPOSIDE
NM_004881; NM_147184
tumor protein p53 inducible protein 3
TP53I3
17374387
|
ETOPOSIDE
NR_015381; NR_015381; NR_015381;
TP53 target 1 (non-protein coding)
TP53TG1
17374387
|
NR_015381; NR_015381; NR_015381;
|
NR_015381; NR_015381
|
ETOPOSIDE
NM_001126240; NM_001126241; NM_001126242;
tumor protein p73
TP73
17716971
|
NM_005427
|
ETOPOSIDE
NM_001071
thymidylate synthetase
TYMS
15713801
|
ETOPOSIDE
NM_007019; NM_181799; NM_181800;
ubiquitin-conjugating enzyme E2C
UBE2C
17374387
|
NM_181801; NM_181802; NM_181803
|
ETOPOSIDE
NM_000463
UDP glucuronosyltransferase 1 family, polypeptide A1
UGT1A1
12969965, 17151191
|
ETOPOSIDE
NM_019093
UDP glucuronosyltransferase 1 family, polypeptide A3
UGT1A3
17151191
|
ETOPOSIDE
NM_019076
UDP glucuronosyltransferase 1 family, polypeptide A8
UGT1A8
17151191
|
ETOPOSIDE
NM_000376; NM_001017535
vitamin D (1,25-dihydroxyvitamin D3) receptor
VDR
12969965, 15713801, 17716971
|
ETOPOSIDE
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
18494554
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
ETOPOSIDE
NM_000553
Werner syndrome, RecQ helicase-like
WRN
10725663
|
ETOPOSIDE
NM_017523; NM_199139
XIAP associated factor 1
XAF1
15843754
|
ETOPOSIDE
NM_001167
X-linked inhibitor of apoptosis
XIAP
14666661
|
ETOPOSIDE
NM_005431
X-ray repair complementing defective repair in Chinese
XRCC2
16417649
|
hamster cells 2
|
ETOPOSIDE
NM_001100118; NM_001100119; NM_005432
X-ray repair complementing defective repair in Chinese
XRCC3
16417649
|
hamster cells 3
|
ETOPOSIDE
NM_003401; NM_022406; NM_022550
X-ray repair complementing defective repair in Chinese
XRCC4
16417649
|
hamster cells 4
|
ETOPOSIDE
NM_021141
X-ray repair complementing defective repair in Chinese
XRCC5
12384553
|
hamster cells 5 (double-strand-break rejoining)
|
BEXAROTENE
NM_001121; NM_016824; NM_019903
adducin 3 (gamma)
ADD3
17178900
|
BEXAROTENE
NM_000024
adrenergic, beta-2-, receptor, surface
ADRB2
17178900
|
BEXAROTENE
NM_001353
aldo-keto reductase family 1, member C1 (dihydrodiol
AKR1C1
17178900
|
dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid
|
dehydrogenase)
|
BEXAROTENE
NM_003739
aldo-keto reductase family 1, member C3 (3-alpha
AKR1C3
17178900
|
hydroxysteroid dehydrogenase, type II)
|
BEXAROTENE
NM_016201
angiomotin like 2
AMOTL2
17178900
|
BEXAROTENE
NM_006407
ADP-ribosylation-like factor 6 interacting protein 5
ARL6IP5
17178900
|
BEXAROTENE
NM_001673; NM_133436; NM_183356
asparagine synthetase
ASNS
17178900
|
BEXAROTENE
NM_004330
BCL2/adenovirus E1B 19 kDa interacting protein 2
BNIP2
17178900
|
BEXAROTENE
—
—
C10ORF10
17178900
|
BEXAROTENE
—
—
C10ORF116
17178900
|
BEXAROTENE
NM_001806
CCAAT/enhancer binding protein (C/EBP), gamma
CEBPG
17178900
|
BEXAROTENE
—
cytochrome c oxidase II
COX2
17178900
|
BEXAROTENE
NM_001902; NM_153742
cystathionase (cystathionine gamma-lyase)
CTH
17178900
|
BEXAROTENE
NM_004390; NM_148979
cathepsin H
CTSH
17178900
|
BEXAROTENE
NM_018947
cytochrome c, somatic
CYCS
17178900
|
BEXAROTENE
NM_000783; NM_057157
cytochrome P450, family 26, subfamily A, polypeptide 1
CYP26A1
17178900
|
BEXAROTENE
NM_001554
cysteine-rich, angiogenic inducer, 61
CYR61
17178900
|
BEXAROTENE
NM_019058
DNA-damage-inducible transcript 4
DDIT4
17178900
|
BEXAROTENE
NM_004753
dehydrogenase/reductase (SDR family) member 3
DHRS3
17178900
|
BEXAROTENE
NM_012242
dickkopf homolog 1 (Xenopus laevis)
DKK1
17178900
|
BEXAROTENE
NM_004417
dual specificity phosphatase 1
DUSP1
17178900
|
BEXAROTENE
NM_004419
dual specificity phosphatase 5
DUSP5
17178900
|
BEXAROTENE
NM_004430
early growth response 3
EGR3
17178900
|
BEXAROTENE
NM_005801
eukaryotic translation initiation factor 1
EIF1
17178900
|
BEXAROTENE
NM_004431
EPH receptor A2
EPHA2
17178900
|
BEXAROTENE
NM_002047
glycyl-tRNA synthetase
GARS
17178900
|
BEXAROTENE
NM_001001994; NM_001001995; NM_001001996;
glycoprotein M6B
GPM6B
17178900
|
NM_005278
|
BEXAROTENE
NM_001010989; NM_001010990; NM_014685
homocysteine-inducible, endoplasmic reticulum stress-
HERPUD1
17178900
|
inducible, ubiquitin-like domain member 1
|
BEXAROTENE
NM_002165; NM_181353
inhibitor of DNA binding 1, dominant negative helix-
ID1
17178900
|
loop-helix protein
|
BEXAROTENE
NM_004907
immediate early response 2
IER2
17178900
|
BEXAROTENE
NM_002178
insulin-like growth factor binding protein 6
IGFBP6
17178900
|
BEXAROTENE
NM_000585; NM_172174
interleukin 15
IL15
17178900
|
BEXAROTENE
NM_000888
integrin, beta 6
ITGB6
17178900
|
BEXAROTENE
NM_004867
integral membrane protein 2A
ITM2A
17178900
|
BEXAROTENE
NM_001099952; NM_002222
inositol 1,4,5-triphosphate receptor, type 1
ITPR1
17178900
|
BEXAROTENE
NM_001032282; NM_005655
Kruppel-like factor 10
KLF10
17178900
|
BEXAROTENE
NM_002275
keratin 15
KRT15
17178900
|
BEXAROTENE
NM_000422
keratin 17
KRT17
17178900
|
BEXAROTENE
NM_002318
lysyl oxidase-like 2
LOXL2
17178900
|
BEXAROTENE
NM_001031804; NM_005360
v-maf musculoaponeurotic fibrosarcoma oncogene
MAF
17178900
|
homolog (avian)
|
BEXAROTENE
NM_001161572; NM_001161573; NM_001161574;
v-maf musculoaponeurotic fibrosarcoma oncogene
MAFF
17178900
|
NM_012323; NM_152878
homolog F (avian)
|
BEXAROTENE
NM_006818
myeloid/lymphoid or mixed-lineage leukemia (trithorax
MLLT11
17178900
|
homolog, Drosophila); translocated to, 11
|
BEXAROTENE
NM_002421
matrix metallopeptidase 1 (interstitial collagenase)
MMP1
17178900
|
BEXAROTENE
NM_006636
methylenetetrahydrofolate dehydrogenase (NADP+
MTHFD2
17178900
|
dependent) 2, methenyltetrahydrofolate cyclohydrolase
|
BEXAROTENE
NM_002539
ornithine decarboxylase 1
ODC1
17178900
|
BEXAROTENE
NM_022817
period homolog 2 (Drosophila)
PER2
17178900
|
BEXAROTENE
NM_000930; NM_033011
plasminogen activator, tissue
PLAT
17178900
|
BEXAROTENE
NM_001005376; NM_001005377; NM_002659
plasminogen activator, urokinase receptor
PLAUR
17178900
|
BEXAROTENE
NM_000935; NM_182943
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
PLOD2
17178900
|
BEXAROTENE
NM_020143
partner of NOB1 homolog (S. cerevisiae)
PNO1
17178900
|
BEXAROTENE
NM_006813
proline-rich nuclear receptor coactivator 1
PNRC1
17178900
|
BEXAROTENE
NM_000965; NM_016152
retinoic acid receptor, beta
RARB
17178900
|
BEXAROTENE
NM_000321
retinoblastoma 1
RB1
16273314
|
BEXAROTENE
NM_021976
retinoid X receptor, beta
RXRB
—
|
BEXAROTENE
NM_002965
S100 calcium binding protein A9
S100A9
17178900
|
BEXAROTENE
NM_005063
stearoyl-CoA desaturase (delta-9-desaturase)
SCD
17178900
|
BEXAROTENE
NM_003016
splicing factor, arginine/serine-rich 2
SFRS2
17178900
|
BEXAROTENE
NM_005067
seven in absentia homolog 2 (Drosophila)
SIAH2
17178900
|
BEXAROTENE
NM_003045
solute carrier family 7 (cationic amino acid transporter,
SLC7A1
17178900
|
y+ system), member 1
|
BEXAROTENE
NM_003486
solute carrier family 7 (cationic amino acid transporter,
SLC7A5
17178900
|
y+ system), member 5
|
BEXAROTENE
NM_001001419; NM_001001420; NM_005903
SMAD family member 5
SMAD5
17178900
|
BEXAROTENE
NM_003118
secreted protein, acidic, cysteine-rich (osteonectin)
SPARC
17178900
|
BEXAROTENE
NM_004613; NM_198951
transglutaminase 2 (C polypeptide, protein-glutamine-
TGM2
17178900
|
gamma-glutamyltransferase)
|
BEXAROTENE
NM_014220
transmembrane 4 L six family member 1
TM4SF1
17178900
|
BEXAROTENE
NM_001015881; NM_004089; NM_198057
TSC22 domain family, member 3
TSC22D3
17178900
|
BEXAROTENE
NM_003115
UDP-N-acteylglucosamine pyrophosphorylase 1
UAP1
17178900
|
BEXAROTENE
NM_003761
vesicle-associated membrane protein 8 (endobrevin)
VAMP8
17178900
|
BEXAROTENE
NM_001079539; NM_005080
X-box binding protein 1
XBP1
17178900
|
CETUXIMAB
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
—
|
CETUXIMAB
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
—
target
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
CETUXIMAB
NM_001432
epiregulin
EREG
—
|
TRASTUZUMAB
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
—
|
TRASTUZUMAB
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
—
resistance
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
TRASTUZUMAB
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
—
target
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
TRASTUZUMAB
NM_001432
epiregulin
EREG
—
|
RITUXIMAB
NM_021950; NM_152866
membrane-spanning 4-domains, subfamily A, member 1
MS4A1
—
target
|
TOSITUMOMAB
NM_021950; NM_152866
membrane-spanning 4-domains, subfamily A, member 1
MS4A1
—
target
|
ALEMTUZUMAB
NM_001803
CD52 molecule
CD52
—
target
|
BEVACIZUMAB
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
—
target
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
EDRECOLOMAB
—
—
TACSTD1
—
target
|
GEMTUZUMAB
NM_001082618; NM_001772
CD33 molecule
CD33
—
target
|
AXITINIB
NM_001160030; NM_001160031; NM_002019
fms-related tyrosine kinase 1 (vascular endothelial
FLT1
—
target
|
growth factor/vascular permeability factor receptor)
|
AXITINIB
NM_002020; NM_182925
fms-related tyrosine kinase 4
FLT4
—
target
|
AXITINIB
NM_002253
kinase insert domain receptor (a type III receptor
KDR
—
target
|
tyrosine kinase)
|
AXITINIB
NM_000222; NM_001093772
v-kit Hardy-Zuckerman 4 feline sarcoma viral
KIT
—
target
|
oncogene homolog
|
AXITINIB
NM_006206
platelet-derived growth factor receptor, alpha
PDGFRA
—
target
|
polypeptide
|
AXITINIB
NM_002609
platelet-derived growth factor receptor, beta
PDGFRB
—
target
|
polypeptide
|
BOSUTINIB
—
—
ABL
17114238
|
BOSUTINIB
NM_005157; NM_007313
c-abl oncogene 1, receptor tyrosine kinase
ABL1
—
target
|
BOSUTINIB
NM_004327; NM_021574
breakpoint cluster region
BCR
—
|
BOSUTINIB
NM_053056
cyclin D1
CCND1
16489032
|
BOSUTINIB
NM_004360
cadherin 1, type 1, E-cadherin (epithelial)
CDH1
16489032
|
BOSUTINIB
NM_001098209; NM_001098210; NM_001904
catenin (cadherin-associated protein), beta 1, 88 kDa
CTNNB1
16489032
|
BOSUTINIB
NM_005417; NM_198291
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene
SRC
16489032
target
|
homolog (avian)
|
BOSUTINIB
NM_001083962; NM_003199
transcription factor 4
TCF4
16489032
|
CEDIRANIB
NM_001160030; NM_001160031; NM_002019
fms-related tyrosine kinase 1 (vascular endothelial
FLT1
—
target
|
growth factor/vascular permeability factor receptor)
|
CEDIRANIB
NM_002020; NM_182925
fms-related tyrosine kinase 4
FLT4
—
target
|
DASATINIB
NM_005157; NM_007313
c-abl oncogene 1, receptor tyrosine kinase
ABL1
—
target
|
DASATINIB
NM_001100108; NM_001136000; NM_001136001;
v-abl Abelson murine leukemia viral oncogene
ABL2
—
target ?
|
NM_005158; NM_007314
homolog 2 (arg, Abelson-related gene)
|
DASATINIB
NM_004327; NM_021574
breakpoint cluster region
BCR
—
|
DASATINIB
NM_004431
EPH receptor A2
EPHA2
—
target
|
DASATINIB
NM_002037; NM_153047; NM_153048
FYN oncogene related to SRC, FGR, YES
FYN
—
|
DASATINIB
NM_000222; NM_001093772
v-kit Hardy-Zuckerman 4 feline sarcoma viral
KIT
—
target
|
oncogene homolog
|
DASATINIB
NM_001042771; NM_005356
lymphocyte-specific protein tyrosine kinase
LCK
—
target
|
DASATINIB
NM_002609
platelet-derived growth factor receptor, beta
PDGFRB
—
target
|
polypeptide
|
DASATINIB
NM_005417; NM_198291
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene
SRC
—
target
|
homolog (avian)
|
DASATINIB
NM_012448
signal transducer and activator of transcription 5B
STAT5B
—
|
DASATINIB
NM_005433
v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1
YES1
—
|
ERLOTINIB
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
—
|
ERLOTINIB
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
12907618
target
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
ERLOTINIB
NM_001432
epiregulin
EREG
—
|
GEFITINIB
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
17938326
resistance
|
GEFITINIB
NM_000674; NM_001048230
adenosine A1 receptor
ADORA1
16685379
|
GEFITINIB
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
17805209
|
GEFITINIB
NM_001657
amphiregulin
AREG
15496427, 16230376, 15723263
sensitivity/
|
resistance
|
GEFITINIB
NM_020371
apoptosis, caspase activation inhibitor
AVEN
15496427
|
GEFITINIB
NM_006568
cell growth regulator with ring finger domain 1
CGRRF1
16685379
|
GEFITINIB
NM_001130105; NM_005713; NM_031361
collagen, type IV, alpha 3 (Goodpasture antigen)
COL4A3BP
15496427
|
binding protein
|
GEFITINIB
NM_014325
coronin, actin binding protein, 1C
CORO1C
15496427
|
GEFITINIB
NM_000761
cytochrome P450, family 1, subfamily A, polypeptide 2
CYP1A2
15788367
unrelated
|
GEFITINIB
NM_000769
cytochrome P450, family 2, subfamily C, polypeptide
CYP2C19
15788367
unrelated
|
19
|
GEFITINIB
NM_000771
cytochrome P450, family 2, subfamily C, polypeptide 9
CYP2C9
15788367
unrelated
|
GEFITINIB
NM_000106; NM_001025161
cytochrome P450, family 2, subfamily D, polypeptide 6
CYP2D6
15788367
drug
|
metabolism
|
GEFITINIB
NM_000774
cytochrome P450, family 2, subfamily F, polypeptide 1
CYP2F1
16685379
|
GEFITINIB
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
15788367
drug
|
metabolism
|
GEFITINIB
NM_000777
cytochrome P450, family 3, subfamily A, polypeptide 5
CYP3A5
15788367
drug
|
metabolism
|
GEFITINIB
NM_004090
dual specificity phosphatase 3
DUSP3
15496427
|
GEFITINIB
NM_001395
dual specificity phosphatase 9
DUSP9
16685379
|
GEFITINIB
NM_005225
E2F transcription factor 1
E2F1
18347146
|
GEFITINIB
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
17805209, 17898861
|
GEFITINIB
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15723263, 15976335, 16361624,
target
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
17290066, 17898861, 17938326
|
GEFITINIB
NM_000121
erythropoietin receptor
EPOR
16685379
|
GEFITINIB
NM_001159969; NM_001981
epidermal growth factor receptor pathway substrate 15
EPS15
16685379
|
GEFITINIB
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
17898861
sensitivity
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
GEFITINIB
NM_001432
epiregulin
EREG
—
|
GEFITINIB
NM_000125; NM_001122740; NM_001122741;
estrogen receptor 1
ESR1
16261397
|
NM_001122742
|
GEFITINIB
NM_020996
fibroblast growth factor 6
FGF6
16685379
|
GEFITINIB
NM_001924
growth arrest and DNA-damage-inducible, alpha
GADD45A
16685379
|
GEFITINIB
NM_006705
growth arrest and DNA-damage-inducible, gamma
GADD45G
16685379
|
GEFITINIB
NM_002047
glycyl-tRNA synthetase
GARS
16685379
|
GEFITINIB
NM_001498
glutamate-cysteine ligase, catalytic subunit
GCLC
15496427
|
GEFITINIB
NM_005273
guanine nucleotide binding protein (G protein), beta
GNB2
16685379
|
polypeptide 2
|
GEFITINIB
NM_000180
guanylate cyclase 2D, membrane (retina-specific)
GUCY2D
16685379
|
GEFITINIB
NM_001945
heparin-binding EGF-like growth factor
HBEGF
15723263
altered by
|
gefitinib
|
GEFITINIB
NM_002038; NM_022872; NM_022873
interferon, alpha-inducible protein 6
IFI6
16685379
|
GEFITINIB
NM_000598; NM_001013398
insulin-like growth factor binding protein 3
IGFBP3
—
|
GEFITINIB
NM_000584
interleukin 8
IL8
15723263
altered by
|
gefitinib
|
GEFITINIB
NM_001003679; NM_001003680; NM_002303
leptin receptor
LEPR
16685379
|
GEFITINIB
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
17805209, 17898861
|
GEFITINIB
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
17805209, 17898861
|
GEFITINIB
NM_000249
mutL homolog 1, colon cancer,
MLH1
16685379
|
nonpolyposis type 2 (E. coli)
|
GEFITINIB
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
16685379
|
enhancer in B-cells 1
|
GEFITINIB
NM_002523
neuronal pentraxin II
NPTX2
16685379
|
GEFITINIB
NM_006177
neural retina leucine zipper
NRL
16685379
|
GEFITINIB
NM_003999
oncostatin M receptor
OSMR
15496427
|
GEFITINIB
NM_003311
pleckstrin homology-like domain, family A, member 2
PHLDA2
15496427
|
GEFITINIB
NM_000314
phosphatase and tensin homolog
PTEN
—
|
GEFITINIB
NM_001004128; NM_002826
quiescin Q6 sulfhydryl oxidase 1
QSOX1
16685379
altered by
|
gefitinib
|
GEFITINIB
NM_016090
RNA binding motif protein 7
RBM7
15496427
|
GEFITINIB
NM_002945
replication protein A1, 70 kDa
RPA1
16685379
|
GEFITINIB
NM_006142
stratifin
SFN
16685379
|
GEFITINIB
NM_003036
v-ski sarcoma viral oncogene homolog (avian)
SKI
16685379
|
GEFITINIB
NM_001099691; NM_003236
transforming growth factor, alpha
TGFA
15723263, 16230376
resistance
|
GEFITINIB
NM_001066
tumor necrosis factor receptor superfamily, member 1B
TNFRSF1B
16685379
|
GEFITINIB
NM_001071
thymidylate synthetase
TYMS
18347146
|
IMATINIB
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
15970668
resistance
|
member 1
|
IMATINIB
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
15970668
resistance
|
IMATINIB
NM_005157; NM_007313
c-abl oncogene 1, receptor tyrosine kinase
ABL1
15329907
target
|
IMATINIB
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
16740780
activity altered
|
by imatinib
|
IMATINIB
NM_001191; NM_138578
BCL2-like 1
BCL2L1
16960866
resistance
|
IMATINIB
NM_004327; NM_021574
breakpoint cluster region
BCR
15329907
|
IMATINIB
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16254145, 16254145, 16166298
resistance
|
IMATINIB
NM_001136017; NM_001136125; NM_001136126;
cyclin D3
CCND3
15100154
|
NM_001760
|
IMATINIB
NM_001781
CD69 molecule
CD69
15100154
|
IMATINIB
NM_005211
colony stimulating factor 1 receptor
CSF1R
—
target
|
IMATINIB
NM_001954; NM_013993; NM_013994
discoidin domain receptor tyrosine kinase 1
DDR1
—
target
|
IMATINIB
NM_000142; NM_022965
fibroblast growth factor receptor 3
FGFR3
14562121
|
IMATINIB
—
—
FRAP1
16740780
activity altered
|
by imatinib
|
IMATINIB
NM_002133
heme oxygenase (decycling) 1
HMOX1
17420286
resistance
|
IMATINIB
NM_000618; NM_001111283; NM_001111284;
insulin-like growth factor 1 (somatomedin C)
IGF1
16740780
|
NM_001111285
|
IMATINIB
NM_000417
interleukin 2 receptor, alpha
IL2RA
15100154
|
IMATINIB
NM_000222; NM_001093772
v-kit Hardy-Zuckerman 4 feline sarcoma viral
KIT
17420286
target V560G
|
oncogene homolog
D816V
|
IMATINIB
NM_001042771; NM_005356
lymphocyte-specific protein tyrosine kinase
LCK
15100154
target
|
IMATINIB
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
15100154
activity altered
|
by imatinib
|
IMATINIB
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
15100154
activity altered
|
by imatinib
|
IMATINIB
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
15100154
activity altered
|
enhancer in B-cells 1
by imatinib
|
IMATINIB
NM_001007792; NM_001012331; NM_002529
neurotrophic tyrosine kinase, receptor, type 1
NTRK1
—
activity altered
|
by imatinib
|
IMATINIB
NM_006206
platelet-derived growth factor receptor, alpha
PDGFRA
17614352
target
|
polypeptide
|
IMATINIB
NM_002609
platelet-derived growth factor receptor, beta
PDGFRB
—
target
|
polypeptide
|
IMATINIB
NM_000321
retinoblastoma 1
RB1
15100154
|
IMATINIB
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
15100154
activity altered
|
(avian)
by imatinib
|
IMATINIB
NM_020630; NM_020975
ret proto-oncogene
RET
15709206
|
IMATINIB
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
16740780
altered by
|
NM_001025369; NM_001025370;
imatinib
|
NM_001033756; NM_003376
|
IMATINIB
NM_000378; NM_024424; NM_024425;
Wilms tumor 1
WT1
15329907
resistance
|
NM_024426
|
LAPATINIB
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
15665275, 16091755
altered by
|
lapatinib
|
LAPATINIB
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16091755
altered by
|
lapatinib
|
LAPATINIB
NM_053056
cyclin D1
CCND1
15665275
altered by
|
lapatinib
|
LAPATINIB
NM_001238; NM_057182
cyclin E1
CCNE1
15665275
altered by
|
lapatinib
|
LAPATINIB
NM_001798; NM_052827
cyclin-dependent kinase 2
CDK2
15665275
altered by
|
lapatinib
|
LAPATINIB
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
15665275
altered by
|
lapatinib
|
LAPATINIB
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
—
|
LAPATINIB
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15665275
target
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
LAPATINIB
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
15665275, 16091755
target
|
homolog 2, neuro/glioblastoma derived oncogene
|
homolog (avian)
|
LAPATINIB
NM_001432
epiregulin
EREG
—
|
LAPATINIB
NM_000125; NM_001122740; NM_001122741;
estrogen receptor 1
ESR1
15665275
|
NM_001122742
|
LAPATINIB
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
16091755
altered by
|
lapatinib
|
LAPATINIB
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
16091755
altered by
|
lapatinib
|
LAPATINIB
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
—
resistance
|
LAPATINIB
—
—
PI3KCA
—
resistance
|
LAPATINIB
NM_000314
phosphatase and tensin homolog
PTEN
—
sensitivity
|
LESTAURTINIB
NM_004119
fms-related tyrosine kinase 3
FLT3
—
target
|
NILOTINIB
NM_005157; NM_007313
c-abl oncogene 1, receptor tyrosine kinase
ABL1
—
target
|
NILOTINIB
NM_004327; NM_021574
breakpoint cluster region
BCR
—
|
NILOTINIB
NM_000222; NM_001093772
v-kit Hardy-Zuckerman 4 feline sarcoma viral
KIT
—
target
|
oncogene homolog
|
NILOTINIB
NM_006206
platelet-derived growth factor receptor, alpha
PDGFRA
—
target
|
polypeptide
|
NILOTINIB
NM_002609
platelet-derived growth factor receptor, beta
PDGFRB
—
target
|
polypeptide
|
SEMAXANIB
NM_002253
kinase insert domain receptor (a type III receptor
KDR
—
target
|
tyrosine kinase)
|
SORAFENIB
NM_001188
BCL2-antagonist/killer 1
BAK1
16007148
death pathway
|
SORAFENIB
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
16007148
death pathway
|
NM_138764; NM_138765
|
SORAFENIB
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
16007148
altered by
|
soraf
|
SORAFENIB
NM_001191; NM_138578
BCL2-like 1
BCL2L1
16007148
altered by
|
soraf
|
SORAFENIB
NM_006538; NM_138621; NM_207002
BCL2-like 11 (apoptosis facilitator)
BCL2L11
16007148
death pathway
|
SORAFENIB
NM_001196; NM_197966; NM_197967
BH3 interacting domain death agonist
BID
16007148
|
SORAFENIB
NM_004333
v-raf murine sarcoma viral oncogene homolog B1
BRAF
—
target
|
SORAFENIB
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16007148
death pathway
|
SORAFENIB
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
16007148
|
NM_033355; NM_033356; NM_033358
|
SORAFENIB
NM_018947
cytochrome c, somatic
CYCS
16007148
death pathway
|
SORAFENIB
NM_001433
endoplasmic reticulum to nucleus signaling 1
ERN1
—
resistance
|
SORAFENIB
NM_004119
fms-related tyrosine kinase 3
FLT3
—
target
|
SORAFENIB
NM_002020; NM_182925
fms-related tyrosine kinase 4
FLT4
—
target
|
SORAFENIB
NM_002253
kinase insert domain receptor (a type III receptor
KDR
—
target
|
tyrosine kinase)
|
SORAFENIB
NM_000222; NM_001093772
v-kit Hardy-Zuckerman 4 feline sarcoma viral
KIT
—
target
|
oncogene homolog
|
SORAFENIB
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
—
resistance
|
SORAFENIB
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
—
resistance
|
SORAFENIB
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
16007148
altered by
|
soraf
|
SORAFENIB
NM_002609
platelet-derived growth factor receptor, beta
PDGFRB
—
target
|
polypeptide
|
SORAFENIB
NM_002880
v-raf-1 murine leukemia viral oncogene homolog 1
RAF1
—
target
|
SORAFENIB
NM_001167
X-linked inhibitor of apoptosis
XIAP
16007148
altered by
|
soraf
|
SUNITINIB
NM_004333
v-raf murine sarcoma viral oncogene homolog B1
BRAF
—
|
SUNITINIB
NM_005211
colony stimulating factor 1 receptor
CSF1R
—
target
|
SUNITINIB
NM_001160030; NM_001160031; NM_002019
fms-related tyrosine kinase 1 (vascular endothelial
FLT1
—
target
|
growth factor/vascular permeability factor receptor)
|
SUNITINIB
NM_004119
fms-related tyrosine kinase 3
FLT3
—
target
|
SUNITINIB
NM_002020; NM_182925
fms-related tyrosine kinase 4
FLT4
—
target
|
SUNITINIB
NM_002253
kinase insert domain receptor (a type III receptor
KDR
—
target
|
tyrosine kinase)
|
SUNITINIB
NM_000222; NM_001093772
v-kit Hardy-Zuckerman 4 feline sarcoma viral
KIT
—
target
|
oncogene homolog
|
SUNITINIB
NM_006206
platelet-derived growth factor receptor, alpha
PDGFRA
—
target
|
polypeptide
|
SUNITINIB
NM_002609
platelet-derived growth factor receptor, beta
PDGFRB
—
target
|
polypeptide
|
SUNITINIB
NM_002880
v-raf-1 murine leukemia viral oncogene homolog 1
RAF1
—
|
SUNITINIB
NM_020630; NM_020975
ret proto-oncogene
RET
—
target
|
VANDETANIB
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
—
|
VANDETANIB
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
—
target
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
VANDETANIB
NM_001432
epiregulin
EREG
—
|
VANDETANIB
NM_002253
kinase insert domain receptor (a type III receptor
KDR
—
target
|
tyrosine kinase)
|
TEMSIROLIMUS
NM_053056
cyclin D1
CCND1
16954435
resistance?
|
TEMSIROLIMUS
NM_004095
eukaryotic translation initiation factor 4E binding
EIF4EBP1
16033649
altered by
|
protein 1
temsirolimus
|
TEMSIROLIMUS
NM_000125; NM_001122740; NM_001122741;
estrogen receptor 1
ESR1
16954435
|
NM_001122742
|
TEMSIROLIMUS
—
—
FRAP1
16033649
target
|
TEMSIROLIMUS
NM_000321
retinoblastoma 1
RB1
16954435
|
TEMSIROLIMUS
NM_003161
ribosomal protein S6 kinase, 70 kDa, polypeptide 1
RPS6KB1
16954435, 16954435, 16033649
altered by
|
temsirolimus
|
EVEROLIMUS
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
16033851
altered by
|
everolimus
|
EVEROLIMUS
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
—
resistance
|
EVEROLIMUS
NM_053056
cyclin D1
CCND1
16033851
altered by
|
everolimus
|
EVEROLIMUS
NM_001759
cyclin D2
CCND2
16033851
altered by
|
everolimus
|
EVEROLIMUS
NM_001136017; NM_001136125; NM_001136126;
cyclin D3
CCND3
16033851
altered by
|
NM_001760
everolimus
|
EVEROLIMUS
NM_001130678; NM_001130679; NM_001968
eukaryotic translation initiation factor 4E
EIF4E
16033851
altered by
|
everolimus
|
EVEROLIMUS
NM_004095
eukaryotic translation initiation factor 4E binding
EIF4EBP1
16033851
|
protein 1
|
EVEROLIMUS
NM_004953; NM_182917; NM_198241;
eukaryotic translation initiation factor 4 gamma, 1
EIF4G1
16033851
altered by
|
NM_198242; NM_198244
everolimus
|
EVEROLIMUS
—
—
FRAP1
16033851
target
|
EVEROLIMUS
NM_000321
retinoblastoma 1
RB1
16033851
|
EVEROLIMUS
NM_001010
ribosomal protein S6
RPS6
16033851
|
EVEROLIMUS
NM_003161
ribosomal protein S6 kinase, 70 kDa, polypeptide 1
RPS6KB1
16033851
altered by
|
everolimus
|
FLAVOPIRIDOL
NM_004323
BCL2-associated athanogene
BAG1
15972445
altered by
|
flavopiridol
|
FLAVOPIRIDOL
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
12517783, 15634644, 15770523
unrelated
|
NM_138764; NM_138765
|
FLAVOPIRIDOL
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
12170773, 12517783, 15770523,
unrelated
|
15972445
|
FLAVOPIRIDOL
NM_001191; NM_138578
BCL2-like 1
BCL2L1
12517783, 15634644
altered by
|
flavopiridol
|
FLAVOPIRIDOL
NM_001196; NM_197966; NM_197967
BH3 interacting domain death agonist
BID
12170773, 15634644
unrelated
|
FLAVOPIRIDOL
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
12517783
altered by
|
flavopiridol
|
FLAVOPIRIDOL
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
12517783, 16012789
altered by
|
flavopiridol
|
FLAVOPIRIDOL
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
12170773, 12517783, 15634644,
death pathway
|
15770523, 16012789
|
FLAVOPIRIDOL
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
15634644, 16012789
unrelated
|
NM_033355; NM_033356; NM_033358
|
FLAVOPIRIDOL
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
12170773, 15634644
death pathway
|
FLAVOPIRIDOL
NM_031966
cyclin B1
CCNB1
12517783
sensitivity
|
FLAVOPIRIDOL
NM_053056
cyclin D1
CCND1
12517783, 15634644
sensitivity
|
FLAVOPIRIDOL
NM_001130829; NM_001786; NM_033379
cell division cycle 2, G1 to S and G2 to M
CDC2
12517783
target
|
FLAVOPIRIDOL
NM_001798; NM_052827
cyclin-dependent kinase 2
CDK2
12517783
target
|
FLAVOPIRIDOL
NM_000075
cyclin-dependent kinase 4
CDK4
12517783
target
|
FLAVOPIRIDOL
NM_004935
cyclin-dependent kinase 5
CDK5
—
|
FLAVOPIRIDOL
NM_001145306; NM_001259
cyclin-dependent kinase 6
CDK6
—
|
FLAVOPIRIDOL
NM_001799
cyclin-dependent kinase 7
CDK7
—
|
FLAVOPIRIDOL
NM_001260
cyclin-dependent kinase 8
CDK8
—
|
FLAVOPIRIDOL
NM_001261
cyclin-dependent kinase 9
CDK9
—
target
|
FLAVOPIRIDOL
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
15180955, 15770523
altered by
|
flavopiridol
|
FLAVOPIRIDOL
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
15180955
|
FLAVOPIRIDOL
NM_018947
cytochrome c, somatic
CYCS
12170773, 12170773, 12517783,
death pathway
|
15634644
|
FLAVOPIRIDOL
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
12517783, 15634644
death pathway
|
FLAVOPIRIDOL
NM_001963
epidermal growth factor (beta-urogastrone)
EGF
—
|
FLAVOPIRIDOL
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
—
|
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
FLAVOPIRIDOL
NM_001432
epiregulin
EREG
—
|
FLAVOPIRIDOL
NM_002105
H2A histone family, member X
H2AFX
15078984
|
FLAVOPIRIDOL
NM_013247; NM_145074
HtrA serine peptidase 2
HTRA2
12517783
death pathway
|
FLAVOPIRIDOL
NM_001315; NM_139012; NM_139013;
mitogen-activated protein kinase 14
MAPK14
15634644
|
NM_139014
|
FLAVOPIRIDOL
NM_002750; NM_139046; NM_139047;
mitogen-activated protein kinase 8
MAPK8
15634644
|
NM_139049
|
FLAVOPIRIDOL
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
12517783, 15634644,
altered by
|
15972445, 12517783
flavopiridol
|
FLAVOPIRIDOL
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
12170773, 15634644, 15770523,
|
15972445, 12517783, 12170773,
|
16012789
|
FLAVOPIRIDOL
NM_005609
phosphorylase, glycogen, muscle
PYGM
—
|
FLAVOPIRIDOL
NM_000321
retinoblastoma 1
RB1
15078984, 15180955, 15297405
|
FLAVOPIRIDOL
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
15180955, 15297405
unrelated
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
FLAVOPIRIDOL
NM_001167
X-linked inhibitor of apoptosis
XIAP
12517783, 15972445, 12517783,
altered by
|
15972445, 15385934, 12517783
flavopiridol
|
ROSCOVITINE
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
16230394, 16275999
death pathway
|
NM_138764; NM_138765
|
ROSCOVITINE
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16230394
altered by
|
roscovitine
|
ROSCOVITINE
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16140939
death pathway
|
ROSCOVITINE
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
16140939
death pathway
|
ROSCOVITINE
NM_001130829; NM_001786; NM_033379
cell division cycle 2, G1 to S and G2 to M
CDC2
15231455, 15
target
|
ROSCOVITINE
NM_001798; NM_052827
cyclin-dependent kinase 2
CDK2
—
target
|
ROSCOVITINE
NM_000075
cyclin-dependent kinase 4
CDK4
15741232
|
ROSCOVITINE
NM_004935
cyclin-dependent kinase 5
CDK5
15741232
target
|
ROSCOVITINE
NM_001145306; NM_001259
cyclin-dependent kinase 6
CDK6
15741232
|
ROSCOVITINE
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
16275999
altered by
|
roscovitine
|
ROSCOVITINE
NM_018947
cytochrome c, somatic
CYCS
16140939, 16275999
death pathway
|
ROSCOVITINE
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
16275999
|
ROSCOVITINE
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
16275999
altered by
|
roscovitine
|
ROSCOVITINE
—
—
PDCD8
16275999
death pathway
|
ROSCOVITINE
NM_000321
retinoblastoma 1
RB1
14653808, 15231455, 15741232
altered by
|
roscovitine
|
ROSCOVITINE
NM_003109; NM_138473
Sp1 transcription factor
SP1
14653808
altered by
|
roscovitine
|
ROSCOVITINE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
16003486, 16
sensitivity
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
ROSCOVITINE
NM_001167
X-linked inhibitor of apoptosis
XIAP
16140939, 16230394, 16275999
altered by
|
roscovitine
|
AFLIBERCEPT
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
—
target
|
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
DENILEUKIN
NM_000417
interleukin 2 receptor, alpha
IL2RA
—
target
|
DIFTITOX
|
DENILEUKIN
NM_000878
interleukin 2 receptor, beta
IL2RB
—
target
|
DIFTITOX
|
DENILEUKIN
NM_000206
interleukin 2 receptor, gamma (severe combined
IL2RG
—
target
|
DIFTITOX
immunodeficiency)
|
ARSENIC
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
15979894, 15979894, 14642128
resistance
|
TRIOXIDE
member 1
|
ARSENIC
NM_004827
ATP-binding cassette, sub-family G (WHITE), member 2
ABCG2
17547211
resistance
|
TRIOXIDE
|
ARSENIC
NM_005157; NM_007313
c-abl oncogene 1, receptor tyrosine kinase
ABL1
14633726
|
TRIOXIDE
|
ARSENIC
NM_006111
acetyl-Coenzyme A acyltransferase 2
ACAA2
15761015
|
TRIOXIDE
|
ARSENIC
NM_001116
adenylate cyclase 9
ADCY9
15761015
|
TRIOXIDE
|
ARSENIC
NM_001134647; NM_198595
actin filament associated protein 1
AFAP1
15761015
|
TRIOXIDE
|
ARSENIC
NM_005100; NM_144497
A kinase (PRKA) anchor protein 12
AKAP12
17547211
|
TRIOXIDE
|
ARSENIC
NM_001628
aldo-keto reductase family 1, member B1 (aldose
AKR1B1
17547211
|
TRIOXIDE
reductase)
|
ARSENIC
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
16882451, 17077332
|
TRIOXIDE
|
ARSENIC
NM_000688; NM_199166
aminolevulinate, delta-, synthase 1
ALAS1
15725085
|
TRIOXIDE
|
ARSENIC
NM_005589
aldehyde dehydrogenase 6 family, member A1
ALDH6A1
17547211
|
TRIOXIDE
|
ARSENIC
NM_005165
aldolase C, fructose-bisphosphate
ALDOC
15725085
|
TRIOXIDE
|
ARSENIC
NM_018466
asparagine-linked glycosylation 13 homolog
ALG13
15761015
|
TRIOXIDE
(S. cerevisiae)
|
ARSENIC
NM_001629
arachidonate 5-lipoxygenase-activating protein
ALOX5AP
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_001149; NM_020987
ankyrin 3, node of Ranvier (ankyrin G)
ANK3
15761015
|
TRIOXIDE
|
ARSENIC
NM_001083625; NM_015208
ankyrin repeat domain 12
ANKRD12
15761015
|
TRIOXIDE
|
ARSENIC
NM_001150
alanyl (membrane) aminopeptidase
ANPEP
15949261
|
TRIOXIDE
|
ARSENIC
NM_001002857; NM_001002858; NM_001136015;
annexin A2
ANXA2
17547211
|
TRIOXIDE
NM_004039
|
ARSENIC
NM_001284
adaptor-related protein complex 3, sigma 1 subunit
AP3S1
15761015
|
TRIOXIDE
|
ARSENIC
NM_020980
aquaporin 9
AQP9
15336539, 16968895
|
TRIOXIDE
|
ARSENIC
NM_015161
ADP-ribosylation factor-like 6 interacting protein 1
ARL6IP1
14703492
|
TRIOXIDE
|
ARSENIC
NM_006407
ADP-ribosylation-like factor 6 interacting protein 5
ARL6IP5
16430862, 16468075
|
TRIOXIDE
|
ARSENIC
—
—
ARL7
15725085
|
TRIOXIDE
|
ARSENIC
NM_025139
armadillo repeat containing 9
ARMC9
15761015
|
TRIOXIDE
|
ARSENIC
NM_001673; NM_133436; NM_183356
asparagine synthetase
ASNS
17547211
|
TRIOXIDE
|
ARSENIC
NM_000050; NM_054012
argininosuccinate synthetase 1
ASS1
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_001001787; NM_001677
ATPase, Na+/K+ transporting, beta 1 polypeptide
ATP1B1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001001323; NM_001682
ATPase, Ca++ transporting, plasma membrane 1
ATP2B1
12852829, 18
|
TRIOXIDE
|
ARSENIC
NM_001001485; NM_001001486; NM_001001487;
ATPase, Ca++ transporting, type 2C, member 1
ATP2C1
—
|
TRIOXIDE
NM_014382
|
ARSENIC
NM_001001937; NM_004046
ATP synthase, H+ transporting, mitochondrial F1
ATP5A1
15949261
|
TRIOXIDE
complex, alpha subunit 1, cardiac muscle
|
ARSENIC
—
ATP synthase 6; ATPase subunit 6
ATP6
14703492, 15949261
|
TRIOXIDE
|
ARSENIC
NM_001105529; NM_006095
ATPase, aminophospholipid transporter (APLT), class
ATP8A1
15761015
|
TRIOXIDE
I, type 8A, member 1
|
ARSENIC
NM_001184
ataxia telangiectasia and Rad3 related
ATR
16891316
|
TRIOXIDE
|
ARSENIC
NM_001185
alpha-2-glycoprotein 1, zinc-binding
AZGP1
17547211
|
TRIOXIDE
|
ARSENIC
NM_021813
BTB and CNC homology 1, basic leucine zipper
BACH2
15725085
|
TRIOXIDE
transcription factor 2
|
ARSENIC
NM_012342
BMP and activin membrane-bound inhibitor homolog
BAMBI
15725085
|
TRIOXIDE
(Xenopus laevis)
|
ARSENIC
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
11135700, 11775218, 15622746,
|
15665116,
|
TRIOXIDE
NM_138764; NM_138765
16010437, 16867262, 16020671,
|
16867262, 16882451, 16972261
|
ARSENIC
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
11775218, 12490120, 16105982,
|
TRIOXIDE
11780464,
|
(following) 16818652, 11589617, 11135700, 11775218, 12845720, 15979894, 16029599, 16007134, 16904648, 11775218, 16010437, 16867262, 16818652, 16867262,
|
16904648, 15622746, 11775218, 16966277
|
ARSENIC
NM_001114735; NM_004049
BCL2-related protein A1
BCL2A1
12130515
|
TRIOXIDE
|
ARSENIC
NM_001191; NM_138578
BCL2-like 1
BCL2L1
11468182, 15622746, 16105982,
|
TRIOXIDE
15665116
|
ARSENIC
NM_017429
beta-carotene 15,15′-monooxygenase 1
BCMO1
15761015
|
TRIOXIDE
|
ARSENIC
NM_004327; NM_021574
breakpoint cluster region
BCR
14633726
|
TRIOXIDE
|
ARSENIC
NM_003766
beclin 1, autophagy related
BECN1
16882451
|
TRIOXIDE
|
ARSENIC
—
—
BHLHB2
15761015
|
TRIOXIDE
|
ARSENIC
NM_001196; NM_197966; NM_197967
BH3 interacting domain death agonist
BID
15665116, 16972261
|
TRIOXIDE
|
ARSENIC
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
15587394, 16328441
|
TRIOXIDE
|
ARSENIC
NM_000713
biliverdin reductase B (flavin reductase (NADPH))
BLVRB
15725085
|
TRIOXIDE
|
ARSENIC
NM_003666
basic leucine zipper nuclear factor 1
BLZF1
15761015
|
TRIOXIDE
|
ARSENIC
NM_004052
BCL2/adenovirus E1B 19 kDa interacting protein 3
BNIP3
15592527
|
TRIOXIDE
|
ARSENIC
NM_004331
BCL2/adenovirus E1B 19 kDa interacting protein 3-like
BNIP3L
15592527
|
TRIOXIDE
|
ARSENIC
NM_001725
bactericidal/permeability-increasing protein
BPI
15761015
|
TRIOXIDE
|
ARSENIC
—
—
BRDG1
15761015
|
TRIOXIDE
|
ARSENIC
NM_017797
BTB (POZ) domain containing 2
BTBD2
15725085
|
TRIOXIDE
|
ARSENIC
NM_014962; NM_181443
BTB (POZ) domain containing 3
BTBD3
15725085
|
TRIOXIDE
|
ARSENIC
—
—
C14ORF105
15761015
|
TRIOXIDE
|
ARSENIC
—
—
C16ORF58
15761015
|
TRIOXIDE
|
ARSENIC
—
—
C5ORF13
15725085
|
TRIOXIDE
|
ARSENIC
—
—
C6ORF48
17547211
|
TRIOXIDE
|
ARSENIC
—
—
C8ORF4
15761015
|
TRIOXIDE
|
ARSENIC
NM_001005505; NM_006030
calcium channel, voltage-dependent, alpha 2/delta
CACNA2D2
15761015
|
TRIOXIDE
subunit 2
|
ARSENIC
NM_021251; NM_023083; NM_023085;
calpain 10
CAPN10
15761015
|
TRIOXIDE
NM_023089
|
ARSENIC
NM_004930
capping protein (actin filament) muscle Z-line, beta
CAPZB
12852829
|
TRIOXIDE
|
ARSENIC
NM_001014437; NM_001014438; NM_001751;
cysteinyl-tRNA synthetase
CARS
12852829
|
TRIOXIDE
NM_139273
|
ARSENIC
NM_001230; NM_032974; NM_032977
caspase 10, apoptosis-related cysteine peptidase
CASP10
12388546
|
TRIOXIDE
|
ARSENIC
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
14668793, 15979894,
|
TRIOXIDE
15979894, 15665116, 16951922,
|
16867262, 16951922
|
ARSENIC
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
16010437, 16972261
|
TRIOXIDE
NM_033355; NM_033356; NM_033358
|
ARSENIC
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
16010437, 17
|
TRIOXIDE
|
ARSENIC
NM_001753
caveolin 1, caveolae protein, 22 kDa
CAV1
15725085
|
TRIOXIDE
|
ARSENIC
NM_001233; NM_198212
caveolin 2
CAV2
15725085, 15761015
|
TRIOXIDE
|
ARSENIC
NM_001093729; NM_024781
coiled-coil domain containing 102B
CCDC102B
15761015
|
TRIOXIDE
|
ARSENIC
NM_144718
coiled-coil domain containing 52
CCDC52
15761015
|
TRIOXIDE
|
ARSENIC
NM_004167; NM_032964; NM_032965
chemokine (C-C motif) ligand 15
CCL15
15761015
|
TRIOXIDE
|
ARSENIC
NM_002982
chemokine (C-C motif) ligand 2
CCL2
15761015
|
TRIOXIDE
|
ARSENIC
NM_005064; NM_145898
chemokine (C-C motif) ligand 23
CCL23
15761015
|
TRIOXIDE
|
ARSENIC
NM_001111045; NM_001111046; NM_001111047;
cyclin A1
CCNA1
15761015
|
TRIOXIDE
NM_003914
|
ARSENIC
NM_031966
cyclin B1
CCNB1
12783709
|
TRIOXIDE
|
ARSENIC
NM_004701
cyclin B2
CCNB2
17547211
|
TRIOXIDE
|
ARSENIC
NM_053056
cyclin D1
CCND1
—
|
TRIOXIDE
|
ARSENIC
NM_001766
CD1d molecule
CD1D
15761015
|
TRIOXIDE
|
ARSENIC
NM_000610; NM_001001389; NM_001001390;
CD44 molecule (Indian blood group)
CD44
15553829
|
TRIOXIDE
NM_001001391; NM_001001392
|
ARSENIC
NM_001803
CD52 molecule
CD52
15761015
|
TRIOXIDE
|
ARSENIC
NM_001252
CD70 molecule
CD70
15761015
|
TRIOXIDE
|
ARSENIC
NM_006889; NM_175862
CD86 molecule
CD86
15761015
|
TRIOXIDE
|
ARSENIC
NM_003607; NM_014826
CDC42 binding protein kinase alpha (DMPK-like)
CDC42BPA
15761015
|
TRIOXIDE
|
ARSENIC
NM_024529
cell division cycle 73, Paf1/RNA polymerase II complex
CDC73
15761015
|
TRIOXIDE
component, homolog (S. cerevisiae)
|
ARSENIC
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
12749819, 15961274
|
TRIOXIDE
|
ARSENIC
NM_000077; NM_058195; NM_058197
cyclin-dependent kinase inhibitor 2A (melanoma, p16,
CDKN2A
15191659, 16008847, 16008847,
|
TRIOXIDE
inhibits CDK4)
15191659
|
ARSENIC
NM_004936; NM_078487
cyclin-dependent kinase inhibitor 2B (p15, inhibits
CDKN2B
11877046, 12679007, 12679007
|
TRIOXIDE
CDK4)
|
ARSENIC
NM_001130851; NM_005192
cyclin-dependent kinase inhibitor 3
CDKN3
17547211
|
TRIOXIDE
|
ARSENIC
NM_001805
CCAAT/enhancer binding protein (C/EBP), epsilon
CEBPE
12130515
|
TRIOXIDE
|
ARSENIC
NM_014679
centrosomal protein 57 kDa
CEP57
14703492
|
TRIOXIDE
|
ARSENIC
NM_001710
complement factor B
CFB
17547211
|
TRIOXIDE
|
ARSENIC
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
16105982, 16105982, 16174796
|
TRIOXIDE
|
ARSENIC
NM_001114121; NM_001114122; NM_001274
CHK1 checkpoint homolog (S. pombe)
CHEK1
16891316
|
TRIOXIDE
|
ARSENIC
NM_001005735; NM_007194; NM_145862
CHK2 checkpoint homolog (S. pombe)
CHEK2
16891316
|
TRIOXIDE
|
ARSENIC
NM_001819
chromogranin B (secretogranin 1)
CHGB
15761015
|
TRIOXIDE
|
ARSENIC
NM_001276
chitinase 3-like 1 (cartilage glycoprotein-39)
CHI3L1
15761015
|
TRIOXIDE
|
ARSENIC
NM_021615
carbohydrate (N-acetylglucosamine 6-O)
CHST6
15761015, 15
|
TRIOXIDE
sulfotransferase 6
|
ARSENIC
NM_014430
cell death-inducing DFFA-like effector b
CIDEB
17547211
|
TRIOXIDE
|
ARSENIC
NM_006079
Cbp/p300-interacting transactivator, with Glu/Asp-rich
CITED2
15725085
|
TRIOXIDE
carboxy-terminal domain, 2
|
ARSENIC
NM_006825
cytoskeleton-associated protein 4
CKAP4
12852829
|
TRIOXIDE
|
ARSENIC
NM_001828
Charcot-Leyden crystal protein
CLC
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_022570; NM_197947; NM_197948;
C-type lectin domain family 7, member A
CLEC7A
15725085
|
TRIOXIDE
NM_197949; NM_197950; NM_197954
|
ARSENIC
NM_001130675; NM_004362
calmegin
CLGN
17547211
|
TRIOXIDE
|
ARSENIC
NM_178868
CKLF-like MARVEL transmembrane domain
CMTM8
15761015
|
TRIOXIDE
containing 8
|
ARSENIC
NM_014515
CCR4-NOT transcription complex, subunit 2
CNOT2
15761015
|
TRIOXIDE
|
ARSENIC
NM_014900
COBL-like 1
COBLL1
15761015
|
TRIOXIDE
|
ARSENIC
NM_006438
collectin sub-family member 10 (C-type lectin)
COLEC10
15761015
|
TRIOXIDE
|
ARSENIC
NM_006837
COP9 constitutive photomorphogenic homolog subunit
COPS5
17077332
|
TRIOXIDE
5 (Arabidopsis)
|
ARSENIC
NM_001011666; NM_004904; NM_182898;
cAMP responsive element binding protein 5
CREB5
15761015
|
TRIOXIDE
NM_182899
|
ARSENIC
NM_000756
corticotropin releasing hormone
CRH
15761015
|
TRIOXIDE
|
ARSENIC
NM_016441
cysteine rich transmembrane BMP regulator 1
CRIM1
15761015, 16
|
TRIOXIDE
(chordin-like)
|
ARSENIC
NM_000395
colony stimulating factor 2 receptor, beta, low-affinity
CSF2RB
15070760
|
TRIOXIDE
(granulocyte-macrophage)
|
ARSENIC
NM_001317; NM_022640; NM_022641
chorionic somatomammotropin hormone 1 (placental
CSH1
15761015
|
TRIOXIDE
lactogen)
|
ARSENIC
NM_001077204; NM_024790
centrosome and spindle pole associated protein 1
CSPP1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001127656; NM_003476
cysteine and glycine-rich protein 3 (cardiac LIM
CSRP3
15725085
|
TRIOXIDE
protein)
|
ARSENIC
NM_000099
cystatin C
CST3
15725085
|
TRIOXIDE
|
ARSENIC
NM_001903
catenin (cadherin-associated protein), alpha 1, 102 kDa
CTNNA1
15761015
|
TRIOXIDE
|
ARSENIC
NM_004390; NM_148979
cathepsin H
CTSH
15761015
|
TRIOXIDE
|
ARSENIC
NM_002996
chemokine (C—X3—C motif) ligand 1
CX3CL1
17547211
|
TRIOXIDE
|
ARSENIC
NM_000398; NM_001129819; NM_007326
cytochrome b5 reductase 3
CYB5R3
15725085
|
TRIOXIDE
|
ARSENIC
NM_000101
cytochrome b-245, alpha polypeptide
CYBA
15070760
|
TRIOXIDE
|
ARSENIC
NM_001127383; NM_024843
cytochrome b reductase 1
CYBRD1
15761015
|
TRIOXIDE
|
ARSENIC
NM_018947
cytochrome c, somatic
CYCS
16972261
|
TRIOXIDE
|
ARSENIC
NM_001042355; NM_001042412; NM_015247
cylindromatosis (turban tumor syndrome)
CYLD
15761015
|
TRIOXIDE
|
ARSENIC
NM_000499
cytochrome P450, family 1, subfamily A, polypeptide 1
CYP1A1
11678611, 12490585
|
TRIOXIDE
|
ARSENIC
NM_016593
cytochrome P450, family 39, subfamily A, polypeptide 1
CYP39A1
15761015
|
TRIOXIDE
|
ARSENIC
NM_022820; NM_057095; NM_057096
cytochrome P450, family 3, subfamily A, polypeptide
CYP3A43
15761015
|
TRIOXIDE
43
|
ARSENIC
NM_018659
cytokine-like 1
CYTL1
15761015, 15761015, 15070760
|
TRIOXIDE
|
ARSENIC
NM_001141969; NM_001141970; NM_001350
death-domain associated protein
DAXX
17081986
|
TRIOXIDE
|
ARSENIC
NM_001005375; NM_020420
deleted in azoospermia 4
DAZ4
15761015
|
TRIOXIDE
|
ARSENIC
NM_014618
deleted in bladder cancer 1
DBC1
15761015
|
TRIOXIDE
|
ARSENIC
NM_004083
DNA-damage-inducible transcript 3
DDIT3
11678611, 12749819
|
TRIOXIDE
|
ARSENIC
NM_004084
defensin, alpha 1
DEFA1
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_001925
defensin, alpha 4, corticostatin
DEFA4
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_012242
dickkopf homolog 1 (Xenopus laevis)
DKK1
17547211
|
TRIOXIDE
|
ARSENIC
NM_007034
DnaJ (Hsp40) homolog, subfamily B, member 4
DNAJB4
15761015
|
TRIOXIDE
|
ARSENIC
NM_015190
DnaJ (Hsp40) homolog, subfamily C, member 9
DNAJC9
15761015
|
TRIOXIDE
|
ARSENIC
NM_001130823; NM_001379
DNA (cytosine-5-)-methyltransferase 1
DNMT1
12679007
|
TRIOXIDE
|
ARSENIC
NM_022552; NM_153759; NM_175629;
DNA (cytosine-5-)-methyltransferase 3 alpha
DNMT3A
12679007
|
TRIOXIDE
NM_175630
|
ARSENIC
NM_006892; NM_175848; NM_175849;
DNA (cytosine-5-)-methyltransferase 3 beta
DNMT3B
12679007
|
TRIOXIDE
NM_175850
|
ARSENIC
NM_001394; NM_057158
dual specificity phosphatase 4
DUSP4
15725085
|
TRIOXIDE
|
ARSENIC
NM_001376
dynein, cytoplasmic 1, heavy chain 1
DYNC1H1
15725085
|
TRIOXIDE
|
ARSENIC
NM_004714; NM_006483; NM_006484
dual-specificity tyrosine-(Y)-phosphorylation regulated
DYRK1B
15070760
|
TRIOXIDE
kinase 1B
|
ARSENIC
—
—
EBI2
15761015
|
TRIOXIDE
|
ARSENIC
NM_005228; NM_201282; NM_201283;
epidermal growth factor receptor (erythroblastic
EGFR
15961274
|
TRIOXIDE
NM_201284
leukemia viral (v-erb-b) oncogene homolog, avian)
|
ARSENIC
NM_001964
early growth response 1
EGR1
12749819
|
TRIOXIDE
|
ARSENIC
—
—
ELA2A
15761015
|
TRIOXIDE
|
ARSENIC
—
—
ENDOGL1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001429
E1A binding protein p300
EP300
15031205
|
TRIOXIDE
|
ARSENIC
NM_001135554; NM_001135555; NM_001431
erythrocyte membrane protein band 4.1-like 2
EPB41L2
15761015
|
TRIOXIDE
|
ARSENIC
NM_000120; NM_001136018
epoxide hydrolase 1, microsomal (xenobiotic)
EPHX1
17547211
|
TRIOXIDE
|
ARSENIC
NM_000502
eosinophil peroxidase
EPX
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_015576
ELKS/RAB6-interacting/CAST family member 2
ERC2
15761015
|
TRIOXIDE
|
ARSENIC
NM_016570
ERGIC and golgi 2
ERGIC2
—
|
TRIOXIDE
|
ARSENIC
NM_000125; NM_001122740; NM_001122741;
estrogen receptor 1
ESR1
12014631
|
TRIOXIDE
NM_001122742
|
ARSENIC
NM_001040275; NM_001040276; NM_001437
estrogen receptor 2 (ER beta)
ESR2
12014631
|
TRIOXIDE
|
ARSENIC
NM_016337
Enah/Vasp-like
EVL
15725085
|
TRIOXIDE
|
ARSENIC
NM_001993
coagulation factor III (thromboplastin, tissue factor)
F3
15761015, 16206674
|
TRIOXIDE
|
ARSENIC
NM_147189
family with sequence similarity 110, member B
FAM110B
15761015
|
TRIOXIDE
|
ARSENIC
NM_017709
family with sequence similarity 46, member C
FAM46C
15725085
|
TRIOXIDE
|
ARSENIC
NM_000136
Fanconi anemia, complementation group C
FANCC
15070760
|
TRIOXIDE
|
ARSENIC
NM_000043; NM_152871; NM_152872;
Fas (TNF receptor superfamily, member 6)
FAS
15979894, 12478894,
|
TRIOXIDE
NM_152873; NM_152874; NM_152875;
15979894, 15382040, 11135700,
|
NM_152876; NM_152877
12452020, 16029599, 12126518
|
ARSENIC
NM_000639
Fas ligand (TNF superfamily, member 6)
FASLG
12452020, 12
|
TRIOXIDE
|
ARSENIC
NM_006329
fibulin 5
FBLN5
15761015
|
TRIOXIDE
|
ARSENIC
NM_012304
F-box and leucine-rich repeat protein 7
FBXL7
15725085
|
TRIOXIDE
|
ARSENIC
NM_015850; NM_023105; NM_023106;
fibroblast growth factor receptor 1
FGFR1
15761015, 17027752
|
TRIOXIDE
NM_023107; NM_023108; NM_023110;
|
NM_023111
|
ARSENIC
NM_000141; NM_001144913; NM_001144914;
fibroblast growth factor receptor 2
FGFR2
15761015
|
TRIOXIDE
NM_001144915; NM_001144916;
|
NM_001144917; NM_001144918;
|
NM_001144919; NM_022970
|
ARSENIC
NM_001042729; NM_001042747; NM_005248
Gardner-Rasheed feline sarcoma viral (v-fgr)
FGR
15761015
|
TRIOXIDE
oncogene homolog
|
ARSENIC
NM_001024948; NM_017737
formin binding protein 1-like
FNBP1L
15761015
|
TRIOXIDE
|
ARSENIC
NM_005252
v-fos FBJ murine osteosarcoma viral oncogene
FOS
11678611, 11678611, 14682389,
|
TRIOXIDE
homolog
12749819, 14682389
|
ARSENIC
NM_001102371; NM_024955
FAD-dependent oxidoreductase domain containing 2
FOXRED2
15761015
|
TRIOXIDE
|
ARSENIC
NM_002031
fyn-related kinase
FRK
15761015
|
TRIOXIDE
|
ARSENIC
NM_003088
fascin homolog 1, actin-bundling protein
FSCN1
15761015, 15
|
TRIOXIDE
(Strongylocentrotus purpuratus)
|
ARSENIC
NM_002032
ferritin, heavy polypeptide 1
FTH1
15725085, 15
|
TRIOXIDE
|
ARSENIC
NM_001465; NM_199335
FYN binding protein (FYB-120/130)
FYB
15761015
|
TRIOXIDE
|
ARSENIC
NM_005458
gamma-aminobutyric acid (GABA) B receptor, 2
GABBR2
15761015
|
TRIOXIDE
|
ARSENIC
NM_144618
GA binding protein transcription factor, beta subunit 2
GABPB2
12852829
|
TRIOXIDE
|
ARSENIC
NM_001924
growth arrest and DNA-damage-inducible, alpha
GADD45A
11678611, 15761015, 11678611
|
TRIOXIDE
|
ARSENIC
NM_000157; NM_001005741; NM_001005742;
glucosidase, beta; acid (includes glucosylceramidase)
GBA
15761015
|
TRIOXIDE
NM_001005749; NM_001005750
|
ARSENIC
NM_002061
glutamate-cysteine ligase, modifier subunit
GCLM
15725085
|
TRIOXIDE
|
ARSENIC
NM_024711
GTPase, IMAP family member 6
GIMAP6
15761015
|
TRIOXIDE
|
ARSENIC
NM_001135213; NM_001135214; NM_014776;
G protein-coupled receptor kinase interacting ArfGAP 2
GIT2
15761015
|
TRIOXIDE
NM_057169; NM_057170; NM_139201
|
ARSENIC
NM_000165
gap junction protein, alpha 1, 43 kDa
GJA1
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_000169
galactosidase, alpha
GLA
17547211
|
TRIOXIDE
|
ARSENIC
NM_001142339; NM_002071; NM_182978
guanine nucleotide binding protein (G protein), alpha
GNAL
15761015
|
TRIOXIDE
activating activity polypeptide, olfactory type
|
ARSENIC
NM_001039966; NM_001098201; NM_001505
G protein-coupled estrogen receptor 1
GPER
17547211
|
TRIOXIDE
|
ARSENIC
NM_005277; NM_201591; NM_201592
glycoprotein M6A
GPM6A
15761015
|
TRIOXIDE
|
ARSENIC
NM_004778
G protein-coupled receptor 44
GPR44
15761015
|
TRIOXIDE
|
ARSENIC
NM_018654
G protein-coupled receptor, family C, group 5,
GPRC5D
15725085
|
TRIOXIDE
member D
|
ARSENIC
NM_000581; NM_201397
glutathione peroxidase 1
GPX1
16867262
|
TRIOXIDE
|
ARSENIC
NM_001146320; NM_023927
GRAM domain containing 3
GRAMD3
15070760
|
TRIOXIDE
|
ARSENIC
NM_001004056; NM_001004057; NM_182982
G protein-coupled receptor kinase 4
GRK4
15761015
|
TRIOXIDE
|
ARSENIC
NM_145740
glutathione S-transferase alpha 1
GSTA1
11678611
|
TRIOXIDE
|
ARSENIC
NM_000852
glutathione S-transferase pi 1
GSTP1
15231573, 15665116
|
TRIOXIDE
|
ARSENIC
NM_001513; NM_145870; NM_145871
glutathione transferase zeta 1
GSTZ1
15761015
|
TRIOXIDE
|
ARSENIC
NM_002105
H2A histone family, member X
H2AFX
16891316
|
TRIOXIDE
|
ARSENIC
NR_024052; NR_024052; NR_024052;
HLA complex group 18
HCG18
15761015
|
TRIOXIDE
NR_024052; NR_024052; NR_024052;
|
NR_024052; NR_024052; NR_024052;
|
NR_024052; NR_024052; NR_024052;
|
NR_024053; NR_024053; NR_024053;
|
NR_024053; NR_024053; NR_024053;
|
NR_024053; NR_024053; NR_024053;
|
NR_024053; NR_024053; NR_024053
|
ARSENIC
NM_001525
hypocretin (orexin) receptor 1
HCRTR1
15761015
|
TRIOXIDE
|
ARSENIC
NM_000601; NM_001010931; NM_001010932;
hepatocyte growth factor (hepapoietin A; scatter factor)
HGF
15761015
|
TRIOXIDE
NM_001010933; NM_001010934
|
ARSENIC
NM_001530; NM_181054
hypoxia inducible factor 1, alpha subunit (basic helix-
HIF1A
12482858, 16330433
|
TRIOXIDE
loop-helix transcription factor)
|
ARSENIC
—
—
HIG2
15725085
|
TRIOXIDE
|
ARSENIC
NM_003521
histone cluster 1, H2bm
HIST1H2BM
15761015
|
TRIOXIDE
|
ARSENIC
NM_003542
histone cluster 1, H4c
HIST1H4C
17547211
|
TRIOXIDE
|
ARSENIC
NM_003493
histone cluster 3, H3
HIST3H3
12388546
|
TRIOXIDE
|
ARSENIC
NM_000188; NM_033496; NM_033497;
hexokinase 1
HK1
15761015
|
TRIOXIDE
NM_033498; NM_033500
|
ARSENIC
NM_005514
major histocompatibility complex, class I, B
HLA-B
15761015, 16
|
TRIOXIDE
|
ARSENIC
NM_002117
major histocompatibility complex, class I, C
HLA-C
15761015, 16
|
TRIOXIDE
|
ARSENIC
NM_019111
major histocompatibility complex, class II, DR alpha
HLA-
15725085
|
TRIOXIDE
DRA
|
ARSENIC
NM_001098478; NM_001098479; NM_018950
major histocompatibility complex, class I, F
HLA-F
15725085
|
TRIOXIDE
|
ARSENIC
NM_002127
major histocompatibility complex, class I, G
HLA-G
15761015, 16
|
TRIOXIDE
|
ARSENIC
NM_002131; NM_145899; NM_145901;
high mobility group AT-hook 1
HMGA1
17547211
|
TRIOXIDE
NM_145902; NM_145903; NM_145905
|
ARSENIC
NM_001130688; NM_001130689; NM_002129
high-mobility group box 2
HMGB2
14703492
|
TRIOXIDE
|
ARSENIC
NM_005517
high-mobility group nucleosomal binding domain 2
HMGN2
17547211
|
TRIOXIDE
|
ARSENIC
NM_002133
heme oxygenase (decycling) 1
HMOX1
16487037, 17547211, 15725085
|
TRIOXIDE
|
ARSENIC
NM_002153
hydroxysteroid (17-beta) dehydrogenase 2
HSD17B2
17547211
|
TRIOXIDE
|
ARSENIC
NM_005526
heat shock transcription factor 1
HSF1
15978632
|
TRIOXIDE
|
ARSENIC
—
—
HSP27
15665116
|
TRIOXIDE
|
ARSENIC
NM_005345
heat shock 70 kDa protein 1A
HSPA1A
12749819
|
TRIOXIDE
|
ARSENIC
NM_002154
heat shock 70 kDa protein 4
HSPA4
11678611, 11678611, 14682389,
|
TRIOXIDE
15665116, 14682389
|
ARSENIC
NM_005347
heat shock 70 kDa protein 5 (glucose-regulated protein,
HSPA5
11678611
|
TRIOXIDE
78 kDa)
|
ARSENIC
NM_002155
heat shock 70 kDa protein 6 (HSP70B′)
HSPA6
15978632
|
TRIOXIDE
|
ARSENIC
NM_001540
heat shock 27 kDa protein 1
HSPB1
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_001098520; NM_001098521; NM_001098522;
HIV-1 Tat interactive protein 2, 30 kDa
HTATIP2
15761015
|
TRIOXIDE
NM_001098523; NM_006410
|
ARSENIC
NM_002162
intercellular adhesion molecule 3
ICAM3
15761015
|
TRIOXIDE
|
ARSENIC
NM_002165; NM_181353
inhibitor of DNA binding 1, dominant negative helix-
ID1
15761015
|
TRIOXIDE
loop-helix protein
|
ARSENIC
NM_002166
inhibitor of DNA binding 2, dominant negative helix-
ID2
15761015
|
TRIOXIDE
loop-helix protein
|
ARSENIC
NM_000202; NM_006123
iduronate 2-sulfatase
IDS
15761015
|
TRIOXIDE
|
ARSENIC
NM_004907
immediate early response 2
IER2
12749819
|
TRIOXIDE
|
ARSENIC
NM_005531
interferon, gamma-inducible protein 16
IFI16
15761015
|
TRIOXIDE
|
ARSENIC
NM_022168
interferon induced with helicase C domain 1
IFIH1
15761015
|
TRIOXIDE
|
ARSENIC
NM_000605
interferon, alpha 2
IFNA2
12560223, 17077332
|
TRIOXIDE
|
ARSENIC
NM_000619
interferon, gamma
IFNG
14668793, 16914093
|
TRIOXIDE
|
ARSENIC
NM_001007245; NM_001550
interferon-related developmental regulator 1
IFRD1
17547211
|
TRIOXIDE
|
ARSENIC
NM_000597
insulin-like growth factor binding protein 2, 36 kDa
IGFBP2
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_001553
insulin-like growth factor binding protein 7
IGFBP7
15725085
|
TRIOXIDE
|
ARSENIC
NM_001556
inhibitor of kappa light polypeptide gene enhancer in B-
IKBKB
—
|
TRIOXIDE
cells, kinase beta
|
ARSENIC
NM_001559
interleukin 12 receptor, beta 2
IL12RB2
15761015
|
TRIOXIDE
|
ARSENIC
NM_006850; NM_181339
interleukin 24
IL24
15580305
|
TRIOXIDE
|
ARSENIC
NM_000600
interleukin 6 (interferon, beta 2)
IL6
12560223
|
TRIOXIDE
|
ARSENIC
NM_001557
interleukin 8 receptor, beta
IL8RB
15761015
|
TRIOXIDE
|
ARSENIC
NM_005540
inositol polyphosphate-5-phosphatase, 75 kDa
INPP5B
15761015
|
TRIOXIDE
|
ARSENIC
NM_002196
insulinoma-associated 1
INSM1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001031715; NM_022784
IQ motif containing H
IQCH
15761015
|
TRIOXIDE
|
ARSENIC
NM_002198
interferon regulatory factor 1
IRF1
14668793, 16914093
|
TRIOXIDE
|
ARSENIC
NM_000419
integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa
ITGA2B
15761015
|
TRIOXIDE
complex, antigen CD41)
|
ARSENIC
NM_000632; NM_001145808
integrin, alpha M (complement component 3 receptor 3
ITGAM
16430862, 16468075
|
TRIOXIDE
subunit)
|
ARSENIC
NM_002211; NM_033666; NM_033667;
integrin, beta 1 (fibronectin receptor, beta polypeptide,
ITGB1
12852829
|
TRIOXIDE
NM_033668; NM_033669; NM_133376
antigen CD29 includes MDF2, MSK12)
|
ARSENIC
NM_014288
integrin beta 3 binding protein (beta3-endonexin)
ITGB3BP
17547211
|
TRIOXIDE
|
ARSENIC
NM_000889
integrin, beta 7
ITGB7
15761015
|
TRIOXIDE
|
ARSENIC
NM_004867
integral membrane protein 2A
ITM2A
15725085
|
TRIOXIDE
|
ARSENIC
NM_002228
jun oncogene
JUN
12749819
|
TRIOXIDE
|
ARSENIC
NM_005354
jun D proto-oncogene
JUND
15761015, 17077332
|
TRIOXIDE
|
ARSENIC
NM_000238; NM_172056; NM_172057
potassium voltage-gated channel, subfamily H (eag-
KCNH2
15070760, 15213294
|
TRIOXIDE
related), member 2
|
ARSENIC
NM_138444
potassium channel tetramerisation domain containing
KCTD12
15761015
|
TRIOXIDE
12
|
ARSENIC
NR_022006; NR_022006; NR_022006;
KIAA0087
KIAA0087
15761015
|
TRIOXIDE
NR_022006; NR_022006; NR_022006;
|
NR_022006; NR_022006
|
ARSENIC
NM_020947
KIAA1609
KIAA1609
15761015
|
TRIOXIDE
|
ARSENIC
NM_017596
kinesin family member 21B
KIF21B
15761015
|
TRIOXIDE
|
ARSENIC
NM_000899; NM_003994
KIT ligand
KITLG
15761015
|
TRIOXIDE
|
ARSENIC
NM_003597
Kruppel-like factor 11
KLF11
15761015
|
TRIOXIDE
|
ARSENIC
NM_001730
Kruppel-like factor 5 (intestinal)
KLF5
15761015
|
TRIOXIDE
|
ARSENIC
NM_005554
keratin 6A
KRT6A
15949261
|
TRIOXIDE
|
ARSENIC
NM_001032998; NM_003937
kynureninase (L-kynurenine hydrolase)
KYNU
15761015
|
TRIOXIDE
|
ARSENIC
NM_002293
laminin, gamma 1 (formerly LAMB2)
LAMC1
12852829
|
TRIOXIDE
|
ARSENIC
NM_001014987; NM_001014988; NM_001014989;
linker for activation of T cells
LAT
15761015
|
TRIOXIDE
NM_014387
|
ARSENIC
NM_002308; NM_009587
lectin, galactoside-binding, soluble, 9
LGALS9
15761015
|
TRIOXIDE
|
ARSENIC
NM_001008530; NM_005606
legumain
LGMN
15725085
|
TRIOXIDE
|
ARSENIC
NM_005780
lipoma HMGIC fusion partner
LHFP
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_014368; NM_199160
LIM homeobox 6
LHX6
15761015
|
TRIOXIDE
|
ARSENIC
NM_001013253; NM_001013254; NM_001013255;
lymphocyte-specific protein 1
LSP1
15761015
|
TRIOXIDE
NM_002339
|
ARSENIC
NM_145867
leukotriene C4 synthase
LTC4S
15761015
|
TRIOXIDE
|
ARSENIC
NM_001161572; NM_001161573; NM_001161574;
v-maf musculoaponeurotic fibrosarcoma oncogene
MAFF
16487037
|
TRIOXIDE
NM_012323; NM_152878
homolog F (avian)
|
ARSENIC
NM_002359; NM_032711
v-maf musculoaponeurotic fibrosarcoma oncogene
MAFG
16487037
|
TRIOXIDE
homolog G (avian)
|
ARSENIC
NM_002360
v-maf musculoaponeurotic fibrosarcoma oncogene
MAFK
16487037
|
TRIOXIDE
homolog K (avian)
|
ARSENIC
NM_005907
mannosidase, alpha, class 1A, member 1
MAN1A1
15761015
|
TRIOXIDE
|
ARSENIC
NM_000240
monoamine oxidase A
MAOA
15761015
|
TRIOXIDE
|
ARSENIC
NM_002756; NM_145109
mitogen-activated protein kinase kinase 3
MAP2K3
16818652
|
TRIOXIDE
|
ARSENIC
NM_003010
mitogen-activated protein kinase kinase 4
MAP2K4
15978632
|
TRIOXIDE
|
ARSENIC
NM_002758
mitogen-activated protein kinase kinase 6
MAP2K6
16818652
|
TRIOXIDE
|
ARSENIC
NM_003980
microtubule-associated protein 7
MAP7
15761015
|
TRIOXIDE
|
ARSENIC
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
15580305, 15961274, 16328441,
|
TRIOXIDE
16328441, 15961274, 17050201
|
ARSENIC
NM_001315; NM_139012; NM_139013;
mitogen-activated protein kinase 14
MAPK14
16818652, 17
|
TRIOXIDE
NM_139014
|
ARSENIC
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
15580305, 15961274, 16328441,
|
TRIOXIDE
16328441, 15961274, 17050201
|
ARSENIC
NM_002749; NM_139032; NM_139033;
mitogen-activated protein kinase 7
MAPK7
15580305
|
TRIOXIDE
NM_139034
|
ARSENIC
NM_002750; NM_139046; NM_139047;
mitogen-activated protein kinase 8
MAPK8
15580305, 15961274, 16646077,
|
TRIOXIDE
NM_139049
16818652
|
ARSENIC
NM_001135044; NM_002752; NM_139068;
mitogen-activated protein kinase 9
MAPK9
15580305, 16818652
|
TRIOXIDE
NM_139069; NM_139070
|
ARSENIC
NM_001005415; NM_001005416; NM_016496
membrane-associated ring finger (C3HC4) 2
MARCH2
15761015
|
TRIOXIDE
|
ARSENIC
—
—
MASK
17547211
|
TRIOXIDE
|
ARSENIC
NM_001112732; NM_024979
MCF.2 cell line derived transforming sequence-like
MCF2L
12852829
|
TRIOXIDE
|
ARSENIC
NM_004526
minichromosome maintenance complex component 2
MCM2
17547211
|
TRIOXIDE
|
ARSENIC
NM_002395
malic enzyme 1, NADP(+)-dependent, cytosolic
ME1
15725085
|
TRIOXIDE
|
ARSENIC
NM_032390
MKI67 (FHA domain) interacting nucleolar
MKI67IP
14703492
|
TRIOXIDE
phosphoprotein
|
ARSENIC
NM_002421
matrix metallopeptidase 1 (interstitial collagenase)
MMP1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001127891; NM_004530
matrix metallopeptidase 2 (gelatinase A, 72 kDa
MMP2
15553829, 16624393, 16624393
|
TRIOXIDE
gelatinase, 72 kDa type IV collagenase)
|
ARSENIC
NM_001032278; NM_024302
matrix metallopeptidase 28
MMP28
15761015
|
TRIOXIDE
|
ARSENIC
NM_004994
matrix metallopeptidase 9 (gelatinase B, 92 kDa
MMP9
15949266, 16624393
|
TRIOXIDE
gelatinase, 92 kDa type IV collagenase)
|
ARSENIC
NM_005373
myeloproliferative leukemia virus oncogene
MPL
15761015
|
TRIOXIDE
|
ARSENIC
NM_000250
myeloperoxidase
MPO
12130515
|
TRIOXIDE
|
ARSENIC
NM_016065
mitochondrial ribosomal protein S16
MRPS16
14703492
|
TRIOXIDE
|
ARSENIC
NM_005098
musculin (activated B-cell factor-1)
MSC
15761015
|
TRIOXIDE
|
ARSENIC
NM_012228
methionine sulfoxide reductase B2
MSRB2
15725085
|
TRIOXIDE
|
ARSENIC
NM_175617
metallothionein 1E
MT1E
15725085
|
TRIOXIDE
|
ARSENIC
NM_005950
metallothionein 1G
MT1G
15725085
|
TRIOXIDE
|
ARSENIC
NM_005951
metallothionein 1H
MT1H
15725085
|
TRIOXIDE
|
ARSENIC
NR_001447; NR_001447; NR_001447;
metallothionein 1L (gene/pseudogene)
MT1L
15725085
|
TRIOXIDE
NR_001447; NR_001447; NR_001447
|
ARSENIC
—
metallothionein 1 pseudogene 2
MT1P2
15725085
|
TRIOXIDE
|
ARSENIC
NM_005952
metallothionein 1X
MT1X
15725085
|
TRIOXIDE
|
ARSENIC
NM_005953
metallothionein 2A
MT2A
11678611, 11678611, 15725085,
|
TRIOXIDE
14682389, 14682389
|
ARSENIC
NM_004689
metastasis associated 1
MTA1
12478894
|
TRIOXIDE
|
ARSENIC
NM_001008528; NM_001008529; NM_198530
matrix-remodelling associated 7
MXRA7
17547211
|
TRIOXIDE
|
ARSENIC
NM_001080416; NM_001144755
v-myb myeloblastosis viral oncogene homolog (avian)-
MYBL1
15725085
|
TRIOXIDE
like 1
|
ARSENIC
NM_002467
v-myc myelocytomatosis viral oncogene homolog
MYC
11714746, 12903512, 12903497,
|
TRIOXIDE
(avian)
11775218, 11775218, 12903512,
|
11714746, 15622746, 15761015
|
ARSENIC
NM_005378
v-myc myelocytomatosis viral related oncogene,
MYCN
12478894
|
TRIOXIDE
neuroblastoma derived (avian)
|
ARSENIC
NM_001130158; NM_001161819; NM_012223
myosin IB
MYO1B
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_012330
MYST histone acetyltransferase (monocytic leukemia) 4
MYST4
15761015
|
TRIOXIDE
|
ARSENIC
NM_153029
NEDD4 binding protein 1
N4BP1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001079691; NM_052818
NEDD4 binding protein 2-like 1
N4BP2L1
15761015
|
TRIOXIDE
|
ARSENIC
NM_005967
NGFI-A binding protein 2 (EGR1 binding protein 2)
NAB2
15761015
|
TRIOXIDE
|
ARSENIC
NM_014903
neuron navigator 3
NAV3
15761015
|
TRIOXIDE
|
ARSENIC
NM_000265
neutrophil cytosolic factor 1
NCF1
15070760, 15761015, 15070760
|
TRIOXIDE
|
ARSENIC
NM_000433; NM_001127651
neutrophil cytosolic factor 2
NCF2
15070760
|
TRIOXIDE
|
ARSENIC
—
NADH dehydrogenase, subunit 4 (complex I)
ND4
14703492
|
TRIOXIDE
|
ARSENIC
NM_006656
sialidase 3 (membrane sialidase)
NEU3
15070760
|
TRIOXIDE
|
ARSENIC
NM_003204
nuclear factor (erythroid-derived 2)-like 1
NFE2L1
16487037
|
TRIOXIDE
|
ARSENIC
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
12560223
|
TRIOXIDE
enhancer in B-cells inhibitor, alpha
|
ARSENIC
NM_004556
nuclear factor of kappa light polypeptide gene
NFKBIE
12560223
|
TRIOXIDE
enhancer in B-cells inhibitor, epsilon
|
ARSENIC
NM_000269; NM_198175
non-metastatic cells 1, protein (NM23A) expressed in
NME1
12452020, 12478894
|
TRIOXIDE
|
ARSENIC
NM_002517
neuronal PAS domain protein 1
NPAS1
15761015
|
TRIOXIDE
|
ARSENIC
NM_002523
neuronal pentraxin II
NPTX2
15761015
|
TRIOXIDE
|
ARSENIC
NM_000176; NM_001018074; NM_001018075;
nuclear receptor subfamily 3, group C, member 1
NR3C1
17081986
|
TRIOXIDE
NM_001018076; NM_001018077;
(glucocorticoid receptor)
|
NM_001020825; NM_001024094
|
ARSENIC
NM_005013
nucleobindin 2
NUCB2
17547211
|
TRIOXIDE
|
ARSENIC
NM_024815
nudix (nucleoside diphosphate linked moiety X)-type
NUDT18
15761015
|
TRIOXIDE
motif 18
|
ARSENIC
NM_020401
nucleoporin 107 kDa
NUP107
17547211
|
TRIOXIDE
|
ARSENIC
NM_015311
obscurin-like 1
OBSL1
15761015
|
TRIOXIDE
|
ARSENIC
NM_002552; NM_181741; NM_181742
origin recognition complex, subunit 4-like (yeast)
ORC4L
15761015
|
TRIOXIDE
|
ARSENIC
NM_001017956; NM_001017957; NM_001017958;
osteosarcoma amplified 9, endoplasmic reticulum
OS9
17547211
|
TRIOXIDE
NM_006812
associated protein
|
ARSENIC
NM_000917; NM_001017962; NM_001142595;
prolyl 4-hydroxylase, alpha polypeptide I
P4HA1
15725085
|
TRIOXIDE
NM_001142596
|
ARSENIC
NM_000437
platelet-activating factor acetylhydrolase 2, 40 kDa
PAFAH2
15761015
|
TRIOXIDE
|
ARSENIC
NM_152911; NM_207127; NM_207128
polyamine oxidase (exo-N4-amino)
PAOX
15761015
|
TRIOXIDE
|
ARSENIC
NM_024897; NM_198406
progestin and adipoQ receptor family member VI
PAQR6
15725085
|
TRIOXIDE
|
ARSENIC
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
16328441, 16328441, 16646077
|
TRIOXIDE
|
ARSENIC
NM_002583
PRKC, apoptosis, WT1, regulator
PAWR
16966277
|
TRIOXIDE
|
ARSENIC
NM_002592; NM_182649
proliferating cell nuclear antigen
PCNA
12783709, 16029599
|
TRIOXIDE
|
ARSENIC
NM_006200
proprotein convertase subtilisin/kexin type 5
PCSK5
15761015
|
TRIOXIDE
|
ARSENIC
NM_014456; NM_145341
programmed cell death 4 (neoplastic transformation
PDCD4
17259349
|
TRIOXIDE
inhibitor)
|
ARSENIC
NM_001111307; NM_001111308; NM_001111309;
phosphodiesterase 4A, cAMP-specific
PDE4A
15070760
|
TRIOXIDE
NM_006202
(phosphodiesterase E2 dunce homolog, Drosophila)
|
ARSENIC
NM_001037339; NM_001037340; NM_001037341;
phosphodiesterase 4B, cAMP-specific
PDE4B
15761015
|
TRIOXIDE
NM_002600
(phosphodiesterase E4 dunce homolog, Drosophila)
|
ARSENIC
NM_001002810; NM_001002811; NM_001002812;
phosphodiesterase 4D interacting protein
PDE4DIP
15761015
|
TRIOXIDE
NM_014644; NM_022359
|
ARSENIC
NM_005451; NM_203352; NM_213636
PDZ and LIM domain 7 (enigma)
PDLIM7
15761015
|
TRIOXIDE
|
ARSENIC
NM_002613; NM_031268
3-phosphoinositide dependent protein kinase-1
PDPK1
14633726
|
TRIOXIDE
|
ARSENIC
NM_178140
PDZ domain containing 2
PDZD2
15761015
|
TRIOXIDE
|
ARSENIC
NM_000442
platelet/endothelial cell adhesion molecule
PECAM1
15761015
|
TRIOXIDE
|
ARSENIC
NM_003630
peroxisomal biogenesis factor 3
PEX3
15761015
|
TRIOXIDE
|
ARSENIC
NM_002630
progastricsin (pepsinogen C)
PGC
17547211
|
TRIOXIDE
|
ARSENIC
NM_002632
placental growth factor
PGF
17547211
|
TRIOXIDE
|
ARSENIC
NM_003311
pleckstrin homology-like domain, family A, member 2
PHLDA2
15761015
|
TRIOXIDE
|
ARSENIC
NM_032634; NM_152850
phosphatidylinositol glycan anchor biosynthesis, class O
PIGO
15761015
|
TRIOXIDE
|
ARSENIC
—
—
PIK4CA
12852829
|
TRIOXIDE
|
ARSENIC
NM_001018109; NM_003662
pirin (iron-binding nuclear protein)
PIR
15761015
|
TRIOXIDE
|
ARSENIC
NM_004571
PBX/knotted 1 homeobox 1
PKNOX1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001005376; NM_001005377; NM_002659
plasminogen activator, urokinase receptor
PLAUR
15761015
|
TRIOXIDE
|
ARSENIC
NM_016274
pleckstrin homology domain containing, family O
PLEKHO1
15761015
|
TRIOXIDE
member 1
|
ARSENIC
NM_005761
plexin C1
PLXNC1
15761015
|
TRIOXIDE
|
ARSENIC
NM_002675; NM_033238; NM_033239;
promyelocytic leukemia
PML
15748426, 15748426, 16891316,
|
TRIOXIDE
NM_033240; NM_033244; NM_033246;
16330433, 17081986
|
NM_033247; NM_033249; NM_033250
|
ARSENIC
—
—
PPGB
15725085
|
TRIOXIDE
|
ARSENIC
NM_006347
peptidylprolyl isomerase H (cyclophilin H)
PPIH
17547211
|
TRIOXIDE
|
ARSENIC
NM_002709; NM_206876
protein phosphatase 1, catalytic subunit, beta isoform
PPP1CB
12852829
|
TRIOXIDE
|
ARSENIC
NM_006093
proteoglycan 3
PRG3
15761015
|
TRIOXIDE
|
ARSENIC
NM_002738; NM_212535
protein kinase C, beta
PRKCB
15725085
|
TRIOXIDE
|
ARSENIC
NM_016644
proline rich 16
PRR16
15761015
|
TRIOXIDE
|
ARSENIC
NM_002769
protease, serine, 1 (trypsin 1)
PRSS1
15761015
|
TRIOXIDE
|
ARSENIC
NM_002798
proteasome (prosome, macropain) subunit, beta type, 6
PSMB6
12852829
|
TRIOXIDE
|
ARSENIC
NM_004159; NM_148919
proteasome (prosome, macropain) subunit, beta type,
PSMB8
15725085
|
TRIOXIDE
8 (large multifunctional peptidase 7)
|
ARSENIC
NM_000959; NM_001039585
prostaglandin F receptor (FP)
PTGFR
15761015
|
TRIOXIDE
|
ARSENIC
NM_016077
peptidyl-tRNA hydrolase 2
PTRH2
14703492
|
TRIOXIDE
|
ARSENIC
NM_004219
pituitary tumor-transforming 1
PTTG1
17547211
|
TRIOXIDE
|
ARSENIC
NM_001015508; NM_013357
purine-rich element binding protein G
PURG
15761015
|
TRIOXIDE
|
ARSENIC
NM_012293
peroxidasin homolog (Drosophila)
PXDN
15761015
|
TRIOXIDE
|
ARSENIC
NM_004163
RAB27B, member RAS oncogene family
RAB27B
15761015
|
TRIOXIDE
|
ARSENIC
NM_001126103; NM_001126104; NM_013277
Rac GTPase activating protein 1
RACGAP1
17547211
|
TRIOXIDE
|
ARSENIC
NM_001100397; NM_007023
Rap guanine nucleotide exchange factor (GEF) 4
RAPGEF4
15761015
|
TRIOXIDE
|
ARSENIC
NM_000964; NM_001024809; NM_001145301;
retinoic acid receptor, alpha
RARA
15748426, 16891316, 16330433
|
TRIOXIDE
NM_001145302
|
ARSENIC
NM_007211
Ras association (RaIGDS/AF-6) domain family (N-
RASSF8
15761015
|
TRIOXIDE
terminal) member 8
|
ARSENIC
NM_002139
RNA binding motif protein, X-linked
RBMX
12852829
|
TRIOXIDE
|
ARSENIC
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
16105982, 16174796, 16174796
|
TRIOXIDE
(avian)
|
ARSENIC
NM_001042681; NM_001042682; NM_012102
arginine-glutamic acid dipeptide (RE) repeats
RERE
15761015
|
TRIOXIDE
|
ARSENIC
NM_002914; NM_181471
replication factor C (activator 1) 2, 40 kDa
RFC2
17547211
|
TRIOXIDE
|
ARSENIC
NM_002923
regulator of G-protein signaling 2, 24 kDa
RGS2
12852829
|
TRIOXIDE
|
ARSENIC
NM_006397
ribonuclease H2, subunit A
RNASEH2A
17547211
|
TRIOXIDE
|
ARSENIC
NM_014746
ring finger protein 144A
RNF144A
15761015
|
TRIOXIDE
|
ARSENIC
NM_001134337; NM_001134338; NM_007219
ring finger protein 24
RNF24
15761015
|
TRIOXIDE
|
ARSENIC
NM_005977; NM_183043; NM_183044
ring finger protein (C3H2C3 type) 6
RNF6
15761015
|
TRIOXIDE
|
ARSENIC
NM_002941; NM_133631
roundabout, axon guidance receptor, homolog 1
ROBO1
15725085
|
TRIOXIDE
(Drosophila)
|
ARSENIC
NM_000985; NM_001035006
ribosomal protein L17
RPL17
12852829
|
TRIOXIDE
|
ARSENIC
NM_000980
ribosomal protein L18a
RPL18A
15725085
|
TRIOXIDE
|
ARSENIC
NM_000978
ribosomal protein L23
RPL23
14703492
|
TRIOXIDE
|
ARSENIC
NM_000971
ribosomal protein L7
RPL7
12852829
|
TRIOXIDE
|
ARSENIC
NM_001019; NM_001030009
ribosomal protein S15a
RPS15A
14703492
|
TRIOXIDE
|
ARSENIC
NM_003161
ribosomal protein S6 kinase, 70 kDa, polypeptide 1
RPS6KB1
14633726
|
TRIOXIDE
|
ARSENIC
NM_001042576; NM_004587
ribosome binding protein 1 homolog 180 kDa (dog)
RRBP1
15761015
|
TRIOXIDE
|
ARSENIC
NM_015659
ribosomal L1 domain containing 1
RSL1D1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001005861; NM_002958
RYK receptor-like tyrosine kinase
RYK
15761015
|
TRIOXIDE
|
ARSENIC
NM_002966
S100 calcium binding protein A10
S100A10
15949261
|
TRIOXIDE
|
ARSENIC
NM_002964
S100 calcium binding protein A8
S100A8
15761015, 15
|
TRIOXIDE
|
ARSENIC
NM_002965
S100 calcium binding protein A9
S100A9
15761015
|
TRIOXIDE
|
ARSENIC
NM_015265
SATB homeobox 2
SATB2
15761015
|
TRIOXIDE
|
ARSENIC
NM_138967
secretory carrier membrane protein 5
SCAMP5
15761015
|
TRIOXIDE
|
ARSENIC
NM_002411
secretoglobin, family 2A, member 2
SCGB2A2
15761015
|
TRIOXIDE
|
ARSENIC
NM_021626
serine carboxypeptidase 1
SCPEP1
15725085
|
TRIOXIDE
|
ARSENIC
NM_021920
secretin
SCT
15761015
|
TRIOXIDE
|
ARSENIC
NM_002998
syndecan 2
SDC2
15761015, 12852829, 15725085
|
TRIOXIDE
|
ARSENIC
NM_002999
syndecan 4
SDC4
15761015
|
TRIOXIDE
|
ARSENIC
NM_003005
selectin P (granule membrane protein 140 kDa, antigen
SELP
16206674
|
TRIOXIDE
CD62)
|
ARSENIC
NM_030666
serpin peptidase inhibitor, clade B (ovalbumin),
SERPINB1
15761015
|
TRIOXIDE
member 1
|
ARSENIC
NM_014755
SERTA domain containing 2
SERTAD2
15725085
|
TRIOXIDE
|
ARSENIC
NM_001039465; NM_006925
splicing factor, arginine/serine-rich 5
SFRS5
14703492
|
TRIOXIDE
|
ARSENIC
NM_003026
SH3-domain GRB2-like 2
SH3GL2
15761015
|
TRIOXIDE
|
ARSENIC
NM_001245; NM_198845; NM_198846
sialic acid binding Ig-like lectin 6
SIGLEC6
15761015
|
TRIOXIDE
|
ARSENIC
NM_007163
solute carrier family 14 (urea transporter), member 2
SLC14A2
15761015
|
TRIOXIDE
|
ARSENIC
NM_005073
solute carrier family 15 (oligopeptide transporter),
SLC15A1
15761015
|
TRIOXIDE
member 1
|
ARSENIC
NM_004171
solute carrier family 1 (glial high affinity glutamate
SLC1A2
17547211
|
TRIOXIDE
transporter), member 2
|
ARSENIC
NM_002555; NM_183233
solute carrier family 22, member 18
SLC22A18
15725085
|
TRIOXIDE
|
ARSENIC
NM_006516
solute carrier family 2 (facilitated glucose transporter),
SLC2A1
17064664
|
TRIOXIDE
member 1
|
ARSENIC
NM_080546
solute carrier family 44, member 1
SLC44A1
15761015
|
TRIOXIDE
|
ARSENIC
NM_017842
solute carrier family 48 (heme transporter), member 1
SLC48A1
15761015, 16
|
TRIOXIDE
|
ARSENIC
NM_178498
solute carrier family 5 (sodium/glucose cotransporter),
SLC5A12
15761015
|
TRIOXIDE
member 12
|
ARSENIC
NM_004211
solute carrier family 6 (neurotransmitter transporter,
SLC6A5
15761015
|
TRIOXIDE
glycine), member 5
|
ARSENIC
NM_001145044; NM_013272
solute carrier organic anion transporter family, member
SLCO3A1
15761015
|
TRIOXIDE
3A1
|
ARSENIC
NM_001003688; NM_005900
SMAD family member 1
SMAD1
15761015
|
TRIOXIDE
|
ARSENIC
NM_001002800; NM_005496
structural maintenance of chromosomes 4
SMC4
17547211
|
TRIOXIDE
|
ARSENIC
NM_000454
superoxide dismutase 1, soluble
SOD1
16867262
|
TRIOXIDE
|
ARSENIC
NM_018419
SRY (sex determining region Y)-box 18
SOX18
15761015
|
TRIOXIDE
|
ARSENIC
NM_007017; NM_178424
SRY (sex determining region Y)-box 30
SOX30
15761015
|
TRIOXIDE
|
ARSENIC
NM_003107
SRY (sex determining region Y)-box 4
SOX4
15725085
|
TRIOXIDE
|
ARSENIC
NM_003109; NM_138473
Sp1 transcription factor
SP1
11714746, 15761015
|
TRIOXIDE
|
ARSENIC
NM_001130438; NM_003127
spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)
SPTAN1
12852829
|
TRIOXIDE
|
ARSENIC
NM_175039; NM_175040
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
ST6GALNAC4
17547211
|
TRIOXIDE
1,3)-N-acetylgalactosaminide alpha-2,6-
|
sialyltransferase 4
|
ARSENIC
NM_015136
stabilin 1
STAB1
15761015
|
TRIOXIDE
|
ARSENIC
NM_007315; NM_139266
signal transducer and activator of transcription 1,
STAT1
14668793, 16914093
|
TRIOXIDE
91 kDa
|
ARSENIC
NM_001009181; NM_003154
statherin
STATH
15761015
|
TRIOXIDE
|
ARSENIC
NM_001128204; NM_001128205; NM_001128206;
sulfatase 1
SULF1
15725085
|
TRIOXIDE
NM_015170
|
ARSENIC
NM_015551
sushi domain containing 5
SUSD5
15761015
|
TRIOXIDE
|
ARSENIC
NM_001135774; NM_003490; NM_133633
synapsin III
SYN3
15761015
|
TRIOXIDE
|
ARSENIC
NM_003898
synaptojanin 2
SYNJ2
12852829
|
TRIOXIDE
|
ARSENIC
NM_001083962; NM_003199
transcription factor 4
TCF4
15761015
|
TRIOXIDE
|
ARSENIC
NR_001566; NR_001566; NR_001566;
telomerase RNA component
TERC
11714746
|
TRIOXIDE
NR_001566; NR_001566; NR_001566
|
ARSENIC
NM_003218; NM_017489
telomeric repeat binding factor (NIMA-interacting) 1
TERF1
16129045
|
TRIOXIDE
|
ARSENIC
NM_005652
telomeric repeat binding factor 2
TERF2
16129045
|
TRIOXIDE
|
ARSENIC
NM_198253; NM_198255
telomerase reverse transcriptase
TERT
11714746, 16966277, 15761015,
|
TRIOXIDE
15761015, 16129045, 11714746,
|
16966277, 16285558, 15996315
|
ARSENIC
NM_003222
transcription factor AP-2 gamma (activating enhancer
TFAP2C
15761015
|
TRIOXIDE
binding protein 2 gamma)
|
ARSENIC
NM_003225
trefoil factor 1
TFF1
12014631
|
TRIOXIDE
|
ARSENIC
NM_001024847; NM_003242
transforming growth factor, beta receptor II (70/80 kDa)
TGFBR2
12852829
|
TRIOXIDE
|
ARSENIC
NM_003254
TIMP metallopeptidase inhibitor 1
TIMP1
16624393
|
TRIOXIDE
|
ARSENIC
NM_003255
TIMP metallopeptidase inhibitor 2
TIMP2
16624393
|
TRIOXIDE
|
ARSENIC
NM_015444
transmembrane protein 158
TMEM158
15761015
|
TRIOXIDE
|
ARSENIC
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
12560223
|
TRIOXIDE
|
ARSENIC
NM_006290
tumor necrosis factor, alpha-induced protein 3
TNFAIP3
17547211
|
TRIOXIDE
|
ARSENIC
NM_001077654; NM_014350
tumor necrosis factor, alpha-induced protein 8
TNFAIP8
17547211
|
TRIOXIDE
|
ARSENIC
NM_001066
tumor necrosis factor receptor superfamily, member 1B
TNFRSF1B
15761015
|
TRIOXIDE
|
ARSENIC
NM_001039664; NM_003790; NM_148965;
tumor necrosis factor receptor superfamily, member 25
TNFRSF25
15761015
|
TRIOXIDE
NM_148966; NM_148967; NM_148970
|
ARSENIC
NM_001561
tumor necrosis factor receptor superfamily, member 9
TNFRSF9
16010437
|
TRIOXIDE
|
ARSENIC
NM_003808; NM_172087; NM_172088
tumor necrosis factor (ligand) superfamily, member 13
TNFSF13
15761015
|
TRIOXIDE
|
ARSENIC
NM_001244
tumor necrosis factor (ligand) superfamily, member 8
TNFSF8
15761015
|
TRIOXIDE
|
ARSENIC
NM_001067
topoisomerase (DNA) II alpha 170 kDa
TOP2A
16884364
|
TRIOXIDE
|
ARSENIC
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
11714746, 14682389, 11714746,
|
TRIOXIDE
NM_001126114; NM_001126115;
15622746, 11775218, 15979894,
|
NM_001126116; NM_001126117
12490120, 16467208
|
ARSENIC
NM_022112
tumor protein p53 regulated apoptosis inducing protein 1
TP53AIP1
15031205, 16467208
|
TRIOXIDE
|
ARSENIC
NM_001076787; NM_006034
tumor protein p53 inducible protein 11
TP53I11
12883691, 15225615, 15761015
|
TRIOXIDE
|
ARSENIC
NM_001126240; NM_001126241; NM_001126242;
tumor protein p73
TP73
15031205, 16467208
|
TRIOXIDE
NM_005427
|
ARSENIC
NM_003295
tumor protein, translationally-controlled 1
TPT1
15949261
|
TRIOXIDE
|
ARSENIC
NM_013293
transformer 2 alpha homolog (Drosophila)
TRA2A
15761015
|
TRIOXIDE
|
ARSENIC
NM_147200; NM_147686
TRAF3 interacting protein 2
TRAF3IP2
15761015
|
TRIOXIDE
|
ARSENIC
NM_006470
tripartite motif-containing 16
TRIM16
15725085
|
TRIOXIDE
|
ARSENIC
NM_004237
thyroid hormone receptor interactor 13
TRIP13
17547211
|
TRIOXIDE
|
ARSENIC
NM_001136035; NM_001142554; NM_017722
TRM1 tRNA methyltransferase 1 homolog
TRMT1
15725085
|
TRIOXIDE
(S. cerevisiae)
|
ARSENIC
NM_001015881; NM_004089; NM_198057
TSC22 domain family, member 3
TSC22D3
17081986
|
TRIOXIDE
|
ARSENIC
NM_017931
tetratricopeptide repeat domain 38
TTC38
15761015
|
TRIOXIDE
|
ARSENIC
NM_006472
thioredoxin interacting protein
TXNIP
15725085
|
TRIOXIDE
|
ARSENIC
NM_001071
thymidylate synthetase
TYMS
17547211
|
TRIOXIDE
|
ARSENIC
NM_007019; NM_181799; NM_181800;
ubiquitin-conjugating enzyme E2C
UBE2C
17547211
|
TRIOXIDE
NM_181801; NM_181802; NM_181803
|
ARSENIC
NM_003338
ubiquitin-conjugating enzyme E2D 1 (UBC4/5
UBE2D1
15761015
|
TRIOXIDE
homolog, yeast)
|
ARSENIC
NM_004181
ubiquitin carboxyl-terminal esterase L1 (ubiquitin
UCHL1
15725085
|
TRIOXIDE
thiolesterase)
|
ARSENIC
NM_003355
uncoupling protein 2 (mitochondrial, proton carrier)
UCP2
15761015
|
TRIOXIDE
|
ARSENIC
NM_001025366; NM_001025367; NM_001025368;
vascular endothelial growth factor A
VEGFA
12482858, 15949266, 16928304
|
TRIOXIDE
NM_001025369; NM_001025370;
|
NM_001033756; NM_003376
|
ARSENIC
NM_004666
vanin 1
VNN1
15761015
|
TRIOXIDE
|
ARSENIC
NM_018256
WD repeat domain 12
WDR12
15725085
|
TRIOXIDE
|
ARSENIC
NM_025222
WD repeat domain 82
WDR82
15761015
|
TRIOXIDE
|
ARSENIC
NM_018639
WD repeat and SOCS box-containing 2
WSB2
15725085
|
TRIOXIDE
|
ARSENIC
NM_000378; NM_024424; NM_024425;
Wilms tumor 1
WT1
16966277
|
TRIOXIDE
NM_024426
|
ARSENIC
NM_001167
X-linked inhibitor of apoptosis
XIAP
16105982, 16
|
TRIOXIDE
|
ARSENIC
NM_001469
X-ray repair complementing defective repair in Chinese
XRCC6
15761015
|
TRIOXIDE
hamster cells 6
|
ARSENIC
NM_003407
zinc finger protein 36, C3H type, homolog (mouse)
ZFP36
12749819
|
TRIOXIDE
|
ARSENIC
NM_004926
zinc finger protein 36, C3H type-like 1
ZFP36L1
15725085
|
TRIOXIDE
|
ARSENIC
NM_003453; NM_197968
zinc finger, MYM-type 2
ZMYM2
17027752
|
TRIOXIDE
|
ARSENIC
NM_018102; NM_199441
zinc finger protein 334
ZNF334
15761015
|
TRIOXIDE
|
ARSENIC
NM_001007094; NM_003421
zinc finger protein 37A
ZNF37A
15761015
|
TRIOXIDE
|
ARSENIC
NM_001077349; NM_033196
zinc finger protein 682
ZNF682
15761015
|
TRIOXIDE
|
ARSENIC
NM_001142305; NM_016643
zinc finger protein 771
ZNF771
15761015
|
TRIOXIDE
|
ARSENIC
NM_001005413; NM_007057; NM_032997
ZW10 interactor
ZWINT
17547211
|
TRIOXIDE
|
BORTEZOMIB
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
15781649
unrelated
|
BORTEZOMIB
NM_001160; NM_013229; NM_181861;
apoptotic peptidase activating factor 1
APAF1
16024631
death pathway
|
NM_181868; NM_181869
|
BORTEZOMIB
NM_001188
BCL2-antagonist/killer 1
BAK1
16024631
death pathway
|
BORTEZOMIB
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
16024631
death pathway
|
NM_138764; NM_138765
|
BORTEZOMIB
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
15781649, 16022909, 16024631
altered by
|
bortezomib
|
BORTEZOMIB
NM_001191; NM_138578
BCL2-like 1
BCL2L1
12893773, 15543232, 15781649,
altered by
|
16024631
bortezomib
|
BORTEZOMIB
NM_006538; NM_138621; NM_207002
BCL2-like 11 (apoptosis facilitator)
BCL2L11
16024631
death pathway
|
BORTEZOMIB
NM_001196; NM_197966; NM_197967
BH3 interacting domain death agonist
BID
12893773
death pathway
|
BORTEZOMIB
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
12893773, 15543232, 15781649,
altered by
|
16024631
bortezomib
|
BORTEZOMIB
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
12893773, 16024631
altered by
|
bortezomib
|
BORTEZOMIB
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16373703
|
BORTEZOMIB
NM_001216
carbonic anhydrase IX
CA9
16061869
altered by
|
bortezomib
|
BORTEZOMIB
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
12893773, 15735676, 16024631,
death pathway
|
16675587, 17121930
|
BORTEZOMIB
NM_001227; NM_033338; NM_033339;
caspase 7, apoptosis-related cysteine peptidase
CASP7
16024631
death pathway
|
NM_033340
|
BORTEZOMIB
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
12893773, 15735676, 16024631
death pathway
|
NM_033355; NM_033356; NM_033358
|
BORTEZOMIB
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
12893773, 15735676, 16024631
death pathway
|
BORTEZOMIB
NM_053056
cyclin D1
CCND1
12893773, 15781649
sensitivity
|
BORTEZOMIB
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
12893773, 15543232
|
BORTEZOMIB
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
15543232
|
BORTEZOMIB
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
12893773, 16024631
altered by
|
bortezomib
|
BORTEZOMIB
NM_018947
cytochrome c, somatic
CYCS
12893773, 16024631
death pathway
|
BORTEZOMIB
NM_000761
cytochrome P450, family 1, subfamily A, polypeptide 2
CYP1A2
15764713
drug
|
metabolism
|
BORTEZOMIB
NM_000769
cytochrome P450, family 2, subfamily C, polypeptide
CYP2C19
15764713
drug
|
19
metabolism
|
BORTEZOMIB
NM_000771
cytochrome P450, family 2, subfamily C, polypeptide 9
CYP2C9
15764713
drug
|
metabolism
|
BORTEZOMIB
NM_000106; NM_001025161
cytochrome P450, family 2, subfamily D, polypeptide 6
CYP2D6
15764713
drug
|
metabolism
|
BORTEZOMIB
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
15764713
drug
|
metabolism
|
BORTEZOMIB
NM_004083
DNA-damage-inducible transcript 3
DDIT3
16024631
altered by
|
bortezomib
|
BORTEZOMIB
NM_004401; NM_213566
DNA fragmentation factor, 45 kDa, alpha polypeptide
DFFA
15735676
|
BORTEZOMIB
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
12893773, 16024631
death pathway
|
BORTEZOMIB
NM_001530; NM_181054
hypoxia inducible factor 1, alpha subunit (basic helix-
HIF1A
16061869
altered by
|
loop-helix transcription factor)
bortezomib
|
BORTEZOMIB
—
—
HSP27
—
resistance
|
BORTEZOMIB
NM_005347
heat shock 70 kDa protein 5 (glucose-regulated protein,
HSPA5
16024631
altered by
|
78 kDa)
bortezomib
|
BORTEZOMIB
NM_013247; NM_145074
HtrA serine peptidase 2
HTRA2
16024631
death pathway
|
BORTEZOMIB
NM_002228
jun oncogene
JUN
15735676
altered by
|
bortezomib
|
BORTEZOMIB
NM_002755
mitogen-activated protein kinase kinase 1
MAP2K1
12893773
|
BORTEZOMIB
NM_003010
mitogen-activated protein kinase kinase 4
MAP2K4
15735676
|
BORTEZOMIB
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
12893773
altered by
|
bortezomib
|
BORTEZOMIB
NM_001315; NM_139012; NM_139013;
mitogen-activated protein kinase 14
MAPK14
12893773
altered by
|
NM_139014
bortezomib
|
BORTEZOMIB
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
12893773
altered by
|
bortezomib
|
BORTEZOMIB
NM_002750; NM_139046; NM_139047;
mitogen-activated protein kinase 8
MAPK8
12893773
altered by
|
NM_139049
bortezomib
|
BORTEZOMIB
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
12893773
resistance
|
BORTEZOMIB
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
12893773, 16230421, 17164350
resistance
|
enhancer in B-cells 1
|
BORTEZOMIB
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
15543232
altered by
|
enhancer in B-cells inhibitor, alpha
bortezomib
|
BORTEZOMIB
NM_001001716; NM_002503
nuclear factor of kappa light polypeptide gene
NFKBIB
15543232
altered by
|
enhancer in B-cells inhibitor, beta
bortezomib
|
BORTEZOMIB
NM_004556
nuclear factor of kappa light polypeptide gene
NFKBIE
15543232
|
enhancer in B-cells inhibitor, epsilon
|
BORTEZOMIB
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
12893773, 15735676
altered by
|
bortezomib
|
BORTEZOMIB
—
—
PDCD8
12893773, 16024631
|
BORTEZOMIB
NM_021127
phorbol-12-myristate-13-acetate-induced protein 1
PMAIP1
16024631
death pathway
|
BORTEZOMIB
NM_002793
proteasome (prosome, macropain) subunit, beta type, 1
PSMB1
—
target
|
resistance
|
BORTEZOMIB
NM_002794
proteasome (prosome, macropain) subunit, beta type, 2
PSMB2
—
target
|
resistance
|
BORTEZOMIB
NM_001130725; NM_001144932; NM_002797
proteasome (prosome, macropain) subunit, beta type, 5
PSMB5
—
target
|
resistance
|
BORTEZOMIB
NM_002807
proteasome (prosome, macropain) 26S subunit, non-
PSMD1
—
target ?
|
ATPase, 1
|
BORTEZOMIB
NM_002808
proteasome (prosome, macropain) 26S subunit, non-
PSMD2
—
target ?
|
ATPase, 2
|
BORTEZOMIB
NM_002880
v-raf-1 murine leukemia viral oncogene homolog 1
RAF1
12893773
altered by
|
bortezomib
|
BORTEZOMIB
NM_000321
retinoblastoma 1
RB1
12893773
|
BORTEZOMIB
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
12893773, 16061869, 16230421,
resistance
|
(avian)
17164350
|
BORTEZOMIB
NM_006142
stratifin
SFN
16373703
|
BORTEZOMIB
NM_003150; NM_139276; NM_213662
signal transducer and activator of transcription 3
STAT3
17164350
altered by
|
(acute-phase response factor)
bortezomib
|
BORTEZOMIB
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
16230421
|
BORTEZOMIB
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
15543232, 16061869, 16373703
unrelated
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
BORTEZOMIB
NM_021138
TNF receptor-associated factor 2
TRAF2
16024631
|
BORTEZOMIB
NM_001167
X-linked inhibitor of apoptosis
XIAP
12893773, 15543232, 16024631
altered by
|
bortezomib
|
CELECOXIB
NM_001105515; NM_005845
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC4
18690847
|
member 4
|
CELECOXIB
NM_001023587; NM_005688
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC5
18690847
|
member 5
|
CELECOXIB
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
14654083, 16123214, 17270149
altered by
|
celecoxib
|
CELECOXIB
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
14654083
|
NM_138764; NM_138765
|
CELECOXIB
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
14654083
|
CELECOXIB
NM_001191; NM_138578
BCL2-like 1
BCL2L1
14654083
|
CELECOXIB
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16004971, 16123214, 17270149,
altered by
|
16707021, 17270149
celecoxib
|
CELECOXIB
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16123214
death pathway
|
CELECOXIB
NM_053056
cyclin D1
CCND1
15489888, 17270149
altered by
|
celecoxib
|
CELECOXIB
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
—
resistance
|
CELECOXIB
NM_001278
conserved helix-loop-helix ubiquitous kinase
CHUK
15489888
|
CELECOXIB
NM_000103; NM_031226
cytochrome P450, family 19, subfamily A, polypeptide 1
CYP19A1
15964185
altered by
|
celecoxib
|
CELECOXIB
NM_001927
desmin
DES
18089846
|
CELECOXIB
NM_004864
growth differentiation factor 15
GDF15
18089846
|
CELECOXIB
NM_000852
glutathione S-transferase pi 1
GSTP1
18089846
|
CELECOXIB
NM_000576
interleukin 1, beta
IL1B
16357062
altered by
|
celecoxib
|
CELECOXIB
NM_000600
interleukin 6 (interferon, beta 2)
IL6
16702388
altered by
|
celecoxib
|
CELECOXIB
NM_002755
mitogen-activated protein kinase kinase 1
MAP2K1
16123214
|
CELECOXIB
NM_030662
mitogen-activated protein kinase kinase 2
MAP2K2
16123214
|
CELECOXIB
NM_021960; NM_182763
myeloid cell leukemia sequence 1 (BCL2-related)
MCL1
14654083
|
CELECOXIB
NM_002417
antigen identified by monoclonal antibody Ki-67
MKI67
16507397
|
CELECOXIB
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
15489888
|
enhancer in B-cells 1
|
CELECOXIB
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
15489888
|
enhancer in B-cells inhibitor, alpha
|
CELECOXIB
NM_002507
nerve growth factor receptor (TNFR superfamily,
NGFR
17447067
|
member 16)
|
CELECOXIB
NM_001159995; NM_001159996; NM_001159999;
neuregulin 1
NRG1
16357062
altered by
|
NM_001160001; NM_001160008;
celecoxib
|
NM_004495; NM_013956; NM_013957;
|
NM_013958; NM_013959;
|
NM_013960; NM_013961; NM_013962;
|
NM_013964
|
CELECOXIB
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
16123214
altered by
|
celecoxib
|
CELECOXIB
NM_002613; NM_031268
3-phosphoinositide dependent protein kinase-1
PDPK1
—
target
|
CELECOXIB
NM_000963
prostaglandin-endoperoxide synthase 2 (prostaglandin
PTGS2
15489888, 16004971, 16507397,
target
|
G/H synthase and cyclooxygenase)
18089846
|
CELECOXIB
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
15489888, 16685529, 17097285
altered by
|
(avian)
celecoxib
|
CELECOXIB
NM_000351
steroid sulfatase (microsomal), isozyme S
STS
16178010
|
CELECOXIB
NM_003167
sulfotransferase family, cytosolic, 2A,
SULT2A1
15483193, 17239972
altered by
|
dehydroepiandrosterone (DHEA)-preferring, member 1
celecoxib
|
CELECOXIB
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
15489888, 16702388
|
CELECOXIB
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
16507397
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
COLCHICINE
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
15342794, 15725475, 16007523
resistance
|
member 1
|
COLCHICINE
NM_004996; NM_019862; NM_019898;
ATP-binding cassette, sub-family C (CFTR/MRP),
ABCC1
12067707
resistance
|
NM_019899; NM_019900
member 1
|
COLCHICINE
NM_000611; NM_001127223; NM_001127225;
CD59 molecule, complement regulatory protein
CD59
17045307
|
NM_001127226; NM_001127227;
|
NM_203329; NM_203330; NM_203331
|
COLCHICINE
NM_001025076; NM_001025077; NM_001083591;
CUG triplet repeat, RNA binding protein 2
CUGBP2
11478917
|
NM_006561
|
COLCHICINE
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
16007523, 16
drug
|
metabolism
|
COLCHICINE
NM_001556
inhibitor of kappa light polypeptide gene enhancer in B-
IKBKB
17029595
|
cells, kinase beta
|
COLCHICINE
NM_002228
jun oncogene
JUN
12221076
death pathway/
|
survival
|
COLCHICINE
NM_002750; NM_139046; NM_139047;
mitogen-activated protein kinase 8
MAPK8
12221076
death pathway/
|
NM_139049
survival
|
COLCHICINE
NM_001135044; NM_002752; NM_139068;
mitogen-activated protein kinase 9
MAPK9
12221076
death pathway/
|
NM_139069; NM_139070
survival
|
COLCHICINE
NM_000243
Mediterranean fever
MEFV
—
|
COLCHICINE
NM_001136022; NM_004554
nuclear factor of activated T-cells, cytoplasmic,
NFATC4
17044076
|
calcineurin-dependent 4
|
COLCHICINE
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
15744361
|
enhancer in B-cells 1
|
COLCHICINE
NM_020529
nuclear factor of kappa light polypeptide gene
NFKBIA
17029595
|
enhancer in B-cells inhibitor, alpha
|
COLCHICINE
NM_000176; NM_001018074; NM_001018075;
nuclear receptor subfamily 3, group C, member 1
NR3C1
15744361
|
NM_001018076; NM_001018077;
(glucocorticoid receptor)
|
NM_001020825; NM_001024094
|
COLCHICINE
NM_004103; NM_173174; NM_173175;
PTK2B protein tyrosine kinase 2 beta
PTK2B
11478917
|
NM_173176
|
COLCHICINE
NM_006788
ralA binding protein 1
RALBP1
15386349
unrelated
|
COLCHICINE
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
15744361
|
(avian)
|
COLCHICINE
NM_000353
tyrosine aminotransferase
TAT
15744361
altered by
|
colchicine
|
COLCHICINE
NM_000546; NM_001126112; NM_001126113;
tumor protein p53
TP53
12221076
cell death
|
NM_001126114; NM_001126115;
|
NM_001126116; NM_001126117
|
COLCHICINE
NM_030773
tubulin, beta 1
TUBB1
—
target
|
COLCHICINE
NM_001069
tubulin, beta 2A
TUBB2A
—
target
|
OBLIMERSEN
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
11095261, 15867202
target
|
OBLIMERSEN
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
16675587
|
OBLIMERSEN
—
—
IGH-6
15867202
|
TEGAFUR
NM_001785
cytidine deaminase
CDA
18537153
|
TEGAFUR
NM_000762
cytochrome P450, family 2, subfamily A, polypeptide 6
CYP2A6
11376561, 12172220, 11376561,
target
|
15980104
|
TEGAFUR
NM_000110
dihydropyrimidine dehydrogenase
DPYD
18537153
|
TIPIFARNIB
NM_000927
ATP-binding cassette, sub-family B (MDR/TAP),
ABCB1
15122075
resistance
|
member 1
|
TIPIFARNIB
NM_017460
cytochrome P450, family 3, subfamily A, polypeptide 4
CYP3A4
15122075
|
TIPIFARNIB
NM_000777
cytochrome P450, family 3, subfamily A, polypeptide 5
CYP3A5
15122075
|
TIPIFARNIB
NM_000463
UDP glucuronosyltransferase 1 family, polypeptide A1
UGT1A1
15122075
|
VORINOSTAT
NM_001014431; NM_001014432; NM_005163
v-akt murine thymoma viral oncogene homolog 1
AKT1
15781658, 16144943
|
VORINOSTAT
NM_001188
BCL2-antagonist/killer 1
BAK1
15781658, 16144943
death pathway
|
VORINOSTAT
NM_004324; NM_138761; NM_138763;
BCL2-associated X protein
BAX
15781658, 15897598
death pathway
|
NM_138764; NM_138765
|
VORINOSTAT
NM_000633; NM_000657
B-cell CLL/lymphoma 2
BCL2
15897598, 16144943, 15897598
resistance
|
VORINOSTAT
NM_001114735; NM_004049
BCL2-related protein A1
BCL2A1
15897598
resistance
|
VORINOSTAT
NM_001191; NM_138578
BCL2-like 1
BCL2L1
12893773, 16144943, 15897598
resistance
|
VORINOSTAT
NM_006538; NM_138621; NM_207002
BCL2-like 11 (apoptosis facilitator)
BCL2L11
16144943
death pathway
|
VORINOSTAT
NM_001196; NM_197966; NM_197967
BH3 interacting domain death agonist
BID
12893773, 17410615,
death pathway
|
17410615, 15897598
|
VORINOSTAT
NM_001166
baculoviral IAP repeat-containing 2
BIRC2
12893773, 16377638
|
VORINOSTAT
NM_001165; NM_182962
baculoviral IAP repeat-containing 3
BIRC3
12893773, 15897598, 16377638
altered by
|
vorinostat
|
VORINOSTAT
NM_001012270; NM_001012271; NM_001168
baculoviral IAP repeat-containing 5
BIRC5
16144943, 17410615, 17410615,
altered by
|
18156316
vorinostat
|
VORINOSTAT
NM_032982; NM_032983
caspase 2, apoptosis-related cysteine peptidase
CASP2
15897598
death pathway
|
VORINOSTAT
NM_004346; NM_032991
caspase 3, apoptosis-related cysteine peptidase
CASP3
12893773, 15781658, 15897598,
death pathway
|
17410615
|
VORINOSTAT
NM_001227; NM_033338; NM_033339;
caspase 7, apoptosis-related cysteine peptidase
CASP7
15897598
death pathway
|
NM_033340
|
VORINOSTAT
NM_001080124; NM_001080125; NM_001228;
caspase 8, apoptosis-related cysteine peptidase
CASP8
12893773, 15781658, 15897598,
death pathway
|
NM_033355; NM_033356; NM_033358
17410615
|
VORINOSTAT
NM_001229; NM_032996
caspase 9, apoptosis-related cysteine peptidase
CASP9
12893773, 15897598
death pathway
|
VORINOSTAT
NM_053056
cyclin D1
CCND1
12893773, 17431121, 12893773
altered by
|
vorinostat
|
VORINOSTAT
NM_000389; NM_078467
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1A
12893773,
altered by
|
16144943, 17431121, 15897598,
vorinostat
|
12893773, 14707268, 17431121
|
VORINOSTAT
NM_004064
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B
16144943, 17431121, 17431121
altered by
|
vorinostat
|
VORINOSTAT
NM_001127183; NM_001127184; NM_003879
CASP8 and FADD-like apoptosis regulator
CFLAR
12893773, 15897598
resistance
|
VORINOSTAT
NM_018947
cytochrome c, somatic
CYCS
12893773, 15781658
death pathway
|
VORINOSTAT
NM_000499
cytochrome P450, family 1, subfamily A, polypeptide 1
CYP1A1
15713371
altered by
|
vorinostat
|
VORINOSTAT
NM_000104
cytochrome P450, family 1, subfamily B, polypeptide 1
CYP1B1
15713371
altered by
|
vorinostat
|
VORINOSTAT
NM_019887; NM_138929
diablo homolog (Drosophila)
DIABLO
12893773
death pathway
|
VORINOSTAT
NM_001005862; NM_004448
v-erb-b2 erythroblastic leukemia viral oncogene
ERBB2
16144943
altered by
|
homolog 2, neuro/glioblastoma derived oncogene
vorinostat
|
homolog (avian)
|
VORINOSTAT
NM_004964
histone deacetylase 1
HDAC1
15930892
target
|
VORINOSTAT
NM_001527
histone deacetylase 2
HDAC2
—
target
|
VORINOSTAT
NM_003883
histone deacetylase 3
HDAC3
15930892
target
|
VORINOSTAT
NM_006044
histone deacetylase 6
HDAC6
15930892
target
|
VORINOSTAT
NM_018486
histone deacetylase 8
HDAC8
—
target
|
VORINOSTAT
NM_003493
histone cluster 3, H3
HIST3H3
17431121
altered by
|
vorinostat
|
VORINOSTAT
NM_013247; NM_145074
HtrA serine peptidase 2
HTRA2
16026644
death pathway
|
VORINOSTAT
NM_002755
mitogen-activated protein kinase kinase 1
MAP2K1
12893773, 15781658
|
VORINOSTAT
NM_002745; NM_138957
mitogen-activated protein kinase 1
MAPK1
12893773, 15781658
|
VORINOSTAT
NM_001315; NM_139012; NM_139013;
mitogen-activated protein kinase 14
MAPK14
12893773
altered by
|
NM_139014
vorinostat
|
VORINOSTAT
NM_001040056; NM_001109891; NM_002746
mitogen-activated protein kinase 3
MAPK3
12893773, 15781658
|
VORINOSTAT
NM_002750; NM_139046; NM_139047;
mitogen-activated protein kinase 8
MAPK8
12893773, 15781658, 15964800
altered by
|
NM_139049
vorinostat
|
VORINOSTAT
NM_003998
nuclear factor of kappa light polypeptide gene
NFKB1
12893773
altered by
|
enhancer in B-cells 1
vorinostat
|
VORINOSTAT
NM_001618
poly (ADP-ribose) polymerase 1
PARP1
12893773, 16377638,
altered by
|
17431121, 15897598
vorinostat
|
VORINOSTAT
—
—
PDCD8
12893773, 15781658, 16026644
death pathway
|
VORINOSTAT
NM_002880
v-raf-1 murine leukemia viral oncogene homolog 1
RAF1
12893773, 16144943, 12893773
altered by
|
vorinostat
|
VORINOSTAT
NM_000965; NM_016152
retinoic acid receptor, beta
RARB
16832676
|
VORINOSTAT
NM_000321
retinoblastoma 1
RB1
12893773, 14707268, 15897598
altered by
|
vorinostat
|
VORINOSTAT
NM_001145138; NM_021975
v-rel reticuloendotheliosis viral oncogene homolog A
RELA
12893773, 15964800
altered by
|
(avian)
vorinostat
|
VORINOSTAT
NM_000594
tumor necrosis factor (TNF superfamily, member 2)
TNF
16377638
|
VORINOSTAT
NM_003810
tumor necrosis factor (ligand) superfamily, member 10
TNFSF10
17410615
|
VORINOSTAT
NM_001167
X-linked inhibitor of apoptosis
XIAP
12893773, 15964800,
altered by
|
16144943, 17410615, 17410615
vorinostat
|
|
TABLE 2
|
|
Found Targets
|
List (with fold-
Avg Abs (FC)
|
Chemical
Target Genes
Target Genes List
Found Targets
changes)
Avg Abs (FC)
UP-REG
Score
|
|
|
Nucleotides
|
Nucleotides >> Antimetabolites
|
Nucleotides >> Antimetabolites >> Folic acid
|
METHOTREXATE
35
ABCB1 ABCC1 ABCC2
19
ABCC1 (7.70) ABCC2 (4.39,
7.36
6.93
197
|
(Abitrexate, Antifolan, Arbitrexate,
ABCC4 ABCG2 ALB ALPI
(10 + 9)
5.45) ABCC4 (2.34) ATIC
|
Emtexate, Folex, Ledertrexate,
ATIC CD4 CD68 CD8A
(54.3%)
(3.75) NAT1 (2.39) PARP1
|
Metatrexan, Methotrate, Mexate,
CYP3A4 DHFR DKK1
(2.68) PRC1 (3.44) TYMS
|
Rheumatrex, Trexall)
GSTM1 ICAM1 IL8 MMP3
(3.69) UBE2C (9.47) WNT5A (28.92)
|
MTHFR MTR NAT1 ODC1
ABCB1 (−3.59) CD68 (−3.38)
|
PARP1 PRC1 RB1 SELE SLC19A1
CYP3A4 (−7.84) DKK1 (−16.44)
|
SLC46A1 TAGLN TIMP1 TYMS
ICAM1 (−8.24) IL8 (−16.97)
|
UBE2C VDR WISP1 WNT5A
SLC19A1 (−3.24) TIMP1 (−4.76) VDR (−6.07)
|
PEMETREXED
8
DHFR FPGS GART GGH RBM17
4
GART (2.18) TYMS (3.69)
3.50
2.94
73
|
(Alimta)
SLC19A1 TYMP TYMS
(2 + 2)
SLC19A1 (−3.24) TYMP (−3.83, −5.95)
|
(50.0%)
|
Nucleotides >> Antimetabolites >> Purine
|
FLUDARABINE
25
ADA AKT1 ARNT BCL2
6
CCNA2 (5.27) CCNE1 (5.62)
3.56
3.88
62
|
(Fludara, Fludura)
CCNA2 CCND1 CCNE1
(4 + 2)
HIST3H3 (2.04) VEGFA
|
CDKN1B CYCS DIABLO
(24.0%)
(2.60) CCND1 (−2.52) MCL1 (−3.34)
|
ERK HIF1A HIST3H3
|
HIST4H4 MAP2K1
|
MAP2K2 MAPK1 MAPK3
|
MCL1 PDCD8 POLA1
|
RRM1 STAT1 VEGFA
|
XIAP
|
Nucleotides >> Antimetabolites >> Pyrimidine
|
FLUOROURACIL
132
ABCB1 ABCC1 ABCG2
64
ABCC1 (7.70) ADSS (3.13,
7.06
5.18
137
|
(5 FU, Fluorouracil,
ACADL ADSS AIFM1
(35 + 29)
3.02) BECN1 (2.18) CA12
|
Adrucil, Arumel, Carac,
AMFR AMT ANGPTL2
(48.5%)
(21.62, 17.07, 11.24, 25.25)
|
Carzonal, Effluderm,
AREG ATP5O BARX2
CASP2 (2.27) CASP3 (2.14)
|
Efudex, Efudix, Efurix,
BAX BBS4 BCL2 BDH1
CASP8 (8.85, 2.67) CCNE2
|
FU, Fluoroblastin,
BECN1 BIRC5 BNIP3
(3.25) CCNF (2.52) CDCA8
|
Fluoroplex, Fluracil,
BNIP3L BOLL BTG3 BUB3
(2.55) CTNND2 (3.12, 2.44)
|
Fluracilum, Fluri, Fluril,
C13ORF34 CA12 CASP2
CTTN (2.13) DTYMK (2.69,
|
Fluro, Uracil, Ftoruracil,
CASP3 CASP7 CASP8
2.60) E2F3 (2.71) EML2
|
Kecimeton, Phthoruracil,
CASP9 CCND3 CCNE2
(4.55) FEN1 (2.79, 2.41)
|
Phtoruracil, Queroplex,
CCNF CCNG2 CDCA8
FOXO3 (2.21) GOLGA8A
|
Timazin, URF, Ulup)
CDKN1A CDKN1C CIDEB
(8.56) GSTP1 (3.00) KPNA2
|
CKS2 CTNND2 CTTN
(2.49) LTB4DH (18.28)
|
CYR61 DPYD DRD5
MED13L (6.09) MELK (6.04)
|
DTYMK E2F3 EGFR
MKI67 (5.91) NDUFA10
|
EIF2B2 EIF3S3 EML2
(2.42) NKAIN1 (22.33)
|
ERBB2 ERBB4 ERCC1
PARP1 (2.68) PCDHA5
|
ERCC2 ERP29 F3 F8
(2.75) PRC1 (3.44) RAD23B
|
FANCG FAS FEN1 FGF7
(2.57, 2.55, 4.15) RNF34
|
FOXO3 GADD45A GAMT
(2.18, 2.49, 2.45) RRM2
|
GFRA1 GOLGA8A GSTP1
(3.30, 3.47) TYMS (3.69)
|
GSTT1 HINT1 HIST1H1D
UBE2C (9.47) ZNF552 (8.76,
|
HNRPC IGFBP4 IL8RA
2.45)
|
IRAK1 JMJD2B KIAA1467
ABCB1 (−3.59) ACADL (−19.18)
|
KIF3A KPNA2 KRAS
AMFR (−5.37)
|
LGALS8 LMNB1 LTB4DH
ANGPTL2 (−2.89, −3.89)
|
M6PR MALT1 MAPK13
AREG (−119.30) BTG3 (−7.01)
|
MAPT MED13L MELK
CDKN1A (−7.85, −4.44)
|
METRN MKI67 MYC
CDKN1C (−7.69) CYR61 (−3.69,
|
NDUFA10 NKAIN1
−2.81, −3.06) DPYD (−2.82,
|
NUCKS1 PARP1 PCDHA5
−4.07, −4.30) EGFR (−12.64)
|
PDAP1 PGR PPP3CA
ERBB4 (−3.94, −3.33)
|
PRC1 PRNP PSCD3
F3 (−3.63) F8 (−3.51, −2.90)
|
PSG9 PSRC1 RAD23B
FAS (−5.93) FGF7 (−2.01, −3.09,
|
RAMP1 RNF34 RPL3
−3.61) GAMT (−3.39, −2.43)
|
RRM2 RTKN SCUBE2
GFRA1 (−5.66) IGFBP4
|
SERPINE2 SFN SNAPC1
(−2.66) IL8RA (−5.26)
|
TERF2 THNSL2 TMSB4X
LGALS8 (−2.28) PGR (−11.29)
|
TMSL8 TNFRSF10B TP53
PPP3CA (−2.42) PRNP (−3.95)
|
TYMP TYMS UBE2C
TMSB4X (−2.05)
|
UPP1 UPRT UXT
TMSL8 (−11.70) TNFRSF10B
|
WBSCR1 XAF1 ZNF32
(−2.25) TYMP (−3.83, −5.95)
|
ZNF552 ZNF582 ZRSR2
UPP1 (−3.24, −2.71, −2.28)
|
CAPECITABINE
5
CES1 CES2 CES3 DPYD TYMS
4
CES1 (13.90) CES3 (10.19)
7.88
9.26
555
|
(Xeloda)
(3 + 1)
TYMS (3.69)
|
(80.0%)
DPYD (−2.82, −4.07, −4.30)
|
GEMCITABINE
12
BAX BCL2 CASP3 CDKN1A
4
CASP3 (2.14) PARP1 (2.68)
3.66
2.84
70
|
(DDFC, DFDC, GEO,
CMPK PARP1 PDPK1 RBM17 RRM1
(3 + 1)
TYMS (3.69)
|
Gemcin, Gemcitabina,
SLC29A1 TP53 TYMS
(33.3%)
CDKN1A (−7.85, −4.44)
|
Gemcitabine, HCl,
|
Gemcitabine
|
hydrochloride,
|
Gemcitabinum, Gemtro,
|
Gemzar)
|
DNA
|
DNA >> Alkylating agents
|
DNA >> Alkylating agents >> Nitrogen mustards
|
CYCLOPHOSPHAMIDE
56
ABCB1 ABCC1 ABCG2
29
ABCC1 (7.70) BECN1 (2.18)
6.89
7.19
218
|
(ASTA, Asta B 518, CP,
AMFR BAG1 BBS4 BCL2
(17 + 12)
CA12 (21.62, 17.07, 11.24,
|
CPA, CTX, CY, Clafen,
BECN1 BTG3 BUB3 CA12
(51.8%)
25.25) CASP3 (2.14)
|
Claphene,
CASP3 CASP9 CDKN1B
CTNND2 (3.12, 2.44)
|
Cyclophosphamid,
CTNNBIP1 CTNND2
CYP2B6 (10.92, 3.17) E2F3
|
Cyclophosphamide
CYP2B6 E2F3 EGFR
(2.71) GSTA1 (16.89) ILF3
|
Monohydrate,
EIF1AX EIF4EBP1 ERBB2
(3.78) MED13L (6.09) MELK
|
Cyclophosphamide
ERBB4 ESR1 ESR2
(6.04) MKI67 (5.91) NKAIN1
|
Sterile,
GAMT GFRA1 GSTA1
(22.33) RRM2 (3.30, 3.47)
|
Cyclophosphamidum,
GTF3C1 IGFBP4 ILF3
ST14 (2.22) STK39 (6.44,
|
Cyclophosphan,
IRS1 JMJD2B KIAA1467
6.78) ZNF552 (8.76, 2.45)
|
Cyclophosphane,
KIF3A MAPK14 MAPT
ABCB1 (−3.59) AMFR (−5.37)
|
Cyclophosphoramide,
MED13L MELK METRN
BTG3 (−7.01) CTNNBIP1 (−7.17)
|
Cyclostin,
MGMT MKI67 NAIP
EGFR (−12.64) ERBB4
|
Cyklofosfamid,
NKAIN1 PGR PLOD1
(−3.94, −3.33) GAMT (−3.39, −2.43)
|
Cytophosphan,
PLOD3 RAMP1 RRM2
GFRA1 (−5.66) IGFBP4
|
Cytoxan, Cytoxan,
SCUBE2 SRM ST14
(−2.66) IRS1 (−13.62) PGR (−11.29)
|
Lyoph,
STK39 THNSL2 TP53
PLOD1 (−2.05)
|
EndoxanEndoxan, R,
ZNF552
|
Endoxan-Asta,
|
Endoxana, Endoxanal,
|
Endoxane, Enduxan,
|
Genoxal, Hexadrin
|
Lyophilized, Cytoxan,
|
Mitoxan, Neosar,
|
Procytox, Rcra, Waste,
|
Number, U058,
|
Revimmune,
|
Semdoxan, Sendoxan,
|
Senduxan,
|
Zyklophosphamid)
|
IFOSFAMIDE
10
BCL2 CASP9 CYP2A6
5
CYP2B6 (10.92, 3.17)
11.00
4.08
122
|
(Cyfos, Holoxan, 1000,
CYP2B6 CYP3A4 CYP3A5
(3 + 2)
DNMT1 (2.20) GSTP1 (3.00)
|
IFEX, Ifex/Mesnex Kit,
DNMT1 GSTM1 GSTP1
(50.0%)
CYP3A4 (−7.84) CYP3A5 (−34.94)
|
Ifosfamide/Mesna Kit,
GSTT1
|
Isoendoxan, Mitoxana,
|
Naxamide)
|
MELPHALAN
9
ABCC1 BIRC5 CASP2
5
ABCC1 (7.70) CASP2 (2.27)
6.40
6.40
355
|
(Alkeran, L-PAM, L-
CASP3 CDA GSTA1
(5 + 0)
CASP3 (2.14) GSTA1 (16.89)
|
Phenylalanine mustard,
GSTP1 MGMT MGST2
(55.6%)
GSTP1 (3.00)
|
L-Sarcolysin, L-
|
Sarcolysine, L-
|
Sarkolysin, Levofalan,
|
Melfalan, Mephalan,
|
Phenylalanine mustard,
|
Phenylalanine nitrogen
|
mustard, Sarcolysine,
|
Sarkolysin)
|
DNA >> Alkylating agents >> Nitrosoureas
|
CARMUSTINE
230
ABCB1 ABCC1 ACTC1
106
ABCC1 (7.70) AGT (3.57)
5.24
4.73
102
|
(Becenun, Bi CNU,
ACTG2 ACTN1 ADAM15
(50 + 56)
AKT2 (2.40, 3.07, 2.01)
|
BiCNU, Carmubris,
ADAMTS4 ADCYAP1
(46.1%)
ALAD (4.21) AMH (2.39)
|
Gliadel, Gliadel Wafer,
ADRA1B AGT AGTRL1
AQP8 (3.03) B4GALT5 (2.55,
|
Nitrumon)
AKT2 ALAD ALOX15B
2.84) BAIAP3 (2.18) BECN1
|
AMH APC2 AQP8
(2.18) BICD1 (13.67) BLK
|
ARGBP2 ARPC2 ARTN
(3.63) CDC25C (8.00) CDK8
|
ASMTL ATP1A3 ATP4B
(2.39) CEACAM3 (2.96, 2.75)
|
ATP5D ATP6V0C ATXN2L
CHEK1 (4.69) CKM (20.86)
|
AVPR1A B4GALT5
CLTCL1 (5.12) CRABP1
|
BAIAP2 BAIAP3 BCL10
(3.09) CYP19A1 (2.64)
|
BCL2 BCL2L1 BECN1
DHX16 (2.71) DVL1 (2.75,
|
BICD1 BLK BMP7 BRF1
2.21) EIF2B1 (2.16) EPHX1
|
CA6 CALB2 CCL2 CD151
(4.56) EZH2 (4.80) FNTA
|
CD68 CD79A CD80
(3.94) FTH1 (2.42, 2.32,
|
CDC25C CDK8 CDKN1A
2.35) FTL (3.51, 4.41, 3.40)
|
CDX4 CEACAM3 CEBPB
GCM1 (2.70) GOLGA2 (2.44,
|
CHEK1 CHRM4 CHRNB3
2.57) GPR37 (2.96) GRB7
|
CHRNG CKM CLTCL1
(2.78) GSR (10.75, 10.84)
|
CNTNAP1 COL9A1
GSTA1 (16.89) GSTP1 (3.00)
|
COX6A2 CRABP1 CRAT
HNF1A (3.45) INPPL1 (2.26)
|
CRYBB1 CST5 CTF1
KCNH2 (4.05) MAP4K2
|
CTNNAL1 CYP19A1
(2.72) MAPK10 (3.15)
|
DHX16 DNASE1L2 DVL1
MAT1A (6.12) MDK (17.02)
|
ECM2 EEF1G EIF2B1
MED1 (2.44) NPAS1 (4.81)
|
EIF6 EPHX1 ESRRA
PRC1 (3.44) PTPN3 (2.46,
|
EZH2 FBN1 FKBP1A
2.03) RAD51 (4.60)
|
FNTA FOXJ1 FTH1 FTL
SLCO1A2 (2.31) SMPD2
|
FYN GABRA2 GABRA6
(2.55) SNCG (2.23) UGT8
|
GAMT GAST GCM1 GDI1
(5.58, 9.40)
|
GDI2 GFAP GHSR
ABCB1 (−3.59) ACTG2 (−9.33)
|
GNRHR GOLGA2
ACTN1 (−2.46, −2.62)
|
GOLGA4 GP1BB GPR25
ADAMTS4 (−3.13, −5.12)
|
GPR32 GPR37 GPR65
ADRA1B (−7.78) ALOX15B (−17.05)
|
GRB7 GRN GSR GSTA1
ATP1A3 (−5.85)
|
GSTM1 GSTM3 GSTP1
BAIAP2 (−4.34, −2.72, −3.14)
|
GTF2F1 H2AFX HADHSC
BCL10 (−2.16, −3.00) BMP7 (−16.37,
|
HAGH HCFC1 HMGN2
−4.33) BRF1 (−3.38)
|
HNF1A HOXA4 ICAM5
CALB2 (−5.76) CCL2 (−8.86)
|
IDS IER3 IKBKG INPPL1
CD151 (−2.41) CD68 (−3.38)
|
INSIG1 INSL3 IRS1 ISLR
CDKN1A (−7.85, −4.44)
|
ITGA3 ITIH1 KCNH2
COX6A2 (−2.12) CRAT (−3.15)
|
KIF5A KRT17 KRT31
CST5 (−2.40) CTNNAL1
|
LAD1 LAIR1 LAMB3
(−5.85) FBN1 (−2.95) FKBP1A
|
LMX1B LOXL1 LRCH4
(−5.05) FOXJ1 (−5.38, −2.05)
|
LRMP MAD1L1 MAP4K2
FYN (−2.59) GAMT (−3.39, −2.43)
|
MAPK10 MAT1A MDK
GDI2 (−2.36) GPR65 (−2.59)
|
MED1 MGAT3 MGMT
GSTM3 (−3.01) HOXA4
|
MSR1 MUC2 MVD
(−8.73) IER3 (−4.31) IRS1 (−13.62)
|
MYBPH MYD88 MYOD1
KRT17 (−5.21) LAIR1
|
MYOG NDUFC1 NKX2-2
(−2.82) LAMB3 (−23.74)
|
NPAS1 NPBWR2 NRTN
LOXL1 (−2.57) MAD1L1 (−2.73)
|
OMP PAEP PAX8 PBX2
MGAT3 (−12.97) MSR1
|
PCBD1 PCDHGC3
(−2.93, −2.73) MYBPH (−4.47)
|
PCOLCE PCYT1A
MYD88 (−2.51) NRTN (−7.31)
|
PFKFB2 PFKM PFN1
PAX8 (−5.65) PCOLCE (−3.31)
|
PIK3R3 PMS2L11
PZP (−2.82) RCN1 (−2.52,
|
POLR2E PPM1G PRC1
−2.24) RNASE4 (−2.13)
|
PRL PRM2 PSCD1 PTPN3
SGCA (−17.29) SLC16A2 (−6.80)
|
PZP RAD23A RAD51
SNRPB2 (−2.25)
|
RAD9 RCN1 RGR RIT2
SOCS1 (−5.85, −5.20) SPEG
|
RNASE4 SEPT5 SFPQ
(−5.28) ST8SIA1 (−6.37)
|
SGCA SHMT2 SHOX
TCF21 (−20.30) TSPAN4 (−3.44,
|
SIAT1 SLC10A1 SLC16A2
−3.61) WIPF1 (−2.18, −3.58)
|
SLC30A3 SLC6A2
ZYX (−3.12)
|
SLCO1A2 SMARCD1
|
SMPD2 SNAPC1 SNAPC3
|
SNCG SNRPB2 SOCS1
|
SPEG SPRR2B SRP14
|
SRY ST8SIA1 STAM STS
|
STX1B STXBP2 TAC1
|
TCF21 TEGT TLE3
|
TNFRSF11B TP53 TRAF1
|
TSPAN4 TUBB TUBG1
|
UGT8 UPF1 VGF WIPF1
|
YWHAH ZBTB17 ZYX
|
FOTEMUSTINE
2
MGMT TXNRD1
1
TXNRD1 (12.56)
12.56
12.56
627
|
(Muphoran)
(1 + 0)
|
(50.0%)
|
DNA >> Alkylating agents >> Platinum
|
CARBOPLATIN
11
ALB BAX BCL2 BCL2L12
4
BCL2L12 (4.27) CASP3
3.76
3.03
82
|
(Paraplatin, Paraplatin-AQ)
BIRC2 CASP3 CASP9
(3 + 1)
(2.14) PARP1 (2.68)
|
DCT FAS PARP1 RBM17
(36.4%)
FAS (−5.93)
|
CISPLATIN
111
A2M ABCB1 ABCC1
54
ABCC1 (7.70) ABCC2 (4.39,
5.10
4.46
108
|
(Abiplatin, Biocisplatinum, Briplatin,
ABCC2 ABCC5 AKT1
(27 + 27)
5.45) ABCC5 (4.30, 6.53)
|
Carboquone, Cis Pt II, Cismaplat,
AKT2 AKT3 ALB APEX1
(48.6%)
AKT2 (2.40, 3.07, 2.01)
|
Cisplatine, Cisplatyl, Citoplationo,
AXL BAX BCL2 BCL2L1
BCL2L12 (4.27) CASP2
|
Lederplatin, Neoplatin, Plastin, Platamine,
BCL2L12 BIRC2 BIRC3
(2.27) CASP3 (2.14) CASP8
|
Platiblastin, Platidiam, Platinex, Platinol,
BIRC5 CASP2 CASP3
(8.85, 2.67) CREBBP (2.11,
|
Platinol-AQ, Platinoxan, Randa)
CASP8 CASP9 CAT
2.52) ETV4 (2.09) GSTP1
|
CDKN1A CFLAR CLU
(3.00) HSPE1 (5.96) KRT4
|
CNTF CREBBP CYCS
(8.00) LASS4 (5.10) MCM2
|
CYP3A4 DIABLO DPYD
(3.39) MED1 (2.44) NCOA3
|
EDN2 EGFR EP300
(3.29, 4.36, 3.16) NR1I2
|
ERBB2 ERCC1 ERCC2
(3.23) PARP1 (2.68) PMAIP1
|
ETV4 FADD FANCG FAS
(12.40) PTK2 (2.54)
|
FASLG FGFR3 FOSL1
SLC31A1 (2.02, 2.41)
|
GDF15 GSTM1 GSTM3
SPINT2 (6.04) TF (9.84,
|
GSTP1 GSTT1 GUK1
8.91) TXN (4.58, 5.09) TYMS
|
HIF1A HSPE1 HTRA2
(3.69) VEGFA (2.60)
|
IFITM1 IGFBP3 IL4R
A2M (−4.77) ABCB1 (−3.59)
|
ITGA9 ITGB4 JUN KRT19
AKT3 (−3.90, −3.96) BIRC3 (−2.84)
|
KRT4 LASS4 MCM2
CAT (−3.31) CDKN1A (−7.85,
|
MED1 MGMT MMP10
−4.44) CYP3A4 (−7.84)
|
MMP15 MMP16 MRPS27
DPYD (−2.82, −4.07, −4.30)
|
MT1A MT2A MT3 MVP
EDN2 (−3.91) EGFR (−12.64)
|
NAIP NCOA3 NOTCH4
FAS (−5.93) FGFR3 (−8.75)
|
NR1I2 NTHL1 PARP1
GSTM3 (−3.01) IL4R (−4.02)
|
PCNA PDIA3 PFDN5
ITGA9 (−2.21) JUN (−2.62)
|
PGK1 PMAIP1 PRNP
MMP10 (−2.05) MT1A (−7.47)
|
PTEN PTGS2 PTK2 RB1
MT2A (−8.59, −9.15) MVP (−2.25)
|
RHOC RPL36 RPS5
NOTCH4 (−2.63, −3.15)
|
RUNX3 SFN SLC31A1
PFDN5 (−2.17) PRNP (−3.95)
|
SOCS1 SPINT2 TF TP53
PTEN (−2.30, −2.56) PTGS2 (−36.04,
|
TP73 TRAM1 TRAP1
−32.79) SOCS1 (−5.85,
|
TUBA1A TXN TYMS
−5.20) TRAM1 (−3.53)
|
VEGFA XIAP XPA XRCC1
|
ZFP36L1
|
OXALIPLATIN
17
BCL2 BCL2L1 BIRC5
8
CCNA2 (5.27) CCNB1 (3.17)
5.20
3.95
139
|
(DACPLAT, Eloxatin, Elplat,
CCNA2 CCNB1 CCNE1
(6 + 2)
CCNE1 (5.62) CDC2 (2.92)
|
Foloxatine, Transplatin)
CDC2 CDK2 CDKN1B
(47.1%)
GSTP1 (3.00) TYMS (3.69)
|
EGFR ERCC1 ERCC2
EGFR (−12.64) IL8RA (−5.26)
|
GSTP1 IL8RA MYC RB1
|
TYMS
|
DNA >> Alkylating agents >> Alkyl sulfonates
|
BUSULFAN
5
GSTA1 GSTM1 GSTP1
2
GSTA1 (16.89) GSTP1 (3.00)
9.95
9.95
397
|
(Busulfex, Citosulfan, Leucosulfan,
MGMT MGST2
(2 + 0)
|
Mablin, Mielevcin, Mielosan, Mielucin,
(40.0%)
|
Milecitan, Mileran, Misulban, Mitosan,
|
Mitostan, Myeleukon, Myeloleukon,
|
Myelosan, Mylecytan, Myleran, Myleran
|
Tablets)
|
DNA >> Alkylating agents >> Hydrazines
|
PROCARBAZINE
1
MGMT
—
—
—
—
—
|
(Matulane, Nathulane, Natulan, Natulan
|
hydrochloride, Natulanar, Natunalar)
|
DNA >> Alkylating agents >> Triazenes
|
DACARBAZINE
22
APEX1 BIRC5 CASP3
9
CASP3 (2.14) CASP8 (8.85,
7.30
7.13
162
|
(Deticene)
CASP8 CD38 CD69
(5 + 4)
2.67) MAP3K1 (2.06, 2.62)
|
CYP1A1 CYP1A2 EPO
(40.9%)
SLC2A1 (22.83) VEGFA
|
IFNA1 IFNA2 IL8 IRF1
(2.60)
|
MAP3K1 MAPK1 MAPK3
IL8 (−16.97) IRF1 (−2.23)
|
MCL1 MGMT POLA2
MCL1 (−3.34) TNFSF10 (−7.51)
|
SLC2A1 TNFSF10 VEGFA
|
TEMOZOLOMIDE
10
AGT DCT MGMT MPG
3
AGT (3.57) PARP1 (2.68)
6.21
6.21
186
|
(Temodal, Temodar)
PARP1 PMAIP1 POLB
(3 + 0)
PMAIP1 (12.40)
|
POLI POLL TP53
(30.0%)
|
DNA >> Alkylating agents >> Aziridines
|
THIOTEPA
5
GSTA1 GSTA2 GSTM1
3
GSTA1 (16.89) GSTA2
11.90
11.90
713
|
(Thioplex, Thiotepa)
GSTP1 MGMT
(3 + 0)
(15.07, 16.53) GSTP1 (3.00)
|
(60.0%)
|
DNA >> Alkylating agents >> Other
|
ECTEINASCIDIN 743
4
CCNA2 CCNB1 CCNB2
4
CCNA2 (5.27) CCNB1 (3.17)
3.77
3.77
376
|
(Trabectedin, ET-743,
E2F1
(4 + 0)
CCNB2 (4.19) E2F1 (2.45)
|
Yondelis)
(100.0%)
|
DNA >> Spindle poisons/Mitotic inhibitors
|
DNA >> Spindle poisons/Mitotic inhibitors >> Taxanes
|
DOCETAXEL
33
ABCB1 ABCC1 ABCC2
15
ABCC1 (7.70) ABCC2 (4.39,
8.72
3.67
77
|
(Taxotere)
BCL2 BCL2L1 BIRC5
(7 + 8)
5.45) CASP3 (2.14)
|
CASP3 CFLAR CYP19A1
(45.5%)
CYP19A1 (2.64) GSTP1
|
CYP1B1 CYP3A4 ERBB2
(3.00) PARP1 (2.68) VEGFA
|
GSTP1 HIF1A HRAS IL6
(2.60)
|
MAPK1 MAPK3 MDM2
ABCB1 (−3.59) CYP1B1 (−3.87)
|
PAR1 PARP1 PGR POR
CYP3A4 (−7.84) HRAS
|
PTGS2 RAF1 RB1 SKP2
(−2.10) IL6 (−39.79) PGR (−11.29)
|
TNF TNFRSF10B TP53
PTGS2 (−36.04, −32.79)
|
TUBB TUBB1 VEGFA
TNFRSF10B (−2.25)
|
PACLITAXEL
129
ABCB1 ABCC1 ABCC2
65
ABCC1 (7.70) ABCC2 (4.39,
6.54
6.14
147
|
(Epitaxol, LipoPac,
AIFM1 AKR1C2 AKT1
(31 + 34)
5.45) AKT2 (2.40, 3.07, 2.01)
|
Onxol, Paxceed,
AKT2 AKT3 AMFR APAF1
(50.4%)
ASPM (5.55, 8.12) AURKA
|
Paxene, Taxol, Taxol A,
ARR3 ASPM AURKA BAD
(4.00) BECN1 (2.18) CA12
|
Vascular Wrap, Xorane)
BAX BBS4 BCL2 BCL2L1
(21.62, 17.07, 11.24, 25.25)
|
BECN1 BID BIRC2 BIRC3
CASP3 (2.14) CASP8 (8.85,
|
BIRC5 BMP7 BTG3
2.67) CCNB1 (3.17) CTNND2
|
C7ORF23 CA12 CALCA
(3.12, 2.44) CYP19A1 (2.64)
|
CASP3 CASP7 CASP8
E2F3 (2.71) FTH1 (2.42,
|
CASP9 CAV1 CCNB1
2.32, 2.35) FTL (3.51, 4.41,
|
CCND1 CD46 CD47
3.40) GSTP1 (3.00) MED1
|
CDKN1A CFLAR CLU
(2.44) MED13L (6.09) MELK
|
CTCF CTNND2 CTSL1
(6.04) NAT1 (2.39) NCOA3
|
CXCR4 CXCR6 CXCR7
(3.29, 4.36, 3.16) NKAIN1
|
CYCS CYP19A1 CYP2C8
(22.33) NR1I2 (3.23) PARP1
|
CYP3A4 DIABLO E2F3
(2.68) PRC1 (3.44) RRM2
|
EGFR ERBB4 FAS FASLG
(3.30, 3.47) S100P (41.69)
|
FDPS FTH1 FTL FURIN
TOP2A (5.88) TYMS (3.69)
|
FXYD3 GADD45A GAMT
VEGFA (2.60) ZNF552 (8.76,
|
GFRA1 GSTM1 GSTM5
2.45)
|
GSTP1 GSTT1 HIF1A
ABCB1 (−3.59) AKT3 (−3.90, −3.96)
|
ICAM1 IFI30 IGFBP4
AMFR (−5.37) BIRC3 (−2.84)
|
ITGB5 JMJD2B JUN
BMP7 (−16.37, −4.33)
|
KIAA1467 KIF3A KRT13
BTG3 (−7.01) CAV1 (−22.26, −24.68)
|
MAPK1 MAPK14 MAPK3
CCND1 (−2.52) CD47
|
MAPK8 MAPK9 MAPT
(−6.41, −16.99) CDKN1A (−7.85,
|
MCL1 MDM2 MED1
−4.44) CXCR4 (−2.72)
|
MED13L MELK METRN
CXCR6 (−2.50) CYP3A4 (−7.84)
|
MMP9 MT1E MT2A MYC
EGFR (−12.64) ERBB4
|
NAT1 NCOA3 NFKB1
(−3.94, −3.33) FAS (−5.93)
|
NFKBIA NKAIN1 NR1I2
FURIN (−2.72) FXYD3 (−2.65)
|
PARP1 PDPK1 PMP22
GAMT (−3.39, −2.43) GFRA1
|
POR PRC1 PTEN PTGS2
(−5.66) GSTM5 (−3.70, −6.54)
|
RAMP1 RB1 RBL2 RELA
ICAM1 (−8.24) IGFBP4 (−2.66)
|
RFX5 RPL23A RPLP1
JUN (−2.62) MAPK8 (−2.06)
|
RRM2 RTKN S100P
MCL1 (−3.34) MMP9 (−10.90)
|
SCUBE2 TFF1 THNSL2
MT1E (−15.67) MT2A
|
TNFRSF10B TOP2A TP53
(−8.59, −9.15) NFKBIA (−4.00)
|
TUBB TUBB1 TYMS
PMP22 (−6.22) PTEN (−2.30, −2.56)
|
VEGFA XIAP ZNF552
PTGS2 (−36.04, −32.79)
|
TNFRSF10B (−2.25)
|
DNA >> Spindle poisons/Mitotic inhibitors >> Vinca Alkaloids
|
VINBLASTINE
13
ABCB1 ABCC1 ABCC2
9
ABCC1 (7.70) ABCC2 (4.39,
3.57
4.40
135
|
(Nincaluicolflastine, Rozevin,
CASP2 IKBKB JUN
(4 + 5)
5.45) CASP2 (2.27) IKBKB
|
Velban, Velbe Vinblastin, Vinblastina,
MAPK8 MAPK9 NFATC4
(69.2%)
(2.08, 2.59, 3.48)
|
Vinblastine Sulfate, Vinblastinum,
NFKBIA TNFRSF10B
ABCB1 (−3.59) JUN (−2.62)
|
Vincaleucoblastin, Vincaleucoblastine,
TP53 TUBB2A
MAPK8 (−2.06) NFKBIA (−4.00)
|
Vincaleukoblastine, Vincoblastine)
TNFRSF10B (−2.25)
|
VINCRISTINE
70
ABCB1 ABCC1 ABCC2
31
ABCC1 (7.70) ABCC2 (4.39,
6.79
6.69
152
|
(Marqibo, Onco TCS, Oncovin, Vincasar,
AKT1 APAF1 APOA1
(16 + 15)
5.45) ASPM (5.55, 8.12)
|
Vincasar PFS, Vincrex, Vincristine
ASPM AURKA BAD BAX
(44.3%)
AURKA (4.00) CASP2 (2.27)
|
Sulfate PFS, Vinkristin)
BCL2 CASP1 CASP10
CASP3 (2.14) CASP8 (8.85,
|
CASP2 CASP3 CASP4
2.67) CES1 (13.90) E2F1
|
CASP5 CASP6 CASP7
(2.45) GULP1 (21.16, 15.15)
|
CASP8 CASP9 CAT
MAP3K7 (3.78) PRC1 (3.44)
|
CEBPB CES1 CFTR CYC1
RARB (2.96) SLC2A1 (22.83)
|
E2F1 EGFR FADD FAIM2
TYMS (3.69) XBP1 (2.26)
|
GAPDH GSTM1 GULP1
ABCB1 (−3.59) CASP1 (−4.93)
|
HRAS IAPP IGF1 IGF1R
CASP4 (−2.29, −2.55)
|
IL6 LMNA LMNB1
CASP5 (−2.47) CAT (−3.31)
|
MAP2K4 MAP3K7 MAPK1
EGFR (−12.64) HRAS (−2.10)
|
MDM2 MEF2A MGMT
IGF1 (−5.82, −4.31, −5.16, −5.25)
|
MYC NFKB1 P11 PCAF
IL6 (−39.79) LMNA (−2.45)
|
PRC1 PRNP PTK2B
PCAF (−4.52, −6.85)
|
PTPN13 RARB RBM17
PRNP (−3.95) PTPN13 (−3.49)
|
RELA ROS1 RUNX3
ROS1 (−5.49) VDR (−6.07)
|
SLC2A1 SOS1 STAT1
|
STAT2 STAT3 TNF TP53
|
TUBB2A TYMS VDR XBP1
|
VINFLUNINE
1
TUBB1
—
—
—
—
—
|
VINDESINE
1
TUBB1
—
—
—
—
—
|
(DAVA, Eldesine, Eldisine)
|
VINORELBINE
3
RBM17 SLC29A1 TUBB2A
—
—
—
—
—
|
(Navelbine, Navelbine Base)
|
DNA >> Spindle poisons/Mitotic inhibitors >> Other
|
EPOTHILONES
17
BAX BCL2 BCL2L1 BIRC3
3
BIRC3 (−2.84) MCL1 (−3.34)
3.66
0.00
0
|
MCL1 TUBA1 TUBA2
(0 + 3)
TUBB4 (−4.81)
|
TUBA3 TUBA6 TUBA8
(17.6%)
|
TUBB1 TUBB2A TUBB2C
|
TUBB3 TUBB4 TUBB4Q
|
XIAP
|
DNA >> Cytotoxic/Antitumor antibiotics
|
DNA >> Cytotoxic/Antitumor antibiotics >> Anthracyclines
|
DOXORUBICIN
444
ABCB1 ABCB1A ABCB4
198
ABCC1 (7.70) ABCC3 (8.66)
5.97
5.64
123
|
(ADM, Adriablastin,
ABCB5 ABCC1 ABCC3
(97 + 101)
AKR1C3 (3.54) AKT2 (2.40,
|
Adriamycin, Adriamycin
ABCG2 ADAM19
(44.6%)
3.07, 2.01) ATM (2.79)
|
PFS, Adriamycin RDF,
ADAMTS5 AHCY AIFM1
BCL2L11 (3.13) BCL2L12
|
Adriamycin
AKR1A1 AKR1C2 AKR1C3
(4.27) BECN1 (2.18) BIK
|
Semiquinone,
AKT1 AKT2 AKT3 ALB
(3.06) BUB1B (12.77) CA12
|
Adriblastin, Adriblastina,
AMFR ANGPT1 AP4E1
(21.62, 17.07, 11.24, 25.25)
|
Caelyx, DM2, Doxil,
APAF1 API5 APOA1 APP
CABC1 (3.10) CASP2 (2.27)
|
Doxo, Myocet, RDF
ARHGEF1 ARHGEF17
CASP3 (2.14) CASP8 (8.85,
|
Rubex, Resmycin,
ARL6IP5 ATF4 ATM
2.67) CBR1 (6.01) CCNA2
|
Rubex)
ATP6V0E1 AZGP1
(5.27) CCNB1 (3.17) CCNE1
|
B4GALT1 BACH1 BAD
(5.62) CDC2 (2.92) CDC25C
|
BAG1 BAK1 BAX BBS12
(8.00) CDKN2A (18.18, 9.22)
|
BBS4 BCL2 BCL2A1
CENPA (3.86) CES1 (13.90)
|
BCL2L1 BCL2L11
CHEK1 (4.69) CHEK2 (2.55)
|
BCL2L12 BECN1 BID BIK
CLIP1 (2.08) CPT1A (2.21)
|
BIRC2 BIRC3 BIRC5
CREBBP (2.11, 2.52)
|
BIRC6 BIRC7 BIRC8
CTNND2 (3.12, 2.44)
|
BTG1 BTG2 BTG3 BUB1B
CYP2B6 (10.92, 3.17) DEK
|
BUB3 C21ORF87
(2.71) DNMT1 (2.20) DTYMK
|
C5ORF13 C7ORF23 CA12
(2.69, 2.60) E2F1 (2.45)
|
CABC1 CALD1 CAPN6
E2F3 (2.71) EGF (16.93)
|
CASP1 CASP10 CASP2
EHMT2 (4.08, 2.31, 2.75)
|
CASP3 CASP4 CASP5
ERBB3 (2.54, 3.81, 4.45)
|
CASP6 CASP7 CASP8
ETV6 (2.09) FOXO3 (2.21)
|
CASP9 CBR1 CCL2
FTL (3.51, 4.41, 3.40) G6PD
|
CCNA2 CCNB1 CCND1
(5.12) GSTA1 (16.89) GSTP1
|
CCND2 CCNE1 CD44
(3.00) GULP1 (21.16, 15.15)
|
CDC2 CDC25C CDK10
HCRTR1 (2.33) HDAC1
|
CDK2 CDKN1A CDKN1B
(6.44) HFE (3.86, 3.08)
|
CDKN2A CEBPB CENPA
HSAJ2425 (2.32) HSPA9
|
CES1 CFLAR CFTR
(2.34) HSPB1 (4.23, 3.70,
|
CHEK1 CHEK2 CHUK
3.27) HSPD1 (3.65, 5.01)
|
CISH CLDN1 CLIP1
IKBKB (2.08, 2.59, 3.48) ILF3
|
CLPTM1 CLU COL18A1
(3.78) KCNH2 (4.05) KRT18
|
COX2 CPT1A CREBBP
(3.49, 2.64, 3.00, 2.48) LY75
|
CRISP2 CRYAA CRYAB
(4.92) MAD2L1 (3.87)
|
CSPG4 CTGF CTNNBIP1
MAP3K7 (3.78) MDK (17.02)
|
CTNND2 CTSB CTSD
MED13L (6.09) MELK (6.04)
|
CTSG CXCL6 CYC1
MLL (2.05, 2.04) MME (3.38,
|
CYCS CYP1A1 CYP27B1
4.93) MRPS18A (2.34)
|
CYP2B6 DDEF1 DDIT3
NKAIN1 (22.33) NOLC1
|
DEK DGKI DHPS DIABLO
(2.54, 2.56) OXTR (4.19)
|
DKK2 DNAJA1 DNMT1
PARP1 (2.68) PDCD5 (3.33)
|
DPP4 DSPP DTYMK E2F1
PMAIP1 (12.40) PRKDC
|
E2F3 ECHS1 ECOP EDN1
(2.47, 2.93) PROC (27.80)
|
EFNB3 EGF EGFR EGR1
PSMB7 (2.15) PTK2 (2.54)
|
EHMT2 EIF1AX EIF2A
PTPRH (42.24) RAD51 (4.60)
|
EIF4EBP1 EP300 EPHA2
RARB (2.96) RHCG (3.15)
|
ERAP1 ERBB2 ERBB3
RRM2 (3.30, 3.47) SMAD3
|
ERBB4 ESR1 ESR2 ETV6
(4.63, 3.78) SOD1 (2.68,
|
F3 F7 FADD FAIM2 FAS
2.37) SSH3 (3.00, 3.18) ST14
|
FASLG FCGR3A FDFT1
(2.22) STK39 (6.44, 6.78)
|
FHL2 FKBP5 FKBP8 FN1
TCF3 (4.52, 3.83) TERT
|
FOLR1 FOS FOXJ1
(3.67) TNFRSF25 (7.01)
|
FOXO1 FOXO3 FSHB FTL
TOP2A (5.88) TRIM28 (2.33)
|
FTMT FUT4 G6PD
TUBA4A (2.16) TYMS (3.69)
|
GADD45G GAMT GAPDH
UQCRH (3.18, 3.28) VEGFA
|
GATA1 GDF15 GFI1B
(2.60) ZMYM2 (3.03, 4.70)
|
GFRA1 GLO1 GNRHR
ZNF552 (8.76, 2.45)
|
GP9 GPX1 GSK3B GSTA1
ABCB1 (−3.59) ADAMTS5 (−3.42)
|
GSTA4 GSTP1 GTF3C1
AKT3 (−3.90, −3.96)
|
GULP1 H2AFX HBG2
AMFR (−5.37) ANGPT1 (−13.77,
|
HCRTR1 HDAC1 HFE
−19.66) APP (−3.45)
|
HGF HIF1A HIST1H2BC
ARL6IP5 (−3.81, −3.50)
|
HLA-DQB1 HLA-DRB4
ATP6V0E1 (−4.06) BCL2A1 (−18.59,
|
HMP19 HNRNPM HRAS
−2.78) BIRC3 (−2.84)
|
HS3ST1 HSAJ2425
BTG2 (−3.68) BTG3 (−7.01)
|
HSP90AA1 HSPA4 HSPA5
CAPN6 (−3.15) CASP1 (−4.93)
|
HSPA8 HSPA9 HSPB1
CASP4 (−2.29, −2.55)
|
HSPD1 HTRA1 HUWE1
CASP5 (−2.47) CCL2 (−8.86)
|
IAPP IFNA1 IGF1 IGF1R
CCND1 (−2.52) CCND2 (−7.50,
|
IGFBP4 IKBKB IKBKG IL6
−3.63, −13.98) CD44 (−5.46)
|
IL8 ILF3 IRS1 JAG2
CDKN1A (−7.85, −4.44)
|
JMJD2B JUN KCNH2
CISH (−6.49, −6.90) CRISP2
|
KCNJ13 KCNJ16 KDSR
(−3.03) CRYAB (−3.91)
|
KHSRP KIAA1467 KIF3A
CSPG4 (−4.23) CTGF (−2.88)
|
KLF2 KRT18 LGALS3
CTNNBIP1 (−7.17) CTSB (−2.39)
|
LIG4 LIMA1 LMNA LMNB1
CTSD (−2.66) CTSG (−8.64)
|
LY75 MAD2L1 MAP2K1
CXCL6 (−7.14) DKK2 (−2.84,
|
MAP2K2 MAP2K3
−19.13) DPP4 (−21.02)
|
MAP2K4 MAP2K6
EDN1 (−4.13) EFNB3 (−4.49)
|
MAP3K7 MAP3K8 MAPK1
EGFR (−12.64) EGR1 (−6.04)
|
MAPK14 MAPK3 MAPK8
ERBB4 (−3.94, −3.33) F3 (−3.63)
|
MAPK9 MAPT MCL1
FAS (−5.93) FCGR3A (−2.85)
|
MDH2 MDK MDM2
FN1 (−3.36, −3.49, −4.91)
|
MED13L MEF2A MELK
FOXJ1 (−5.38, −2.05)
|
METAP2 METRN MFGE8
FOXO1 (−2.47, −3.13) GAMT
|
MGMT MLL MLLT3 MME
(−3.39, −2.43) GFRA1 (−5.66)
|
MMP1 MMP2 MRPS18A
GP9 (−2.54) HGF (−2.73, −6.54)
|
MSH6 MT1G MT1L MT2A
HLA-DQB1 (−3.19, −3.83)
|
MTR MTSS1 MVP MYC
HLA-DRB4 (−4.14)
|
NAIP NBN NDUFB7
HRAS (−2.10) HSPA5 (−2.00)
|
NFKB1 NFKB2 NFKBIA
IGF1 (−5.82, −4.31, −5.16, −5.25)
|
NID1 NKAIN1 NMBR
IGFBP4 (−2.66) IL6 (−39.79)
|
NOLC1 NOS2 NR4A1
IL8 (−16.97) IRS1 (−13.62)
|
OR12D2 OR2F1 OXTR
JUN (−2.62) KCNJ16 (−14.12)
|
P11 P2RX2 P2RY6
KDSR (−2.45) KLF2 (−3.43,
|
PARP1 PAX6 PCAF PCNA
−2.31) LMNA (−2.45)
|
PDCD5 PDPK1 PITX1
MAP2K3 (−3.18, −3.56)
|
PLAU PLOD1 PLOD3
MAP2K6 (−4.53) MAPK8 (−2.06)
|
PMAIP1 POLD4 POMT2
MCL1 (−3.34) MMP1 (−58.24)
|
POR PPARD PPT2
MMP2 (−4.48) MT1G (−11.42,
|
PRKACA PRKCA PRKCD
−6.38) MT1L (−11.08)
|
PRKDC PRL PRNP PROC
MT2A (−8.59, −9.15) MTSS1
|
PROCR PSMA1 PSMA2
(−2.60) MVP (−2.25) NFKBIA
|
PSMA3 PSMA4 PSMA5
(−4.00) NR4A1 (−5.37) PCAF
|
PSMA6 PSMA7 PSMB2
(−4.52, −6.85) PLOD1 (−2.05)
|
PSMB3 PSMB7 PTEN
PRKCA (−3.26) PRNP (−3.95)
|
PTGS2 PTK2 PTK2B
PROCR (−2.63) PTEN (−2.30,
|
PTPN13 PTPRH RAD51
−2.56) PTGS2 (−36.04, −32.79)
|
RALBP1 RAMP1 RARB
PTPN13 (−3.49) RELB
|
RB1 RBL1 RBL2 RBM17
(−2.34) ROS1 (−5.49)
|
RBPMS REL RELA RELB
SERPINE1 (−2.71)
|
RGS13 RHCG ROS1
SLC22A16 (−13.33) SLIT3 (−4.84)
|
RRM2 RUNX1 RUNX3
SMAD2 (−2.15, −3.51)
|
SAT SCNN1G SCUBE2
SMAD7 (−2.99) TGM2 (−6.85,
|
SEC22B SERPINE1
−4.62) THBD (−5.54) THBS1
|
SERPINH1 SKP2
(−2.30, −3.06) TMSB4X (−2.05)
|
SLC22A16 SLC22A5
TNFRSF10B (−2.25)
|
SLC29A1 SLC38A2
TNFSF10 (−7.51) TRIM34 (−3.03)
|
SLC5A5 SLC9A1 SLIT3
TUBB4 (−4.81) UPP1 (−3.24,
|
SMAD2 SMAD3 SMAD4
−2.71, −2.28) VDR (−6.07)
|
SMAD7 SMC1A SOD1
ZFP36L2 (−2.99)
|
SOD2 SOS1 SP1 SPARC
|
SPHK2 SRM SSH3 ST14
|
STAT1 STAT2 STAT3
|
STK39 STMN1 STX3
|
TAGLN TCF3 TERT TFF1
|
TGFB1 TGM2 THBD
|
THBS1 THNSL2 TIA1
|
TLX3 TMSB4X TNF
|
TNFRSF10A TNFRSF10B
|
TNFRSF1A TNFRSF1B
|
TNFRSF25 TNFSF10
|
TOMM20 TOP2A TOP2B
|
TP53 TP73 TRAP1
|
TRIM23 TRIM28 TRIM34
|
TRP53 TTPA TUBA4A
|
TUBB TUBB4 TYMS
|
UGCG UGT2B4 UPP1
|
UQCRH VDR VEGFA
|
XIAP ZFP36L2 ZMYM2
|
ZNF22 ZNF552
|
EPIRUBICIN
7
ABCB1 ABCC1 ABCG2
4
ABCC1 (7.70) CASP3 (2.14)
4.83
5.24
224
|
(Ellence, Epi-Dx, Epiadriamycin,
BIRC5 CASP3 CHD1
(3 + 1)
TOP2A (5.88)
|
Epidoxorubicin, Epirubicina, Epirubicine,
TOP2A
(57.1%)
ABCB1 (−3.59)
|
Epirubicinum, IMI 28, Pharmorubicin Pfs,
|
Pidorubicina, Pidorubicine,
|
Pidorubicinum, Ridorubicin)
|
DNA >> Cytotoxic/Antitumor antibiotics >> Anthracenediones
|
MITOXANTRONE
25
ABCB1 ABCG2 AMOTL1
11
CASP2 (2.27) ELAVL4 (8.24,
5.46
5.64
135
|
(Mitox, Novantron,
BIRC2 CASC3 CASP2
(6 + 5)
12.95) RARB (2.96) SYTL2
|
Novantrone)
ELAVL4 ELOVL5
(44.0%)
(10.42, 7.94) TMEM99 (2.94)
|
EPB41L2 FAM130A1 IRX1
TOP2A (5.88)
|
LAMA2 LEMD2 MAFF
ABCB1 (−3.59) AMOTL1 (−9.67,
|
MDM2 PACRGL RARB
−12.72) IRX1 (−2.23)
|
RASA1 RBM17 RRAGD
LAMA2 (−5.62) MAFF (−3.57)
|
SFRP4 SYTL2 TMEM99
|
TOP2A XIAP
|
DNA >> Cytotoxic/Antitumor antibiotics >> Streptomyces
|
BLEOMYCIN
7
BIRC2 BLMH CAT LIG1
4
LIG1 (3.03) LIG3 (2.27)
3.53
2.65
75
|
(Bleo, Bleonexane)
LIG3 SOCS1 XRCC1
(2 + 2)
CAT (−3.31) SOCS1 (−5.85, −5.20)
|
(57.1%)
|
MITOMYCIN
25
ALDH3A1 APP ATF4
13
ALDH3A1 (12.05) BMP4
5.50
6.14
196
|
(Ametycin, Ametycine,
BMP4 CCNB1 CD59
(8 + 5)
(3.33) CCNB1 (3.17) GSTP1
|
Mit-C, Mito-C, Mitocin-
EGR1 EPHA2 GSTP1
(52.0%)
(3.00) LIG1 (3.03) NFYA
|
C, Mitomycin C,
HLA-C LIG1 MAPRE1
(2.84) NQO1 (18.75) RFC4
|
Mitomycin-C,
MGMT MMP14 NFYA
(2.95)
|
Mitomycinum,
NQO1 POR PRNP RB1
APP (−3.45) CD59 (−8.71, −4.89,
|
Mitomycinum C,
RBBP7 RFC4 RPS3A
−4.77, −7.00) EGR1 (−6.04)
|
Mitomycyna C,
RUNX3 SUB1 TP53
PRNP (−3.95) RPS3A (−2.73,
|
Mitozytrex, Muamycin,
−2.31, −2.81, −2.51, −2.45, −2.68)
|
Mutamycin, Mytomycin,
|
Mytozytrex)
|
DNA >> Cytotoxic/Antitumor antibiotics >> Other
|
HYDROXYUREA
21
BAX C13ORF34 CASP3
13
CASP3 (2.14) CCNA2 (5.27)
4.64
4.27
162
|
(Biosupressin, Droxia,
CCNA2 CCNB1 CCND1
(8 + 5)
CCNB1 (3.17) CCNE1 (5.62)
|
Hidrix, Hydrea, Hydreia,
CCND2 CCND3 CCNE1
(61.9%)
CDCA8 (2.55) KPNA2 (2.49)
|
Hydura, Hydurea,
CCNG1 CDCA8 CDKN1A
PRC1 (3.44) UBE2C (9.47)
|
Litaler, Litalir, Onco-
CKS2 EDN3 FAS KPNA2
CCND1 (−2.52) CCND2 (−7.50,
|
Carbide, Oxyurea,
PRC1 PSRC1 RRM1 TP53
−3.63, −13.98) CCNG1 (−3.23)
|
Ureaphil)
UBE2C
CDKN1A (−7.85, −4.44)
|
FAS (−5.93)
|
DNA >> Topoisomerase inhibitors
|
DNA >> Topoisomerase inhibitors >> Camptotheca
|
CAMPTOTHECIN
47
ABCB1 AGRN ALB ANXA4
20
CASP2 (2.27) CASP3 (2.14)
4.28
2.70
46
|
BAX BCL2 BIRC5 CAB39
(8 + 12)
CCNB1 (3.17) CEACAM1
|
CASP2 CASP3 CCNB1
(42.6%)
(2.43, 2.23) GSTP1 (3.00)
|
CDK2 CDKN1A CEACAM1
PARP1 (2.68) PRC1 (3.44)
|
CEBPZ CTSB EI24
VEGFA (2.60)
|
EPM2AIP1 FDXR GSTP1
ABCB1 (−3.59) CDKN1A (−7.85,
|
HNRNPC IL1B IL8 JUN
−4.44) CTSB (−2.39)
|
MAP2K3 MAP3K5 MAPK9
IL1B (−12.47) IL8 (−16.97)
|
MDM2 NCK2 PARP1 PLK3
JUN (−2.62) MAP2K3 (−3.18, −3.56)
|
PPP1R1B PRC1 RB1
PLK3 (−2.94) PPP1R1B
|
RBL1 RBL2 SDC1 TAP1
(−5.77) SDC1 (−2.52) THBS1
|
TAX1BP3 THBS1 TNFSF9
(−2.30, −3.06) TNFSF9 (−2.43)
|
TOP1 TP53 TP53I3
|
TP53TG1 VEGFA XIAP
|
TOPOTECAN
7
ABCG2 ARNT H2AFX
1
VEGFA (2.60)
2.60
2.60
37
|
(Hycamptamine,
HIF1A TOP1 TOP1MT
(1 + 0)
|
Hycamptin, Hycamtin)
VEGFA
(14.3%)
|
IRINOTECAN
204
ABCB1 ABCC1 ABCC2
104
ABCC1 (7.70) ABCC2 (4.39,
7.59
6.54
169
|
(CP0, Camptosar,
ABCC4 ABCG2 ADD3
(53 + 51)
5.45) ABCC4 (2.34) AURKB
|
IRINOTECAN, CPT-11)
AKAP10 ALAS2 ALDH1A1
(51.0%)
(2.61) BCL9 (5.39) BUB1
|
ANGPTL2 ANXA6 APC
(2.75) CCNA2 (5.27) CCNB2
|
ARAF AREG ARHGAP5
(4.19) CCNF (2.52) CCR6
|
ARID4A ATF3 ATG10
(2.28) CDC2 (2.92) CDKN3
|
ATP5O AURKB BCL7A
(5.50) CENPF (7.39, 8.14)
|
BCL9 BIRC5 BMP8A
CES1 (13.90) CES3 (10.19)
|
BOLL BUB1 CASP4
CREBBP (2.11, 2.52)
|
CCNA2 CCNB2 CCNF
CYP2B6 (10.92, 3.17)
|
CCR1 CCR6 CD70 CD80
CYP2C9 (3.97) CYP2D6
|
CDC2 CDC25B CDC2L5
(3.52, 3.15) DENND4A (2.86,
|
CDK5R2 CDKN1A CDKN3
2.30) DYRK2 (3.69, 2.90,
|
CENPE CENPF CES1
2.19, 2.26) EML2 (4.55)
|
CES2 CES3 CHD1
ETV6 (2.09) GATA3 (6.10)
|
COL6A1 COMMD6
GOLGA8A (8.56) MAD2L1
|
CREBBP CYP1A2
(3.87) MCM4 (4.63) MX2
|
CYP2A6 CYP2B6
(2.64) NEK2 (23.93, 26.08)
|
CYP2C19 CYP2C8
PLEKHH3 (2.59) PLK1 (2.97,
|
CYP2C9 CYP2D6 CYP2E1
2.70) PMAIP1 (12.40)
|
CYP3A4 CYP3A5
PROM1 (4.29) PTGES (9.53)
|
DCLRE1A DDB2 DEFA1
RAC3 (2.23) RAD23B (2.57,
|
DENND4A DMWD DNMT2
2.55, 4.15) RBBP5 (2.08,
|
DPYD DRD5 DRG1
2.99) RFC3 (4.94, 4.23) SPIB
|
DUSP2 DYRK1A DYRK2
(4.00) STK38 (4.45, 4.62)
|
EBI2 EGFR EGR1 EML2
STK4 (2.65) TAF2 (2.17,
|
EP300 ERBB4 ETS2 ETV6
2.48) TBCC (2.21, 2.21)
|
F8 FANCG FASLG FGF2
TOB1 (2.20) TOP2A (5.88)
|
FN1 FOS FOSB GATA3
TPX2 (5.74) TTK (20.36)
|
GDF15 GOLGA8A
TYMS (3.69) UBE2C (9.47)
|
GPR109B GPX3 H2AFX
UGT1A6 (35.81, 53.16)
|
HBEGF HIST1H2AC
UGT1A8 (30.25) YES1 (2.33)
|
HMMR HRG HSPA4L ID2
ZFX (2.61)
|
IGF1 IL1B IL8 ITGAV
ABCB1 (−3.59) ALAS2 (−5.81,
|
ITGAX ITGB3BP JUN
−8.89) ANGPTL2 (−2.89, −3.89)
|
KLF9 KRT5 LGALS8 LTF
ANXA6 (−3.31) AREG (−119.30)
|
MAD2L1 MAL MALL
CASP4 (−2.29, −2.55)
|
MAP3K5 MCF2L MCM4
CCR1 (−2.53, −4.69) CDKN1A
|
MDM2 MEF2B MGMT
(−7.85, −4.44) COL6A1 (−3.54)
|
MMP9 MPO MSH2
CYP3A4 (−7.84) CYP3A5 (−34.94)
|
MTHFS MX2 NCK1
DPYD (−2.82, 4.07, −4.30)
|
NCOA1 NEK2 NID1 OSMR
EBI2 (−5.77) EGFR (−12.64)
|
PCDHGC3 PDE4B
EGR1 (−6.04) ERBB4
|
PLEKHH3 PLK1 PLK2
(−3.94, −3.33) ETS2 (−3.94 −5.62,
|
PLK3 PMAIP1 POR
−5.40) F8 (−3.51, −2.90)
|
PPP3CB PRKCA PRKCB
FGF2 (−9.80) FN1 (−3.36, −3.49,
|
PRKCD PRKCI PROM1
−4.91) GPX3 (−4.85)
|
PSG9 PTGES PTPN13
HBEGF (−5.28, −5.37)
|
PTPN22 PTPRD PTPRN
HSPA4L (−2.34) ID2 (−2.96, −3.38)
|
RAC3 RAD23B RB1
IGF1 (−5.82, −4.31, −5.16,
|
RBBP5 RBL1 RELA RFC3
−5.25) IL1B (−12.47) IL8
|
RGS1 RUNX1 SDC4
(−16.97) ITGAX (−2.53, −2.13)
|
SERPINE2 SESN2 SFN
ITGB3BP (−2.46) JUN (−2.62)
|
SGK SLC16A4 SLC9A3R2
KLF9 (4.25) KRT5 (−12.89)
|
SNAG1 SPIB STK38 STK4
LGALS8 (−2.28) LTF (−20.86)
|
SULT1A4 TAF2 TBCC
MAL (−7.99) MALL (−2.75, −2.73)
|
TGFA THY1 TMEM41B
MMP9 (−10.90) OSMR
|
TMSB4X TNFAIP6 TOB1
(−5.11, −3.52) PDE4B (−5.96)
|
TOB2 TOP1 TOP1MT
PLK3 (−2.94) PPP3CB (−2.30)
|
TOP2A TOPORS TP53
PRKCA (−3.26) PTPN13 (−3.49)
|
TPX2 TRADD TRAF1 TTK
PTPRD (−6.35) SESN2
|
TYMP TYMS UBE2C
(−2.98) SLC16A4 (−7.88)
|
UCHL5 UGT1A1 UGT1A10
TMEM41B (−2.16) TMSB4X (−2.05)
|
UGT1A6 UGT1A7
TNFAIP6 (−22.06)
|
UGT1A8 UGT1A9 XRCC4
TYMP (−3.83, −5.95) ZFP36L2 (−2.99)
|
YES1 ZFP36L2 ZFX
|
ZNF32 ZNF582 ZRSR2
|
DNA >> Topoisomerase inhibitors >> Podophyllum
|
ETOPOSIDE
102
ABCB1 ABCC1 ABCC2
53
ABCC1 (7.70) ABCC2 (4.39,
8.65
6.31
167
|
(Eposin, Etopophos, Lastet, Toposar,
ABCC3 AGRN AKT1
(27 + 26)
5.45) ABCC3 (8.66)
|
Vepesid, Vepesid J, Zuyeyidal)
ALDH3A1 ANXA4 AREG
(52.0%)
ALDH3A1 (12.05) BIK (3.06)
|
ATF4 BAK1 BCL2 BCL2L1
BRCA1 (3.05) CASP2 (2.27)
|
BCL2L2 BIK BIRC2 BIRC3
CASP3 (2.14) CCNA2 (5.27)
|
BIRC5 BRCA1 BTC
CEACAM1 (2.43, 2.23)
|
CAB39 CALCA CASP2
CYP2B6 (10.92, 3.17)
|
CASP3 CASP7 CASP9
CYP2C9 (3.97) EGF (16.93)
|
CCNA2 CD44 CDK2
ERBB3 (2.54, 3.81, 4.45)
|
CDKN1A CDKN1B
ETV6 (2.09) FOXO3 (2.21)
|
CEACAM1 CEBPZ CFLAR
GSTP1 (3.00) PARP1 (2.68)
|
CYP27B1 CYP2A6
PRC1 (3.44) RAD52 (7.35)
|
CYP2B6 CYP2C8 CYP2C9
RAD54L (8.38) TOP2A (5.88)
|
CYP3A4 CYP3A5 DDIT3
TYMS (3.69) UBE2C (9.47)
|
EGF EGFR EI24
UGT1A8 (30.25) WRN (3.29)
|
EPM2AIP1 ERBB2 ERBB3
XRCC2 (5.72)
|
ERBB4 EREG ETV6 FDXR
ABCB1 (−3.59) AREG (−119.30)
|
FOXO1 FOXO3 GSTM1
BIRC3 (−2.84) BTC (−3.47,
|
GSTP1 HBEGF HSPA5
−22.42) CD44 (−5.46)
|
MAP2K3 MAP2K7
CDKN1A (−7.85, −4.44)
|
MAP3K5 MCL1 MDM2
CYP3A4 (−7.84) CYP3A5 (−34.94)
|
NCK2 NFKBIA PARP1
EGFR (−12.64) ERBB4
|
PLK3 PRC1 PRNP PTEN
(−3.94, −3.33) EREG (−25.83)
|
RAD52 RAD54L RBM17
FOXO1 (−2.47, −3.13) HBEGF
|
RUNX1 RUNX3 SDC1
(−5.28, −5.37) HSPA5 (−2.00)
|
TAP1 TAX1BP3 TGFA
MAP2K3 (−3.18, −3.56) MCL1
|
TMSB4X TNFRSF10A
(−3.34) NFKBIA (−4.00) PLK3
|
TNFRSF10B TNFSF10
(−2.94) PRNP (−3.95) PTEN (−2.30,
|
TNFSF9 TOP2A TOP2B
−2.56) SDC1 (−2.52)
|
TP53 TP53I3 TP53TG1
TMSB4X (−2.05) TNFRSF10B
|
TP73 TYMS UBE2C
(−2.25) TNFSF10 (−7.51)
|
UGT1A1 UGT1A3
TNFSF9 (−2.43) VDR (−6.07)
|
UGT1A8 VDR WRN XAF1
|
XIAP XRCC2 XRCC3
|
XRCC4
|
DNA >> Other
|
DNA >> Other >> All
|
BEXAROTENE
68
ADD3 ADRB2 AKR1C1
39
AKR1C1 (31.20, 14.60,
8.93
12.16
214
|
(Targret, Targretin, Targretin-gel,
AKR1C3 AMOTL2
(12 + 27)
19.24, 4.57) AKR1C3 (3.54)
|
Targretyn, Targrexin)
ARL6IP5 ASNS BNIP2
(57.4%)
CYP26A1 (99.46) KRT15
|
C10ORF10 C10ORF116
(2.99) PER2 (3.13) PNO1
|
CEBPG COX2 CTH CTSH
(3.43) RARB (2.96) RXRB
|
CYCS CYP26A1 CYR61
(2.45) SLC7A1 (3.17)
|
DDIT4 DHRS3 DKK1
SLC7A5 (2.98) UAP1 (2.13)
|
DUSP1 DUSP5 EGR3
XBP1 (2.26)
|
EIF1 EPHA2 GARS
ADRB2 (−10.39) AMOTL2 (−2.31)
|
GPM6B HERPUD1 ID1
ARL6IP5 (−3.81, −3.50)
|
IER2 IGFBP6 IL15 ITGB6
ASNS (−3.65) CTH (−4.18)
|
ITM2A ITPR1 KLF10
CTSH (−3.47) CYR61 (−3.69, −2.81,
|
KRT15 KRT17 LOXL2
−3.06) DDIT4 (−2.17)
|
MAF MAFF MLLT11
DKK1 (−16.44) DUSP1 (−5.64)
|
MMP1 MTHFD2 ODC1
GPM6B (−11.99) ID1 (−2.07)
|
PER2 PLAT PLAUR
IGFBP6 (−3.88) IL15 (−2.46)
|
PLOD2 PNO1 PNRC1
ITGB6 (−21.40) ITM2A (−3.63)
|
RARB RB1 RXRB S100A9
ITPR1 (−2.44) KLF10 (−2.47)
|
SCD SFRS2 SIAH2
KRT17 (−5.21) MAF (−2.53, −3.02)
|
SLC7A1 SLC7A5 SMAD5
MAFF (−3.57) MMP1 (−58.24)
|
SPARC TGM2 TM4SF1
PLAUR (−5.48) PLOD2
|
TSC22D3 UAP1 VAMP8
(−2.46) S100A9 (−2.26) SCD
|
XBP1
(−8.09, −15.46, −10.15) TGM2
|
(−6.85, −4.62)
|
Cellular
|
Cellular >> CI monoclonal antibodies
|
Cellular >> CI monoclonal antibodies >> Receptor tyrosine kinase
|
CETUXIMAB
1
EGFR
1
EGFR (−12.64)
12.64
0.00
0
|
(Erbitux)
(0 + 1)
|
(100.0%)
|
TRASTUZUMAB
2
EGFR ERBB2
1
EGFR (−12.64)
12.64
0.00
0
|
(Herceptin)
(0 + 1)
|
(50.0%)
|
Cellular >> CI monoclonal antibodies >> Anti-CD20
|
RITUXIMAB
1
MS4A1
1
MS4A1 (7.61)
7.61
7.61
761
|
(Rituxan)
(1 + 0)
|
(100.0%)
|
TOSITUMOMAB
1
MS4A1
1
MS4A1 (7.61)
7.61
7.61
761
|
(Bexxar)
(1 + 0)
|
(100.0%)
|
Cellular >> CI monoclonal antibodies >> Other
|
ALEMTUZUMAB
1
CD52
1
CD52 (−5.80)
5.80
0.00
0
|
(Campath,
(0 + 1)
|
MabCampath)
(100.0%)
|
BEVACIZUMAB
1
VEGFA
1
VEGFA (2.60)
2.60
2.60
259
|
(Avastin)
(1 + 0)
|
(100.0%)
|
EDRECOLOMAB
1
TACSTD1
—
—
—
—
—
|
(Panorex)
|
GEMTUZUMAB
1
CD33
1
CD33 (−3.02, −3.56)
3.29
0.00
0
|
(Mylotarg)
(0 + 1)
|
(100.0%)
|
Cellular >> Tyrosine kinase inhibitors
|
Cellular >> Tyrosine kinase inhibitors >> All
|
AXITINIB
6
FLT1 FLT4 KDR KIT
5
FLT1 (−2.68) FLT4 (−2.80)
10.12
0.00
0
|
PDGFRA PDGFRB
(0 + 5)
KDR (−2.85, −2.51) KIT (−38.04)
|
(83.3%)
PDGFRA (−4.21, −4.58)
|
BOSUTINIB
3
ABL1 BCR SRC
3
ABL1 (3.58) SRC (2.09)
2.69
2.84
189
|
(2 + 1)
BCR (−2.40)
|
(100.0%)
|
CEDIRANIB
2
FLT1 FLT4
2
FLT1 (−2.68) FLT4 (−2.80)
2.74
0.00
0
|
(Recentin)
(0 + 2)
|
(100.0%)
|
DASATINIB
11
ABL1 ABL2 BCR EPHA2
6
ABL1 (3.58) SRC (2.09)
8.51
2.67
72
|
(Sprycel)
FYN KIT LCK PDGFRB
(3 + 3)
YES1 (2.33)
|
SRC STAT5B YES1
(54.5%)
BCR (−2.40) FYN (−2.59) KIT
|
(−38.04)
|
ERLOTINIB
1
EGFR
1
EGFR (−12.64)
12.64
0.00
0
|
(Tarceva)
(0 + 1)
|
(100.0%)
|
GEFITINIB
48
ABCG2 ADORA1 AREG
22
CYP2C9 (3.97) CYP2D6
13.20
6.42
66
|
(Iressa, Irressat, Tarceva)
AVEN CGRRF1
(5 + 17)
(3.52, 3.15) EGF (16.93)
|
COL4A3BP CORO1C
(45.8%)
GCLC (7.00, 3.83) NRL
|
CYP1A2 CYP2C19
(2.45)
|
CYP2C9 CYP2D6 CYP2F1
ADORA1 (−2.74) AREG (−119.30)
|
CYP3A4 CYP3A5 DUSP3
COL4A3BP (−2.58)
|
DUSP9 EGF EGFR EPOR
CORO1C (−3.41, −5.23)
|
EPS15 ERBB2 ESR1
CYP2F1 (−2.63) CYP3A4 (−7.84)
|
FGF6 GADD45A
CYP3A5 (−34.94) EGFR
|
GADD45G GARS GCLC
(−12.64) HBEGF (−5.28, −5.37)
|
GNB2 GUCY2D HBEGF
IFI6 (−7.89) IL8 (−16.97)
|
IFI6 IL8 LEPR MAPK1
LEPR (−22.59, −4.51) NPTX2
|
MAPK3 MLH1 NFKB1
(−11.45) OSMR (−5.11, −3.52)
|
NPTX2 NRL OSMR
PHLDA2 (−3.07) QSOX1 (−4.99)
|
PHLDA2 QSOX1 RBM7
SKI (−4.75, −2.71, −3.52)
|
RPA1 SFN SKI TGFA
|
TNFRSF1B
|
IMATINIB
29
ABCB1 ABCG2 ABL1
11
ABL1 (3.58) DDR1 (3.07,
7.04
3.06
31
|
(Gleevec, Glivec)
AKT1 BCL2L1 BCR BIRC5
(3 + 8)
2.69, 3.21) VEGFA (2.60)
|
CCND3 CD69 CSF1R
(37.9%)
ABCB1 (−3.59) BCR (−2.40)
|
DDR1 FGFR3 FRAP1
FGFR3 (−8.75) IGF1 (−5.82, −4.31,
|
HMOX1 IGF1 IL2RA KIT
−5.16, −5.25) IL2RA(−2.77,
|
LCK MAPK1 MAPK3
−4.16) KIT (−38.04)
|
NFKB1 NTRK1 PDGFRA
PDGFRA (−4.21, −4.58) WT1
|
PDGFRB RB1 RELA RET
(−2.49)
|
VEGFA WT1
|
LAPATINIB
11
AKT1 BIRC5 CCND1
3
CCNE1 (5.62)
6.93
5.62
51
|
(Tycerb, Tykerb)
CCNE1 CDK2 CDKN1B
(1 + 2)
CCND1 (−2.52) EGFR (−12.64)
|
EGFR ERBB2 ESR1
(27.3%)
|
MAPK1 MAPK3
|
LESTAURTINIB
1
FLT3
1
FLT3 (−8.47)
8.47
0.00
0
|
(0 + 1)
|
(100.0%)
|
NILOTINIB
5
ABL1 BCR KIT PDGFRA
4
ABL1 (3.58)
12.11
3.58
71
|
(Ketek)
PDGFRB
(1 + 3)
BCR (−2.40) KIT (−38.04)
|
(80.0%)
PDGFRA (−4.21, −4.58)
|
SEMAXANIB
1
KDR
1
KDR (−2.85, −2.51)
2.68
0.00
0
|
(0 + 1)
|
(100.0%)
|
SORAFENIB
18
BAK1 BAX BCL2 BCL2L1
9
BCL2L11 (3.13) BRAF (2.27)
7.63
3.32
73
|
(Nexavar)
BCL2L11 BID BRAF
(4 + 5)
CASP3 (2.14) CASP8 (8.85,
|
CASP3 CASP8 CYCS
(50.0%)
2.67)
|
FLT3 FLT4 KDR KIT MCL1
FLT3 (−8.47) FLT4 (−2.80)
|
PDGFRB RAF1 XIAP
KDR (−2.85, −2.51) KIT (−38.04)
|
MCL1 (−3.34)
|
SUNITINIB
11
BRAF CSF1R FLT1 FLT3
7
BRAF (2.27)
8.76
2.27
20
|
(SU-11248, Sutent)
FLT4 KDR KIT PDGFRA
(1 + 6)
FLT1 (−2.68) FLT3 (−8.47)
|
PDGFRB RAF1 RET
(63.6%)
FLT4 (−2.80) KDR (−2.85, −2.51)
|
KIT (−38.04) PDGFRA
|
(−4.21, −4.58)
|
VANDETANIB
2
EGFR KDR
2
EGFR (−12.64) KDR (−2.85, −2.51)
7.66
0.00
0
|
(Zactima)
(0 + 2)
|
(100.0%)
|
Cellular >> mTOR inhibitors
|
Cellular >> mTOR inhibitors >> All
|
TEMSIROLIMUS
6
CCND1 EIF4EBP1 ESR1
2
RPS6KB1 (2.20, 2.29)
2.38
2.25
37
|
(Torisel)
FRAP1 RB1 RPS6KB1
(1 + 1)
CCND1 (−2.52)
|
(33.3%)
|
EVEROLIMUS
11
AKT1 CCND1 CCND2
3
RPS6KB1 (2.20, 2.29)
4.38
2.25
20
|
(Certican)
CCND3 EIF4E EIF4EBP1
(1 + 2)
CCND1 (−2.52) CCND2 (−7.50,
|
EIF4G1 FRAP1 RB1 RPS6
(27.3%)
−3.63, −13.98)
|
RPS6KB1
|
Cellular >> Cyclin-dependant kinase inhibitors
|
Cellular >> Cyclin-dependant kinase inhibitors >> All
|
FLAVOPIRIDOL
35
BAG1 BAX BCL2 BCL2L1
13
CASP3 (2.14) CASP8 (8.85,
3.91
3.04
60
|
(HMR-1275, Alvocidib)
BID BIRC3 BIRC5 CASP3
(7 + 6)
2.67) CCNB1 (3.17) CDC2
|
CASP8 CASP9 CCNB1
(37.1%)
(2.92) CDK6 (2.18, 2.25)
|
CCND1 CDC2 CDK2
CDK8 (2.39) PARP1 (2.68)
|
CDK4 CDK5 CDK6 CDK7
BIRC3 (−2.84) CCND1 (−2.52)
|
CDK8 CDK9 CDKN1A
CDKN1A (−7.85, −4.44) EGFR
|
CDKN1B CYCS DIABLO
(−12.64) MAPK8 (−2.06)
|
EGFR H2AFX HTRA2
MCL1 (−3.34)
|
MAPK14 MAPK8 MCL1
|
PARP1 PYGM RB1 TP53
|
XIAP
|
ROSCOVITINE
17
BAX BIRC5 CASP3
5
CASP3 (2.14) CDC2 (2.92)
3.35
2.43
42
|
(Seliciclib)
CASP9 CDC2 CDK4 CDK5
(3 + 2)
CDK6 (2.18, 2.25)
|
CDK6 CDKN1A CYCS
(29.4%)
CDKN1A (−7.85, −4.44) MCL1
|
DIABLO MCL1 PDCD8
(−3.34)
|
RB1 SP1 TP53 XIAP
|
Cellular >> Other
|
Cellular >> Other >> All
|
AFLIBERCEPT
1
VEGFA
1
VEGFA (2.60)
2.60
2.60
259
|
(VEGF Trap)
(1 + 0)
|
(100.0%)
|
DENILEUKIN
3
IL2RA IL2RB IL2RG
1
IL2RA (−2.77, −4.16)
3.47
0.00
0
|
DIFTITOX
(0 + 1)
|
(Ontak)
(33.3%)
|
Other/Ungrouped
|
Other/Ungrouped >> Other
|
Other/Ungrouped >> Other >> Other
|
ARSENIC TRIOXIDE
496
ABCB1 ABCG2 ABL1
246
ABL1 (3.58) AKAP12 (4.65,
6.01
5.42
99
|
(Arsenite, Arsenolite,
ACAA2 ADCY9 AFAP1
(91 + 154 + 1)
2.82) AKR1B1 (18.32)
|
Arsodent, Claudelite,
AKAP12 AKR1B1 AKT1
(49.6%)
ATP8A1 (3.45) ATR (2.33)
|
Claudetite, Trisenox)
ALAS1 ALDH6A1 ALDOC
BACH2 (2.04) BAMBI (2.21)
|
ALG13 ALOX5AP ANK3
BECN1 (2.18) BLVRB (2.08)
|
ANKRD12 ANPEP ANXA2
BLZF1 (2.70) CAPN10 (2.13,
|
AP3S1 AQP9 ARL6IP1
7.15, 2.57) CASP3 (2.14)
|
ARL6IP5 ARL7 ARMC9
CASP8 (8.85, 2.67) CCNB1
|
ASNS ASS1 ATP1B1
(3.17) CCNB2 (4.19)
|
ATP2B1 ATP2C1 ATP5A1
CDC42BPA (2.48) CDKN2A
|
ATP6 ATP8A1 ATR
(18.18, 9.22) CDKN3 (5.50)
|
AZGP1 BACH2 BAMBI
CHEK1 (4.69) CHEK2 (2.55)
|
BAX BCL2 BCL2A1
CHGB (3.36, 6.71) CLGN
|
BCL2L1 BCMO1 BCR
(3.78) CMTM8 (3.87) DNMT1
|
BECN1 BHLHB2 BID
(2.20) DNMT3B (4.55)
|
BIRC5 BLVRB BLZF1
DUSP4 (2.60) EPHX1 (4.56)
|
BNIP3 BNIP3L BPI
ERC2 (7.66, 17.63) FGFR1
|
BRDG1 BTBD2 BTBD3
(6.81, 6.75, 7.28, 9.06, 5.07,
|
C14ORF105 C16ORF58
6.12) FOXRED2 (2.33) FRK
|
C5ORF13 C6ORF48
(20.73) FTH1 (2.42, 2.32,
|
C8ORF4 CACNA2D2
2.35) GABPB2 (3.34, 5.13)
|
CAPN10 CAPZB CARS
GCLM (38.53) GSTA1
|
CASP10 CASP3 CASP8
(16.89) GSTP1 (3.00) HCG18
|
CASP9 CAV1 CAV2
(2.45, 2.85, 2.24) HCRTR1
|
CCDC102B CCDC52
(2.33) HIG2 (9.01) HIST3H3
|
CCL15 CCL2 CCL23
(2.04) HMGA1 (2.56, 6.05)
|
CCNA1 CCNB1 CCNB2
HSPA1A (4.07, 2.39) HSPB1
|
CCND1 CD1D CD44 CD52
(4.23, 3.70, 3.27) IFRD1
|
CD70 CD86 CDC42BPA
(6.54, 6.75) IGFBP2 (2.42)
|
CDC73 CDKN1A CDKN2A
IKBKB (2.08, 2.59, 3.48)
|
CDKN2B CDKN3 CEBPE
IQCH (2.10) KCNH2 (4.05)
|
CEP57 CFB CFLAR
KLF5 (2.46) KYNU (2.22,
|
CHEK1 CHEK2 CHGB
2.53) LAT (2.44) MAFG
|
CHI3L1 CHST6 CIDEB
(3.54, 5.15) MAP7 (4.36,
|
CITED2 CKAP4 CLC
4.74) MCM2 (3.39) ME1
|
CLEC7A CLGN CMTM8
(8.79, 22.62, 9.07) NPAS1
|
CNOT2 COBLL1
(4.81) NUP107 (2.16) ORC4L
|
COLEC10 COPS5 CREB5
(2.05) PAQR6 (2.43) PARP1
|
CRH CRIM1 CSF2RB
(2.68) PAWR (2.19) PIR
|
CSH1 CSPP1 CSRP3
(2.63) PTRH2 (2.31) RNF24
|
CST3 CTNNA1 CTSH
(2.24) RPL23 (5.58)
|
CX3CL1 CYB5R3 CYBA
RPS6KB1 (2.20, 2.29)
|
CYBRD1 CYCS CYLD
RSL1D1 (2.55) SCPEP1
|
CYP1A1 CYP39A1
(2.35) SLC2A1 (22.83)
|
CYP3A43 CYTL1 DAXX
SLC44A1 (2.84) SLC5A12
|
DAZ4 DBC1 DDIT3 DEFA1
(6.44, 4.94) SMC4 (2.40)
|
DEFA4 DKK1 DNAJB4
SOD1 (2.68, 2.37) SOX4
|
DNAJC9 DNMT1 DNMT3A
(2.17) SYNJ2 (4.91, 9.38)
|
DNMT3B DUSP4
TERT (3.67) TFAP2C (3.61)
|
DYNC1H1 DYRK1B EBI2
TNFRSF25 (7.01) TOP2A
|
EGFR EGR1 ELA2A
(5.88) TP53I11 (2.08, 2.00)
|
ENDOGL1 EP300
TRIP13 (8.20) TRMT1 (2.04)
|
EPB41L2 EPHX1 EPX
TYMS (3.69) UBE2C (9.47)
|
ERC2 ERGIC2 ESR1
UCHL1 (26.51) VEGFA
|
ESR2 EVL F3 FAM110B
(2.60) WDR12 (4.78) ZMYM2
|
FAM46C FANCC FAS
(3.03, 4.70) ZNF334 (12.87)
|
FASLG FBLN5 FBXL7
ZNF682 (3.69, 7.03) ZWINT
|
FGFR1 FGFR2 FGR
(6.72)
|
FNBP1L FOS FOXRED2
ABCB1 (−3.59) ACAA2 (−2.69)
|
FRK FSCN1 FTH1 FYB
ADCY9 (−2.46)
|
GABBR2 GABPB2
ALDH6A1 (−2.90) ALDOC (−4.73)
|
GADD45A GBA GCLM
ALOX5AP (−5.07, −7.13)
|
GIMAP6 GIT2 GJA1 GLA
ANK3 (−9.06, −7.92, −7.43)
|
GNAL GPM6A GPR30
ANPEP (−5.41) AQP9 (−13.82)
|
GPR44 GPRC5D GPX1
ARL6IP5 (−3.81, −3.50)
|
GRAMD3 GRK4 GSTA1
ARMC9 (−5.30, −5.49) ASNS
|
GSTP1 GSTZ1 H2AFX
(−3.65) ASS1 (−2.76) BCL2A1
|
HCG18 HCRTR1 HGF
(−18.59, −2.78) BCR (−2.40)
|
HIF1A HIG2 HIST1H2BM
BHLHB2 (−2.28) BTBD3 (−2.40,
|
HIST1H4C HIST3H3 HK1
−2.31) CACNA2D2 (−17.47)
|
HLA-B HLA-C HLA-DRA
CAV1 (−22.26, −24.68)
|
HLA-F HLA-G HMGA1
CAV2 (−14.35, −7.56)
|
HMGB2 HMGN2 HMOX1
CCDC102B (−2.74, −2.50)
|
HSD17B2 HSF1 HSP27
CCL15 (−4.50) CCL2 (−8.86)
|
HSPA1A HSPA4 HSPA5
CCL23 (−15.78, −18.04)
|
HSPA6 HSPB1 HTATIP2
CCND1 (−2.52) CD44 (−5.46)
|
ICAM3 ID1 ID2 IDS IER2
CD52 (−5.80) CD86 (−5.13, −2.01)
|
IFI16 IFIH1 IFNA2 IFNG
CDKN1A (−7.85, −4.44)
|
IFRD1 IGFBP2 IGFBP7
CFB (−9.87) CHI3L1 (−3.97, −12.11)
|
IKBKB IL12RB2 IL24 IL6
CHST6 (−15.14)
|
IL8RB INPP5B INSM1
CITED2 (−2.04) CKAP4 (−3.35)
|
IQCH IRF1 ITGA2B
CLEC7A (−2.69, −3.19)
|
ITGAM ITGB1 ITGB3BP
COBLL1 (−3.44) CREB5 (−9.32,
|
ITGB7 ITM2A JUN JUND
−11.86) CSF2RB (−2.47)
|
KCNH2 KCTD12
CST3 (−2.29) CTSH (−3.47)
|
KIAA0087 KIAA1609
CX3CL1 (−3.73, −9.86, −4.60)
|
KIF21B KITLG KLF11
CYB5R3 (−2.89, −2.40, −2.01)
|
KLF5 KRT6A KYNU
CYBRD1 (−2.20) CYTL1 (−6.17)
|
LAMC1 LAT LGALS9
DBC1 (−3.01) DKK1 (−16.44)
|
LGMN LHFP LHX6 LSP1
EBI2 (−5.77) EGFR (−12.64)
|
LTC4S MAFF MAFG
EGR1 (−6.04) ELA2A
|
MAFK MAN1A1 MAOA
(−4.13) EVL (−2.26) F3 (−3.63)
|
MAP2K3 MAP2K4
FAM110B (−3.73) FAM46C (−2.08)
|
MAP2K6 MAP7 MAPK1
FAS (−5.93) FBLN5 (−2.08)
|
MAPK14 MAPK3 MAPK7
FBXL7 (−4.06) FGFR2
|
MAPK8 MAPK9 MARCH2
(−31.03, −2.09, −16.52) FGR (−6.72,
|
MASK MCF2L MCM2 ME1
−9.45, −8.54) FYB (−2.23)
|
MKI67IP MMP1 MMP2
GIMAP6 (−2.66) GJA1
|
MMP28 MMP9 MPL MPO
(−9.56) GPM6A (−34.94)
|
MRPS16 MSC MSRB2
GRAMD3 (−2.12) HGF (−2.73,
|
MT1E MT1G MT1H MT1L
−6.54) HLA-DRA (−4.55)
|
MT1X MT2A MTA1
HSD17B2 (−17.74) HSPA5 (−2.00)
|
MXRA7 MYBL1 MYC
HSPA6 (−4.66) ID1 (−2.07)
|
MYCN MYO1B MYST4
ID2 (−2.96, −3.38) IFI16
|
N4BP1 N4BP2L1 NAB2
(−3.75, −3.71) IL6 (−39.79)
|
NAV3 NCF1 NCF2 ND4
IL8RB (−3.46) IRF1 (−2.23)
|
NEU3 NFE2L1 NFKBIA
ITGAM (−3.25) ITGB3BP (−2.46)
|
NFKBIE NME1 NPAS1
ITM2A (−3.63) JUN (−2.62)
|
NPTX2 NR3C1 NUCB2
KCTD12 (−4.62) KITLG
|
NUDT18 NUP107 OBSL1
(−2.48, −3.23, −6.48) KRT6A (−11.07)
|
ORC4L OS9 P4HA1
LGALS9 (−2.05)
|
P53AIP1 PAFAH2 PAOX
LGMN (−2.41) LHFP (−3.42)
|
PAQR6 PARP1 PAWR
LSP1 (−2.10) LTC4S (−2.70)
|
PCNA PCSK5 PDCD4
MAFF (−3.57) MAN1A1 (−2.01)
|
PDE4A PDE4B PDE4DIP
MAOA (−3.11) MAP2K3
|
PDLIM7 PDPK1 PDZD2
(−3.18, −3.56) MAP2K6 (−4.53)
|
PECAM1 PEX3 PGC PGF
MAPK8 (−2.06) MARCH2 (−3.34,
|
PHLDA2 PIGO PIK4CA
−3.08) MMP1 (−58.24)
|
PIR PKNOX1 PLAUR
MMP2 (−4.48) MMP28 (−8.08,
|
PLEKHO1 PLXNC1 PML
−14.29) MMP9 (−10.90) MT1E
|
PPGB PPIH PPP1CB
(−15.67) MT1G (−11.42, −6.38)
|
PRG3 PRKCB PRR16
MT1H (−8.15, −8.00) MT1L (−11.08)
|
PRSS1 PSMB6 PSMB8
MT1X (−8.45, −9.49)
|
PTGFR PTRH2 PTTG1
MT2A (−8.59, −9.15) MXRA7
|
PURG PXDN RAB27B
(−2.88, 4.06, −3.93, −3.20)
|
RACGAP1 RAPGEF4
MYO1B (−3.04, −2.30, −2.61)
|
RARA RASSF8 RBMX
NAV3 (−6.48, −8.99) NCF1 (−3.16,
|
RELA RERE RFC2 RGS2
−3.30) NCF2 (−3.56)
|
RNASEH2A RNF144A
NFKBIA (−4.00) NPTX2 (−11.45)
|
RNF24 RNF6 ROBO1
NUCB2 (−3.02, −3.50)
|
RPL17 RPL18A RPL23
NUDT18 (−4.22) OBSL1 (−5.40,
|
RPL7 RPS15A RPS6KB1
−4.33) P4HA1 (−2.49)
|
RRBP1 RSL1D1 RYK
PDE4B (−5.96) PDE4DIP (−6.65,
|
S100A10 S100A8 S100A9
−2.11, −2.32, −2.90)
|
SATB2 SCAMP5
PDLIM7 (−2.16) PDZD2 (−33.94)
|
SCGB2A2 SCPEP1 SCT
PECAM1 (−4.62) PGC
|
SDC2 SDC4 SELP
(−3.76, −25.02) PGF (−2.56)
|
SERPINB1 SERTAD2
PHLDA2 (−3.07) PLAUR (−5.48)
|
SFRS5 SH3GL2 SIGLEC6
PLEKHO1 (−2.69) PML
|
SLC14A2 SLC15A1
(−2.88, −3.32, −3.67, −3.53)
|
SLC1A2 SLC22A18
PPP1CB (−5.15, −2.92)
|
SLC2A1 SLC44A1
PRR16 (−16.52) PTGFR (−7.80)
|
SLC5A12 SLC6A5
PXDN (−3.39, −3.20)
|
SLCO3A1 SMAD1 SMC4
RASSF8 (−5.90, −17.88, −2.19,
|
SOD1 SOX18 SOX30
−10.81) RGS2 (−9.73)
|
SOX4 SP1 SPTAN1
RNF144A (−2.56) RPL17 (−3.08,
|
ST6GALNAC4 STAB1
−2.59, −2.80) RPL7 (−2.15,
|
STAT1 STATH SULF1
−2.41) S100A8 (−10.28)
|
SUSD5 SYN3 SYNJ2
S100A9 (−2.26) SDC2 (−3.99)
|
TCF4 TERC TERF1
SELP (−4.50) SERPINB1 (−2.41)
|
TERF2 TERT TFAP2C
SH3GL2 (−5.52)
|
TFF1 TGFBR2 TIMP1
SMAD1 (−3.04) SUSD5 (−2.47)
|
TIMP2 TMEM158 TNF
TCF4 (−3.68, −2.69)
|
TNFAIP3 TNFAIP8
TGFBR2 (−3.67, −4.16) TIMP1
|
TNFRSF1B TNFRSF25
(−4.76) TIMP2 (−3.34)
|
TNFRSF9 TNFSF13
TNFAIP3 (−3.78, −3.05)
|
TNFSF8 TOP2A TP53
TNFAIP8 (−3.52) TNFSF13 (−4.94)
|
TP53I11 TP73 TPT1
TPT1 (−2.57, −2.61, −2.20)
|
TRA2A TRAF3IP2 TRIM16
UBE2D1 (−2.48) VNN1
|
TRIP13 TRMT1 TSC22D3
(−2.97, −2.90) WT1 (−2.49)
|
TTC38 TXNIP TYMS
DNMT3A (2.41, −2.89)
|
UBE2C UBE2D1 UCHL1
|
UCP2 VEGFA VNN1
|
WDR12 WDR82 WSB2
|
WT1 XIAP XRCC6 ZFP36
|
ZFP36L1 ZMYM2 ZNF334
|
ZNF37A ZNF682 ZNF771
|
ZWINT
|
BORTEZOMIB
61
AKT1 APAF1 BAK1 BAX
18
BCL2L11 (3.13) CASP3
3.99
4.28
63
|
(Velcade)
BCL2 BCL2L1 BCL2L11
(9 + 9)
(2.14) CASP8 (8.85, 2.67)
|
BID BIRC2 BIRC3 BIRC5
(29.5%)
CYP2C9 (3.97) CYP2D6
|
CA9 CASP3 CASP7
(3.52, 3.15) NFKBIB (2.90,
|
CASP8 CASP9 CCND1
2.95, 2.86) PARP1 (2.68)
|
CDKN1A CDKN1B CFLAR
PMAIP1 (12.40) PSMB5
|
CYCS CYP1A2 CYP2C19
(2.22)
|
CYP2C9 CYP2D6 CYP3A4
BIRC3 (−2.84) CCND1 (−2.52)
|
DDIT3 DFFA DIABLO
CDKN1A (−7.85, −4.44)
|
HIF1A HSPA5 HTRA2 JUN
CYP3A4 (−7.84) HSPA5 (−2.00)
|
MAP2K1 MAP2K4 MAPK1
JUN (−2.62) MAPK8 (−2.06)
|
MAPK14 MAPK3 MAPK8
MCL1 (−3.34) NFKBIA
|
MCL1 NFKB1 NFKBIA
(−4.00)
|
NFKBIB NFKBIE PARP1
|
PDCD8 PMAIP1 PSMB1
|
PSMB2 PSMB5 PSMD1
|
PSMD2 RAF1 RB1 RELA
|
SFN STAT3 TNF TP53
|
TRAF2 XIAP
|
CELECOXIB
17
AKT1 BIRC5 CASP3
8
CASP3 (2.14) CYP19A1
12.38
2.46
57
|
(Celebra, Celebrex)
CCND1 CYP19A1 ILB IL6
(4 + 4)
(2.64) NRG1 (2.37) PARP1
|
MAP2K1 MAP2K2 NRG1
(47.1%)
(2.68)
|
PARP1 PDPK1 PTGS2
CCND1 (−2.52) IL1B (−12.47)
|
RELA STS SULT2A1 TNF
IL6 (−39.79) PTGS2 (−36.04, −32.79)
|
COLCHICINE
21
ABCB1 ABCC1 CD59
9
ABCC1 (7.70) IKBKB (2.08,
4.96
5.21
49
|
(Col-probenecid, Colbenemid,
CUGBP2 CYP3A4 IKBKB
(2 + 7)
2.59, 3.48)
|
Condylon, Proben-C)
JUN MAPK8 MAPK9
(42.9%)
ABCB1 (−3.59) CD59 (−8.71, −4.89,
|
MEFV NFATC4 NFKB1
−4.77, −7.00) CUGBP2
|
NFKBIA NR3C1 PTK2B
(−7.53, −8.05) CYP3A4 (−7.84)
|
RALBP1 RELA TAT TP53
JUN (−2.62) MAPK8 (−2.06)
|
TUBB1 TUBB2A
NFKBIA (−4.00)
|
OBLIMERSEN
2
BCL2 IGH-6
—
—
—
—
—
|
(Genasense, Augmerosen)
|
TEGAFUR
1
CYP2A6
—
—
—
—
—
|
(UFT)
|
TIPIFARNIB
4
ABCB1 CYP3A4 CYP3A5
3
ABCB1 (−3.59) CYP3A4 (−7.84)
15.46
0.00
0
|
(Zarnestra)
UGT1A1
(0 + 3)
CYP3A5 (−34.94)
|
(75.0%)
|
VORINOSTAT
47
AKT1 BAK1 BAX BCL2
17
BCL2L11 (3.13) CASP2
4.07
3.36
71
|
(Zolinza)
BCL2A1 BCL2L1 BCL2L11
(10 + 7)
(2.27) CASP3 (2.14) CASP8
|
BID BIRC2 BIRC3 BIRC5
(36.2%)
(8.85, 2.67) HDAC1 (6.44)
|
CASP2 CASP3 CASP7
HDAC2 (4.18) HDAC6 (2.00)
|
CASP8 CASP9 CCND1
HIST3H3 (2.04) PARP1
|
CDKN1A CDKN1B CFLAR
(2.68) RARB (2.96)
|
CYCS CYP1A1 CYP1B1
BCL2A1 (−18.59, −2.78)
|
DIABLO ERBB2 HDAC1
BIRC3 (−2.84) CCND1 (−2.52)
|
HDAC2 HDAC3 HDAC6
CDKN1A (−7.85, −4.44)
|
HDAC8 HIST3H3 HTRA2
CYP1B1 (−3.87) MAPK8 (−2.06)
|
MAP2K1 MAPK1 MAPK14
TNFSF10 (−7.51)
|
MAPK3 MAPK8 NFKB1
|
PARP1 PDCD8 RAF1
|
RARB RB1 RELA TNF
|
TNFSF10 XIAP
|
|